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Chapter 1
General introduction and outline of the thesis
Partly based on: 
A new era in the diagnosis and treatment of atypical haemolytic uremic syndrome. 
D. Westra1, J.F.M. Wetzels2, E.B. Volokhina1, L.P. van den Heuvel1, N.C.A.J. van de Kar1
Departments of 1Pediatric Nephrology and 2Nephrology, Radboud university medical centre, 
Nijmegen, The Netherlands. 
Neth J Med 2012;70(3):121-129. Review.
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The hemolytic uremic syndrome (HUS) is a rare and severe disease, characterized by the triad 
hemolytic anemia, thrombocytopenia, and acute renal failure. HUS is characterized histologically by 
thrombotic microangiopathy (TMA): vascular abnormalities with glomerular endothelial damage, 
swelling of the endothelium, endothelial detachment of the basement membrane, intima fibrosis, 
and thrombosis. The most important causes of thrombotic microangiopathies (both HUS and 
thrombotic thrombocytopenic purpura [TTP]) are shown in Table 1.1.1-3  
 
Table 1.1. Causes of thrombotic microangiopathy (hemolytic uremic syndromes and thrombotic 
thrombocytopenic purpura). 
Infectious 
Infection with Shiga-like toxin producing Escherichia coli (STEC-HUS) 
Infection with neuraminidase producing Streptococcus pneumoniae (SP-HUS) 
Human Immunodeficiency virus (HIV) 
Complement dysregulation 
Genetic abnormalities in complement (regulating) proteins 
Acquired defects (autoantibodies against FH) 
Mutations in coagulation genes 
Mutations in thrombomodulin (THBD), diacylglycerol kinase ε (DGKE), or plasminogen (PLG) 
ADAMTS13 deficiency 
Mutations in ADAMTS13 
Autoantibodies against ADAMTS13 
Clinically associated with 
Systemic diseases: SLE, antiphospholipid syndrome, defective cobalamin C metabolism 
Medication: ticlopedin, mitomycin, bleomycin, cysplatin, quinine, tacrolimus, cyclosporin, rifampicin, 
clopidopogrel, bevacizumab, interferon γ 
Malignancies: chemotherapy 
Viruses: cytomegalovirus, parvovirus 
Pregnancy: oral contraceptives, pre-eclampsia, HELLP syndrome 
Glomerulopathies: C3 glomerulopathy 
Bone marrow transplantation: radiation, medication, graft vs host disease 
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; FH, 
complement factor H; HELLP, haemolysis, elevated liver enzymes and low platelets; MPGN, membranoproliferative 
glomerulonephritis; SLE, systemic lupus erythematosus. 
 
In recent years, the knowledge of the pathogenesis of the hemolytic uremic syndrome has extended 
tremendously as shown in Figure 1.1.4 In more than 90% of the cases, the disease is triggered by an 
infection with Shiga-like toxin producing Escherichia coli (STEC). Non-STEC-HUS is seen in 5-10% of all 
pediatric HUS cases, can appear at any age and may be sporadic or familial. These patients have a 
poor prognosis with a high mortality and morbidity in the acute phase of the disease and 
The hemolytic uremic syndrome (HUS) is a rare and severe disease, characterized by the triad 
hemolytic anemia, thrombocytopenia, and acute renal failure. HUS is characterized histologically by 
thrombotic microangiopathy (TMA): vascular abnormalities with glomerular endothelial damage, 
swelling of the endothelium, endothelial detachment of the basement membrane, intima fibrosis, 
and thrombosis. The most important causes of thrombotic microangiopathies (both HUS and 
thrombotic thrombocytopenic purpura [TTP]) are shown in Table 1.1.1-3  
 
Table 1.1. Causes of thrombotic microangiopathy (hemolytic uremic syndromes and thrombotic 
thrombocytopenic purpura). 
Infectious 
Infection with Shiga-like toxin producing Escherichia coli (STEC-HUS) 
Infection with neuraminidase producing Streptoco cus pneumoniae (SP-HUS) 
Human Immunodeficiency virus (HIV) 
Complement dysregulation 
Genetic abnormalities in complement (regulating) proteins 
Acquired defects (autoantibodies against FH) 
Mutations in coagulation genes 
Mutations in thrombomodulin (THBD), diacylglycerol kinase ε (DGKE), or plasminogen (PLG) 
ADAMTS13 deficiency 
Mutations in ADAMTS13 
Autoantibodies against ADAMTS13 
Clinically a sociated with 
Systemic diseases: SLE, antiphospholipid syndrome, defective cobalamin C metabolism 
Medication: ticlopedin, mitomycin, bleomycin, cysplatin, quinine, tacrolimus, cyclosporin, rifampicin, 
clopidopogrel, bevacizumab, interferon γ 
Malignancies: chemotherapy 
Viruses: cytomegalovirus, parvovirus 
Pregnancy: oral contraceptives, pre-eclampsia, HE LP syndrome 
Glomerulopathies: C3 glomerulopathy 
Bone ma row transplantation: radiation, medication, graft vs host disease 
A breviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; FH, 
complement factor H; HE LP, haemolysis, elevated liver enzymes and low platelets; MPGN, membranoproliferative 
glomerulonephritis; SLE, systemic lupus erythematosus. 
 
In recent years, the knowledge of the pathogenesis of the hemolytic uremic syndrome has extended 
tremendously as shown in Figure 1.1.4 In more than 90% of the cases, the disease is tri gered by an 
infection with Shiga-like toxin producing Escherichia coli (STEC). Non-STEC-HUS is seen in 5-10% of all 
pediatric HUS cases, can appear at any age and may be sporadic or familial. These patients have a 
poor prognosis with a high mortality and morbidity in the acute phase of the disease and 
General introduction and outline of the thesis
 1
 12
   Fig
ur
e 
1.
1.
 T
im
el
in
e 
of
 th
e 
ke
y 
ev
en
ts
 in
 th
e 
hi
st
or
y 
of
 th
e 
he
m
ol
yt
ic
 u
re
m
ic
 s
yn
dr
om
e.
 T
hi
s 
fig
ur
e 
ill
us
tr
at
es
 th
e 
pr
og
re
ss
io
n 
in
 re
ce
nt
 y
ea
rs
 o
f t
he
 k
no
w
le
dg
e 
of
 th
e 
un
de
rly
in
g 
ca
us
es
 o
f t
hr
om
bo
tic
 m
ic
ro
an
gi
op
at
hi
es
, i
n 
pa
rt
ic
ul
ar
 H
U
S.
 ‘C
FH
’ s
ta
nd
s 
fo
r c
om
pl
em
en
t f
ac
to
r H
, ‘
CF
HR
’ c
om
pl
em
en
t 
fa
ct
or
 H
 re
la
te
d,
 ‘D
GK
E’
 d
ia
cy
lg
ly
ce
ro
l 
ki
n
as
e 
ε,
 ‘E
M
A’
 E
ur
op
ea
n 
M
ed
ic
in
es
 A
ge
nc
y,
 ’F
DA
’ F
oo
d 
an
d 
Dr
ug
 A
dm
in
ist
ra
tio
n,
 ‘H
U
S’
 h
em
ol
yt
ic
 u
re
m
ic
 s
yn
dr
om
e,
  a
nd
 ‘T
M
A’
 th
ro
m
bo
tic
 m
ic
ro
an
gi
op
at
hy
. A
da
pt
ed
 
w
ith
 p
er
m
iss
io
n 
fro
m
 G
eo
rg
e 
an
d 
Ne
st
er
 (N
 E
ng
 J 
M
ed
 2
01
4;
31
7:
65
4-
66
6)
, C
op
yr
ig
ht
 M
as
sa
ch
us
et
ts
 M
ed
ica
l S
oc
ie
ty
. 
19
73
C
om
pl
em
en
t C
3
de
fic
ie
nc
y 
in
 T
M
A
19
24
Fi
rs
t c
lin
ic
al
 a
nd
 p
at
ho
lo
gi
ca
l
de
sc
rip
tio
n 
of
 th
ro
m
bo
tic
 
m
ic
ro
an
gi
op
at
hy
19
55
Fi
rs
t p
ro
po
sa
l o
f ‘
he
m
ol
yt
ic
ur
em
ic
 s
yn
dr
om
e’
 fo
r c
hi
ld
re
n
w
ith
 re
na
l f
ai
lu
re
, h
em
ol
yt
ic
an
em
ia
, a
nd
 th
ro
m
bo
cy
to
pe
ni
a
19
62
M
ic
ro
an
gi
op
at
hi
c 
he
m
ol
yt
ic
an
em
ia
 w
ith
 th
ro
m
bo
cy
to
pe
ni
a
co
rr
el
at
es
 w
ith
 th
e 
pa
th
ol
og
ic
al
TM
A 
le
si
on
19
75
H
U
S
 c
au
se
d
by
 S
hi
ge
lla
 
dy
se
nt
er
ia
 ty
pe
 I
19
75
Fa
m
ili
al
 T
M
A
19
81
C
om
pl
em
en
t f
ac
to
r H
de
fic
ie
nc
y 
in
 T
M
A
19
83
Fi
rs
t r
ep
or
t o
f E
. c
ol
i
O
15
7:
H
7 
in
 p
at
ie
nt
s 
w
ith
he
m
or
rh
ag
ic
 c
ol
iti
s
19
83
S
hi
ga
 to
xi
n 
pr
od
uc
in
g
st
ra
in
s 
of
 E
. c
ol
i i
n 
H
U
S
19
92
A
ut
os
om
al
 re
ce
ss
iv
e
co
ba
la
m
in
 C
 m
ut
at
io
ns
in
 T
M
A
19
98
C
om
pl
em
en
t f
ac
to
r H
m
ut
at
io
ns
 in
 H
U
S
20
03
M
em
br
an
e 
co
fa
ct
or
 p
ro
te
in
 
m
ut
at
io
ns
 in
 H
U
S
20
04
C
om
pl
em
en
t f
ac
to
r I
m
ut
at
io
ns
 in
 H
U
S
20
05
C
om
pl
em
en
t f
ac
to
r H
au
to
an
tib
od
ie
s 
in
 H
U
S
20
06
C
FH
 a
nd
 C
FH
R
 h
yb
rid
pr
ot
ei
ns
 in
 H
U
S
20
07
C
om
pl
em
en
t f
ac
to
r B
m
ut
at
io
ns
 in
 H
U
S
20
09
C
om
pl
em
en
t C
3
m
ut
at
io
ns
 in
 H
U
S
20
09
Th
ro
m
bo
m
od
ul
in
m
ut
at
io
ns
 in
 H
U
S
19
91
D
oc
um
en
ta
tio
n 
of
ef
fic
ac
y 
of
 p
la
sm
a
ex
ch
an
ge
 in
 T
M
A
20
11
E
cu
liz
um
ab
 re
ce
iv
es
 
FD
A 
an
d 
E
M
A
ap
pr
ov
al
 fo
r a
H
U
S
tre
at
m
en
t
20
14
P
la
sm
in
og
en
 g
en
e
m
ut
at
io
ns
 in
 T
M
A
20
13
D
G
K
E
 m
ut
at
io
ns
 
in
 T
M
A
19
20
s
19
30
s
19
40
s
19
50
s
19
60
s
19
70
s
19
80
s
19
90
s
20
00
s
20
10
s
19
30
s
19
40
s
19
50
s
G
en
er
al
 d
is
co
ve
rie
s 
fo
r T
M
A
S
hi
ga
-to
xi
n 
m
ed
ia
te
d 
H
U
S
C
om
pl
em
en
t-m
ed
ia
te
d 
H
U
S
C
oa
gu
la
tio
n-
m
ed
ia
te
d 
H
U
S
M
et
ab
ol
is
m
-m
ed
ia
te
d 
H
U
S
Tr
ea
tm
en
t i
nn
ov
at
io
ns
S
. p
ne
um
on
ia
e-
m
ed
ia
te
d 
H
U
S
19
71
H
U
S
 c
au
se
d 
by
S
tre
pt
oc
oc
cu
s
pn
eu
m
on
ia
e
Chapter 1
 13
progression to end stage renal disease (ESRD) in 50% of the cases.5, 6 Causes of this so-called atypical 
HUS have been identified, as shown in Table 1.1, including disorders of complement regulation  
(aHUS) and various non-enteric infections such as Streptococcus pneumoniae infections (SP-HUS). 
Viruses, malignancies, drugs, bone marrow and kidney transplantation, pregnancy, and systemic 
diseases are associated with the disease as well.  
 
1.1. STEC infection and the hemolytic uremic syndrome  
 
1.1.1. Current opinions on the pathophysiology of STEC-HUS 
The most common cause of the hemolytic uremic syndrome in childhood is an infection with Shiga-
like toxin producing bacteria. Usually this is STEC, but Shigella dysenteriae type 1 has been reported 
to cause a number of cases of HUS as well.7,8 The reservoir of STEC is mainly the gut of cattle, in 
which bacteria are harmless. Fecal contamination of meat in slaughterhouses (especially ground 
beef), biological food product (e.g. dairy products, fruit, and raw vegetables), and water can cause 
the bacteria to reach the human food chain. Person-to-person transmission have been described as 
well.9, 10 After oral ingestion of contaminated food and surviving the acidity of the stomach, STEC 
reaches the gut, where it adheres to the enterocytes of the gastrointestinal mucosa.9 This adherence 
will directly lead to upregulation of the production of pro-inflammatory chemokines by the intestinal 
epithelial cells, resulting in an inflammation of the intestine and (bloody) diarrhea.11 By adhering to 
enterocytes, STEC remains in the gut lumen and utilizes a type III secretion system (TTSS), a multi-
component organelle made up of about twenty gene products.12, 13 The TTSS is used to inject 
multiple virulence effector proteins directly into the infected cell to ensure that infected cell remain 
alive.13 Shiga-like toxin (Stx) producing bacteria make various exotoxins, mainly Stx-1 and Stx-2. 
Once Stx reaches the circulation, it has to be transported to the renal endothelium to cause TMA in 
the kidney; Stx, however, has only once been detected in blood of STEC-HUS patients and only in the 
first hours of presentation.14 Many different cell types have been suggested: erythrocytes, platelets, 
polymorphonuclear leukocytes, and peripheral blood monocytes have been mentioned as toxin 
carrier, but the exact carrier has not been identified yet.15-20 Stx1 can induce the synthesis of several 
cytokines in monocytes and these locally produced cytokines may contribute in the pathogenesis of 
HUS.19   
It is assumed that in the kidney, the toxin is internalized into glomerular endothelial cells by binding 
to the globotriaoceramide receptor (Gb3 or CD77).
21 The presence of the inflammatory mediators 
TNFα, IL-1, or LPS increases the availability of Gb3 on endothelial cells, making them more sensitive 
General introduction and outline of the thesis
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for Stx.22 Once bound to Gb3, the toxin is internalized via the Golgi apparatus to the endoplasmatic 
reticulum (ER), a process that is called retrograde transport.23 Stx is able to escape lysosomal 
degradation and becomes toxic to the ribosome after reaching the cytosol. Cleavage of 28S rRNA by 
the A-subunit of the toxin will inhibit protein synthesis, as protein elongation cannot occur. 
Furthermore, in the ER a stress response is induced that signals stress-activated protein kinase and 
apoptosis initiation.23, 24 Eventually, all this can contribute to glomerular endothelial cell damage, 
increased thrombogenecity of the vasculature, platelet activation, and local intravascular 
thrombosis, with STEC-HUS as result. 
 
1.1.2. Epidemiology and clinical course of STEC-HUS 
Although over 200 different serotypes of STEC have been associated with human disease 25, most 
cases of HUS are associated with STEC serotype O157:H7. Other serotypes like O157:H-, O26, O111, 
O103, and O145 have increasingly been mentioned.26-28 The highest incidence of STEC-HUS is seen in 
Argentina (13.9/100,000 children under 5 years of age), which is much higher than in the U.S. where 
the incidence is expected to be 2.1/100,000 in general and 6.1/100,000 in children under 5 years of 
age.14, 29, 30 The disease may be sporadic or present in an outbreak and more cases are seen in 
warmer seasons: about 60% occurs between June and September.30  
In a five year time period (2008-2012), 2964 STEC infections were reported to the Dutch National 
Institute for Public Health and the Environment (RIVM); 1711 isolates were sent in for serotyping.10  
The RIVM confirmed 869 of these isolates to be indeed STEC, of which 35.6% were typed as O157 
and 64.4% as non-O157. A voluntary questionnaire, including demographics, signs and symptoms, 
antibiotic use, and evolution of disease, was completed by 280 STEC patients. HUS was diagnosed in 
13 STEC O157 patients and in four STEC non-O157 patients, with a median age of 3 years (range 0-60 
years) and 29 years (range 2-81 years), respectively. Non-O157-HUS serogroups were O26 (n=2), 
O83 (n=1), and O non-typable (n=1).10 
Only 5% - 15% of the people that are infected with the bacteria develop HUS. In general, young 
children are sensitive for the development of HUS. In the recent German STEC outbreak in 2011, 
however, the world’s largest so far, mostly adults above 20 years and predominantly females were 
affected. This was attributed to the changes in the microbial characteristics of the bacteria (STEC 
O104:H4), which shares virulence characteristics of both typical STEC strains and enteroaggregative 
E. coli strains, indicating that changes in the bacterial characteristics can lead to changes in host 
profile.31 Although a greater proportion of patients infected with STEC O104:H4 eventually 
developed HUS, both the clinical course of individual patients and the mortality (~4%) seemed to be 
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1.1.3. Diagnosis of STEC infection in HUS patients 
An accurate and timely diagnosis of STEC infection in HUS patients provides the potential benefit of 
making the right diagnosis and guiding the clinician’s care of these children. Ideally it should also 
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control and public health disease surveillance. Recommended for diagnosis of STEC is both a culture 
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diagnosis of a STEC infection.34, 40 An overview of diagnostic tools to be performed in patients 
suspected for HUS in shown in Table 1.2. 
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Table 1.2. Overview of investigations to be performed in patients suspected with HUS. 
Underlying cause of TMA Technique 
Disorders of complement regulation  
C3 and C4 levels nephelometry (serum)* 
C3d levels immuno electrophoresis (EDTA plasma) *,† 
FH and FI levels ELISA (serum)* 
Autoantibodies against FH ELISA (serum)* 
Surface expression CD46 FACS (EDTA blood) 
Mutational screening CFH, CFI, CD46, C3, CFB, 
THBD, DGKE, and PLG sequencing analysis (EDTA blood) 
ADAMTS13 deficiency  
ADAMTS13 activity FRETS vWF73 (citrate plasma)* 
Rare HUS causes  
Defective cobalamin metabolism  
- homocystein levels HLPC (potassium-EDTA plasma)*,† 
- methylmalonic acid levels LC-Tandem MS (potassium-EDTA plasma)*,† 
- mutational screening MMACHC sequencing analysis (EDTA blood) 
HIV serology 
Pregnancy pregnancy test 
HELLP syndrome liver enzymes 
Antiphospholipid syndrome anti-phospolipid antibody 
Systemic lupus erythematosus - antinuclear antibody 
 - lupus anticoagulant 
STEC infection Fecal culture and/or rectal swab, stx1 and stx2 detection by PCR/EIA, anti-O157 LPS antibody (ELISA) 
Streptococcus pneumoniae infection culture, PCR, Coombs test, peanut lectin activity test, transferrin isoelectric focusing 
HUS due to medication see Table 1.1 
* Serum and EDTA plasma samples need to be centrifuged as soon as possible after sampling (preferably within 60 minutes).  
† For the analysis of C3d, homocystein, and methylmalonic acid levels, (potassium-) EDTA blood needs to be placed on ice 
immediately after sampling.  
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; CD46, 
membrane cofactor protein; DGKE, diacylglycerol kinase ε; FB, complement factor B; FH, complement factor H; FI, complement 
factor I; EDTA, ethylenediaminetetraacetic acid; EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; FACS, 
fluorescent-activated cell sorting; FRETS vWF73, fluorescence- quenching substrate for ADAMTS13; HELLP, haemolysis, elevated 
liver enzymes and low platelets; HIV, human immunodeficiency virus; HPLC, high-performance liquid chromatography; LC-
Tandem MS, liquid chromatography–tandem mass spectrometry; MMACHC, methylmalonic aciduria and homocystinuria type C 
protein; THBD, thrombomodulin. 
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1.1.4. Treatment options in STEC-HUS  
Treatment of STEC-HUS is still purely symptomatic and is aimed to prevent gastrointestinal, 
hematological, vascular, and renal complications. Within the first four days of diarrhea and no signs 
of renal failure, volume expansion can prevent oligoanuric renal failure and STEC-HUS.41 Many 
patients receive packed red blood cells to correct the low hemoglobin level. Dialysis is indicated in 
case of severe electrolyte imbalance, uremic symptoms, or fluid overload that fails to respond to 
conservative methods.33 Antibiotic treatment in children with an STEC infection is contraindicated: it 
increases the risk of HUS development (RR 14.3, 95% CI 2.9-70.7), probably due to increased toxin 
release by the bacteria and the killing of sensitive but harmless bacteria in the gut, so that the 
virulent STEC can get the upper hand.42  
Many treatments have been tested in clinically controlled trials (Stx-binding agents, intravenous IgG, 
plasma therapy, fibrinolytic agents, corticosteroids, antiplatelet drugs, and antioxidants), but none 
of them has shown to have any effect over placebo in the acute phase of the disease.36. Length of 
anuria (more than 10 days) and prolonged dialysis are the most important risk factors for a poor 
outcome.39 For a good long-term renal outcome, careful blood pressure control and renin-
angiotensin system blockade may be beneficial.33, 43 For the minority who progress into ESRD 
(~3%)39, kidney transplantation is the final option. The outcome  of kidney transplantation in 
children with STEC-HUS is good, with recurrence rates of almost 0% and a graft survival at 10 years 
that is better than in control children whom needed a kidney transplantation due to another 
disease.44 
The use of eculizumab, a complement inhibitor which is approved for atypical HUS, in the treatment 
of STEC-HUS is debated. In most published cases, eculizumab has been administered to most 
severely ill patients in which HUS was already resolving.45, 46 Larger cohorts in the German STEC 
O104 outbreak showed no significant differences on mortality or on signs and symptoms of severe 
TMA and no controlled trial has been conducted so far.47  
 
1.2. Streptococcus pneumoniae and the hemolytic uremic syndrome 
 
1.2.1. Current opinions on the pathophysiology of SP-HUS 
Streptococcus pneumoniae is a Gram-positive, lancet-shaped cocci and a normal inhabitant of the 
human upper respiratory tract. It generally causes no illness, but still is the most common cause of 
pneumoniae, paranasal sinusitis, otitis media, and bacterial meningitis. In 1971, a Streptococcus 
pneumoniae infection was associated with HUS for the first time (Figure 1.1).48  
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The current hypothesis of the pathogenesis of SP-HUS is the desialysation of glycoproteins of red 
blood cells, thrombocytes, and endothelial cells by the bacteria’s neuraminidase, leading to the 
exposure of the Thomson Friedenreich cryptantigen (T-antigen) on the surface structures of these 
cells.48, 49 Naturally occurring circulating IgM antibodies against this T-antigen can bind to the 
exposed T-antigen, resulting in the agglutination of red blood cells in vitro.50 However, the exact role 
of these anti-T-antigen antibodies in the pathogenesis of SP-HUS is not known: T-antigen activation 
can be caused by more than 77 well-defined serotypes, most of them not associated with 
pneumococcal HUS.51 
 
1.2.2. Epidemiology and clinical course of SP-HUS 
SP-HUS is a rare complication that occurs in about 0.4-0.6% of the patients diagnosed with invasive 
pneumococcal disease (IPD); the incidence is highest in children under 2 years.52, 53 As in other 
countries, the incidence of IPD had tremendously declined in The Netherlands since the introduction 
of the 7-valent pneumococcal conjugate vaccine (PCV7) into the Dutch vaccination program in 2006: 
the overall incidence in children <5 years of age decreased from 43.2/100,000 to 18.4/100,000.54 
Since the introduction of PVC7, an increase has been seen in cases associated with nonvaccine-
covered serotypes: for instance, the incidence of serotype 19A infection increased from 1% in the 
prevaccine era to 20% in the postvaccine era.55 This serotype is not covered in the Dutch vaccination 
program by both PCV7 and the nowadays used 10-valent pneumococcal conjugate vaccine Synflorix. 
After the introduction of the pneumococcal vaccination in the US, where serotype 19A is also not 
included in the vaccination program, most SP-HUS cases are now associated with this serotype.56 
SP-HUS usually develops 7 to 9 days after the onset of the symptoms related to the infection; cases 
are associated with pneumonia, empyema, and meningitis.53, 57 The high incidence of empyema (an 
accumulation of pus in a natural existing anatomical cavity), which is found in 51-66% of SP-HUS 
cases associated with pneumonia, suggests that a heavy bacterial load may increase the risk of HUS 
in the setting of pulmonary infection.50, 58 
Patients with SP-HUS are usually younger at presentation and have a more severe disease course 
than patients with STEC-HUS. A higher morbidity (25-50%) and mortality (2-12%) rate has been 
reported over the years as compared to STEC-HUS.50, 57, 58 Patients have more frequent need for 
acute dialysis, require more platelet and red blood cell transfusions, and have a much longer 
duration of thrombocytopenia.50 These are two-to-three times higher rates than in patients with 
STEC-HUS. The mortality rate is highest in patients with pneumococcal meningitis complicated by 
HUS: in literature reports, 28% of the patients with SP-HUS have meningitis, but 88% of the deaths 
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acute dialysis, require more platelet and red blood cell transfusions, and have a much longer 
duration of thrombocytopenia.50 These are two-to-three times higher rates than in patients with 
STEC-HUS. The mortality rate is highest in patients with pneumococcal meningitis complicated by 
HUS: in literature reports, 28% of the patients with SP-HUS have meningitis, but 88% of the deaths 
occurred in this group.53 The poor prognosis in patients with pneumococcal meningitis is thought to 
be coherent with the observation that in severe meningitis the neuraminidase activity in the central 
nervous system is elevated.59  
Because of limited studies and short follow-up periods, the long-term outcome of SP-HUS is not 
clear yet. End-stage renal disease occurs in 10-16% of the patients.57 Percentages of patients that 
remain with sequelae like elevated serum creatinine, proteinuria, hypertension, or neurological 
sequelae range from 16-60%.53, 57 It seems that the greatest risk for the development of long-term 
renal sequelae is the need for dialysis for more than 20 days.56 
 
1.2.3. Diagnosis of SP-HUS 
Diagnosis of SP-HUS can be challenging due to the clinical similarity to disseminated intravascular 
coagulation. The lack of familiarity with SP-HUS by the general pediatrician and other pediatric 
specialists can delay the diagnosis: in one case series, almost every diagnosis was made by a 
nephrologist, and for half of the patients the diagnosis was overlooked by other specialists.56  
Clinical symptoms and laboratory findings involve evidence of hemolytic anemia, thrombocytopenia, 
acute renal failure, a positive result of a peanut lectin activity test, a positive result of a Coombs test, 
a normal of slightly elevated prothrombin time, and a abnormal transferrin isoelectric focussing (IEF) 
pattern (Table 1.2).53 Evidence of Streptococcus pneumoniae in blood or cerebrospinal fluid might be 
absent, as only 10%-30% of the patients with pneumonia have a positive blood culture.56  
The sensitivity of the peanut lectin activity test, which measures the exposure of T-antigen, is very 
high (100%), but unfortunately, the specificity is only 48% for SP-HUS: patients with uncomplicated 
invasive pneumococcal disease and pneumococcus-associated hemolytic anemia will have a positive 
result as well.60 The Coombs test, which detects the T-antigen-antibody interaction at the plasma 
membrane of erythrocytes, is highly specific for the disease (90%) 60, but it is not known what the 
incidence is in other forms of pneumococcal infection. The transferrin IEF in SP-HUS patients differs 
from patterns in other hypoglycosylation diseases, like CDG I and alcohol abuse, and from patterns 
in other forms of HUS, which means that it is possible to dissociate SP-HUS from these clinical 
entities on the basis of transferring IEF.61 
 
1.2.4. Treatment options in SP-HUS 
In SP-HUS, it is essential to control the abnormalities caused by the renal failure, hemolytic anemia, 
and thrombocytopenia by means of transfusion of red blood cells and/or platelets. Dialysis or 
hemodiafiltration is often required to restore fluid and mineral abnormality and to treat the renal 
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failure. Transfusion of washed red blood cells or platelets is preferred, due to the presence of anti-
Thomsom Friedenreich IgM antibodies in unwashed blood products. For the same reason it is 
important to avoid priming the dialysis system with unwashed blood products prior to 
hemodiafiltration in young children.53 The use of fresh-frozen plasma or plasma products is 
associated with increased hemolysis and needs to be avoided.62 To treat the pneumococcal 
infection, antibiotics like vancomycin and an extended-spectrum cephalosporin are needed.63 In 
literature, no evidence is found that plasmapheresis is of any value in the treatment of SP-HUS.  
 
1.3. The complement system and the hemolytic uremic syndrome 
 
1.3.1. Current opinions on the pathophysiology of aHUS 
Already in the seventies of 20th century decreased plasma levels of the complement proteins C3 and 
complement factor B (FB; encoded by the gene CFB) in both sporadic and familial cases of HUS have 
been identified.64 The presence of increased breakdown products of these proteins suggested an 
activation of the alternative pathway of the complement system could be involved in the 
pathogenesis of the disease.65 In the last decade, evidence has been shown between these so-called 
atypical HUS (aHUS) and genetic abnormalities in complement (regulating) genes, resulting in 
hyperactivation of the complement system, eventually leading to glomerular endothelial activation 
and thrombosis. 
 
Activation and regulation of the complement system 
The human complement system is part of the innate immunity and consists of more than 40 plasma 
and membrane-associated proteins. The most important roles of the complement system are the 
recognition of pathogens (opsonization), the activation and chemotaxis of leukocytes, and the 
induction of cell lysis by incorporation of the membrane attack complex (MAC).66, 67 Three activation 
pathways are recognized: the classical pathway, the mannose binding lectin pathway, and the 
alternative pathway. The latter is mostly affected in aHUS. 
To prevent continued and unopposed complement activation on host cells and resulting cell 
damage, the complement system is tightly regulated. Each pathway has its own regulators 
(inhibitors), but some regulators work on more than one pathway (Figure 1.2; inhibitors shown in 
italic). Non-host surfaces that either lack membrane-bound regulators, do not produce their own 
regulators, or cannot bind soluble regulators are attacked and damaged by the complement system.  
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The key regulators of the alternative pathway are complement factor H (protein: FH; gene: CFH), 
complement factor I (protein: FI; gene: CFI), and membrane co-factor protein (protein: MCP or 
CD46; gene: CD46). These complement regulatory proteins are either constitutively present on the 
endothelial cell membrane or are bound by the endothelial glycocalyx. The normal mechanism of 
complement regulation at the cell surface by these regulators is schematically shown in Figure 1.3A. 
 
Mutations in complement genes in aHUS patients 
A loss-of-function mutation in a complement regulating gene, or a gain-of-function mutation in a 
gene that encodes a complement activator, will lead to an uncontrolled activation of the 
complement system, resulting in formation of the membrane attack complex on cell surfaces of 
especially endothelial cells in the microcirculation of the kidney. As a result, endothelial cells are 
activated and damaged and leukocytes are attracted, releasing oxygen radicals and proteinases, 
which can further damage the endothelium. This eventually will result in increased platelet 
adherence and the formation of microthrombi in the kidney, thus explaining the characteristics triad 
of aHUS: acute renal failure, thrombocytopenia, and hemolytic anemia. 
In 1998, Warwicker et al. were the first to describe a mutation in the gene encoding FH in familial 
cases of aHUS.68 Nowadays, a genetic aberration in one of the proteins of the alternative 
complement pathway can be found in at least 50% of the aHUS patients. Mutations, usually 
heterozygous, have been identified in the complement inhibitors FH, FI, CD46, and FHR-5, and in the 
activators C3 and FB (Figure 1.1).69-77 Mechanisms of disease for several mutations are shown in 
Figure 1.3. In several patients, mutations have been identified in more than one complement 
gene.72, 78 In addition, aHUS is associated with the presence of a combination of single nucleotide 
polymorphisms in FH (FHTGTGT haplotype) or CD46 (CD46GGAAC haplotype).
79, 80 Not unexpected, aHUS 
can also be caused by antibodies that impair the action of the complement regulatory proteins. Thus 
far, autoantibodies against FH (αFH) have been identified in aHUS patients.
81 These αFH 
autoantibodies can block the epitopes of FH that are involved in binding to the endothelial cell 
membrane, resulting in defective regulation of the complement at the site of the endothelium, 
which can lead to endothelial damage.82 The development of these αFH antibodies is associated 
with a polymorphic homozygous deletion of complement factor H related proteins (FHR-1 and FHR-
3; encoded by CFHR1 and CFHR3).81 In only a few studies, mutation have been identified in genes 
that are not solely involved in the complement system, but also in the coagulation system (Figure 
1.1). Thrombomodulin (THBD) was the first coagulation gene in which pathogenic mutations were 
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Figure 1.2. Schematic overview of the three activation pathways of the complement system. Activation via the 
classical, lectin, or alternative pathway leads to production of C3 convertases, that can cleave C3 in C3b and the 
anaphylatoxin C3a. Active C3b finally initiates the production of membrane attack complexes that can cause lysis 
of the cells. The regulators of the complement system, important in the protection of host cells against 
complement activation, are shown in italic. Abbreviations: C1-inh, C1 inhibitor; C4bp, C4 binding protein; CR1, 
complement receptor-1; DAF, decay accelerating factor; MAC, membrane attack complex; MASP, mannose 
associated serine protease; MBL, mannose binding lectin; CD46, membrane cofactor protein. 
 
described.73 Thrombomodulin still has a link with the complement system, as it can regulate the 
alternative pathway via the inactivation of C3b by Factor I.73 The second coagulation gene associated 
with aHUS does not have a clear link with the complement system. Loss of function of diacylglycerol 
kinase ε (encoded by DGKE) might result in a prothrombotic state, but the exact mechanism how 
this can result in aHUS is not yet clear.83 At first, DGKE mutations were associated with normal 
complement levels, but recently a homozygous nonsense mutation in DGKE was identified in a 
family with hypocomplementemic aHUS; no other cause of these low complement levels could be 
found in associated complement genes or in the presences of αFH.84 Very recently, mutations were 
identified in a third coagulation protein, plasminogen (PLG), the precursor of plasmin that can 
degrade fibrin clots. In 4 out of 36 aHUS in which next generation sequencing (targeted genomic 
enrichment and massively parallel sequencing) was performed, a potentially pathogenic variation 
was identified in PLG.85 It needs to be mentioned that three of these patients had deleterious 
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identified in a third coagulation protein, plasminogen (PLG), the precursor of plasmin that can 
degrade fibrin clots. In 4 out of 36 aHUS in which next generation sequencing (targeted genomic 
enrichment and massively parallel sequencing) was performed, a potentially pathogenic variation 
was identified in PLG.85 It needs to be mentioned that three of these patients had deleterious 
nonsynonymous rare variants in complement genes as well. In this specific study, PLG had the 
second greatest number of mutations after CFH, but this high mutation rate still needs to be 
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Figure 1.3. Schematic model for the mechanism of alternative complement pathway regulation at host cell 
surfaces. In normal circumstances small amounts of C3b are deposited on cell surfaces, but these molecules are 
rapidly eliminated by FI, with the help of the cofactors FH and CD46 (A). In case of a loss-of-function mutation in 
FH (B) or CD46 (C), deposited C3b on host cells cannot be efficiently be eliminated. This is followed by 
complement activation that can lead to complement mediated damage of plasma exposed cells, such as 
glomerular endothelial cells. In case of a gain-of-function mutation in a molecule that participates in activation of 
the alternative pathway (C3, FB), endothelial cells will be damaged despite the presence of functional regulators 
(D). Adapted with permission from Jokiranta et al (Mol Immunol. 2007;44:3889-3900.), Copyright Elsevier Limited. 
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Incomplete penetrance of aHUS 
Mutations in complement (regulating) genes can be found in healthy family members: the 
penetrance of disease among carriers of mutations in CFH, CFI, and CD46 is approximately 50-60%.29, 
71, 92 This indicates that the genetic aberrations are probably important for the development of 
aHUS, but not the sole cause. Affected patients may carry combined mutations, in more than one 
gene 71, 72, or carry a mutation in combination with the associated FH or CD46 haplotype 
(complotype).92 Family members whom only carried one mutation or no polymorphisms were not 
affected 79, but this could be due to incomplete penetrance as well. Atypical HUS may not occur until 
adulthood, even in patients with multiple genetic defects. This indicates that an environmental 
factor, like a complement trigger, is probably needed to develop the disease. For instance, Caprioli 
et al. reported that in 77% of the patients with a mutation in FH, FI, or CD46, the clinical symptoms 
were preceded by flulike symptoms, gastroenteritis, or other infections71. This was also reported by 
Geerdink et al.93 
 
1.3.2. Epidemiology and clinical features of aHUS 
The incidence of aHUS is not known precisely, but is estimated to be ~2 per million in the United 
States.78 Instead of STEC-HUS, in which in general more pediatric patients are seen, aHUS can arise 
at any age (1 day – 83 years). Patients with DGKE mutations are usually diagnosed before 1 year of 
age and autoantibodies against Factor H are seen mostly in children between 7 and 11 years78; in 
our cohort, all patients with C3 mutation presented with aHUS in adulthood.94 Sporadic and familial 
cases have been identified. In more than half of the cases, the disease is triggered by an infectious 
event, mainly upper respiratory tract infection or diarrhea/gastroenteritis, and fever, making the 
differentiation between STEC-HUS and aHUS sometimes difficult.29, 71, 93 Extrarenal manifestations 
are reported in only 10% to 20% of the patients, mostly neurological95; as in other chronic kidney 
diseases, vascular complications are seen in patients on dialysis (unpublished data Loirat et al.). 
 
1.3.3. Diagnosis of aHUS 
As many clinical symptoms in aHUS overlap those in STEC-HUS, the diagnosis of aHUS is difficult. An 
overview of investigations to be performed in patients with HUS is shown in Table 1.2. STEC 
infection has to be ruled out in pediatric patients and considered in adults, as unusual presentation 
of STEC-HUS can occur, i.e. without diarrhea (~10) or at older age as in the German outbreak.35 The 
presence of ADAMTS13 deficiency needs be investigated to exclude TTP: an activity below 5-10% 
could indicate acquired anti-ADAMTS13 autoantibodies (in the majority of the patients) or a genetic 
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overview of investigations to be performed in patients with HUS is shown in Table 1.2. STEC 
infection has to be ruled out in pediatric patients and considered in adults, as unusual presentation 
of STEC-HUS can occur, i.e. without diarrhea (~10) or at older age as in the German outbreak.35 The 
presence of ADAMTS13 deficiency needs be investigated to exclude TTP: an activity below 5-10% 
could indicate acquired anti-ADAMTS13 autoantibodies (in the majority of the patients) or a genetic 
abnormality. Other rare HUS causes, like a defective cobalamin C metabolism, Streptococcus 
pneumoniae infection, and the HELLP syndrome should be considered and investigated at 
presentation. 
Recent guidelines recommend the screening for complement abnormalities in patients with aHUS.96, 
97 Complement activity (CH50 and AP50) and serological complement components (C3, C4, C3d, FH, 
and FI) can be measured in serum or plasma, drawn before the start of therapy. It must be realized 
that most assays measure the presence and not the activity of the protein. Moreover, abnormalities 
in complement regulation may only occur at the level of the endothelial cell surface, and not 
systemically.98 Therefore, serological levels of individual proteins may be normal in patients with 
complement dysregulation and thus cannot not exclude a genetic complement disorder.5, 71, 99 The 
surface expression of membrane-bound CD46 on mononuclear leukocytes can be investigated by 
fluorescent-activated cell sorting (FACS), but again: normal expression does not rule out impaired 
function of CD46.100 Mutational screening should be performed in the complement and coagulation 
genes that have been associated with aHUS (CFH, CFI, CD46, C3, CFB, CFHR5, THBD, DGKE, PLG), 
irrespective of serum C3, FH, or FI levels. The gene encoding cobalamin C (MMACHC) can be 
screened for abnormalities once a cobalamin C deficiency is detected. The presence of αFH can be 
identified in serum by enzyme-linked immunosorbent assay. An overview of the investigations to be 
performed in patients with aHUS is shown in Table 1.2. 
 
1.3.4. Treatment options in aHUS 
Treatment must be started urgently to be effective, preferably within 24 hours after diagnosis. At 
this moment it takes up to one to three months to perform genetic studies that are needed to 
specify the underlying cause. Furthermore, currently still no complement abnormalities can be 
found in the 40% of patients. Therefore, it is advised to start plasmapheresis, which replaces missing 
or deficient proteins and removes disease causing antibodies, as the first treatment option when the 
diagnosis is still not clear. New treatment options such as complement inhibitors are now available 
as first line treatment in aHUS as well, especially for those patients that do not respond to 
plasmapheresis in the first days. 
 
Plasma therapy 
In the most recent guidelines, it is recommended to start plasmapheresis within 24 hours of 
diagnosis.96, 97 It is suggested to exchange 1.5 times the expected plasma volume (60-75 ml/kg) and 
replace plasma with fresh frozen plasma or virus-inactivated pooled plasma. There are no evidence 
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based treatment schedules for plasmapheresis treatment reported in literature.  As CD46 is a 
membrane-bound protein and a defect CD46 protein can therefore not be substituted by plasma 
therapy, this has limited value in the treatment of aHUS. Remission is achieved anyhow in 80-90% of 
patients with CD46 mutations without plasma treatment.29. However, since it is not known which 
complement genes are involved in the pathogenesis of aHUS at first presentation and since it is 
known that combined mutations in complement genes can occur, plasma therapy still has its place 
in treatment of aHUS. Besides plasmapheresis, avoiding triggers of endothelial injury, such as 
hypertension and hypercholesteraemia, by adequate blood pressure control and the use of statins 
are important treatment options in the acute phase of the disease and should be maintained once in 
remission. 
 
Complement inhibiting therapy: eculizumab 
In 2012, the recombinant, humanized, monoclonal anti-C5 antibody eculizumab (Soliris®, Alexion 
Pharmaceuticals, Cheshire, CT, USA) has been registered for the treatment of aHUS patients by the 
FDA and EMA. Eculizumab specifically binds to C5, thereby blocking the cleavage of C5 into the 
anaphylatoxin C5a and C5b and the formation of the membrane attack complex C5b-9 is prevented 
in vitro (Figure 1.1). In one patient with the acquired pregnancy condition of hemolysis, elevated 
liver enzymes, and low platelets (HELLP) syndrome, however, C5a levels increased despite 
eculizumab treatment, while C5b-9 generation was blocked.101 This indicates that the enzymatic 
generation of C5a in vivo might not be blocked by eculizumab, but further research is needed. 
Eculizumab has been approved worldwide for the treatment of paroxysmal nocturnal 
hemoglobinuria (PNH), a hematological disease associated with loss of regulation of the terminal 
complement pathway on erythrocytes.102 Since the first successful reports of eculizumab treatment 
in aHUS patients in 2005, many reports have followed, describing patients that received eculizumab 
to rescue their native kidneys or to prevent a recurrence in a graft after transplantation (reviewed 
by Loirat et al.78 and Köse et al.103).  
Two international multicentre prospective phase 2 open-label clinical trials in adolescent and adult 
aHUS patients and a retrospective study in children have been conducted so far.104 The results 
showed that thrombocyte levels increased and renal function improved already from the first dose 
of eculizumab. None of the patients required a TMA intervention (plasmapheresis or dialysis) during 
the treatment. Eculizumab was well tolerated in these clinical studies. Adverse effects that were 
most frequently reported were hypertension, upper respiratory tract infection, and diarrhea. 
Treatment with eculizumab does increase the risk of severe infection and sepsis. As immunity 
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to rescue their native kidneys or to prevent a recurrence in a graft after transplantation (reviewed 
by Loirat et al.78 and Köse et al.103).  
Two international multicentre prospective phase 2 open-label clinical trials in adolescent and adult 
aHUS patients and a retrospective study in children have been conducted so far.104 The results 
showed that thrombocyte levels increased and renal function improved already from the first dose 
of eculizumab. None of the patients required a TMA intervention (plasmapheresis or dialysis) during 
the treatment. Eculizumab was well tolerated in these clinical studies. Adverse effects that were 
most frequently reported were hypertension, upper respiratory tract infection, and diarrhea. 
Treatment with eculizumab does increase the risk of severe infection and sepsis. As immunity 
against Neisseria meningitis depends on the terminal complement pathway, prevention of 
meningococcal infection by vaccination or antibiotic prophylaxis is crucial in patients treated with 
eculizumab. Children need to be vaccinated against pneumococcus and Haemophilus influenza as 
well.  
Eculizumab is very expensive: current estimates are up to 500,000 Euro’s per treatment year. The 
burden of two-weekly visits to the hospital for the treatment is high. Although this drug certainly has 
changed the future perspectives of patients with aHUS, many unsolved questions remain: who 
should receive the drug, which optimal treatment schedules should be used, and how long should 
therapy be continued. It is even undecided if prophylactic treatment is needed. Cost effectiveness 
should be evaluated in carefully conducted prospective cohort studies.  
 
Transplantation 
The clinical outcome of renal transplantation in patients with aHUS is dismal. Approximately 50% of 
patients with aHUS will develop recurrent disease and graft loss. There are no clinical predictors for 
the outcome of transplantation, although the use of a calcineurin inhibitor after transplantation is 
associated with an even higher recurrence rate.105 Unfortunately, patients with aHUS are also more 
prone to develop acute rejections, which also affects graft survival. Knowledge of the underlying 
genetic defect is helpful in predicting prognosis. The recurrence risk in patients with a FH mutation is 
75-90%, for patients with a FI mutation this is 45-80%, and in case of a C3 mutation, the risk of an 
aHUS recurrence is 40-70%.106 Recurrences have been seen in patients with FB and thrombomodulin 
mutations, as well. On the other hand, patients with a mutation in the gene encoding the 
membrane-bound CD46 have a low risk to develop a disease recurrence in the graft.  
Knowledge of the underlying genetic defect is also critical when considering a living-related kidney 
transplantation. Until recently, living kidney donations were considered unjustified in patients with 
aHUS: there is not only a high risk of graft failure in the recipient, more importantly the donor may 
be a carrier of the mutation and could develop aHUS due to uncontrolled complement activation 
during the donor procedure.107 If a mutation is identified in the acceptor, family members can be 
screened for this mutation, and only donors without this mutation can be accepted for donation. Of 
note, if no mutations are found, current policy is to not accept any related donor, as genetic 
aberrations may be present in not yet associated genes. 
The burden of endothelial injury in a post-transplantation setting, caused for instance by 
immunosuppresive drugs, viral infections or rejection, might trigger de novo HUS in the presence of 
mild genetic susceptibility to HUS.108 Possible causes of recurrent and de novo post-transplant HUS, 
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both genetic and environmental, are shown in Figure 1.4. Although the influence of environmental 
factors leading to endothelial injury is probably higher in de novo HUS, genetic aberrations in the 
complement system are still found in 30% of the patients diagnosed with de novo post-transplant 
HUS.108 To minimize the environmental risks, adequate control of blood pressure and 
hypercholesterolemia in combination with the prudent use of calcineurin inhibitors during renal 
transplantation is warranted.108 
 
Figure 1.4. Genetic and environmental factors associated with post-transplant HUS. Endothelial injury in the 
graft can occur due to genetic aberrations in the alternative pathway of complement system (more often in 
recurrent post-transplant aHUS) or by environmental factors (more often in de novo post-transplant HUS). The 
presence of the CD46GGAAC haplotype, associated with the pathogenesis of aHUS, in the donor could influence a 
recurrence as well, although this has not been investigated extensively.  
 
1.3.5. Outcome in aHUS  
Without treatment, the prognosis of patients with aHUS is poor, up to 25% of patients may not 
survive the acute phase and up to 50% of the patients progress to ESRD.5, 6 The outcome of disease 
is dependent on the underlying genetic aberrations. Eighty to 90% of the patients with a mutation in 
the membrane-bound CD46 protein often go into remission, although recurrences often occur.29, 71 
In contrast, 60-70% of the patients with a mutation in a fluid phase protein (FH, FI or C3) will 
develop terminal renal failure within one year after diagnosis; in patients with αFH this amount is 
30%.109 Not many patients with an aberration in CFB have been reported yet, but in one study with 
seven aHUS patients of a CFB mutation, six of them lost renal function within two year after 
diagnosis.74 The underlying complement defect also determines whether therapy is needed and if it 
will be effective. For instance, in patients with an CD46 mutation alone, plasma therapy is of limited 
added value: remission is achieved in 80-90% of these patients without plasma treatment.29 Since 
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develop terminal renal failure within one year after diagnosis; in patients with αFH this amount is 
30%.109 Not many patients with an aberration in CFB have been reported yet, but in one study with 
seven aHUS patients of a CFB mutation, six of them lost renal function within two year after 
diagnosis.74 The underlying complement defect also determines whether therapy is needed and if it 
will be effective. For instance, in patients with an CD46 mutation alone, plasma therapy is of limited 
added value: remission is achieved in 80-90% of these patients without plasma treatment.29 Since 
CD46 is a membrane-bound protein, a defect CD46 protein can therefore not be substituted by 
plasma therapy. 
Most recent literature data suggest that aHUS outcome may have improved over the last decade, 
especially in children.109 This improvement already occurred in the era before the introduction of 
complement inhibition therapy and might be related to early and more intensive plasmapheresis 
treatment and improved conservative treatment options. The recent registration of eculizumab has 
dramatically improved the outcome further in aHUS patients: in the vast majority of patients in the 
trials, TMA activity disappeared, plasmapheresis therapy could be stopped permanently, estimated 
glomerular filtration rate increased, and dialysis could be discontinued.104   
 
1.4. The complement system in STEC-HUS and SP-HUS 
 
1.4.1. Complement and STEC-HUS 
The first reports of involvement of the complement system in HUS in general have been published 
before the etiology of STEC-HUS, SP-HUS and aHUS were known. More than thirty years ago, when 
breakdown products of C3 and FB were found in children with HUS. At that time, the different 
causes of HUS were still unknown and it was not clear whether these patients had STEC-HUS or 
not.65 In 1990, however, low serum C3 levels and renal C3 deposition were reported in HUS patients 
preceded by an STEC infection.110 In 2009, a report was published about elevated plasma levels of 
complement fragments of the alternative pathway (only FB and sC5b-9 were measured) in STEC-HUS 
patients during the first month after onset of the disease, but a small research population was used 
(seventeen patients) and only four control patients that were not age-matched were included.111 
Their results were confirmed in a Swedish cohort of 10 STEC-HUS patients, in which C3a and sC5b 
levels were increased in the acute phase of disease and normalized in the convalescent phase.112 
Ståhl et al. also showed complement activation on blood cell particles in STEC-HUS patients.112 So, 
complement activation has clearly been shown in patients with STEC-HUS, but it is not known 
whether this activation is a purely infection-related phenomenon or if it is part of the pathogenesis 
of the disease.  
 
In recent years, investigators have sought for a possible active role of the complement system in 
STEC-HUS by shiga toxin. Orth et al showed the direct binding of purified Stx2 to the main 
complement regulator factor H.113 The binding sites for Stx2 were mapped to short consensus 
repeats (SCRs) 6-8 and 18-20 of FH, both regions that are involved in surface recognition and 
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membrane binding of the protein.114 Binding of Stx2 resulted in a delayed cofactor activity on the 
cell surface, but not in the fluid phase 113, which is also seen for loss-of-function mutations in CFH. 
Stx2 can further modulate the expression of the membrane-bound regulator CD59, but not that of 
CD46 and CD55, on glomerular endothelial cells, resulting in enhanced complement activation on 
the cell surface.115 In vivo, coinfection with Stx2 and LPS resulted in glomerular endothelial C3 
deposition, thrombocytopenia, and renal function impairment in a murine model of STEC-HUS. This 
was not observed in FB-deficient mice, indicating the importance of the alternative complement 
pathway. Stx1 can trigger complement C3 activation at the cell surface in vitro.116 It needs to be 
mentioned that in all these experiments, the used Stx concentrations were much higher than the 
levels that were measured in STEC-HUS patients and the exact role of complement binding and 
activation by Stx1 and Stx2 in humans therefore remains unclear.14 
Not only shiga toxins can manipulate the activation of the complement system. The STEC 
autotransporter EspP was shown to cleave C3/C3b and C5 and decrease complement activation in 
serum.117 The zinc metalloprotease StcE, which is found in STEC O157:H7, is able to downregulate 
the classical complement pathway.118 These examples show that STEC is very well able to 
manipulate complement in multiple ways. 
 
The use of complement inhibition in STEC-HUS has been prompted by a letter to the New England 
Journal of Medicine, in which the treatment of three severely affected HUS patients with 
neurological involvement was described.45 Eculizumab was given late in the disease (5-10 days after 
the onset) and HUS was already resolving in each patient (decreasing LDH and/or rising thrombocyte 
count). Two of the patients also received plasma exchange and/or dialysis prior to eculizumab 
initiation. Therefore, it is unclear from this case series that the improvements were due to 
eculizumab treatment or were a normal recovery process seen in STEC-HUS. Due to this publication 
and the public pressure, the manufacturer made the off-label use of eculizumab in the German 
O104:H4 outbreak in 2011 possible. The exact influence of complement inhibition on the outcome 
of these patients is not clear, but in larger cohorts, no significant differences were seen on mortality 
or on signs and symptoms of severe thrombotic microangiopathy complications.47, 119, 120 In most 
cases, eculizumab was administered to the most severely ill patients (e.g. neurological involvement, 
need for renal replacement therapy) and a selection bias is present. Therefore, the need for a 
randomized controlled trial, in which eculizumab treatment in STEC-HUS is prospectively evaluated, 
is warranted. 
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1.4.2. Complement and SP-HUS 
Animal studies have demonstrated that the complement system has an significant role in immunity 
to pneumococcal infection.121-124 Furthermore, in several microbiology studies, it has been shown 
that Streptococcus pneumoniae have the capacity to bind complement factor H by their produced 
proteins PspC and Tuf, thereby elongating their survival in the host.125-128 Other pneumococcal 
proteins, including the PspC family member Hic and the glycolytic enzyme phosphoglycerate kinase 
can inhibit the formation of the membrane attack complex on the surface of S. pneumoniae.129, 130 
Furthermore, during autolysis of the bacteria, the important virulence factor pneumolysin is 
released, which activates the complement system, leading to complement depletion and reduced 
opsonisation.131  
 
1.5. Aims and outline of this thesis 
 
Dysregulation of the alternative pathway of the complement system due to genetic mutations is 
believed to play an essential role in the pathogenesis of the atypical form of the hemolytic uremic 
syndrome. Complement factor H, the most important regulator of the alternative pathway and 
protector of host cells against complement activation, had been established to be the most frequent 
mutated protein in the genetic analysis of aHUS patients. In earlier studies, it has been shown that 
Streptococcus pneumoniae and STEC both have mechanisms to evade the complement system, 
thereby protecting itself against complement activation. Taken into account: 1. the importance of a 
dysregulation of the complement system in the atypical form of HUS, 2. the knowledge that bacteria 
use these complement regulators to survive in the host and 3. the similarity of the clinical 
manifestations of atypical and infection-related HUS, the aim of this thesis is to study and define the 
role of the complement system in three forms of HUS (STEC-HUS, SP-HUS, and aHUS). If the 
complement system has an important role in the pathogenesis of infection-related HUS as well, new 
therapeutic possibilities, for instance complement inhibitors, may have a place in the treatment of 
STEC-HUS and SP-HUS. 
 
In Section I of this thesis, the mutational screening of genes encoding associated complement 
(regulating) proteins in a research group of 70 aHUS patients will be described. In Chapter 2, we 
examine FH, FI, CD46, and FB, and the presence of autoantibodies against FH; the results of the FHR-
5 screening are shown in Chapter 3. The functional consequences of newly identified C3 mutations 
are investigated in Chapter 4. In nine aHUS patients in which no mutations had been identified 
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previously, we performed next generation sequencing; the results of this study are described in 
Chapter 5. The genotype – phenotype correlation in our pediatric aHUS population has been studied 
in Chapter 6. The difficulties a physician can be faced with during the therapeutic management of a 
patient with both STEC-HUS and hemophilia A are displayed in Chapter 7. 
 
To further define the role of complement dysregulation in all forms of HUS, infection-related or 
atypical, we executed several biochemical studies, of which the results are depicted in Section II of 
this thesis. It is thought that the dysregulation of the complement system in aHUS occurs mostly at 
the level of the glomerular endothelium and not in the fluid phase98, but on the other hand, 
alternative pathway activation products are present of aHUS patients. To further investigate 
complement activation in the circulation and to identify potential biomarkers for diagnosis, in 
Chapter 8 we will evaluate the levels of complement activation in the acute phase and in remission 
in aHUS patients of all ages with the currently available sophisticated methods. As potential 
biomarkers might be able to discriminate between infection-induced HUS and aHUS at time of 
diagnosis, this study is extended to pediatric STEC-HUS, aHUS, and SP-HUS patients, and age-
matched controls in Chapter 9. Although it has been shown that factor H can bind to capsulated 
bacteria such as Streptococcus pneumoniae and Neisseria meningitidis, no comprehensive research 
has been performed on the possibility of complement modulating proteins in STEC. Possible 
mechanisms of the STEC bacteria to evade the complement system are investigated in Chapter 10. 
To test the hypothesis that both a key environmental trigger and defective host complement 
regulation are required for HUS to develop, mice deficient in factor H were infected with an invasive 
and mutated Streptococcus pneumoniae species. In Chapter 11, the results of this study are 
described. Finally, in Chapter 12, a general discussion of the findings reported in this thesis and an 
outline of future perspectives are displayed. 
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Chapter 2
Genetic disorders in complement (regulating) genes in patients 
with atypical hemolytic uremic syndrome
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Abstract 
 
Atypical HUS is thought to be caused by predisposing mutations in genes encoding complement 
(regulating) proteins, such as Factor H (CFH), Factor I (CFI), membrane co-factor protein (MCP or 
CD46), and Factor B (CFB), or by autoantibodies against factor H (αFH) in combination with a 
homozygous polymorphic deletion of the genes encoding complement Factor H related proteins 1 
and 3 (ΔCFHR1/3). The clinical impact of this knowledge is high, as it might be a prognostic factor for 
the outcome of renal transplantations and kidney donations. Mutational screening, by means of PCR 
and DNA sequencing, is performed in the above mentioned genes in a group of 72 aHUS patients. 
Also, the presence of αFH and ΔCFHR1/3  was tested in patients and controls. In 23 patients, a 
genetic aberration in at least one gene or the presence of αFH was found. A heterozygous mutation 
was observed in CFH in nine patients, in CFI in seven patients, and in CD46 in three patients. No 
mutations were observed in CFB. Seven patients presented αFH, of whom five also carried ΔCFHR1/3 
Three patients carried a combined mutation (two patients: CFI and CD46:; one patient: CFI, αFH, and 
ΔCFHR1/ 3). A significant difference between patients and controls was detected for the presence of 
all three associated polymorphisms in CFH. Genetic abnormalities or the presence of αFH were 
detected in 31.9% of the aHUS patients. Furthermore, bigenic mutations were present, indicating 
that routine DNA mutation analysis of all complement factors associated with aHUS is important.  
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Introduction 
 
Hemolytic uremic syndrome (HUS) is a rare and severe disease, which is characterized by thrombotic 
microangiopathy, hemolytic anemia, thrombocytopenia and acute renal failure.36  In most cases, 
HUS is seen in childhood, is preceded by watery or bloody diarrhea, and is caused by Shiga-like toxin 
(Stx-) producing Escherichia coli (STEC).132, 133 Non-STEC-HUS is seen in 5% to 10% of all HUS cases; 
these patients have a much poorer prognosis. Up to 50% of these so-called atypical cases progress 
to end-stage renal disease (ESRD) and 25% may result in death during the acute phase of the 
disease.37, 134-136 In recent years, a clear link has been established between atypical HUS (aHUS) and 
genetic abnormalities in regulator genes of the alternative pathway of the complement system. 
Mutations have been described in genes encoding complement factor H (protein: FH; gene: CFH), 
complement factor I (FI; CFI), and membrane co-factor protein (MCP or CD46), three important 
regulatory proteins of the alternative pathway.69-71, 80, 136 Up to now, mutations in aHUS patients are 
predominantly found in the CFH gene and in lesser amounts in CFI and CD46. Very recently, the 
presence of autoantibodies against FH (αFH) in combination with a homozygous polymorphic 
deletion of complement factor H-related genes CFHR1 and CFHR3 (ΔCFHR1/3), have been associated 
with aHUS 81, 137, as well as mutations in genes encoding complement factor B (FB; CFB)74, 
complement C375, and thrombomodulin73. 
Knowing the genetic variations present in aHUS patients is important, because it can be of 
prognostic value for the outcome of renal transplantation and kidney donations. In general, around 
50% of the patients that underwent renal transplantation had a recurrence of the disease in the 
graft and graft failure occurred in more than 90% of them.71 However, several groups have shown 
that patients with a mutation in the CFH or CFI gene have a worse outcome after kidney 
transplantation (recurrence: 80-100%) than patients with a CD46 mutation (recurrence 0–20%).71, 
138, 139 
In the present study, mutations in genes encoding (regulating) proteins of the alternative pathway of 
the complement system (CFH, CFI, CD46, and CFB), and the presence of αFH in combination with 
ΔCFHR1/3 were studied in a cohort of 72 Dutch and Belgian patients diagnosed with aHUS. Of 19 
patients, EDTA serum was available to identify the presence of αFH. 
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Subjects and methods 
 
Study population 
The research population consisted of 72 aHUS patients (33 children and 39 adults; age 5 months to 
55 years at onset), referred to the Pediatric Nephrology Centre of the Radboud university medical 
centre. All patients were diagnosed with atypical, non-STEC HUS. The patients were of Dutch or 
Belgian origin, mostly with a Caucasian background. In ten patients from four families the familial 
form of aHUS was identified; the other 62 patients were diagnosed with sporadic aHUS. Permission 
to study DNA material was given by all patients or their parents. 
 
Genetic analysis of genes encoding CFH, CD46, FI, and FB  
Genomic DNA, isolated from peripheral blood leukocytes as described by Miller et al.140,  was 
amplified for CFH (NCBI RefSeq NM_000186), CFI (NM_000204), CD46 (NM_172361), and CFB 
(NM_001710) by means of PCR. Primer data are available on request. Fragments included both DNA 
sequences of the individual exons, and the splice donor and acceptor site. The amplimers were 
subjected to double stranded DNA sequence analysis on an ABI 3130 xl GeneticAnalyzer (Applied 
Biosystems). Sequence analysis was performed using Sequencher 4.8 software. The genomic DNA 
from 82 healthy ethnically matched control individuals was used to confirm novel mutations. A 
mutation is defined as any change in the sequence of a DNA molecule produced in mitosis or 
meiosis; an unknown change that is present in more than one of the 82 controls is considered as a 
polymorphism. Potential pathogenicity of genetic alterations was checked in literature, the HUS 
database (http://www.fh-hus.com), evolutionary conservation, splice site prediction programs 
(http://www.fruitfly.org/seq_tools/splice.html and http://www.cbs.dtu.dk/services/NetGene2), and 
SIFT (http://sift.jcvi.org). 
 
Autoantibodies against Factor H 
Nineteen patients and controls were tested for the presence of αFH by means of ELISA, as described 
before.137 A positive control sample was obtained via Dr. Dragon-Durey (Paris, France). Test results 
were considered positive if they were above twice the standard deviation calculated from controls 
and samples were tested at least three times. 
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Deletion of the genes CFHR1 and CFHR3 
To identify ΔCFHR1/3, genomic DNA was amplified by PCR using specific primers for two regions 
located in a 100-kb region downstream of the gene encoding complement factor H (fragment P1 and 
P2 in Figure 2.1A; R5 and R8 in Zipfel et al.141). Amplification of fragment P1 fails in case of ΔCFHR1/3 
(Figure 2.1B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. (A) Location of amplimers used for identification of deletion of CFHR1 and CFHR3. The last three 
SCRs of CFH, the five SCRs of CFHR3,  the five SCRs of CFHR1, and the first SCR of CFHR4 are indicated by vertical 
bars. The horizontal bar indicates the location of ΔCFHR1/3. The position of the two amplimers (P1 and P2) is 
shown; amplification of  fragment P1 fails in case of a homozygous  polymorphic deletion of CFHR1 and CFHR3. 
(B) PCR results of representative patients with deletion of CFHR1 and CFHR3. The left electrophoresis shows the 
PCR product of fragment P1, the right part of the figure displays the PCR product of fragment P2. ‘M’ indicates 
marker; ‘+’ indicates positive control; ‘-‘ negative control; numbers indicate patient subject codes. 
 
Statistical analyses 
Differences between allele frequencies of the strongly associated polymorphisms in the CFH gene  
among patients, controls, and  the European population (mean from NCBI SNP database), and the 
presence of αFH and ΔCFHR1/3 among patients and controls, were analyzed by calculating the 95% 
confidence intervals (95% CI). For analysis between patients and controls, a 95% CI that did not 
include zero was considered statistically significant.   
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Results 
 
Genetic screening of complement factor H  
The total open reading frame of the CFH gene was analyzed in 72 aHUS patients. Seven potential 
pathogenic heterozygous mutations were found in nine patients, as summarized in Table 2.1 and 
Figure 2.2A. Seven of these patients display sporadic aHUS, while two of them are diagnosed with 
the familial form of the disease. Four aberrations found have not been described before (g.-315c>t, 
g.IVS19+1g>a, p.Arg1203Trp, and p.Arg1206Cys); the remaining three are known disease causing 
mutations. Five independent mutations cluster between short consensus repeat (SCR) 16 and 20 
(Figure 2.2A). Five of the detected mutations are missense mutations, one mutation affects the 
donor site of intron 19, causing a sequence that is not recognized as a splice site, and one mutation 
is located near the binding site of NFκβ, a region probably involved in the transcription of CFH during 
inflammation and infection.79 No mutation was found in more than one of 82 healthy controls. 
The presence of all three strongly associated polymorphisms in CFH (g.-331c>t, c.2016A>G, and 
c.2808G>T)71, 79, 142 was found with a significant difference in 52.8% of the patients, in contrast to 
31% of the controls (95% CI: 0.006 – 0.370; Table 2.2A). Allele frequencies of these polymorphisms 
(Table 2.2B and Table 2.2C) in this cohort were not significantly increased compared to those in the 
European population. Compared to the Dutch controls we investigated, the allele frequencies of 
c.2016A>G and c.2808G>T were significantly increased in patients.  
 
Genetic screening of membrane cofactor protein (CD46) 
As shown in Table 2.1 and Figure 2.2B, two heterozygous mutations were found in CD46 in three 
patients with sporadic aHUS. None of the mutations were found in any of 82 healthy controls, and 
both mutations have been described before.143, 144 The deletion of six nucleotides in exon 6 causes a 
deletion of two amino acids (Asp271 and Ser272) and was observed in two unrelated patients, 
whom also carried an FI mutation (c.454G>A and g.IVS12+5g>t, respectively). The other mutation 
affects the splice donor site of exon 2 and results in a splice site that is not recognized. Both 
mutations are located in the amino-terminal region of CD46, confirming the previously described 
importance of this region for complement regulation.145 
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Table 2.1: Characteristics of mutations found in CFH, CD46, and CFI in 17 out of 72 aHUS patients.   
Exon / intron, 
subject code 
Mutation Effect SCR Known / unknown‡ Subgroup 
Complement factor H 
Promotor      
  40 g.-315c>t Transcription NA unknown Sporadic 
Exon 9      
     21 c.1198C>A p.Gln400Lys 7 known155 Sporadic 
Exon 19      
     47 c.2850G>T p.Gln950His 16 known79, 147 Sporadic 
     61 c.2850G>T p.Gln950His 16 known79, 147 Sporadic 
Intron 19      
     29* g.IVS19+1g>a 
Splice site not  
efficiently recognized† 
NA unknown Sporadic 
Exon 23      
     66 c.3607C>T p.Arg1203Trp 20 unknown Sporadic 
     68 c.3616C>T p.Arg1206Cys 20 unknown Familial 
     69 c.3616C>T p.Arg1206Cys 20 unknown Familial 
     62 c.3628C>T p.Arg1210Cys 20 known151, 152 Sporadic 
Membrane co-factor protein (CD46) 
Intron 2      
     50 g.IVS2+2t>g 
Splice site not  
efficiently recognized† 
NA known144 Sporadic 
Exon 6      
     23** c.811-816delGACAGT p.delAsp271-Ser272   4 known143 Sporadic 
     46** c.811-816delGACAGT p.delAsp271-Ser272   4 known143 Sporadic 
Complement factor I 
Exon 3      
     23** c.454G>A p.Val152Met  unknown Sporadic 
     55 c.454G>A p.Val152Met  unknown Sporadic 
Exon 9      
     45 c.1019T>C p.Ile340Thr  known157 Sporadic 
Exon 10      
       2*** c.1071T>G p.Ile357Met  unknown Sporadic 
Exon 11      
     64   c.1420C>T p.Arg474Stop  known70 Sporadic 
Intron 12      
       1 g.IVS12+5g>t 
Splice score decrease 
from 0.93 to 0.86† 
 known71 Sporadic 
     46** g.IVS12+5g>t 
Splice score decrease 
from 0.93 to 0.86† 
 known71 Sporadic 
Patients are numbered according to an individual number. ‘NA’ indicates not applicable;  ‘*’ patient carrying a CFH mutation and 
a homozygous ΔCFHR1/3  (αFH not tested) ; ‘**’ patients carrying both FI and CD46 mutations; ‘***’ patient carrying an CFI 
mutation and αFH in combination with ΔCFHR1/3 ; ‘†’ according to Fruitfly and NetGene2; ‘‡’ according to www.fh-hus.com.  
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Table 2.2A: Incidence and 95% CI of the three strongly associated polymorphisms in CFH in 72 aHUS patients 
and  82 controls. The percentages in the patient population are compared to the percentages in the control 
group by calculating 95% CI. 
 Patients Controls 95% CI (patients – controls) 
Three polymorphisms 52.8% 31.0%  0.006 – 0.370* 
Two polymorphisms   1.4%   8.3% -0.133 – 0.004 
One polymorphism 13.9% 22.6% -0.206 – 0.033 
No polymorphisms 31.9% 38.1% -0.212 – 0.088 
* statistically significant  
 
Table 2.2B: Allele frequencies of the three strongly associated polymorphisms in CFH in 72 patients with aHUS, 
82 controls, and the European population. 
Genetic variant Alleles Patients Controls Eur. pop.1 
Promotor     
g.-331c>t C 
T 
0.583 
0.417 
0.690 
0.310 
0.857 
0.143 
Exon 14     
c.2016A>G A 
G 
0.681 
0.319 
0.792 
0.208 
0.720 
0.280 
Exon 19     
c.2808G>T G 
T 
0.681 
0.319 
0.804 
0.196 
0.838 
0.162 
1 Mean from SNP Database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=snp) 
 
Table 2.2C: 95% CI of individual allele frequencies of the three strongly associated polymorphisms in CFH in 72 
patients with aHUS. The frequencies in the patient population are compared to the frequencies in the control 
group, as well as to those in the European population. 
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c.2016A>G 0.014 – 0.213* -0.787 – 1.426 -0.686 – 1.102 
c.2808G>T 0.027 – 0.222* -0.787 – 1.426 -0.672 – 1.065 
* statistically significant  
 
Genetic screening of complement factor I 
Five independent heterozygous mutational events in seven patients, all diagnosed with sporadic 
aHUS, were found in CFI (Table 2.1). Two patients carried a mutation in both CFI and CD46. Two of 
the observed mutations have not been described before (p.Val152Met and p.Ile357Met). Four 
mutations are located in the serine protease (SP) domain of Factor I 146: two are missense mutations, 
one mutation introduces a premature stop codon, and one affects the donor site of intron 12  
(Figure 2.2C). The aberration p.Val152Met is located in exon 3, causing a amino acid change in the 
(scavenger recptor cysteine rich (SCRC) domain.27 The mutation at the donor site of intron 12 was 
detected in one of the 82 healthy controls; the other mutations were not found in controls. 
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Figure 2.2. Schematic overview of the locations of described CFH (A), CD46 (B), and CFI (C) mutations in aHUS 
patients of this study. SCR indicates short consensus repeat. (A) The white blocks indicated SCRs that are not 
involved in binding processes; the darker grey SCRs bind to C3b; the lighter grey  SCRs bind to sialic acids and 
heparine sulfate; the  black SCRs bind to C3b and sialic acids and heparine sulfate. (B) STP indicates serine-
threonine-proline-rich domain; TM, transmembrane domain; and CT, cytoplasmatic tail. C: FIMAC indicates 
Factor I membrane attack complex domain; SCRC, scavenger receptor cysteine rich domain;  LDLR, low-density 
lipoprotein receptor domain; and SP, serine protease domain. 
 
Genetic screening of complement factor B 
No potential pathogenic mutational events were found in the CFB gene. Several polymorphisms 
were observed, but none of the allele frequencies differed from the European population (data not 
shown). 
 
Presence of autoantibodies against FH and ΔCFHR1/3 
We found ΔCFHR1/3 in seven of the aHUS patients, compared to three of the 82 controls; a 
difference that is not statistically significant (95% CI: -0.019 – 0.140). EDTA plasma of 19 patients 
was investigated for the presence of αFH. In total, seven patients, all children, displayed αFH, of 
which five had ΔCFHR1/3 as well (Table 3). Two patients only presented αFH. In one patient (P60) 
with ΔCFHR1/3, αFH could not be detected. Of patient 29, in which ΔCFHR1/3 was observed, EDTA 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20NH2 COOH
A
g.-315c>t p.Gln400Lys p.Gln950His
p.IVS19+1g>a
p.Arg1203Trp
p.Arg1206Cys
p.Arg1210Cys
1NH2 2 3 4 COOH
SCRs STP TM CT
B
FIMAC SCRC LDLR1+2 SP
p.Val152Met p.Ile340Thr
p.Ile357Met
p.Arg474Stop
g.IVS12+5g>t
C
g.IVS2+2t>g p.delAsp271-Ser272
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plasma was not available to test for autoantibodies; this patient carried a CFH mutation as well. In 
one patient (P2), an additional mutation in FI was found previously. In two controls (2/19; 10,5%), 
αFH were present. The difference between the patients and controls for the presence of αFH was 
considered significant (95% CI was 0.006 – 0.520). 
 
Clinical information 
Clinical information was obtained of all patients with a genetic aberration, except for two patients, 
and is shown in Table 2.3. Fourteen patients were younger than 18 years at onset of disease. 
Mutations in CFH, CFI, or CD46 were found in patients of all ages; αFH were only found in children. 
Plasma C3 levels were measured in twenty patients and were low in ten. One patient died during the 
HUS episode. Five patients needed a transplantation (two with a mutation in CFH, one in CFI and 
CD46, two in CFI); in three of them (two with an CFI mutation, one with a CFH mutation) the disease 
recurred in the graft. 
 
Discussion 
 
In 31.9% of the patients (23/72), a genetic alteration in one of the investigated genes (CFH, CFI, 
CD46, CFB) or the presence of αFH was observed. An heterozygous mutational events was found in 
nine patients in CFH (12.5%), in seven patients in CFI (9.7%), and in three patients in CD46 (4.2%). Six 
mutations were unknown genetic alterations, the remaining were known disease causing mutations. 
Seven of nineteen patients were tested positive for the presence of αFH (36.8%); five of these seven 
patients presented ΔCFHR1/3 as well. Remarkably, three of the patients (4.2%) carried a combined 
mutation (CFI and CD46: 2 patients; CFI, and αFH, ΔCFR1/3: one patient). No mutations were found 
in CFB.  
 
Seventy-one percent of the independent mutations (5/7) in CFH cluster between SCR 16 – 20, which 
confirms the previously described importance of the C-terminus of CFH to the pathogenesis of 
HUS.79, 147-150 A mutant FH protein with loss of binding sites for C3b and polyanions shows a loss of 
the capability to degrade endothelial-bound C3b.150 
The mutations p.Arg1203Trp and p.Arg1206Cys probably cause a lower binding to surface bound 
C3b, as they are located in the same binding site for C3b and polyanions as the p.Arg1210Cys 
mutation that has been described before.151-153 These two unknown mutations are not located at a 
highly conserved codon (Figure 3A), but SIFT (http://sift.jcvi.org) predicts that the substitution of a 
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positively charged, hydrophilic arginine to a neutral, hydrophobic cystine at codon 1206 will not be 
tolerated. The patient with the p.Arg1210Cys mutation, does not possess the FHtgtaat haplotype 
associated with increased risk to aHUS in combination with this variation.153 The splice site mutation 
at the first nucleotide after exon 19 (g.IVS19+1g>a) results in a sequence that is not recognized as a 
splice site by the splice site prediction programs. The p.Gln950His variation was detected previously 
and was reported as a mutation.79 In another study it was declared as polymorphism.147 We did not 
detect this aberration in any of our 82 controls. The amino acid located at codon 950 is highly 
conserved, and a change into a polar, positively charged histidine could result in functional loss of 
the protein. The p.Gln400Lys mutation is located in SCR 7 and surrounded by positively charged 
residues that are important in the binding of FH to GAGs and C-reactive protein.154 The mutation 
was previously found heterozygous in the parents (first cousins) of a child whom died 15 days after 
birth, because of severe HUS.155 The final mutation observed in CFH (g.-315c>t) is located near the 
binding site for NFκβ, an important transcription factor of CFH in case of infection and 
inflammation.79 If NFκβ cannot bind properly to the gene, transcription occurs in lesser amount or 
does not occur at all.  
 
As we found a statistically significant difference between the occurence of polymorphisms 
associated with aHUS in patients and controls, it is suggested that carrying all three disease-
associated polymorphisms leads to a higher risk of developing aHUS.  
 
Both mutations found in CD46 were located in the extracellular SCRs with C3b binding and cofactor 
activity. The deletion in SCR 4 causes reduced CD46 levels and a reduced binding of approximately 
50% to C3b compared to controls.143 Reduced protein levels and reduced binding suggests that the 
mutant protein is less expressed on the cell membrane. The splice site mutation g.IVS2+2t>g leads in 
a homozygous form to a deletion of 144 base pairs and 48 amino acids, caused by a splicing of the 
first 45 base pairs of exon 2 onto exon 3.144 
 
Eighty percent of the mutations found in CFI are located in the light-chain SR domain, which cleaves 
the alpha-chains of C3b and C4b.156 The only variation that is not located in this region is the change 
from a valine into a methionine at codon 152. This mutation is located in the SCRC domain: a 
domain for which the function is still unknown, but probably is involved in protein-protein 
interactions, important in the binding of FI to FH and CD46, to ensure cofactor activity of the latter 
two.146 Furthermore, codon 152 is highly conserved through evolution (Figure 2.3B). Remarkably,  
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Figure 2.3: Evolutionary conservation in mammals of codons that were previously unknown for mutations. 
Depicted are the amino acid at codon 1203 and 1206 of FH (A) and codon 152 (B) and 357 (C) of FI. 
 
this unknown change was found in two patients that were adults at onset of the disease, while the 
other CFI mutations were mostly found in children. The splice site variation found in the intron 12, 
resulting in a decrease of the splice score from 0.93 to 0.86 71, was found in two unrelated patients 
as well as in one healthy control. This fact makes it doubtful whether the variation is a mutation or a 
rare polymorphism. The mutation found at codon 340 has been described before.157 It is located at 
A
Patient   SRTGESVEFVCKWGYCLSSRS
Homo sapiens  SRTGESVEFVCKRGYRLSSRS
Pan trogodytes  SRTGETVEFVCKHGYRLSPRS
Macaca mulatta  SRTGEPVEFRCRSGYYLSSNS
Bos taurus  SKTEDTIEFMCQHGYRQLTPK
Equus caballus  SETGDVVEFACKPGYRAKRDS
Sus scrofa  SRTDDTIEFRCRQGYYRRTPL
Ovis aries  SKTEDTIEFTCRYGYRPRTAL
Canis familiaris SQTRDTVEFECIPGYHSKTNN
Rattus norvegicus SQSGENIEFMCKPGYRKFRGS
Mus musculus  TRTDDTIEFTCKRGYRPTTPI
B
Patient   ICKSSWSMREANMACLDLGFQ
Homo sapiens  ICKSSWSMREANVACLDLGFQ
Pongo abelii  ICKSSWSMREANVACLDLGFQ
Pan troglodytes ICKSSWSMREANVACLDLGFQ
Macaca mulatta  VCKSSWSMREANVACLDLGFQ
Bos taurus  VCGDSWSITEANVACIDRGFQ
Equus caballus  VCKRNWSMTQANVACLDLGFQ
Canis familiaris ICKKSWSILEANVACVDLGFQ
Rattus norvegicus ICKNSWSTVEANVACFDLGF-
Mus musculus  ICKNSWSMAEANVACVDLGF-
C
Patient   RAQLGDLPWQVAMKDASG-IT
Homo sapiens  RAQLGDLPWQVAIKDASG-IT
Pongo abelii  RAQLGDLPWQVGIKDASG-IT
Pan troglodytes RAQLGDLPWQVAIKDASG-IT
Macaca fascicularis LAKLGDFPWQVGIKDAKG-IT
Bos taurus  PAKMGEFPWQMAIKEGDK-IH
Equus caballus  EAHVGDFPWQVAIKDVTERIN
Canis familiaris AAVMGDFPWQVAIKENEK-IK
Rattus norvegicus PAEMGDYPWQVAIKDGDR-IT
Mus musculus  PANVGDYPWQVAIKDGQR-IT
p.Arg1203Trp p.Arg1206Cys
p.Val152Met
p.Ile537Met
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the start of the SP domain, where isoleucine is the first amino acid of a structurally conserved region 
of the catalytically active domain; C3b an C4b coactivity are reduced to 0%.158 The nonsense 
mutation p.Arg474Stop has been associated with heterozygous factor I deficiency and normal C3 
levels.70 Finally, the unknown mutation detected at codon 357 is located at a highly evolutionary 
conserved area of the protein (Figure 2.3C), indicating that a transition of isoleucine into methionine 
might influence the function of the protein. 
Seven out of nineteen aHUS patients (of which five patients presented ΔCFHR1/3 as well) displayed 
αFH (7/19; 36.8%). These five patients were all younger than seven years of age at the onset of the 
disease. The absence of FHR-1 and FHR-3 in the blood of a patient again seems to trigger the 
development of specific autoantibodies that bind to the recognition region of FH, and in this way, 
block the binding of FH to C3 convertases, especially in young patients.82 It is important to test all 
remaining patients for the presence of αFH as well.  
 
The mutation frequencies reported here for CFH, CFI, and CD46 are slightly lower than those 
previously described in other cohorts, especially for CFH.71, 136 This is probably due to the fact that 
most of our patients are diagnosed with sporadic aHUS and the frequency of mutations in these 
patients is lower than in patients with familial aHUS (13% - 20% and 32% - 42%, respectively).71, 79 
Differences may also be explained by regional differences between the cohorts. At this time point, 
already 9.7% of the patients (7/72) shows αFH. Therefore, in this aHUS group about the same 
amount of patients possesses αFH as in the cohort reported by Joszi et al (11%; 16/147).81 The 
presence of ΔCFHR1/3 in this patient population (9.7%) is slightly lower than in other cohort studies, 
where a deletion (both homozygous as well as heterozygous) is identified in 16 – 28% of the patients 
with aHUS.81 In this study, a PCR method is used that only identifies a homozygous deletion of 
CFHR1/3 and not heterozygous deletions or a hybrid CFH/CFHR1 gene 141, which may explain the 
difference in results.  
 
Remarkably, we observed several bigenic abnormalities in our aHUS patients. It is therefore 
important to perform routine DNA mutation analysis of all complement (regulating) genes 
associated with aHUS, before decisions concerning future treatment modalities like kidney donation 
and renal transplantation are made. Patients with a potentially pathogenic mutation or a deletion in 
one of the complement regulators should be discouraged to undergo a renal transplantation, 
especially when the mutation is located in CFH or CFI. As shown by other research groups, patients 
with mutations in these genes have a worse outcome after kidney transplantation than patients 
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important to perform routine DNA mutation analysis of all complement (regulating) genes 
associated with aHUS, before decisions concerning future treatment modalities like kidney donation 
and renal transplantation are made. Patients with a potentially pathogenic mutation or a deletion in 
one of the complement regulators should be discouraged to undergo a renal transplantation, 
especially when the mutation is located in CFH or CFI. As shown by other research groups, patients 
with mutations in these genes have a worse outcome after kidney transplantation than patients 
with a CD46 defect.71, 138, 139 In our research population, only one patient has a defect in CD46 alone; 
the other two patients with a CD46 defect also possess a mutation in CFI. It is not yet known what 
the effect of αFH in combination with ΔCFHR1/3 is on the outcome of a renal transplantation or 
donation, but it may be that these patients will have an increased risk of HUS recurrence in the graft 
and plasma exchange in combination with rituximab is recommended prior to and after 
transplantation.159 
 
More than sixty-eight percent (49/72; 68.1%) of the patients in this study present no αFH or a 
genetic aberration in one of the investigated genes. Genetic disorders in other not yet examined 
genes involved in complement activation, like complement C3 and thrombomodulin, could have a 
role in aHUS as well. Further research on genes involved in complement regulation is needed to 
increase the understanding of the pathogenesis of the disease. Finally, this might lead to better 
treatment tailored to the genetic profile of the patients suffering from atypical hemolytic uraemic 
syndrome. 
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Abstract 
 
Atypical HUS (aHUS) is a severe renal disorder that is associated with mutations in the genes 
encoding proteins of the complement alternative pathway. Previously, we identified pathogenic 
variations in genes encoding complement regulators (FH, FI, and CD46) in our aHUS cohort. In this 
study, we screened for mutations in the alternative pathway regulator complement factor H-related 
protein 5 (protein: FHR-5; gene: CFHR5) in 65 aHUS patients by means of PCR on genomic DNA and 
sequence analysis. Potential pathogenicity of genetic alterations was determined by published data 
on CFHR5 variants, evolutionary conservation, and in silico mutation prediction programs. Detection 
of serum FHR-5 was performed by western blot analysis and ELISA. 
A potentially pathogenic sequence variation was found in FHR-5 in three patients (4.6%). All 
variations were located in SCRs that might be involved in binding to C3b, heparin, or CRP. The 
identified CFHR5 mutations require functional studies to determine their relevance to aHUS, but 
they might be candidates for an altered genetic profile predisposing to the disease. 
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Introduction 
 
Thrombotic microangiopathies are a spectrum of syndromes associated with thrombocytopenia and 
multiple organ failure, of which thrombotic thrombocytopenic purpura (TTP) and the hemolytic 
uremic syndrome (HUS) are the most common. HUS is characterized by hemolytic anemia, 
thrombocytopenia, and acute renal failure, and is preceded by an infection with Shiga-like producing 
Escherichia coli (STEC) in 90-95% of the cases.132, 133 Atypical HUS or aHUS, which is not associated 
with STEC infection, is thought to be caused by dysregulation of the alternative complement 
pathway in 50-60% of the cases. Loss-of-function mutations have been identified in the regulators 
factor H (FH), factor I (FI), membrane cofactor protein (CD46, also known as MCP), and 
thrombomodulin, whilst in the complement activation proteins C3 (C3) and factor B (FB) gain-of-
function mutations were found. 69-75 Recently, the presence of auto-antibodies against FH (αFH) 
(particularly common in the presence of polymorphic homozygous deletion of FHR-1 and FHR-3 
[ΔCFHR1/3]) has been associated with aHUS.81 Genetic variations are of prognostic value for the 
outcome of renal transplantation and kidney donation.29 
Complement factor H-related protein 5 (FHR-5) is a member of the FH protein family that consists of 
six structurally and immunologically related proteins, of which FHR-5 was discovered most recently. 
The 65 kDa protein contains nine short consensus repeats (SCRs); SCR1 and 2 show homology with 
the first two SCRs of FHR-1 and FHR-2, SCRs 3-7 share significant homology with SCR10-14 of FH, and 
SCR8-10 are comparable to SCR19 and SCR20 of FH.160 The protein is strongly associated with 
glomerular complement deposits, suggesting a role in complement regulation. It has already been 
shown that SCRs 5-7 can bind to heparin and C-reactive protein (CRP).161 Furthermore, an inhibition 
of the C3 convertase activity in the fluid phase, a cofactor activity for FI-dependent cleavage of C3b 
to iC3b, and binding to C3b in a dose-dependent and saturable manner was demonstrated, although 
these characteristics have not been linked to specific SCRs.160, 162 According to Monteferrante et al, 
genetic aberrations in FHR-5 might have a secondary role in the pathogenesis of aHUS.163 
Genetic aberrations in CFHR5 have already been associated with other glomerular diseases. In dense 
deposit disease (DDD or MPGN type II) three single nucleotide polymorphisms (SNPs) have been 
identified with significantly different allele frequencies in patients164; in CFHR5 nephropathy a 
duplication in the gene has been associated with disease.165 Furthermore, a synonymous SNP might 
have a protective role in the development of age-related macular degeneration (AMD), an eye 
disease associated with complement dysregulation.166 Previously, a cohort of Dutch and Belgian 
aHUS patients was screened for mutations in CFH, CFI, CD46, and CFB, and for the presence of αFH. 
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In 31.9% of the patients, complement deficiencies were found.72 More than 4.5% of the patients 
carried an alteration in more than one gene. Anyhow, for more than 68% of the cohort, no cause of 
the disease could be identified yet. In the present study, the gene encoding FHR-5 was screened for 
genetic aberrations in 65 aHUS patients and FHR-5 levels were evaluated for two of the identified 
sequence variations. 
 
Materials and methods 
 
Study population 
The research population consisted of 65 aHUS patients, referred to the Pediatric Nephrology Centre 
of the Radboud University Nijmegen Medical Centre. The patients were of Dutch or Belgian origin 
with a Caucasian background. In sixteen aHUS patients the familial form was identified; the 
remaining patients are thought to have sporadic aHUS. Permission to study DNA material was given 
by all patients or their parents. 
 
Genetic analysis of gene encoding FHR-5  
Genomic DNA was amplified for CFHR5 (NCBI RefSeq NM_030787.2) by means of polymerase chain 
reaction; primer data are shown in Table 3.1. The primers are specific for CFHR5. The amplimers, 
including the individual exons and the splice donor and acceptor sites, were subjected to double 
stranded DNA sequence analysis on an ABI 3130 xl GeneticAnalyzer (Applied Biosystems, Carlsbad, 
CA, USA). Sequence analysis was performed using Sequencher 4.8 software. Note that the 
nucleotide and amino acid numbering begins with the start site ATG and, therefore, includes the 
signal peptide. Detected genetic aberrations were confirmed on a second PCR product. Genomic 
DNA from more than 145 healthy, ethnically matched control individuals was used to confirm 
sequence variations that might be potentially pathogenic. Data from the 1000 Genomes Project 
(http://www.1000genomes.org), in which almost all known variants with a population frequency of 
at least 1% are listed, and data from the Exome Variant Server (NHLBI Exome Sequencing Project 
(ESP), Seattle, WA; http://evs.gs.washington.edu/EVS/ [March 2012 accessed]), in which results of 
whole exome sequencing of almost 5400 individuals are provided, was checked for the presence of 
identified sequence variations as well. 
Internal duplication or depletions of the first three exons of CFHR5 and the presence of ΔCFHR1/3 
was assessed in mutated patients by multiplex ligation-dependent probe amplification (P236 A1 
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ARMD mix 1; MRC-Holland, Amsterdam, The Netherlands). Copy number variation was not 
interrogated in other patients. 
 
Table 3.1. Oligonucleotides used to screen the coding region of CFHR5 by means of PCR and sequencing 
analysis. Amplimers include individual exons and the splice donor and acceptor sites. 
SCR Forward Reverse 
1 5’-CAACCCTCCATGAACTTTGA-3’ 5’-CCCCTTCAAATTATCCTCAGC-3’ 
2 5’-GTGATTCATCGATGTAGCTCTTT-3’ 5’-TTCCAGCTCCTCTGGTCATT-3’ 
3 5’-TTTTCAAAGTTTTCCTTTCTTAATG-3’ 5’-TTGGAACCGAAAATCAAATAAA-3’ 
4 5’-CACATTAAATTTGTTTCTGCAATGA-3’ 5’-TCAAATTCTTGTTTCATCACTTCT-3’ 
5 5’-AAAGGCAATTAATTTCTAAGTCAAAA-3’ 5’-AATAAAATGAGTGCTTACTCTGAAAA-3’ 
6 5’-TGTGGATGGAGAATGGACAA-3’ 5’-AAGACCTGAATAAATGGATTGACA-3’ 
7 5’-TGCAGATATTTTATTGACATAATTGTT-3’ 5’-TCTTGTAAAGAAGCAACAAGATCAAC-3’ 
8 5’-CCATTTTCCTGAAACACTACCC-3’ 5’-TTGGGGTACAGTGCAACAGA-3’ 
9 5’-AATTATTTGAATTTCCAGACACCTT-3’ 5’-GGGTTATTCTATGAAATTAGTCCAAAA-3’ 
10 5’-CTTAAATGCAATTTCACTATTCTATGA-3’ 5’-GGCTACATAATGGCTA-3’ 
 
In silico evaluation of pathogenicity 
Potential pathogenicity of genetic alterations was checked in literature, evolutionary conservation, 
in silico prediction programs SIFT (Sorting Intolerant From Tolerant; http://sift.jcvi.org/), PolyPhen-2 
(Polymorphism Phenotyping v2; http://genetics.bwh.harvard.edu/pph2/), and Align GVGD 
(http://agvgd.iarc.fr/index.php), and in splice site prediction software (Human Splicing Finder: 
http://www.umd.be/HSF/; SpliceSiteFinder: http://www.genet.sickkids.on.ca/~ali/splicesite 
finder.html). In SIFT, a change resulting in a value below 0.05 was considered to be not tolerated and 
this change might therefore affect protein function. A high classification in Align GVGD (ordered 
from C0 to C65) indicates an aberration that is likely to interfere with protein function. For 
evolutionary conservation, the UCSC Genome Browser (http://genome.ucsc.edu) was used. 
 
Statistical analysis 
Differences between allele frequencies of SNPs found in patients and in the European population 
(Database of Single Nucleotide Polymorphisms [dbSNP]; http://www.ncbi.nlm.nih.gov/SNP/) were 
analyzed by calculating 95% confidence intervals (CI). Differences were considered statistically 
significant if the 95% CI did not include zero. 
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ARMD mix 1; MRC-Holland, Amsterdam, The Netherlands). Copy number variation was not 
inte rogated in other patients. 
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Detection of FHR-5 in serum  
FHR-5 was detected in serum of HUS patients, whom were not in the acute phase of the disease, 
and in pooled normal human serum (NHP) by means of western blotting analysis and by enzyme-
linked immunosorbent assay (ELISA) using a polyclonal rabbit anti-human FHR-5 antibody160 (a kind 
gift from J. McRae, Immunology Research Centre, Melbourne, Australia) and a HRP-conjungated 
polyclonal swine anti-rabbit IgG antibody (Dako Denmark A/S, Glostrup, Denmark). This antibody 
also detects other members of the FH protein family. Serum of eighteen healthy control individuals 
was used to determine a control range in the ELISA; two other controls were used in the western 
blot.  
 
Determination of sC5b-9 values 
The soluble C5b-9 (sC5b-9) complex, also known as the fluid-phase terminal complement complex 
(TCC) or membrane attack complex, is increased in patients with complement activation. sC5b-9 was 
determined by means of ELISA in serum or plasma samples of HUS patients, whom were not in the 
acute phase of the disease, using a human TCC ELISA kit (Hycult Biotech, Uden, The Netherlands; 
catalog number HK328).  
 
Results 
 
Molecular genetic studies in the human gene encoding FHR-5  
The total open reading frame of the CFHR5 gene was analyzed in 65 aHUS patients. Four 
heterozygous sequence variations were found in six patients (Table 3.2). None of the changes were 
found in any of the controls. The p.Lys144Asn variation was previously described as a non-disease 
causing variant in a HUS family163, is present once in the 1000 Genomes Project, and in 10 out of 
5378 individuals (0.2%) of the Exome Variant Server; no RefSNP (rs) number has been assigned to 
this variation. Evolutionary conservation was moderate to high in all cases. Conservation within SCRs 
of FHR-5 was seen for p.Trp436Cys (Figure 3.1). According to SIFT and Align GVGD, protein function 
will be affected by all sequence variations. PolyPhen-2 predicted three of the four changes to be 
probably or possibly damaging; only p.Lys144Asn was predicted to be benign, probably because it is 
not located in a functional domain of the protein, but between SCR 2 and 3. Therefore, this 
aberration is considered as a previously unknown SNP. Previously, a genetic aberration was found in 
CFH in two patients; in one of these patients αFH were also found (Table 3.2). Clinically relevant data 
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of the patients are shown in Table 3.3. No duplications or depletions of the first three exons of 
CFHR5 have been identified (data not shown).  
 
Single nucleotide polymorphisms 
Three known SNPs (rs9427662, associated with DDD164; rs3748557; and rs35662416, associated with 
AMD166), were identified in the coding region of CFHR5, but allele frequencies did not differ 
statistically from the European population (data not shown). Other SNPs associated with DDD or 
AMD were not identified. One unknown change was identified in the 3’ splice site of exon 3 (c.254-
5C>T), but did not result in a change at splice site level. This aberration was therefore considered as 
a not previously described polymorphism. 
 
Detection of FHR-5 and sC5b-9 in serum  
Serum was only available for three patients (P73, P74, and P75). FHR-5 detection by means of 
western blot and ELISA could therefore be performed for only two different variations: p.Leu105Arg 
and p.Lys144Asn. The results of the western blot and ELISA are shown in Figure 3.2 and 3.3. In the 
western blot, it seems that the FHR-5 level in P75 (p.Leu105Arg) may be higher than NHP; the ELISA 
confirms this result. 
In the same three patients, sC5b-9 levels were determined to analyze complement activation. EDTA 
plasma samples were available for P73 and P74; for P75, only a serum sample was available. Results 
are shown in Table 3.2: P75 (p.Leu105Arg) shows increased sC5b-9 levels. 
 
Discussion 
 
Mutational screening of the gene encoding FHR-5 was performed in 65 aHUS patients. Five 
heterozygous genetic aberrations were identified in six patients (9.2%); one of these sequence 
variations (p.Lys144Asn), identified in three patients, is considered as a previously unknown SNP. 
Again, combined complement defects were identified among the patients (CFHR5 and CFH: one 
patient; CFHR5, CFH, and αFH: one patient). 
 
The sequence variation p.Trp436Cys is located in SCR7 of the protein. McRae et al. demonstrated 
that the binding sites for heparin and CRP are located within SCR5-7, although the exact binding 
sites are not identified yet.162 Complement regulation at sites of tissue damage is important to 
prevent complement-mediated damage of host cells. Binding to the polyanion heparin on host cell  
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of the patients are shown in Table 3.3. No duplications or depletions of the first three exons of 
CFHR5 have been identified (data not shown).  
 
Single nucleotide polymorphisms 
Three known SNPs (rs9427662, associated with DDD164; rs3748557; and rs35662416, associated with 
AMD166), were identified in the coding region of CFHR5, but allele frequencies did not differ 
statistically from the European population (data not shown). Other SNPs associated with DDD or 
AMD were not identified. One unknown change was identified in the 3’ splice site of exon 3 (c.254-
5C>T), but did not result in a change at splice site level. This aberration was therefore considered as 
a not previously described polymorphism. 
 
Detection of FHR-5 and sC5b-9 in serum  
Serum was only available for three patients (P73, P74, and P75). FHR-5 detection by means of 
western blot and ELISA could therefore be performed for only two different variations: p.Leu105Arg 
and p.Lys144Asn. The results of the western blot and ELISA are shown in Figure 3.2 and 3.3. In the 
western blot, it seems that the FHR-5 level in P75 (p.Leu105Arg) may be higher than NHP; the ELISA 
confirms this result. 
In the same three patients, sC5b-9 levels were determined to analyze complement activation. EDTA 
plasma samples were available for P73 and P74; for P75, only a serum sample was available. Results 
are shown in Table 3.2: P75 (p.Leu105Arg) shows increased sC5b-9 levels. 
 
Discussion 
 
Mutational screening of the gene encoding FHR-5 was performed in 65 aHUS patients. Five 
heterozygous genetic aberrations were identified in six patients (9.2%); one of these sequence 
variations (p.Lys144Asn), identified in three patients, is considered as a previously unknown SNP. 
Again, combined complement defects were identified among the patients (CFHR5 and CFH: one 
patient; CFHR5, CFH, and αFH: one patient). 
 
The sequence variation p.Trp436Cys is located in SCR7 of the protein. McRae et al. demonstrated 
that the binding sites for heparin and CRP are located within SCR5-7, although the exact binding 
sites are not identified yet.162 Complement regulation at sites of tissue damage is important to 
prevent complement-mediated damage of host cells. Binding to the polyanion heparin on host cell  
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membranes is probably important in positioning of FHR-5 on host cells to regulate complement 
activity at the site of tissue damage. In this aberration, the nonpolar amino acid tryptophan is 
changed into a polar cysteine, which could influence heparin binding. Furthermore, introduction of a 
cysteine at codon 436 might result in new disulfide bonds and therefore in different protein folding.  
The remaining variations are located in SCR2 and SCR3, which are for 37% homologous to SCR6 and 
SCR7 of FH that show binding capacity to C3b and heparin as well.167 A recombinant FHR-5 protein 
fragment containing SCR1-4, however, did not show CRP and heparin binding, while a SCR3-7 
fragment did show binding capacity. Therefore, the involvement of SCR3 and 4 in heparin and CRP 
binding cannot be ruled out, but alone they are not sufficient enough. Binding to C3b has not been 
localized to specific SCRs of FHR-5 yet, but as C3b binding sites are present in SCR6 and 7 of FH, they 
might be present in SCR2 and 3 of FHR-5 as well. 
All variations might result in decreased complement regulation. Ongoing activity of the alternative 
complement pathway will lead to an increased formation of membrane attack complex and to 
increased  attraction of leukocytes to the site of endothelial damage, resulting in local thrombosis 
and inflammation in the glomerular vessels, and eventually to thrombotic microangiopathy and HUS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Detection of FHR-5 in serum samples of mutated patients by ELISA. FHR-5 antigen levels measured 
by ELISA, expressed as percentage in respect to the mean concentration in the control group of 18 healthy 
individuals (P73: 124.8%, P74: 118.5%, P75: 189.7%, pooled human serum: 116.7%). The range within the 
controls is shown (64% - 152%). 
 
The p.Lys144Asn aberration has been described before in two affected sisters and their healthy 
mother in an aHUS family.163 Another affected family member did not possess this aberration, and 
therefore it did not seem to be the primary cause of HUS in that specific family, but it was not found 
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membranes is probably important in positioning of FHR-5 on host cells to regulate complement 
activity at the site of tissue damage. In this aberration, the nonpolar amino acid tryptophan is 
changed into a polar cysteine, which could influence heparin binding. Furthermore, introduction of a 
cysteine at codon 436 might result in new disulfide bonds and therefore in different protein folding.  
The remaining variations are located in SCR2 and SCR3, which are for 37% homologous to SCR6 and 
SCR7 of FH that show binding capacity to C3b and heparin as well.167 A recombinant FHR-5 protein 
fragment containing SCR1-4, however, did not show CRP and heparin binding, while a SCR3-7 
fragment did show binding capacity. Therefore, the involvement of SCR3 and 4 in heparin and CRP 
binding cannot be ruled out, but alone they are not sufficient enough. Binding to C3b has not been 
localized to specific SCRs of FHR-5 yet, but as C3b binding sites are present in SCR6 and 7 of FH, they 
might be present in SCR2 and 3 of FHR-5 as well. 
All variations might result in decreased complement regulation. Ongoing activity of the alternative 
complement pathway will lead to an increased formation of membrane attack complex and to 
increased  attraction of leukocytes to the site of endothelial damage, resulting in local thrombosis 
and inflammation in the glomerular vessels, and eventually to thrombotic microangiopathy and HUS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Detection of FHR-5 in serum samples of mutated patients by ELISA. FHR-5 antigen levels measured 
by ELISA, expressed as percentage in respect to the mean concentration in the control group of 18 healthy 
individuals (P73: 124.8%, P74: 118.5%, P75: 189.7%, pooled human serum: 116.7%). The range within the 
controls is shown (64% - 152%). 
 
The p.Lys144Asn aberration has been described before in two affected sisters and their healthy 
mother in an aHUS family.163 Another affected family member did not possess this aberration, and 
therefore it did not seem to be the primary cause of HUS in that specific family, but it was not found 
 
in 80 screened control individuals. We identified this sequence variation in three aHUS patients, but 
not in any of 146 control individuals, while it is present once in the 1000 Genomes Project and in 
0.2% of the individuals in the Exome Variant Server. We do agree that p.Lys144Asn does not seem to 
be the primary cause of the disease, as P73 and P74 also carry a pathogenic aberration in FH 
(p.Arg1206Cys)72 and the variation did not appear to influence protein levels in serum. The three 
remaining aberrations could still be the primary cause of aHUS in our patients: they were not found 
in our controls, all prediction programs predicts them to be damaging to protein function, and no 
other genetic variations were identified in these patients yet (Table 3.2). The p.Leu105Arg variation 
showed a slight increase in FHR-5 protein levels. The reasons for this are not clear. We do see that 
sC5b-9 levels are altered in the serum of P75, which indicates a increased complement activation. It 
is known that sC5b-9 levels are higher in serum than in plasma, but even in serum of control 
individuals, levels were not higher than 3.5 AU/ml (data not shown). Although no other genetic 
aberration has been identified in this patient, we cannot conclude that the p.Leu105Arg variation is 
indeed the cause of this increase. The exact functions of FHR-5 are still not known and no functional 
tests are available to investigate this, yet.168 
 
It has been shown that FHR-5 has a high affinity for heparin on host cell surfaces, even higher than 
FH.162 On the other hand, its cofactor and convertase inhibitory activity is lower than FH, which 
suggests a specific complement regulation at the site of glomerular endothelial cell surfaces instead 
of in the fluid phase. This is emphasized by the association with glomerular immune deposits. The 
question remains why a dysregulation of the complement system at the cell surface due to 
variations in FHR-5 can result in both FHR-5 nephropathy, a C3 glomerulonephritis, and aHUS, a 
thrombotic microangiopathy. One explanation might be the different locations of the genetic 
aberrations; in CFHR5 nephropathy, a duplication of SCR1 and SCR2 is seen, while in aHUS, variations 
are also identified in SCR3-9. Anyhow, as the exact biological role of FHR-5 in complement regulation 
is still not fully understand, a precise answer cannot be given. 
 
The outcome of plasmapheresis and renal transplantation is correlated with the type of complement 
mutation.29 Patients with aberrations in complement proteins produced in the liver, like FH and FI, 
have a worse outcome after renal transplantation than patients with a mutation in the membrane-
bound CD46. This could be the case in patients with a change in CFHR5 as well, as this soluble 
protein is produced in the liver, although we do see that one of our transplanted patients (P74), with 
both a mutation in CFH and a previously unknown SNP in CFHR5, still had good graft function after 
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one year. Three other patients had a recurrence of the disease in the graft within one year after 
transplantation. Eculizumab, a monoclonal anti-C5 antibody that has positive effects in the 
treatment of aHUS patients 169, might also be a treatment option for aHUS patients with CFHR5 
aberrations.  
 
The prevalence of potentially pathogenic sequence variations in CFHR5 in our cohort (4.6%) are 
higher than in two other screened aHUS cohorts. Monteferrante et al. identified four different 
genetic alterations in 17.7% (8/45) of their cohort, but three of these variations were found in 1.3% 
of the controls as well.163 In an American cohort, a novel mutation was identified in CFHR5 in 2/144 
(1.4%) aHUS patients.76 The differences between these cohorts and ours might be explained by 
regional differences.  
 
In our research population of 65 aHUS patients, the genes encoding FH, FI, CD46, FB, and FHR-5 
were have been screened. In 38.5% (25/65) of the patients, at least one sequence variation was 
identified in one of the complement genes. Five of these patients (7.7%) carried bigenic aberrations. 
Atypical HUS is now considered to be driven by a combination of genetic susceptibility factors 
(mutations and associated polymorphisms) and an environmental trigger. In the remaining patients, 
no genetic aberrations have been found yet, and therefore, further research on genes involved in 
the complement system and the coagulation cascade is needed to increase the knowledge about the 
pathogenesis of aHUS. Understanding how sequence variations influence aHUS susceptibility will 
require detailed functional analysis so that rare sequence variations are not mistaken as disease-
associated changes. As the exact biological role of FHR-5 in HUS and other renal diseases is not 
known yet168, the investigation of the significance of identified sequence variants to disease 
pathogenesis still has to be established. 
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Abstract 
 
Atypical hemolytic uremic syndrome (aHUS) is associated with mutations affecting complement 
proteins and regulators and with autoantibodies against complement factor H. Approximately half of 
the aHUS patients progress to end-stage renal disease. DNA analysis of the risk factor genes is 
important for prognosis of aHUS recurrence after renal transplantation. Mutational screening of C3, 
encoding the central complement component, was performed by Sanger sequencing in 70 aHUS 
patients. Mutated and wild type recombinant C3b proteins were produced and their affinity to 
complement factor H (FH) was analyzed by ELISA. A single novel missense change p.Lys65Gln in C3 
was found in three aHUS patients. The alteration leads to decreased binding of C3b to FH in vitro. All 
three patients acquired the illness as adults and had a first aHUS episode after renal transplantation 
or suffered recurrence of the disease after transplantation. The p.Lys65Gln variation is likely to be 
associated with aHUS after kidney transplantation and, therefore, might be an important prognostic 
factor. 
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Introduction 
 
The hemolytic uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia, 
and acute renal failure.170 In most cases, HUS is preceded by infection with Shiga-like toxin 
producing Escherichia coli (STEC). Five to 10% of all HUS patients acquire the disease without being 
infected with STEC. These atypical HUS (aHUS) patients have a poor prognosis with up to 50% of 
cases progressing to end stage renal disease (ESRD) and up to 25% of lethal outcomes in the acute 
phase.37 Furthermore, HUS can occur due to a variety of causes, including non-enteric infections 
(Streptococcus pneumoniae), use of medication, and pregnancy.171-173 
The aHUS etiology has been linked to ongoing alternative complement pathway activation. In this 
alternative pathway, complement component C3 is spontaneously activated at a very low rate to 
form C3b. The C3b is able to attach to the surfaces of pathogens and host cells, where it binds  
complement factor B (FB), which in turn is cleaved by complement factor D (FD). The resulting 
C3bBb, or C3 convertase, cleaves and activates C3 leading to amplification of the complement 
cascade, to the formation of a membrane attack complex, and, eventually, to cell lysis. At the 
surface of the normal host cells, C3b is cleaved by complement factor I (FI), while complement factor 
H (FH), membrane cofactor protein (CD46/MCP), and complement receptor type 1 act as cofactors. 
In addition, at the surface of the normal host cells, C3 convertase can be dissociated by regulators.66 
Mutations affecting FH, FI, CD46, C3, FB, thrombomodulin, and the presence of autoantibodies 
against FH are associated with aHUS pathogenesis.69-71, 73-75, 80, 81 Complement deficiencies are 
identified in 50-60% of aHUS patients.29, 95 In particular, new C3 mutations affecting C3 convertase in 
a gain-of-function manner were recently described.174, 175  
Etiological analysis of patients with aHUS is very important, especially in renal transplantation, which 
is frequently required in this patient group. For example, patients that carry mutations in genes 
encoding FH or FI are at higher risk of the disease recurrence in the graft (70-90%), whereas such 
probability is much lower for the aHUS patients carrying CD46 mutations (20%).29, 95 Previously, we 
reported prevalence of mutations in FH, FI, CD46, and FB, and autoantibodies against FH in 
Dutch/Belgian aHUS cohort.72 In this study we report C3 variations found in our aHUS patients. 
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Methods 
 
Study population  
The research population consisted of 70 aHUS patients (age 2 months to 52 years at onset of the 
disease), referred to the Pediatric Nephrology Department of the Radboud University Nijmegen 
Medical Centre. All patients were of Dutch or Belgian origin and diagnosed with non-STEC-HUS. In 15 
patients from 10 families, the familial form of aHUS was identified; the other 55 patients were 
diagnosed with sporadic aHUS. Informed consent of all patients or their parents was obtained 
before the DNA analysis. The missense C3 alterations found in patients were also analyzed in 
genomic DNA from 100 healthy ethnically-matched control individuals.  
 
Sequence analysis of the C3 gene 
Genomic DNA was isolated from peripheral blood leukocytes as described by Miller et al.140 
Fragments of the C3 gene (NCBI mRNA RefSeq NM_000064.2, genomic RefSeq NG_009557.1)176 
were amplified from genomic DNA by means of PCR. Primer sequences are available upon request. 
The obtained PCR products included DNA sequences of the 41 individual exons, flanked by the splice 
donor site and the splice acceptor site. The amplimers were subjected to double-stranded DNA 
sequence analysis on an ABI 3130 xl GeneticAnalyzer (Applied Biosystems). Sequence analyses were 
performed using Sequencher 4.8 software (Gene Codes). Sorting Intolerant From Tolerant (SIFT) 
(http://sift.jcvi.org/)177 and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/)178 mutation 
analysis algorithms were used to access potential pathogenicity of C3 changes on protein level. The 
SIFT scores were obtained by submitting C3 protein sequences of Homo sapiens, Bos taurus, Sus 
scrofa, Canis familiaris, Rattus norvegicus, Mus musculus, and Xenopus tropicalis to the program. 
Substitutions with scores below the threshold of 0.05 are considered intolerant by SIFT and are likely 
to affect protein function.  
 
Recombinant C3b production 
A DNA fragment encoding mature wild type C3 protein was cloned into the PCR4-TOPO (Invitrogen); 
the c.193A>C (p.Lys65Gln) and c.481C>T (p.Arg161Trp) sequence variations were introduced using 
the QuikChange method. Subsequently, the C3 variants were subcloned into a modified pUPE 
expression vector (U-Protein Express BV). The wild type and mutant C3 constructs were expressed in 
HEK293-E cells in the presence of furin to insure correct C3 processing 179. After three days of 
expression, medium was collected and centrifuged (1000g, 15 minutes, 4°C), supernatant was used 
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Recombinant C3b production 
A DNA fragment encoding mature wild type C3 protein was cloned into the PCR4-TOPO (Invitrogen); 
the c.193A>C (p.Lys65Gln) and c.481C>T (p.Arg161Trp) sequence variations were introduced using 
the QuikChange method. Subsequently, the C3 variants were subcloned into a modified pUPE 
expression vector (U-Protein Express BV). The wild type and mutant C3 constructs were expressed in 
HEK293-E cells in the presence of furin to insure correct C3 processing 179. After three days of 
expression, medium was collected and centrifuged (1000g, 15 minutes, 4°C), supernatant was used 
in experiments. The expression levels of C3 in the medium were 2-7 μg/ml. C3b was generated from 
C3 using FB and FD. The medium samples containing 1 μg/ml C3 were incubated with 1.8 μg/ml FB 
and 0.13 μg/ml FD (both from Complement Technology) for 2 hours at 37°C. Cleavage of C3a was 
verified by SDS-PAGE.  
 
Binding affinity assay 
The binding affinity assay was done in ELISA setting. Wells of the ELISA plates were coated with 1 
μg/ml of purified FH (Calbiochem). The coated wells were incubated with medium samples 
containing 125, 250, 500, or 1000 ng/ml of wild type or mutant C3b and the presence of C3b was 
detected using horseradish peroxidase (HRP)-conjugated goat antibodies against C3 (MP 
Biomedicals). 
 
Statistical analyses  
The statistical significance of allelic frequencies was analyzed using the two-tailed Fisher's exact test. 
The statistical analysis of the binding affinity assay results was performed using two-way ANOVA. 
The differences with p<0.05 were considered statistically significant.  
 
Results 
 
DNA alterations identified in C3 in three aHUS patients 
The total open reading frame of the C3 gene was analyzed in 70 patients with aHUS. A novel 
missense DNA change c.193A>C, leading to a p.Lys65Gln substitution, was identified in three 
patients in heterozygous form (Figure 4.1a, Table 4.1).  
Figure 4.1. Novel sequence variation found in three aHUS patients. (A) Sequencing results of healthy control 
(upper panel) and patient (lower panel). Location of c.193A>C is indicated by black box. (B) Sequence alignment 
of the C3 protein regions from various species containing Lys65, altered in aHUS patients. Altered amino acid 
position is marked by black box and its number is indicated. 
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Control
Patient
A B
Patient            VTVTVHDFPGQKLVLSSEKTV
Homo sapiens       VTVTVHDFPGKKLVLSSEKTV
Pan troglotydes    VTVIVHDFPGKKLVLSSEKTV
Macaca mulatta     VNLTVWDFPMRKTVLARSQLI
Equus caballus     VTVTVQDFPAKKQVLSSEKTI
Bos taurus    VSVTVHDFPAKKQVLSNENTQ
Sus scrofa         VSVTVHDFPAKRQVLSSETTT
Canis familiaris   VTVTVHDFPAKKQVLFREKTD
Rattus norvegicus  VTVTVQDFL-KKQVLTSEKTV
Mus musculus       VTVTVQDFL-KRQVLTSEKTV
Xenopus tropicalis VEIIIHEFPCKKLNLASAKVT
Danio rerio    VKISVKNFPAKNVEMM-QKTV
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All of the patients had a sporadic form of the disease and did not carry mutations affecting FH, FI, 
CD46, FB, or thrombomodulin, or were positive for autoantibodies against FH. The novel change was 
not found by us among 100 healthy controls, nor is it reported in dbSNP. It is also not reported in 
NHLBI Exome Sequencing Project (ESP), which carries whole exome sequencing data from over 5000 
human exomes (http://evs.gs.washington.edu/EVS/). The p.Lys65Gln alteration affects a conserved 
residue (Figure 4.1b). It has a SIFT score of 0.00 and is predicted as probably damaging by PolyPhen-
2, indicating intolerance and a possible impact on the C3 structure and/or function. We also 
encountered a recently described p.Arg161Trp (referred to by the authors as p.Arg139Trp, while not 
counting the signal peptide) in 11 patients in heterozygous form.175 Interestingly, although this 
change was not found by us among 100 controls, we did detect it in three healthy parents of aHUS 
patients, while the patients themselves did not possess the change. The prevalence of this 
polymorphism among aHUS patients was significantly higher (p=0.01) than among the screened 
healthy individuals.  
 
Table 4.1. Clinical data available for patients carrying p.Lys65Gln. 
‘aHUS’ indicates atypical hemolytic uremic syndrome; ‘ESRD’, end-stage renal disease. 
a C3 normal values: 0.70–1.50 g/L 
b Kidney transplantation related to thrombotic microangiopathy as a result of malignant hypertension 
c Kidney transplantation related to rapidly progressing glomerulonephritis 
 
The aberration p.Lys65Gln decreases C3b binding to FH in vitro  
The altered amino acid is located in the part of the C3 gene encoding C3b, at the interface of the C3b 
and FH domain 4 (Figure 4.2a).180 Lysine, at position 65 in C3b, is in direct contact with the FH 
glutamate at position 245 (Figure 4.2b). These C3b and FH residues are forming a salt bridge, a 
relatively weak ionic bond between positively charged lysine and negatively charged glutamic acid. 
Replacement of a lysine with a glutamine might, therefore, weaken the interaction between FH and 
C3b. To test this hypothesis, recombinant C3 protein, carrying p.Lys65Gln was produced and cleaved 
using FB and FD to yield C3b. Binding of the recombinant mutant and wild type C3b to purified FH 
was compared in ELISA setting (Figure 4.3a). The p.Lys65Gln change resulted in statistically 
Patient Gender Age at onset 
C3 levels in acute 
aHUS phasea 
Transplantation history Outcome 
1 M 40 0.73-0.95 aHUS after transplantationb Partial recovery 
2 F 18 0.48-0.76 
aHUS after transplantationc and 
aHUS recurrence in second graft 
ESRD 
3 M 45 0.5 
Transplantation after aHUS and 
aHUS recurrence in the graft 
ESRD 
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significant (p<0.001) decrease in FH binding when C3b concentration reached 1000 ng/ml. This 
finding indicates that the DNA alteration leads to the weaker affinity of C3b to FH.  
In contrast to the previously reported data 175, in the similar experiment we also observed a weaker 
binding for C3b variant carrying p.Arg161Trp (Figure 4.3b). Although this decrease is less 
pronounced than that of p.Lys65Gln, it is statistically significant (p<0.05). 
Figure 4.2. Location of Lys65 amino acid altered by the missense mutation in the aHUS patients. C3b domains 
are colored in green and FH domains are shown in purple. Amino acid residue mutated in aHUS patients is 
indicated by red spheres. (A) Structure of C3b in complex with FH domains 1 - 4.25 (B) Enlarged image showing 
direct interaction of Lys65 residue of C3b with Glu245 residue of FH. The images were generated using PyMol. 
 
The p.Lys65Gln alteration is found in adult patients with aHUS in a kidney graft 
All patients carrying p.Lys65Gln were adults at the time of the first aHUS episode.  
The first patient was initially diagnosed with thrombotic microangiopathy as result of malignant 
hypertension in 2003. Hemolytic anemia and thrombocytopenia were not found, the thrombotic 
microangiopathy (TMA) diagnosis was made based on the biopsy results. The patient was referred to 
hemodialysis and later received a living-donor kidney from his sister. Five months later, the patient 
developed thrombotic microangiopathy combined with the declining renal function. Serum C3 levels 
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were at the lower border of the normal range (Table 4.1) and the patient was diagnosed with aHUS. 
Incomplete recovery of the kidney function after this episode was achieved. 
The second patient initially suffered from rapidly progressing glomerulonephritis (RPGN) of 
undefined etiology in 2003. The laboratory findings show no hemolytic anemia or 
thrombocytopenia, renal biopsy was not performed, therefore presence of TMA was not 
determined. The patient received a living-donor kidney transplant from her father. She developed 
aHUS in this renal graft and also in the next cadaver kidney transplant. In the third cadaver kidney 
transplant, the patient developed acute tubular necrosis and was referred to hemodialysis. 
Eventually the patient died due to gram-negative septic shock. 
The third patient developed TMA, diagnosed by renal biopsy, in combination with low C3 levels in 
serum. The patient received a kidney transplant, six months later the aHUS recurred in the graft.  
Interestingly, in all three patients aHUS (re)occurred after kidney transplantation. 
 
Figure 4.3. C3b binding affinity to FH. ELISA plates were coated with purified FH, after that the wells were 
incubated with various concentrations of the recombinantly produced wild type and p.Lys65Gln (A) or 
p.Arg161Trp (B) C3b variants. Binding of the C3b variants was detected using antibodies against C3. ELISA results 
are expressed in arbitrary units (AU). The data represent four independent experiments and is presented as 
mean±SE. Significant differences according to ANOVA with p<0.001 (***) and p<0.05 (*) are indicated. 
 
Discussion 
 
In this study, a novel missense sequence variation c.193A>C was found leading to a p.Lys65Gln 
substitution in the C3 gene. The mutation alters a highly conserved amino acid (Figure 4.1b). All of 
the analyzed species carry a lysine at position 65, except for Macaca mulatta, where its place is 
taken by an arginine, which is, similar to lysine, a positively charged hydrophilic amino acid. On the 
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shown by our data, the replacement of lysine with glutamine compromises C3b-FH interaction. It 
might lead to the decreased rate of C3b cleavage by FI and decreased dissociation of C3 convertase 
by FH decay-acceleration activity in vivo. Inefficient complement inactivation at the cell surface 
would result in damage of endothelium of the glomeruli. 
Further experiments should be considered for future analysis to increase impact of functional role of 
mutation, such as measurement of complement activation products in serum of controls and 
patients, carrying the mutation. Furthermore, complement deposition on human glomerular 
microvascular endothelial cells and  human umbilical vein endothelial cells from patient and control 
serum can be compared. 
Clinical data were available for all three patients. All of the patients acquired aHUS in renal 
transplants. This finding is important, because it indicates that the p.Lys65Gln substitution in C3 
might be associated with poor prognosis in renal transplantation.  
The previously described aberration p.Arg161Trp was found in 11 patients and in three healthy 
parents of other aHUS patients that themselves did not possess the change. The incidence of the 
p.Arg161Trp substitution is significantly higher in the aHUS group than among the healthy 
individuals. This indicates that p.Arg161Trp is rather an aHUS-predisposing single nucleotide 
polymorphism than an aHUS-causing mutation. Furthermore, our data indicate a significant 
weakening of the C3b-FH interaction by p.Arg161Trp. This weakening was not observed 
previously.175 Roumenina et al. used a concentration range 0-300 ng/ml of C3b, while in our studies 
we used a broader C3b concentration range and observed a significant weakening of FH binding at 
1000 ng/ml C3b. Our findings provide new insight into the pathogenicity mechanism of p.Arg161Trp, 
a strongly predisposing aHUS polymorphism.  
Previously, we reported genetic aberrations found in CFH, CFI, CFB and CD46 and presence of 
autoantibodies against FH in our aHUS patient cohort.72 In this study, we described a potentially 
pathogenic p.Lys65Gln mutation in the C3 gene in our patients. Moreover, in 11 patients we 
identified a p.Arg161Trp polymorphism, which is strongly predisposing to aHUS. In total, the 
prevalence of C3 changes in Dutch/Belgian aHUS cohort is 20% (14/70). Together with the previously 
reported findings, 48.6% (34/70) of patients in our aHUS cohort display potential disease causing 
alterations in genes encoding complement (regulating) proteins. 
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Abstract 
 
Atypical hemolytic uremic syndrome (aHUS) is a rare, but severe disease that has a heterogeneous 
genetic background. Mutations in several genes encoding (regulating) proteins of the alternative 
complement pathway have been associated with the disorder. Due to the heterogeneity seen in 
aHUS, making a genetic diagnosis via regular methods is relative expensive, labor intensive, and time 
consuming. Whole exome sequencing (WES), in which all coding exons of a genome can be studied 
simultaneously, may be an attractive alternative strategy for mutation scanning in aHUS patients. 
To investigate the clinical utility of WES for genetic testing in aHUS patients, exomes of ten patients 
diagnosed with familial aHUS were captured and enriched using the 50MB Agilent’s SureSelect 
human exome v4 enrichment kit (Agilent, Santa Clara, CA, USA). DNA of one of the patients served 
as a positive control (tested for a CFI mutation). 
More than 47000 sequence variations were identified per patient. On average, ~230 private variants 
were located in an exon or canonical splice site. All were absent in the dbSNP database or present in 
less than 1% of an in-house database. Overall, 10x coverage, i.e. >10 reads anywhere in an exon, of 
associated aHUS genes was 87%. SCR19 and 20 in CFH were not covered at all. The CFI mutation in 
the control patient was detected.  
As one of the more prominent hotspots for mutations in aHUS patients (SCR19-20 in CFH) is not 
sequenced, the sole application of WES is not possible without any adjustments as it will lead to a 
lower diagnostic yield compared to current diagnostic testing. However, next generation sequencing 
(be it in an exome sequencing or targeted gene panel approach) in combination with conventional 
amplicon based sequencing of the missing CFH region and the deep intronic SNPs of aHUS 
associated haplotypes can be used to maintain or even improve current diagnostic yields in a more 
efficient manner. 
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Introduction 
 
The hemolytic uremic syndrome (HUS) is a rare thrombotic microangiopathy, characterized by 
hemolytic anemia, thrombocytopenia, and acute renal failure.170 In more than 90% of the cases, the 
disease is preceded by an infection with Shiga-like toxin producing Escherichia coli (STEC).133 About 
5% to 10% of the cases are not associated with STEC; these atypical HUS (aHUS) cases have a much 
poorer prognosis, with progression into end-stage renal disease in up to 50% of the cases and a 
mortality of 25% during the acute phase of the disease.29 
In recent years, the role of complement regulation in the pathogenesis of aHUS has made important 
progress. The first description of a possible association between the hemolytic uremic syndrome and 
the alternative pathway of the complement system was made in the 1970s and 1980s, when low C3 
levels, but normal C4 levels were identified in HUS patients.64 The first genetic link was made in 1998 
by Warwicker et al., whom identified heterozygous mutations in complement regulator factor H 
(protein: FH; gene: CFH) after linkage analysis in patients with sporadic and familial HUS.68 Since 
then, seven other genes have been associated with the atypical form of HUS (CD46, CFI, CFB, C3, 
THBD, and recently DGKE and PLG), all involved in the alternative complement pathway or in the 
coagulation system.70, 73-75, 83, 85, 143 Autoantibodies against factor H (αFH), which can bind to 
epitopes of FH that are involved complement regulation, have been identified in patients as well.137 
Knowing which genetic variations are present in patients diagnosed with aHUS is important, as this 
knowledge can be of prognostic value for the outcome of kidney transplantation, as well as for 
decision making in donating a kidney to a family member, and for the successful outcome of 
treatment with the complement inhibitor eculizumab83. 
A large heterogeneity is seen in aHUS: already eight genes have clearly been associated with the 
disease, next to predisposing SNP haplotypes in CFH and CD46.80 Furthermore, an incomplete 
penetrance is seen, as healthy family members can have the same mutation as a patient. A 
combination of mutations and at risk haplotypes might be needed for the disease to develop92, but 
probably a trigger for complement activation is needed as well. 
The current strategies to get to a  genetic diagnosis are using standard amplicon based Sanger 
sequencing methods  and are labor intensive, costly, and time consuming when compared to next 
generation sequencing (NGS) based strategies: to screen the entire coding sequence of all currently 
associated genes, 184 exons (>30 kB) need to be sequenced. Although this diagnostic route detects 
causative mutations in 50-60% of the cases, still over 40% of all aHUS patients cannot be 
explained.29 Whole exome sequencing (WES) is a DNA sequencing approach in which in principle all 
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the coding sequences of the genome can be studied in a single experiment.. This approach is of 
great diagnostic value in genetically heterogeneous diseases, as shown in more common diseases as 
intellectual disability181 and hereditary blindness182, but also for rare diseases like mitochondrial 
disorders183. WES might be an attractive alternative routing for mutation scanning in aHUS patients 
as well. Apart from sequencing all coding regions of the associated aHUS-genes WES would also 
allow the discovery of new aHUS genes in mutation negative patients. 
 
Materials and methods 
 
Patient population 
Ten patients diagnosed with familial aHUS (two or more family members with aHUS) were included 
in this study, of which genomic DNA was extracted from blood according to established protocols. 
The associated genes CFH, CFI, CD46, C3, and CFB were screened before by Sanger sequencing, and 
in eight patients the aHUS associated polymorphism rs147859257 in C3 (p.Arg161Trp)94, 175 was 
identified. This variation is also present in healthy family members of aHUS patients94, in the Exome 
Variant Server in which exome results of >6500 persons are available (http://evs.gs. 
washington.edu/EVS/; allele frequency in the European population: 0.6%), and in four non-aHUS 
patients in our in-house database of 1300 exomes (present in two patients with age-related macular 
degeneration [AMD], a complement-mediated eye disorder in which this variation has been seen in 
other AMD patients as well184-186, but also in two patients with mental retardation). Therefore, in 
our opinion, this variation cannot be the sole disease-causing aberration in these patients, but 
rather is a predisposing rare polymorphism. None of the screened patients were positive for αFH.  
One patient with a previously described FI mutation157 was taken along as a positive control. 
Informed consent to study DNA by means of whole exome sequencing was given by all patients or 
their parents according to the guidelines of the ethical committee of the Radboud university medical 
centre (CMO 2012/301). 
 
Whole exome sequencing, data analysis and filtering strategy 
Genomic DNA was extracted from peripheral blood samples and purified according to the 
manufracturer’s protocol using a Qiagen QIAmp blood maxi kit (Qiagen, Venlo, The Netherlands). 
DNA purity and degradation was checked on agarose gels. The 50MB Agilent’s SureSelect v4 human 
exome design (Agilent, Santa Clara, CA, USA) was used to capture and enrich the exomes. After 
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other AMD patients as well184-186, but also in two patients with mental retardation). Therefore, in 
our opinion, this variation cannot be the sole disease-causing aberration in these patients, but 
rather is a predisposing rare polymorphism. None of the screened patients were positive for αFH.  
One patient with a previously described FI mutation157 was taken along as a positive control. 
Informed consent to study DNA by means of whole exome sequencing was given by all patients or 
their parents according to the guidelines of the ethical committee of the Radboud university medical 
centre (CMO 2012/301). 
 
Whole exome sequencing, data analysis and filtering strategy 
Genomic DNA was extracted from peripheral blood samples and purified according to the 
manufracturer’s protocol using a Qiagen QIAmp blood maxi kit (Qiagen, Venlo, The Netherlands). 
DNA purity and degradation was checked on agarose gels. The 50MB Agilent’s SureSelect v4 human 
exome design (Agilent, Santa Clara, CA, USA) was used to capture and enrich the exomes. After 
amplification, a SOLiD4 sequencer (Life Technologies, Foster City, CA, USA) was used to sequence 
the reads.  
By means of the SOLiD BioScope software version 1.3, reads were mapped to the hg19 reference 
genome and they were annotated using an in-house annotation pipeline.181 Synonymous variants, 
deep intronic, intergenic, and UTR variants were excluded, as were variants with less than 15% 
variation and/or less than five variant reads. All variants in genes already associated with aHUS were 
checked for potential pathogenicity. In all other genes, common variants found in dbSNP or present 
in >1% in an in-house database of 1300 exomes were filtered. Remaining non-synonymous or splice 
site variants were prioritized based on a list of possible candidate genes involved in the complement 
system, coagulation system, and innate immunity, and genes encoding components of endothelial 
cells and the glomerular basement membrane (Supplementary information). Potentially pathogenic 
variants were confirmed by Sanger sequencing. 
 
Results and discussion 
 
With the use of exome sequencing we identified on average 48015 variants in our patients. Variants 
that were present in the dbSNP database or deep intronic variants, true substitutions, variants 
present in more than 1% of our in-house database with whole exome results of >1300 individuals, 
and aberrations that had a read percentage of less than 15% were excluded. This resulted on 
average in 228 sequence variants per patient (Table 5.1). The CFI mutation previously detected in 
patient TMA10 and the associated polymorphism in C3 were used as a positive control. Both 
variants were detected using this exome strategy. No other potentially pathogenic sequence 
variations in any of the other candidate genes involved in the complement system, the coagulation 
system, or the innate immunity were identified in our aHUS cohort.  
The overall horizontal coverage of genes previously associated with aHUS was using a SOLiD 
sequencer 82.1% (170/207 exons showed a vertical coverage >10 reads), as shown in Table 5.2. 
Overall coverage of the genes of our candidate list was 80.4% (Supplementary information); in genes 
with only one exon not present, this was usually exon 1. None of the coding exons of CFHR1 and 
THBD showed coverage of 10 reads or more throughout the exon; this is also true for short 
consensus repeats (SCR) 19 and 20 of CFH (Figure 5.1). SNPs located in regions of polymorphic 
deletions of the genes CFHR1 and CFHR3, associated with the presence of αFH81, do show >10x 
vertical coverage.  
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Table 5.1. Number of identified sequence variation with whole exome sequencing on a SOLiD4 sequencer. 
Variants are prioritized according to a work flow previously published.181 Common variants present in dbSNP, 
deep intronic, intergenic, and UTR variants, synonymous variants, variants present in >1% in an in-house 
database of 1300 exomes and variants with less than 15% variation and/or less than five variant reads were 
excluded. 
 HUS1 HUS2 HUS3 HUS4 HUS5 HUS6 HUS7 HUS8 HUS9 HUS10 
Total identified 
variations 49967 48758 47547 46044 47491 47894 49049 47200 47686 48515 
No dbSNP match 2869 2783 2782 2698 2806 2666 2654 2588 2683 2848 
Present in exon or 
canonical splice site 750 735 753 763 776 701 692 690 664 731 
False substitution 557 536 527 566 557 522 489 516 497 543 
Present in <1% of 
in-house database 304 271 281 311 306 258 217 240 243 263 
% reads >15% 255 242 239 255 262 217 187 197 199 223 
 
Lack of coverage in the SCR19 and 20 of CFH posses a potential problem if one wants to use WES as 
the main clinical sequencing approach. More than 100 different mutations have been identified in 
CFH in aHUS patients and >50% of these are located in SCR20.78 If this part of the gene is not 
detected using WES, the diagnostic yield of this approach will be low. Furthermore, a number of 
SNPs of the associated haplotypes in CFH and CD46 are in deep intronic locations (i.e. rs2796267, 
which is located 547 bases before the first coding nucleotide of CD46) and are also not detected 
simply because these deep intronic targets are missing in the design. 
 
 
 
Figure 5.1. Representative visualization of the lack of coverage of exon 22 (A) and exon 23 (B) of CFH, the 
hotspot for mutations in aHUS, after exome sequencing on a SOLiD4 sequencer. The coding regions of the 
exons and the locations where reads are present in the patients are depicted. 
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There are several other possible reasons why we might not have identified genetic aberrations in 
other genes. First, in the last few years, the dbSNP database has grown tremendously due to next 
generation sequencing. This might impact filter strategies. For instance, the p.Arg1210Cys variant in 
CFH, which clearly influences the binding of FH to C3b152, nowadays has a dbSNP number 
(rs121913059) even though it has a frequency in the European population of only 0.03% (2/6501 in 
the Exome Variant Server, http://evs.gs.washington.edu/EVS/), and based on that would have been 
excluded from our candidate list. All identified variations in associated genes (Table 5.2), including 
those with a dbSNP number, have been checked for pathogenicity., Second, it is very well possible 
we discarded a pathogenic mutation in one of the other candidate genes while prioritizing the 
identified variants. Third, a disease causing variant outside the coding sequences or the presence of 
copy number variations (CNVs) can be other reasons why we were unable to identify the genetic 
cause of aHUS in our patients. This shows the importance to develop robust diagnostic filter 
strategies and to improve in algorithms to detects clinical relevant variants or CNVs. 
 
Table 5.2. Coverage of genes associated with atypical hemolytic uremic syndrome after whole exome 
sequencing on a SOLiD4 sequencer and a HiSeq2000. A read depth threshold of 10 reads within the entire exon 
was used be called covered. 
Gene Number of exons Percentage covered (>10 reads) on a SOLiD4 sequencer 
Percentage covered (>10 reads) 
on a HiSeq2000 
CFH 23 86.9% (20/23) 86.9% (20/23) 
CFI 13 100% (13/13) 100% (13/13) 
CD46 14 100% (14/14) 100% (14/14) 
C3 41 95.1% (39/41) 97.6% (40/41) 
CFB 18 100% (18/18) 100% (18/18) 
THBD 1 0% (0/1) 100% (1/1) 
CFHR1 6 0% (0/6) 66.7% (4/6) 
CFHR2 5 80.0% (4/5) 80.0% (4/5) 
CFHR3 6 50.0% (3/6) 66.7% (4/6) 
CFHR4 10 80.0% (8/10) 80.0% (8/10) 
CFHR5 10 90.0% (9/10) 90.0% (9/10) 
ADAMTS13 29 79.3% (23/29) 93.1% (27/29) 
DGKE 12 81.8% (9/11) 100% (11/11) 
PLG 19 52.6% (10/19) 68.4% (13/19) 
Overall percentage of exons covered 82.1% (170/207) 89.9% (186/207) 
 
The described data set was obtained through exome sequencing on a SOLiD4 sequencer and the 
bioscope software,. In the meantime however, other NGS-sequencing platforms and enrichment kits 
have been introduced The Illumina HiSeq2000, for instance, is now routinely used for clinical exome 
sequencing with  a minimal median coverage of 75x throughout the exome compared with only ~30 
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x on a SOLiD4 sequencer. Also, coverage in aHUS candidate genes has increased tremendously using 
the HiSeq2000 (THBD for instance is now completely covered with this approach; Table 5.2), 
However,  exon 23 of CFH is still shows lack of complete horizontal coverage  (Figure 5.2).  
A recent best practice guideline of the Dutch Society for Clinical Genetic Laboratory Diagnostics187, 
recommend to use diagnostic yield (the established percentage of molecular diagnoses, also 
explained as the number of patients that receive a molecular confirmation) as a selection criterion 
for the performance of NGS based testing. The guideline proposes that a list of ‘core disease genes’ 
should be used containing essential/critical genes for a disease, in this case the associated genes of 
Table 5.2. To be able to implement an NGS-based, the  proposed test should result in a diagnostic 
yield that at least matches that of Sanger sequencing, with the same sensitivity and specificity. As 
exon 23 of CFH is not covered with WES, even with newer techniques than used for this manuscript, 
you miss the disease-causing mutation in up to 7.5% of the patients.78 Thus, if we follow this 
guideline the sole application of WES alone will lead to a lower diagnostic yield and implementation 
of WES as a sequencing strategy is not justified yet. The only way to overcome this issue is to use 
Sanger sequencing to complete mutation analysis of the essential missing coding sequences. 
As an alternative NGS approach, one could design a targeted  analysis of the 207 exons of the core 
disease gene list using a benchtop sequencer, i.e. the iontorrent PGM (Thermofisher) or the MiSeq 
(Illumina), Sanger sequencing might still be needed to cover exons in regions that are difficult to 
sequence by NGS, but the overall time to results is likely much faster when compared to  WES. Also 
the capacity on these benchtop sequencer might be a more cost effective way to get to diagnostic 
valid results. Whole genome sequencing, although an option in the future as well, is in terms of 
efficiency and costs not yet an attractive alternative to exome sequencing approaches.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Visualization of the lack of coverage of exon 23 
of CFH after exome sequencing on an Illumina HiSeq2000. 
The coding region of the exon and the locations within the 
exon with a read depth threshold of 10 are depicted. 
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For now, we propose a diagnostic routing consisting of a combination of amplicon based (Sanger) 
sequencing of the CFH region (at least SCR20 and the complete coding region of CFHR1-5) and the 
deep intronic SNPs of the associated haplotypes, in combination with a NGS based gene panel 
targeting the associated aHUS genes. This strategy will likely match the diagnostic yield to at least 
that of Sanger sequencing only, but it will be achieved in a time and cost effective manner. 
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Supplementary information.  
 
List of candidate genes encoding proteins of the complement system, coagulation system, and innate 
immunity, endothelial cell components, and glomerular basement membrane components. For each gene, the 
percentage of covered exons for P1 on a SOLiD4 sequencer is shown. A vertical coverage of >10 reads over the 
entire exon was used to call an exon completely covered. Genes of which exon 1 was not present, are indicated 
with an asterisk. 
Name Coverage Name Coverage Name Coverage Name Coverage 
ACAN 55.6% (10/18)* CD74 100.0% (6/6) FLT4 93.3% (28/30)* ITGB5 80.0% (12/15)* 
ACE 72.0% (18/25)* CD79A 80.0% (4/5) FN1 78.2% (36/46)* ITGB6 80.0% (12/15) 
ADAMTS2 90.1% (20/22)* CD79B 100.0% (6/6) GP1Ba 50.0% (1/2)* ITGB7 87.5% (14/16)* 
ADAMTS13 79.3% (23/29) CD93 50.0% (1/2) GP6 87.5% (7/8) ITGB8 78.6% (11/14) 
ADAMTS17 86.4% (19/22)* CD97 72.2% (13/18) GPC1 77.8% (7/9)* KDR 96.7% (29/30)* 
ADAMTS19 95.7% (22/23) CFB 100.0% (18/18) GPC2 50.0% (5/10)* LY96 80.0% (4/5) 
ADAMTS20 94.9% (37/39) CFD 20.0% (1/5)* GPC3 77.8% (7/9)* MASP1 96.8% (15/16) 
AGT 100.0% (4/4) CFH 86.9% (20/23) GPC4 88.9% (8/9) MASP2 72.7% (8/11)* 
AGTR1 50.0% (1/2)* CFHR1 0.0% (0/6)* GPC5 75.0% (6/8)* MBL2 75.0% (3/4)* 
APOB 93.1% (27/29)* CFHR2 80.0% (4/5) GPC6 77.8% (7/9) MIF 66.7% (2/3) 
BDKRB2 66.7% (2/3) CFHR3 50.0% (3/6) HSPG2 79.4% (77/79)* MMACHC 75.0% (3/4) 
C1QA 50.0% (1/2)* CFHR4 80.0% (8/10) ICAM1 57.1% (4/7)* PDGFA 42.9% (3/7)* 
C1QB 50.0% (1/2)* CFHR5 90.0% (9/10) ICAM2 100.0% (4/4) PDGFB 66.7% (4/6) 
C1QBP 66.7% (4/6)* CFI 100.0% (13/13) ICAM3 71.4% (5/7) PDGFRA 95.7% (22/23) 
C1QC 33.3% (1/3)* CFP 30.0% (3/10)* ICAM4 66.7% (2/3)* PDGFRB 73.9% (17/23)* 
C1QL1 50.0% (1/2)* CLU 77.8% (7/9)* IFNG 75.0% (3/4)* PGF 50.0% (3/6)* 
C1QL2 50.0% (1/2)* CPB2 90.9% (10/11) IL1A 100.0% (7/7) PLAT 92.3% (12/13) 
C1QL3 50.0% (1/2)* CR1 42.6% (20/47)* IL2 100.0% (4/4) PLG 52.6% (10/19)* 
C1QL4 0.0% (0/2)* CR1L 50.0% (6/12) IL6 100.0% (5/5) PROC 44.4% (4/9)* 
C1R 100% (9/9) CR2 94.7% (18/19)* IL8 100.0% (4/4) PROCR 75.0% (3/4) 
C1RL 83.3% (5/6) DGKE 81.8% (9/11)* IL10 80.0% (4/5) PROS1 46.7% (7/15) 
C1S 91.7% (11/12) F2 85.7% (12/14) IL12A 85.7% (6/7)* PROZ 87.5% (7/8) 
C2 92.9% (13/14) F2R 50.0% (1/2)* IL12RB1 81.3% (13/16) SDC2 100.0% (5/5) 
C3 95.1% (39/41) F3 83.3% (5/6) ITGA1 100.0% (29/29) SERPINB2 100.0% (8/8) 
C3aR1 100.0% (1/1) F5 92.0% (23/25) ITGA2 86.7% (26/29) SERPINC1 100.0% (7/7) 
C4A 0.0% (0/41)* F7 88.9% (8/9) ITGA2B 76.7% (23/30) SERPINE1 77.8% (7/9)* 
C4B 0.0% (0/41)* F8 80.8% (21/26)* ITGA3 69.2% (18/26)* SERPING1 87.5% (7/8)* 
C4BPA 75.0% (9/12) F9 100.0% (8/8) ITGA4 89.2% (25/28) TGFB1 57.1% (4/7)* 
C4BPB 100.0% (7/7) F10 91.7% (11/12) ITGA5 86.7% (26/30)* THBD 0.0% (0/1)* 
C5 90.2% (37/41) F11 83.3% (10/12) ITGA6 84.0% (21/25) TLR1 0.0% (0/4)* 
C5aR1 100.0% (2/2) F12 57.1% (8/14) ITGA7 72.0% (18/25)* TLR2 100.0% (3/3) 
C6 88.9% (16/18) F13A1 92.9% (13/14)* ITGA8 86.7% (26/30)* TLR3 100.0% (5/5) 
C7 94.4 (17/18) F13B 91.7% (11/12) ITGA9 82.1% (23/28)* TLR4 100.0% (3/3) 
C8A 100.0% (11/11) FCN1 100.0% (9/9) ITGA10 93.3% (28/30) TLR5 100.0% (6/6) 
C8B 92.3% (12/13) FCN2 100.0% (7/7) ITGA11 76.7% (27/30)* TLR6 100.0% (2/2) 
C8G 85.7% (6/7) FCN3 100.0% (8/8) ITGAD 86.7% (26/30) TLR7 100.0% (3/3) 
C9 100.0% (11/11) FGA 83.3% (5/6) ITGAE 87.1% (27/31) TLR8 100.0% (2/2) 
CD14 100.0% (2/2) FGB 87.5% (7/8) ITGAL 71.0% (22/31) TNF 75.0% (3/4) 
CD19 78.6% (11/14) FGD5 100.0% (20/20) ITGAM 80.0% (24/30)* VEGFA 87.5% (7/8)* 
CD36 92.8% (13/14) FGG 100.0% (10/10) ITGAV 85.7% (24/28) VEGFB 85.7% (6/7)* 
CD40 100.0% (9/9) FGL1 100.0% (7/7) ITGAX 86.7% (26/30) VEGFC 71.4% (5/7)* 
CD44 90.0% (9/10)* FGL2 100.0% (2/2) ITGB1 75.0% (12/16) VTN 62.5% (5/8) 
CD46 100.0% (14/14) FGR 92.3% (12/13) ITGB2 75.0% (12/16) VWF 55.8% (29/52) 
CD55 81.9% (9/11)* FIGF 100.0% (15/15) ITGB3 87.5% (14/16)*   
CD59 75.0% (3/4)* FLT1 96.7% (29/30)* ITGB4 90.0% (36/40) TOTAL 80.4% (1995/2480) 
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List of candidate genes encoding proteins of the complement system, coagulation system, and innate 
immunity, endothelial cell components, and glomerular basement membrane components. For each gene, the 
percentage of covered exons for P1 on a SOLiD4 sequencer is shown. A vertical coverage of >10 reads over the 
entire exon was used to call an exon completely covered. Genes of which exon 1 was not present, are indicated 
with an asterisk. 
Name Coverage Name Coverage Name Coverage Name Coverage 
ACAN 55.6% (10/18)* CD74 100.0% (6/6) FLT4 93.3% (28/30)* ITGB5 80.0% (12/15)* 
ACE 72.0% (18/25)* CD79A 80.0% (4/5) FN1 78.2% (36/46)* ITGB6 80.0% (12/15) 
ADAMTS2 90.1% (20/22)* CD79B 100.0% (6/6) GP1Ba 50.0% (1/2)* ITGB7 87.5% (14/16)* 
ADAMTS13 79.3% (23/29) CD93 50.0% (1/2) GP6 87.5% (7/8) ITGB8 78.6% (11/14) 
ADAMTS17 86.4% (19/22)* CD97 72.2% (13/18) GPC1 77.8% (7/9)* KDR 96.7% (29/30)* 
ADAMTS19 95.7% (22/23) CFB 100.0% (18/18) GPC2 50.0% (5/10)* LY96 80.0% (4/5) 
ADAMTS20 94.9% (37/39) CFD 20.0% (1/5)* GPC3 77.8% (7/9)* MASP1 96.8% (15/16) 
AGT 100.0% (4/4) CFH 86.9% (20/23) GPC4 88.9% (8/9) MASP2 72.7% (8/11)* 
AGTR1 50.0% (1/2)* CFHR1 0.0% (0/6)* GPC5 75.0% (6/8)* MBL2 75.0% (3/4)* 
APOB 93.1% (27/29)* CFHR2 80.0  (4/5) GPC6 77.8  (7/9) MIF 66.7% (2/3) 
BDKRB2 66.7% (2/3) CFHR3 50.0  (3/6) SP 2 79.4  (77/79)* MMACHC 75.0% (3/4) 
C1QA 50.0% (1/2)* CFHR4 80.0  (8/10) I 1 57.1  (4/7)* PDGFA 42.9% (3/7)* 
C1QB 50.0% (1/2)* CFHR5 .  ( / ) I  100.0  (4/4) PDGFB 6 .7% (4/6) 
C1QBP 6.7% (4/6)* CFI .   I  71.4  (5/7) PDGFRA 95.7% (2 /23) 
C1QC 3.3% (1/3)* CFP .  66.7  (2/3)* PDGFRB 73.9% (17/23)* 
C1QL1 50.0% (1/2)* CL  .  75.0  (3/4)* PGF 50.0% (3/6)* 
C1QL2 50.0% (1/2)* CPB2 .  100.0  (7/7) PLAT 92.3% (12/13) 
C1QL3 50.0% (1/2)* CR1 .  100.0  (4/4) PLG 52.6% (10/19)* 
C1QL4 0.0% (0/2)* CR1L .  100.0  (5/5) PROC 4 .4% (4/9)* 
C1R 1 0% (9/9) CR2 .  ( )  I  100.0  (4/4) PROCR 75.0% (3/4) 
C1RL 83.3% (5/6) DGKE .  ( / )  I  80.0  (4/5) PROS1 46.7% (7/15) 
C1S 91.7% (11/12) F2 85.7  (12/14) IL12  85.7  (6/7)* PROZ 87.5% (7/8) 
C2 92.9% (13/14) F2R 50.0  (1/2)* IL12RB1 81.3  (13/16) SDC2 100.0% (5/5) 
C3 95.1% (39/41) F3 83.3% (5/6) ITGA1 100.0% (29/29) SERPINB2 100.0% (8/8) 
C3aR1 100.0% (1/1) F5 92.0% (23/25) ITGA2 86.7% (26/29) SERPINC1 100.0% (7/7) 
C4A 0.0% (0/41)* F7 88.9% (8/9) ITGA2B 76.7% (23/30) SERPINE1 77.8% (7/9)* 
C4B 0.0% (0/41)* F8 80.8% (21/26)* ITGA3 69.2% (18/26)* SERPING1 87.5% (7/8)* 
C4BPA 75.0% (9/12) F9 100.0% (8/8) ITGA4 89.2% (25/28) TGFB1 57.1% (4/7)* 
C4BPB 100.0% (7/7) F10 91.7% (11/12) ITGA5 86.7% (26/30)* THBD 0.0% (0/1)* 
C5 90.2% (37/41) F11 83.3% (10/12) ITGA6 84.0% (21/25) TLR1 0.0% (0/4)* 
C5aR1 100.0% (2/2) F12 57.1% (8/14) ITGA7 72.0% (18/25)* TLR2 100.0% (3/3) 
C6 88.9% (16/18) F13A1 92.9% (13/14)* ITGA8 86.7% (26/30)* TLR3 100.0% (5/5) 
C7 94.4 (17/18) F13B 91.7% (11/12) ITGA9 82.1% (23/28)* TLR4 100.0% (3/3) 
C8A 100.0% (11/11) FCN1 100.0% (9/9) ITGA10 93.3% (28/30) TLR5 100.0% (6/6) 
C8B 92.3% (12/13) FCN2 100.0% (7/7) ITGA11 76.7% (27/30)* TLR6 100.0% (2/2) 
C8G 85.7% (6/7) FCN3 100.0% (8/8) ITGAD 86.7% (26/30) TLR7 100.0% (3/3) 
C9 100.0% (11/11) FGA 83.3% (5/6) ITGAE 87.1% (27/31) TLR8 100.0% (2/2) 
CD14 100.0% (2/2) FGB 87.5% (7/8) ITGAL 71.0% (22/31) TNF 75.0% (3/4) 
CD19 78.6% (11/14) FGD5 100.0% (20/20) ITGAM 80.0% (24/30)* VEGFA 87.5% (7/8)* 
CD36 92.8% (13/14) FGG 100.0% (10/10) ITGAV 85.7% (24/28) VEGFB 85.7% (6/7)* 
CD40 100.0% (9/9) FGL1 100.0% (7/7) ITGAX 86.7% (26/30) VEGFC 71.4% (5/7)* 
CD44 90.0% (9/10)* FGL2 100.0% (2/2) ITGB1 75.0% (12/16) VTN 62.5% (5/8) 
CD46 100.0% (14/14) FGR 92.3% (12/13) ITGB2 75.0% (12/16) VWF 55.8% (29/52) 
CD55 81.9% (9/11)* FIGF 100.0% (15/15) ITGB3 87.5% (14/16)*   
CD59 75.0% (3/4)* FLT1 96.7% (29/30)* ITGB4 90.0% (36/40) TOTAL 80.4% (1995/2480) 
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APOB 93.1% (27/29)* CFHR2 80.0% (4/5) GPC6 77.8% (7/9) MIF 66.7% (2/3) 
BDKRB2 66.7% (2/3) CFHR3 50.0% (3/6) HSPG2 79.4% (77/79)* MMACHC 75.0% (3/4) 
C1QA 50.0% (1/2)* CFHR4 80.0% (8/10) ICAM1 57.1% (4/7)* PDGFA 42.9% (3/7)* 
C1QB 50.0% (1/2)* CFHR5 90.0% (9/10) ICAM2 100.0% (4/4) PDGFB 66.7% (4/6) 
C1QBP 66.7% (4/6)* CFI 100.0% (13/13) ICAM3 71.4% (5/7) PDGFRA 95.7% (22/23) 
C1QC 33.3% (1/3)* CFP 30.0% (3/10)* ICAM4 66.7% (2/3)* PDGFRB 73.9% (17/23)* 
C1QL1 50.0% (1/2)* CLU 77.8% (7/9)* IFNG 75.0% (3/4)* PGF 50.0% (3/6)* 
C1QL2 50.0% (1/2)* CPB2 90.9% (10/11) IL1A 100.0% (7/7) PLAT 92.3% (12/13) 
C1QL3 50.0% (1/2)* CR1 42.6% (20/47)* IL2 100.0% (4/4) PLG 52.6% (10/19)* 
C1QL4 0.0% (0/2)* CR1L 50.0% (6/12) IL6 100.0% (5/5) PROC 44.4% (4/9)* 
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C3 95.1% (39/41) F3 83.3% (5/6) ITGA1 100.0% (29/29) SERPINB2 100.0% (8/8) 
C3aR1 100.0% (1/1) F5 92.0% (23/25) ITGA2 86.7% (26/29) SERPINC1 100.0% (7/7) 
C4A 0.0% (0/41)* F7 88.9% (8/9) ITGA2B 76.7% (23/30) SERPINE1 77.8% (7/9)* 
C4B 0.0% (0/41)* F8 80.8% (21/26)* ITGA3 69.2% (18/26)* SERPING1 87.5% (7/8)* 
C4BPA 75.0% (9/12) F9 100.0% (8/8) ITGA4 89.2% (25/28) TGFB1 57.1% (4/7)* 
C4BPB 100.0% (7/7) F10 91.7% (11/12) ITGA5 86.7% (26/30)* THBD 0.0% (0/1)* 
C5 90.2% (37/41) F11 83.3% (10/12) ITGA6 84.0% (21/25) TLR1 0.0% (0/4)* 
C5aR1 100.0% (2/2) F12 57.1% (8/14) ITGA7 72.0% (18/25)* TLR2 100.0% (3/3) 
C6 88.9% (16/18) F13A1 92.9% (13/14)* ITGA8 86.7% (26/30)* TLR3 100.0% (5/5) 
C7 94.4 (17/18) F13B 91.7% (11/12) ITGA9 82.1% (23/28)* TLR4 100.0% (3/3) 
C8A 100.0% (11/11) FCN1 100.0% (9/9) ITGA10 93.3% (28/30) TLR5 100.0% (6/6) 
C8B 92.3% (12/13) FCN2 100.0% (7/7) ITGA11 76.7% (27/30)* TLR6 100.0% (2/2) 
C8G 85.7% (6/7) FCN3 100.0% (8/8) ITGAD 86.7% (26/30) TLR7 100.0% (3/3) 
C9 100.0% (11/11) FGA 83.3% (5/6) ITGAE 87.1% (27/31) TLR8 100.0% (2/2) 
CD14 100.0% (2/2) FGB 87.5% (7/8) ITGAL 71.0% (22/31) TNF 75.0% (3/4) 
CD19 78.6% (11/14) FGD5 100.0% (20/20) ITGAM 80.0% (24/30)* VEGFA 87.5% (7/8)* 
CD36 92.8% (13/14) FGG 100.0% (10/10) ITGAV 85.7% (24/28) VEGFB 85.7% (6/7)* 
CD40 100.0% (9/9) FGL1 100.0% (7/7) ITGAX 86.7% (26/30) VEGFC 71.4% (5/7)* 
CD44 90.0% (9/10)* FGL2 100.0% (2/2) ITGB1 75.0% (12/16) VTN 62.5% (5/8) 
CD46 100.0% (14/14) FGR 92.3% (12/13) ITGB2 75.0% (12/16) VWF 55.8% (29/52) 
CD55 81.9% (9/11)* FIGF 100.0% (15/15) ITGB3 87.5% (14/16)*   
CD59 75.0% (3/4)* FLT1 96.7% (29/30)* ITGB4 90.0% (36/40) TOTAL 80.4% (1995/2480) 
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Abstract 
 
Mutations in complement Factor H (CFH), factor I (CFI), factor B (CFB), thrombomodulin (THBD), 
complement component 3 (C3), and membrane cofactor protein (CD46), and autoantibodies against 
factor H (αFH) with or without a homozygous deletion in FH-related protein 1 and 3 (ΔCFHR1/3) 
predispose development of atypical hemolytic uremic syndrome (aHUS). Different mutations in 
genes encoding complement proteins in 45 pediatric aHUS patients were retrospectively linked with 
clinical features, treatment, and outcome. In 47% of the study participants, potentially pathogenic 
genetic anomalies were found (5x CFH, 4x CD46, 4x C3, 3x CFI, 2x FB, and 6x αFH, of which five had 
ΔCFHR1/3); four patients carried combined genetic defects or a mutation together with αFH. In the 
majority (87%), disease onset was preceded by a triggering event; in 25% of cases diarrhea was the 
presenting symptom. More than 50% had normal serum C3 levels at presentation. Relapses were 
seen in half of the patients, and there was renal graft failure in all except one case following 
transplant. Performing adequate DNA analysis is essential for treatment and positive outcome in 
children with aHUS. The impact of intensive initial therapy and renal replacement therapy, as well as 
the high risk of recurrences of aHUS in renal transplant, warrants further understanding of the 
pathogenesis, which will lead to better treatment options. 
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Introduction 
 
Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by hemolytic anemia, 
thrombocytopenia, and acute renal failure secondary to thrombotic microangiopathy.36 It is 
distinguished from typical or Shigatoxin-producing Escherichia coli (STEC) HUS by the absence of 
STEC infection. In recent years, aHUS had been found to be associated with complement alternative 
pathway dysregulation. In almost 60% of aHUS patients, mutations in genes encoding complement-
regulation proteins are reported.29, 139 Aside from mutations in these genes, aHUS has also been 
reported in cobalamin C (cblC) disease caused by mutation in the cblC MMACHC gene.188 
With respect to complement-regulation proteins, most mutations are seen in factor H (protein: FH; 
gene: CFH), but mutations in membrane cofactor protein (MCP or CD46) and factor I (FI; CFI) are also 
known to predispose development of aHUS.3, 5, 6, 9-11 Additionally, gain-of-function mutations in 
factor B (FB; CFB) and complement C3 (C3) are reported.74, 75, 90, 189 Some patients have combined 
mutations. Functional FH deficiency due to autoantibodies against FH (αFH) have recently been 
described, which is highly associated with a polymorphic homozygous deletion of genes encoding 
factor H-related protein 1 and 3 (ΔCFHR1/3).81, 82, 137, 141 Finally, mutations in the thrombomodulin 
genen (THBD), encoding membrane-bound thrombomodulin that modulates complement activation 
on cell surfaces, have been reported in aHUS.73 Genetic complement anomalies are thought to be 
risk factors rather than the only cause of the disease, as patient relatives with the same mutation do 
not always exhibit disease activity. Atypical HUS represents approximately 10% of pediatric HUS 
cases. More than 80% of cases are sporadic, with a better prognosis overall than familial cases, 
which have a higher mutation rate.29, 90 Knowledge about the impact of mutations in complement-
regulating genes upon disease characteristics, response to treatment, and outcome in pediatric 
aHUS patients could help define therapeutic guidelines and be of prognostic value. Therefore, the 
aim of this study was to: (1) document the frequency of known genetic complement abnormalities 
in a cohort of Dutch and Belgian children diagnosed with aHUS, and (2) describe and compare 
disease characteristics, treatment, and clinical outcome of these children. 
 
Methods 
 
Study population 
From 2001 to 2010, genomic DNA was analyzed for genetic disorders in complement (regulating) 
genes (CFH, CFI, CD46, CFB, C3, THBD, and ΔCFHR1/3 with αFH) in 45 Dutch and Belgian pediatric 
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patients diagnosed with aHUS by pediatric nephrologists at six university medical centers in The 
Netherlands and one in Belgium. Diagnosis of aHUS was based on the following findings: hemolytic 
anemia characterized by a hemoglobin (Hb) level <10 g/dl, thrombocytopenia with a platelet count 
<150x109/l, elevated levels of lactate dehydrogenase (LDH), and a negative Coombs test, all in 
association with acute renal impairment. Patients with STEC HUS were excluded by stool cultures, 
polymerase chain reaction (PCR), and/or serologic antibodies against LPS O157. Genetic analysis 
were combined with retrospectively obtained information about patient clinical presentation, 
received treatment, and outcome. Genetic analysis of 25 of these 45 patients has been published 
before in a cohort of adults and children by Westra et al.72 Patients in that and this study are 
indicated in the authors’ earlier study by the following numbers: 2, 3, 4, 5, 6, 9, 15,16, 18, 21, 24, 33, 
36, 39, 40, 41, 42, 43, 44, 45, 48, 54, 58, 62. When two or more family members of the same family 
were affected by the disease at least six months apart, it was considered as familial aHUS. Sporadic 
aHUS patients had no family history of the disease. Complete remission was defined by 
normalization of hematologic parameters (Hb >10 g/dl, thrombocytes >150x109/l, LDH <450 U/l) and 
renal function (glomerular filtration rate [GFR] >80 ml/min/1.73 m2, no proteinuria). In patients with 
partial remission, hematologic normalization was seen, but with renal sequelae (GFR <80 
ml/min/1.73 m2 and/or proteinuria and/or hypertension). The presence of proteinuria was defined 
as >0.2 g/24 h or positive dipstick for proteins. Hypertension was defined as a consistent blood 
pressure >p95 for age and length. Recurrence was reported when a new episode of aHUS presented 
>4 weeks after remission. Chronic treatment was defined by the use of dialysis or plasma therapy for 
>3 months. The average follow-up time was 7.5 years, varying from two weeks in one patient 
previously diagnosed and still hospitalized at time of inclusion, to 17 years in one patient who 
reached adulthood. Permission to study DNA material was given by all patients an/or parents. 
 
Genetic analysis of genes encoding FH, FI, CD46, C3, FB, and THBD 
Genomic DNA was amplified for CFH [National Centre for Biotechnology Information (NCBI) RefSeq 
NM_000186.3], CFI (NM_000204.3), CD46 (NM_002389.3), C3 (NM_000064.2), CFB (NM_001710.4), 
and THBD (NM_000361.2) by means of PCR. Primer data are available upon request. Fragments 
included DNA sequences of the individual exons and the splice donor and acceptor site. Amplimers 
were subjected to double-stranded DNA sequence analysis on an ABI 3130 xl Genetic Analyzer 
(Applied Biosystems). Sequence analysis was performed using Sequencher 4.8 software. Detected 
genetic aberrations were confirmed on a second PCR product. Genomic DNA from >100 healthy 
ethnically matched control individuals was used to confirm sequence variations that might be 
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potentially pathogenic. Potential pathogenicity of genetic alterations was further checked in the 
literature, evolutionary conservation, and in silico prediction programs (Sorting Intolerant From 
Tolerant [SIFT; http://sift.jcvi.org/] and Polymorphism Phenotyping v2 [PolyPhen-2; 
http://genetics.bwh.harvard.edu/pph2/]). For evolutionary conservation, the 17-way vertebrate 
alignment from the University of Califormia Santa Cruz (UCSC) Genome Browser 
(http://genome.uscs.edu) was used. 
 
Autoantibodies against factor H (αFH) and homozygous deletion of FHR-1 and FHR-3 genes 
Serum samples were tested for the presence of αFH by means of enzyme-linked immunnosorbent 
assay (ELISA), as described previously.81 A positive control sample was kindly obtained via Dr. 
Dragon-Durey (Paris, France). Test results were considered positive if they were above twice the 
standard deviation calculated from controls, and samples were tested at least three times 
independently, as described by Dragon-Durey et al.137 A homozygous deletion of CFHR1 and CFHR3 
was identified as described previously.72 In short, genomic DNA was amplified by PCR using specific 
primers located in a 100-kb region downstream of CFH. Amplification of one of the fragments failed 
in case of ΔCFHR1/3. This method does not detect a heterozygous deletion of the two genes or the 
presence of a hybrid CFH/CFHR1 gene. 
 
Results 
 
Patients 
Data on CFH, CFI, CD46, CFB, and C3 mutations characteristics are reported in Table 6.1. Data on 
patient characteristics at presentation, treatment, and clinical outcome for each type of mutation 
are reported in Table 6.2, Table 6.3, and Table 6.4. Due to the small number of patients per mutated 
complement protein, data were analyzed descriptively without statistical comparisons. Clinical data 
on the four patients with a combined mutation or a mutation in combination with a deletion in 
CFHR1/3 and αFH are given in Table 6.5. Forty-five patients diagnosed with aHUS from six different 
university medical centers in The Netherlands and one in Belgium were included. Approximately as 
many males as females were included in this study. 
 
Genetic anomalies 
In 20 out of 45 patients (44%) heterozygous mutations in complement regulating genes and/or 
autoantibodies against FH were found, all but one with a homozygous deletion in CFHR1/3 (Table  
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6.1). Five patients (overall 11%) carried a mutation in CFH, four (overall 9%) in CD46, and also four in 
C3 (overall 9%). Three patients (overall 7%) had a mutation in CFI and two (overall 4%) in CFB. Six 
patient (overall 13%) had autoantibodies against FH. Two of these patients with a genetic anomaly 
carried a combined mutation (CFI/CD46 and CFI/C3). One patient had a CFI mutation and αFH with 
ΔCFHR1/3, and in one patient αFH were seen in combination with a C3 mutation but without 
ΔCFHR1/3. Patients with combined mutations are included in both their mutation groups in Table 
6.2, Table 6.3, and Table 6.4. Characteristics at onset, treatment, and outcome of the four patients 
with combined genetic anomalies are also summarized separately (Table 6.5). No mutations in THBD 
were found in our cohort. 
 
Clinical characteristics 
Familial vs sporadic 
Eleven patients (24%) had familial aHUS, of whom all except two had an associated mutation. We 
included one family with three sisters with a CFH mutation and another family with two cousins with 
a mutation in CFB. Of the other six patients with familial aHUS, only one family member was 
dlndlkjsaccxaaxxx 
Table 6.1. Characteristics of mutations found in CFH, CFI, CD46, CFB, and C3 genes in 17 of 45 pediatric patients 
with atypical hemolytic uremic syndrome (aHUS). 
Subject code, 
exon/intron Mutation Effect Known/unknown
a 
Complement factor H 
Exon 23 (n = 1) c.3628C > T p.Arg1210Cys Known 
Exon 23 (n = 3) c.3572C > T p.Ser1191Leu Known 
Exon 9 (n = 1) c.1198C > A p.Gln400Lys Known 
Complement factor I 
Intron12 (n = 1b) g.IVS12 + 5G > T Splice score decrease from 0.93 to 0.86 Known 
Exon 9 (n = 1d) c.1019T > C p.Ile340Thr Known 
Exon 10 (n = 1d) c.1071T > G p.Ile357Met Unknown 
Membrane cofactor protein 
Exon 6 (n = 1b) c.811-816delGACAGT p.delAsp271-Ser272 Known 
Complement C3 
Exon 4 (n = 4c) c.481C > T p.Arg161Trp Known 175 
Complement factor B 
Exon 18 (n = 2) c.967A > G p.Lys323Glu Known 
Every single mutation is mentioned separately. Patients without mutations but with a homozygous deletion in ΔCFHR1/3 and/or 
autoantibodies against factor H are not listed in this table. Of three patients with an CD46 mutation, DNA analysis was not 
performed in our laboratory. Mutation and effect are therefore not listed above. 
a According to www.fh-hus.com and 175. 
b Patient carrying both CFI and CD46 mutations. 
c One patient carrying both CFI and C3 mutations. 
d Patient carrying CFI mutation and a homozygous deletion in CFHR1/3 and autoantibodies against FH (αFH). 
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b Patient carrying both CFI and CD46 mutations. 
c One patient carrying both CFI and C3 mutations. 
d Patient carrying CFI mutation and a homozygous deletion in CFHR1/3 and autoantibodies against FH (αFH). 
 
included in the study because further data were not available. All four patients in this study with a 
C3 mutation have familial aHUS. Sporadic aHUS was seen in all four patients with a CD46 mutation 
and all five patients with αFH and ΔCFHR1/3. 
 
Onset 
In ten patients (22%), aHUS onset was before 1 year of age, with the youngest patient being only 1 
month old. In only one of these patients was a mutation found (C3/αFH), and only two patients had 
familial aHUS. The majority of aHUS patients (53%) presented between the age of 1 and 7 years, 
which is also the most common age for children with typical HUS to present with the disease, which 
suggests that age at onset cannot always help distinguish between typical and aHUS. In 38/45 
patients, aHUS onset followed a triggering event, such as gastrointestinal symptoms (74%), upper 
respiratory tract infection (45%), and fever (32%). A combination of triggering events was seen as 
well; for instance, vomiting and fever were seen in 8/45 patients. Diarrhea was seen in 11 patients, 
five of whom also had fever. One patient developed aHUS a few days after a hepatitis B vaccination, 
and one patient was positively tested for a Bordetella pertussis infection a few days before aHUS 
onset. Other triggers were infection with Haemophilus influenza (n=1) and a streptococcal infection 
(n=1). 
Hypertension (blood pressure >95 percentile for age) was present at first presentation in 71% of 
patients. Six patients had involvement of the central nervous system due to malignant hypertension 
or cerebral infarction during their first aHUS flare. Two of these patients had a mutation (C3 and 
CFB) and one patient had αFH with ΔCFHR1/3. These three patients had severe seizures; the other 
three patients were extremely agitated of had reduced consciousness. One patient had additional 
visual handicap, and one showed apraxia and aphasia. Pancreas involvement during the first episode 
was seen in only two patients, both without a genetic defect. In 18 of 37 patients (49%) for whom 
data were available, biochemical evaluation showed reduced C3 levels (minimum 210 mg/l, 
reference range 900-1800 mg/l). Four of these patients had a mutation (2x CFB, 1x CFI, 1x C3), and 
four had αFH, of which three also had ΔCFHR1/3. Low C3 levels were always linked with high levels 
of the activation product C3d. However, we also found elevated levels of C3d in six patients with 
normal levels of C3. Of the 25 genetically undefined patients, 11 showed reduced C3 levels, and in 
seven, elevated levels of C3d were found, showing evidence of alternative pathway activation. 
Remarkably, reduced C4 levels were seen in six of the 31 tested patients (19%), with an extreme 
lowest level of 30 mg/l (reference range 150-400 mg/l). A systemic disease, such as systemic lupus 
erythamatosis (SLE) of cryoglobinemia as cause of these low C4 levels was ruled out because of the 
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clinical and laboratory results combined with medical history. One of the patients had a FH 
mutation. 
 
Treatment and outcome of first episode 
The majority of patients (60%) were treated with plasma therapy, including plasma infusion (PI) 
and/or plasma exchange (PE) (Table 6.2). Plasma therapy was applied in 12 patients with a genetic 
defect vs 15 patients without a known genetic anomaly. In 11 patients, plasma therapy was 
combined with dialysis. Nine patients were treated conservatively, three of whom had a genetic 
defect (1x C3, 1x CD46, 1x αFH with ΔCFHR1/3). In only 3/20 patients (15%) with a genetic defect (2x 
CFH, 1x CD46) was complete remission reached after the first episode, compared with 9/24 patients 
(38%) in the other group. One of these patients (CFH mutation) was treated with plasma therapy 
(four infusions with fresh frozen plasma), one with dialysis (CFH mutation), and one patient 
recovered spontaneously (mutation in CD46). All other patients with a genetic anomaly reached 
partial remission after the first flare. Of the nine patients without plasma therapy or dialysis, only 
three reached complete remission (1x CD46, 2x no genetic anomaly). 
Chronic plasma therapy and/or dialysis was applied more often in the group with than in the group 
without a genetic defect (40% vs 30%). One patient died during the first aHUS episode due to 
consequences of the disease. This was the youngest patient in the study, only 1 month old. A genetic 
defect in complement proteins was not found in this patient. 
 
Long-term outcome 
Almost half of the aHUS patients (n = 21) had a relapse (Table 6.3). In the group with a genetic 
anomaly, 13/20 (65%) of patients relapsed. In the group without known anomalies, relapse occurred 
in only 8/25 (32%) patients. A total of 43 relapses was seen, of which 29 (67%) occurred in patients 
with any of the genetic subtypes. A maximum of five relapses was seen in one patient with αFH and 
ΔCFHR1/3. Of all patients with a relapse, 38% had familial aHUS. Most relapses occurred after a viral 
infection, usually of the upper respiratory tract. Time between aHUS onset and the first relapse  
varied widely, from 1 month after remission to a maximum of 8.5 years. In 9/21 patients, aHUS 
relapsed within 1 year, five had a genetic defect (1x CFH, 1x CD46, 1x C3/CFI, and 2x αFH with 
ΔCFHR1/3). Ten patients with a relapse were initially treated with plasma therapy, eight of whom 
received chronic plasma therapy. In most patients, plasma therapy was intensified during the 
relapse. 
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clinical and laboratory results combined with medical history. One of the patients had a FH 
mutation. 
 
Treatment and outcome of first episode 
The majority of patients (60%) were treated with plasma therapy, including plasma infusion (PI) 
and/or plasma exchange (PE) (Table 6.2). Plasma therapy was applied in 12 patients with a genetic 
defect vs 15 patients without a known genetic anomaly. In 11 patients, plasma therapy was 
combined with dialysis. Nine patients were treated conservatively, three of whom had a genetic 
defect (1x C3, 1x CD46, 1x αFH with ΔCFHR1/3). In only 3/20 patients (15%) with a genetic defect (2x 
CFH, 1x CD46) was complete remission reached after the first episode, compared with 9/24 patients 
(38%) in the other group. One of these patients (CFH mutation) was treated with plasma therapy 
(four infusions with fresh frozen plasma), one with dialysis (CFH mutation), and one patient 
recovered spontaneously (mutation in CD46). All other patients with a genetic anomaly reached 
partial remission after the first flare. Of the nine patients without plasma therapy or dialysis, only 
three reached complete remission (1x CD46, 2x no genetic anomaly). 
Chronic plasma therapy and/or dialysis was applied more often in the group with than in the group 
without a genetic defect (40% vs 30%). One patient died during the first aHUS episode due to 
consequences of the disease. This was the youngest patient in the study, only 1 month old. A genetic 
defect in complement proteins was not found in this patient. 
 
Long-term outcome 
Almost half of the aHUS patients (n = 21) had a relapse (Table 6.3). In the group with a genetic 
anomaly, 13/20 (65%) of patients relapsed. In the group without known anomalies, relapse occurred 
in only 8/25 (32%) patients. A total of 43 relapses was seen, of which 29 (67%) occurred in patients 
with any of the genetic subtypes. A maximum of five relapses was seen in one patient with αFH and 
ΔCFHR1/3. Of all patients with a relapse, 38% had familial aHUS. Most relapses occurred after a viral 
infection, usually of the upper respiratory tract. Time between aHUS onset and the first relapse  
varied widely, from 1 month after remission to a maximum of 8.5 years. In 9/21 patients, aHUS 
relapsed within 1 year, five had a genetic defect (1x CFH, 1x CD46, 1x C3/CFI, and 2x αFH with 
ΔCFHR1/3). Ten patients with a relapse were initially treated with plasma therapy, eight of whom 
received chronic plasma therapy. In most patients, plasma therapy was intensified during the 
relapse. 
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Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics
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In 54% of patients, chronic hypertension was seen after the first flare; in 47%, proteinuria sustained. 
Most of these patients had to be treated for several months with antihypertensive agents. In four 
patients, neurological involvement was seen later during the course of disease. Two of these 
patients presented with seizures due to malignant hypertension (CD46 and C3/CFI); one patient 
without a genetic defect had reduced consciousness (computed tomography [CT] scan showed no 
abnormalities), and one patient had dysphasia and sensibility disorders due to an arteria cerebralis 
media stenosis (CFH). Another patient developed necrotizing pancreatitis with transient diabetes 
mellitus 10 years after first presentation, for which a partial pancreatectomy was performed. No 
mutation or deletion was found in this patient. 
Seven patients (2x CFH, 1x CD46, 1x C3/CFI, and three without a known genetic defect) received a 
total number of 13 renal transplants, but in 10/13 grafts, aHUS recurred. Three of these patients had 
familial aHUS. No recurrence was seen in patient with CD46 mutation. Time between 
cbnmakhwbevdbnbc 
Table 6.5. Characteristics at disease onset, during treatment, and outcome of four pediatric atypical hemolytic 
uremic syndrome (aHUS) patients with combined mutations and/or with a homozygous deletion in CFHR1/3 
(ΔCFHR1/3) and/or autoantibodies against FH (αFH). 
Parameter Patient 1 Patient 2 Patient 3 Patient 4 
Combined mutation CFI/CD46 CFI/C3 CFI/CFHR1/3/αFH C3/αFH 
Gender Male Male Male Female 
Age at onset (years) 13 10/12 1 2/12 6 6/12 6/12 
Hemoglobin (g/dl) 7.2 6.3 9.7 5.5 
Platelet count (×109/l) 13 276 120 44 
Creatinine (mmol/l) 94 76 294 72 
C3 (mg/l)a 1000 – 610 670 
C4 (mg/l)b 185 – 200 – 
Plasmatherapy yes No yes Yes 
Dialysis No Yes No No 
Complete remission No No No No 
Partial remission Yes Yes Yes Yes 
Chronic plasmatherapy No No Yes No 
Chronic dialysis No Yes No No 
Death No No No No 
Relapse No Yes No No 
No. of relapses – 4 – – 
Renal transplant No Yes No No 
No. of renal transplants – 3 – – 
No. of relapses in grafts – 2 – – 
Death No No No No 
The numbers of patients for whom data were available are reported in parentheses. 
a Reference range 900−1,800 mg/l. 
b Reference range 150−400 mg/l. 
Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics
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patients, neurological involvement was seen later during the course of disease. Two of these 
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without a genetic defect had reduced consciousne s (computed tomography [CT] scan showed no 
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mellitus 10 years after first presentation, for which a partial pancreatectomy was performed. No 
mutation or deletion was found in this patient. 
Seven patients (2x CFH, 1x CD46, 1x C3/CFI, and three without a known genetic defect) received a 
total number of 13 renal transplants, but in 10/13 grafts, aHUS recu red. Three of these patients had 
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Table 6.5. Characteristics at disease onset, during treatment, and outcome of four pediatric atypical hemolytic 
uremic syndrome (aHUS) patients with combined mutations and/or with a homozygous deletion in CFHR1/3 
(ΔCFHR1/3) and/or autoantibodies against FH (αFH). 
Parameter Patient 1 Patient 2 Patient 3 Patient 4 
Combined mutation CFI/CD46 CFI/C3 CFI/CFHR1/3/αFH C3/αFH 
Gender Male Male Male Female 
Age at onset (years) 13 10/12 1 2/12 6 6/12 6/12 
Hemoglobin (g/dl) 7.2 6.3 9.7 5.5 
Platelet count (×109/l) 13 276 120 4 
Creatinine (mmol/l) 94 76 294 72 
C3 (mg/l)a 1 0 – 610 670 
C4 (mg/l)b 185 – 2 0 – 
Plasmatherapy yes No yes Yes 
Dialysis No Yes No No 
Complete remi sion No No No No 
Partial remi sion Yes Yes Yes Yes 
Chronic plasmatherapy No No Yes No 
Chronic dialysis No Yes No No 
Death No No No No 
Relapse No Yes No No 
No. of relapses – 4 – – 
Renal transplant No Yes No No 
No. of renal transplants – 3 – – 
No. of relapses in grafts – 2 – – 
Death No No No No 
The numbers of patients for whom data were available are reported in parentheses. 
a Reference range 9 0−1,8 0 mg/l. 
b Reference range 150−4 0 mg/l. 
 6
 100 
transplantation and first relapse in renal graft patients varied between six days and four years. 
Additionally, one graft was lost due to arteria renalis thrombosis one day after transplantation; one 
graft was lost due to rejection after four years. One patient died during the acute phase of aHUS. 
Three other patients died later during the course of disease. One patient with no genetic defect died 
nine years after onset because of massive cerebral bleeding due to malignant hypertension. Another 
patient with an CD46 mutation, who had no recurrence of aHUS in the renal transplant, developed 
pulmonary veno-occlusive disease (PVOD), which led eventually to the finding of an inborn error of 
cobalamin metabolism, and he died 7.5 years after his first presentation.190 The last patient died 12 
years after aHUS onset, but not due to the consequences of aHUS. 
 
Discussion 
 
In this study, we found that in 45 children diagnosed with aHUS, genetic disorders in complement-
regulating genes encoding CFH, CFI, CD46, CFB, C3, and THBD, as well as the presence of αFH with or 
without a homozygous deletion in CFHR1/3, are linked with clinical presentation, treatment, and 
outcome. In almost 50% of this pediatric aHUS cohort, a genetic defect in complement-regulating 
genes was found. This finding is compatible with the previous French pediatric report of Sellier-
Leclerc et al. and the Italian adult/pediatric registry reported by Noris et al.90, 139 Most mutations 
(overall 13%) were found in CFH, which corresponds to the literature.71, 72, 90, 139 The number of 
mutations in CD46 and C3 were equal (overall 9%). Fewer mutations (overall 7%) were found in CFI, 
just as seen in the pediatric French cohort. Mutations in CFB are relatively rare and according to the 
literature occur in only 1–2% of patients with aHUS.29, 72, 90 We identified a genetic aberration in CFB 
in 4.4% of our patients, but it must be mentioned that these two patients were related. Delvaeye et 
al. report that about 5% of patients with aHUS have mutations that impair thrombomodulin 
function.73, 90 Remarkably, in our cohort, no aHUS-associated thrombomodulin mutations were 
found. 
Dragon-Durey et al. were the first to describe the association between αFH and aHUS, and more 
recently an association between the presence of αFH and a homozygous polymorphic deletion in 
ΔCFHR1/3 was described.81, 137 In our population, 13% of all patients had αFH, and 83% of these 
patients (overall 11%) had an additional ΔCFHR1/3, which corresponds well to previous published 
data.81, 137, 141, 191 
One of the most important observations in this cohort is that 74% of aHUS patients showed 
gastrointestinal symptoms, of which 25% presented with diarrhea. This clearly shows that 
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function.73, 90 Remarkably, in our cohort, no aHUS-associated thrombomodulin mutations were 
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Dragon-Durey et al. were the first to describe the association between αFH and aHUS, and more 
recently an association between the presence of αFH and a homozygous polymorphic deletion in 
ΔCFHR1/3 was described.81, 137 In our population, 13% of all patients had αFH, and 83% of these 
patients (overall 11%) had an additional ΔCFHR1/3, which corresponds well to previous published 
data.81, 137, 141, 191 
One of the most important observations in this cohort is that 74% of aHUS patients showed 
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postdiarrheal onset does not exclude the possibility of aHUS. This makes differentiating between 
typical HUS and aHUS for the general pediatrician sometimes even more difficult and may even 
result in a delay of adequate treatment in these patients. Also, relapses seem to occur most often 
after a triggering event, usually an upper airway infection or gastroenteritis. Remarkably, in one 
patient, aHUS relapsed twice after a cytomegalovirus infection for which daily PE and ganciclovir 
were initiated.192 In one other patient, aHUS onset followed a hepatitis B vaccination a few days 
earlier. The triggering role of vaccination in this patient was confirmed by a relapse shortly after 
combined anti-diphtheria-pertussis-tetanus-polio vaccination. 
In only 18 of the 37 tested patients (49%) were C3 plasma levels reduced, which indicates, as shown 
by others, that normal C3 levels in aHUS patients do not reflect complement activation on the 
endothelial cell surfaces. Normal C3 levels also do not rule out the existence of mutations in genes 
encoding complement-regulating proteins. Breakdown products of C3 activation, such as C3d, as 
well as soluble complement complex C5b-9 (SC5b-9), might be a better serum marker for 
complement activation in aHUS patients. 
Although at this time results of the use of eculizumab in patients with aHUS look very promising  and 
might replace plasma therapy in the near future, at present, plasma therapy is considered the gold 
standard treatment in patients with aHUS and should be started within 24 h of diagnosis.96, 193, 194 
However, only 60% of our population received plasma therapy (with or without dialysis). This is due 
to the fact that in our study, patients were included at the time their DNA was sent to the laboratory 
between 2001 and 2010, a time when knowledge about aHUS treatment was growing. However, 
those patients’ first or even second HUS episode was sometimes long before that period, when no 
clear therapy schedules were available. Of the patients treated without plasma therapy, 44% were 
diagnosed and already treated before 2000. Only in recent years have new treatment guidelines for 
aHUS been published.96 Since the latest guideline in 2008, every patient in this study was treated 
with plasma therapy. 
In our cohort, seven patients received a total number of 13 kidney transplants. In five of these seven 
patients, transplantation was performed before the existence of genetic complement mutations was 
known and before plasmapheresis as treatment of aHUS was well accepted. Four of these patients 
had a genetic defect (1x CD46, 2x CFH, and 1x CFI/C3). All except one (CD46) graft failed (93%), again 
demonstrating that kidney transplantation is compromised by the risk of recurrence.29, 71, 90, 138, 139, 
195 Renal transplantation in patients with aHUS should not be performed without DNA analysis for all 
involved complement genes due to the fact that this leads to a better defined risk profile for 
relapses. 
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Currently, aHUS patients having a CFH or CFI mutation who will have a single kidney transplantation 
are advised to combine this with prophylactic plasmapheresis and life-long PE, or else these patients 
are advised to have a combined liver–kidney transplantation with preoperative PE, intraoperative PI, 
and posttransplant anticoagulation.195, 196 In the near future, one might expect that lifelong 
prophylactic treatment with complement inhibitors will replace the use of plasma and /or the 
combination of plasma with liver and/or renal transplantation in aHUS patients with CFH or CFI 
mutations.193, 194 
In conclusion, in almost 50% of pediatric aHUS patients, a genetic abnormality was found. In 87% of 
patients, aHUS onset followed a triggering event; 25% of cases presented with diarrhea, which 
makes differentiating between typical and aHUS difficult. Half of the patients (21/43) had a relapse 
(67% of them with a genetic anomaly), and all except one renal graft failed, so renal transplantation 
should not be performed before adequate DNA analysis of the involved complement genes. In the 
near future, next-generation sequencing methods, such as whole exome or genome sequencing, will 
more easily facilitate DNA mutation analysis, and new genes will probably be identified that might 
be associated with aHUS as well. With the use of complement inhibitors in the ongoing trials in aHUS 
patients, a new era in the treatment of patients with aHUS has begun. It has yet to be demonstrated 
whether this treatment will improve the overall results in aHUS patients and hopefully reduce the 
requirement for dialysis and renal transplantations. 
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Abstract 
 
The hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy leading to acute renal 
failure in children. In most cases it is triggered by a shiga-like toxin-producing Escherichia coli (STEC) 
infection. Endothelial damage plays a central role in the pathogenesis of disease. Hemophilia A is a 
genetic disorder leading to factor VIII (FVIII) deficiency, an important factor in the coagulation 
system. Here we describe a hemophilia A patient that developed HUS due to a STEC O26 infection. 
Besides acute renal failure, severe gastro-intestinal and neurological complications occurred. 
Increased amounts of recombinant FVIII (rFVIII) had to be administered during the acute phase of 
the disease to reach acceptable blood levels of FVIII, to control the hemorrhagic colitis, and to 
prevent severe neurological complications. The patient’s treatment schedule of rFVIII during the 
HUS period was a big challenge and we cannot exclude that it contributed to the severity of the HUS 
by enhancing the thrombotic microangiopathic process. The role of factor VIII administration in the 
severe outcome of disease is discussed. 
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prevent severe neurological complications. The patient’s treatment schedule of rFVIII during the 
HUS period was a big challenge and we cannot exclude that it contributed to the severity of the HUS 
by enhancing the thrombotic microangiopathic process. The role of factor VIII administration in the 
severe outcome of disease is discussed. 
 
Introduction 
 
The hemolytic uremic syndrome (HUS), a thrombotic microangiopathy (TMA), is one of the most 
common causes of acute renal failure in children between two and five years of age in Western 
Europe.37 In more than 90%, the disease is triggered by an infection with shiga-like toxin-producing 
Escherichia coli (STEC).133 Most cases are associated with STEC serotype O157:H7, but other 
serotypes have been mentioned.25 Patients have abdominal pains with watery diarrhea, frequently 
followed by bloody diarrhea,  three to eight days after contamination. These symptoms are followed 
by hemolytic anemia, thrombocytopenia, and acute renal failure, sometimes already within 24 
hours.  
Here, we report severe renal, gastro-intestinal, and neurological complications due to a STEC O26 
infection in a 2-year old hemophilia A patient. Increased amounts of recombinant factor VIII (rFVIII) 
had to be administered during the acute phase of the disease. To our knowledge, this is the first 
report of a hemophilia patient that developed STEC-HUS. The treatment of hemophilia in the acute 
phase cannot be excluded to have contributed to the difficult management of the disease and to the 
development of severe complications. 
 
Case report 
 
The patient is the first child in a non-consanguineous family. As his mother is a carrier of hemophilia 
A, FVIII activity was determined in the neonatal period and severe hemophilia A was diagnosed. A 
spinal-epidural bleeding from C1 till sacral level occurred at the age of one year, after which 
prophylactic rFVIII therapy of 500 IU three times a week was started.  
 
At the age of two years and 9 months, he developed abdominal pain, vomiting, and bloody diarrhea. 
Intravenous rehydration was started and due to severe gastro-intestinal blood loss, treatment with 
rFVIII was increased to twice a day 500 IU (35 IU/kg). An abdominal x-ray demonstrated a dilated 
stomach, but no signs of ileus, abdominal or retroperitoneal bleeding. After two days he developed 
oliguria and a blood sample showed all signs of hemolytic uremic syndrome. Fecal samples for STEC 
detection were taken and the patient was transferred to the university hospital. 
  
On admission, a pale, uncomfortable, somnolent boy with slight peri-orbital and pretibial edema 
was seen. He was slightly dehydrated, had normal blood pressure (91/59 mmHg), a heart rate of 
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100-120 beats/min, and a body temperature of 39⁰C. No respiratory and cardiac abnormalities were 
seen. Results of laboratory evaluation at admission, including hemoglobin levels, hematocrit levels, 
thrombocyt count, and white blood cell count are shown in Table 7.1. Abdominal examination 
showed tenderness by palpation. Conservative treatment for renal failure was started. Serologically 
FVIII measured on admission was 15% (10 hours after last rFVIII administration), and due to ongoing 
rectal blood loss, rFVIII dosage was increased to 1000 IU (70 IU/kg) five times a day in the first two 
days, leading to a FVIII activity of 40 - 102% (Figure 7.1A). 
 
 
Figure 7.1. Factor VIII activities (A) and doses used in continuous infusion of rFVIII (B) in our patient. Target 
levels for FVIII activity were 40% to 70%, indicated with the dashed lines. Continuous rFVIII (IU/kg/hr) was 
administered from day 2 until day 26. To maintain FVIII levels at acceptable levels, in the first days and during the 
bleeding at the site of the jugular catheter, extra intravenous rFVIII was given (shown with arrows (A) and in box 
(B)). 
 
On the second evening he developed a tonic-clonic epileptic insult. Laboratory evaluation showed 
slightly decreased serum sodium with normal other electrolytes, decreased serum albumin, and 
elevated urea, creatinine, and glucose (Table 7.1). Blood pressure at that moment was normal 
(115/71, 85/57, and 106/74 mmHg). A CT-scan cerebrum showed symmetrical ventricles, normal 
aspects of cerebellum and brain stem, and no signs of hemorrhagic bleeding. Electric encephalogram 
and cephalorraquid liquid examination were normal. Neurological examination the day after the 
insult demonstrated a lower level of consciousness, discomfort, hypertonia, abnormal posturing of 
the head to the right, aphasia, and increased salivation with discomfort. At this time, bilateral 
symmetric signal intensity changes in the basal ganglia were seen on MRI: a typical finding in HUS 
patients with neurological complications.197  
 
Because of anuria, symptoms of ileus, and severity of neurological condition, continuous veno-
venous hemofiltration (CVVH) was initiated, as well as plasmapheresis. No antibiotics were 
prescribed. Plasmapheresis was stopped after confirmation of a STEC O26 infection. Because of 
A Continuous rFVIII
Extra IV injections of rFVIII
Extra rFVIII intraveneous
Before: 3x 500 IU per week 
Day 0: 2x 700 IU
Day 1: 4x 700 IU
Day 2: 5x 1000 IU
Day 3 and 4: 3x 750 IU
Day 18: 1x 250 IU; 1x 500 IU
Day 19: 1x 500 IU; 2x 1500 IU
Day 20-24: 1x 150 IU
Day 25: 1x 100 IU
Day 26: 1x 150 IU
Afterwards: 3x 500 IU per week
B
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On the second evening he developed a tonic-clonic epileptic insult. Laboratory evaluation showed 
slightly decreased serum sodium with normal other electrolytes, decreased serum albumin, and 
elevated urea, creatinine, and glucose (Table 7.1). Blood pressure at that moment was normal 
(115/71, 85/57, and 106/74 mmHg). A CT-scan cerebrum showed symmetrical ventricles, normal 
aspects of cerebellum and brain stem, and no signs of hemorrhagic bleeding. Electric encephalogram 
and cephalorraquid liquid examination were normal. Neurological examination the day after the 
insult demonstrated a lower level of consciousness, discomfort, hypertonia, abnormal posturing of 
the head to the right, aphasia, and increased salivation with discomfort. At this time, bilateral 
symmetric signal intensity changes in the basal ganglia were seen on MRI: a typical finding in HUS 
patients with neurological complications.197  
 
Because of anuria, symptoms of ileus, and severity of neurological condition, continuous veno-
venous hemofiltration (CVVH) was initiated, as well as plasmapheresis. No antibiotics were 
prescribed. Plasmapheresis was stopped after confirmation of a STEC O26 infection. Because of 
hemorrhagic colitis, severe neurological condition, hypertension, and bleeding at the exit site of the 
jugular catheter, all in combination with thrombocytopenia and persistently low FVIII levels in 
plasma, FVIII treatment was switched to continuous infusion, with a target level of 40-70%. The 
dosage of continuous rFVIII needed to reach these levels varied between 5 and 14 IU/kg/hr (Figure 
7.1B). Erythrocyte transfusions were given eight times. CVVH, combined with antihypertensive 
treatment, was continued for 18 days, in which renal function and hypertension improved. 
 
Three months after discharge, the boy was diagnosed with sigmoid stenosis, necessitating a sigmoid 
resection and end-to-end anastomosis. Currently, one year after the acute phase of disease, his 
creatinine clearance is normal (95 ml/min/1.73m2), but he still has proteinuria and hypertension 
treated with an ACE inhibitor. The prophylactic rFVIII therapy of 500 IU three times a week was 
resumed after discharge. Until now, no FVIII inhibitor had been detected. An intensive rehabilitation 
program was started and led to a clear improvement of the neurological involvement in our patient. 
There is still a slight lateralization to the right side of the body with hypertonia and hyperreflexia on 
the left side.  
 
Table 7.1. Laboratory evaluation at different time points. Day 0 is day of admission to the university pediatric 
nephrology ward. Normal values for children are shown within brackets. 
 Admission Day 0 Day 1 Day 2 At discharge 
serum creatinine (0.17 – 0.51 mg/dL) 2.25 2.71 4.07 4.05 0.66 
serum urea (7.0 – 19.6 mg/dL) 32.5 43.7 70.9 75.6 30.2 
hemoglobin (9.7 – 14.5 g/dL) 10.6 10.1 9.3 8.4 8.4 
hematocrit (0.30 – 0.45 L/L) 0.32 0.30 0.27 0.24 0.25 
thrombocytes (120 – 350 x103/μL) 65 68 72 82 409 
white blood cell count (6.0 – 18.0 103/μL) 22.2 25.4 30.2 23.8 8.1 
serum sodium (135 – 145 mEq/L) 131 127 128 126 138 
serum potassium (3.5 – 4.7 mEq/L) N/A 4.0 4.2 3.6 4.7 
magnesium (1.40 – 2.20 mEq/L) N/A 1.56 1.84 1.52 2.14 
calcium (8.82 – 10.62 mg/dL) N/A 7.90 7.56 6.53 10.4 
serum albumin (3.5 – 5.0 g/dL) N/A 2.3 1.8 1.9 N/A 
glucose (72.1 – 100.9 mg/dL) N/A 109.9 99.1 151.3 N/A 
N/A indicates not available. Conversion factors for units: serum creatinine in mg/dL to μmol/L, ×88.4; serum urea in mg/dL to  
mmol/L, ×0.357; hemoglobin in g/dL to mmol/L, ×0.6206; hemoglobin in g/dL to g/L, ×10; magnesium in mEq/L to mmol/l, ×0.5; 
calcium in mg/dL to mmol/L, ×0.2495; serum albumin in g/dL to g/L, ×10; glucose in mg/dL to mmol/L, x0.05551. No conversion 
necessary for serum sodium in mEq/L and mmol/L, for serum potassion in mEq/L and mmol/L, for thrombocytes in 103/μL and 
109/L, and for white blood cell count in 103/μL and 109/L. 
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calcium in mg/dL to mmol/L, ×0.2495; serum albumin in g/dL to g/L, ×10; glucose in mg/dL to mmol/L, x0.0 51. No conversion 
nece sary for serum sodium in mEq/L and mmol/L, for serum pota sion in mEq/L and mmol/L, for thrombocytes in 103/μL and 
109/L, and for white bl od cell count in 103/μL and 109/L. 
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Discussion 
 
We describe a 2-year-old boy, already known with severe hemophilia A and treated with 
prophylactic rFVIII, who developed a severe form of HUS due to a STEC O26 infection. The dosage of 
rFVIII had to be increased enormously to reach acceptable blood levels of FVIII to control the 
hemorrhagic colitis and a bleeding at the site of the jugular catheter, and to prevent severe 
neurological complications like intracerebral bleedings. Although his renal function recovered after 
18 days of CVVH, proteinuria and hypertension still persist. An intensive rehabilitation program 
made clear neurological progress, but the boy is still not fully rehabilitated. The question rose if the 
intensified treatment with rFVIII could have negatively influenced the outcome of this STEC-HUS 
patient. 
 
Infusion of FVIII results in complex formation with von Willebrand Factor (vWF), the carrier protein 
of FVIII in plasma. FVIII is released from the complex after activation by thrombin and subsequently 
participates in the propagation of the coagulation cascade by acting as a cofactor in the conversion 
of FX to FXa. Factor Xa will activate prothrombin to thrombin, eventually resulting in the formation 
of a stable fibrin clot. It was demonstrated that the thrombi in the glomeruli of typical HUS patients 
consist mostly of fibrin.198 Furthermore, in vitro experiments have shown that shiga toxin induces 
the secretion of vWF from microvascular endothelial cells.199 Next to its FVIII carrier function, vWF 
plays an important role in platelet adhesion after vessel wall injury. In this way, the adhesion of 
platelets will probably lead to increased thrombus formation in the microvasculature of the kidney 
of HUS patients. 
 
The supraphysiological doses of rFVIII needed in the first days of disease to treat the underlying 
pathology of hemophilia A together with the release of increased secretion of vWF by the HUS 
pathology may have contributed further to the TMA. It is known that increased levels of FVIII in 
children can lead to acquired thrombophilia, a state of hypercoagulability.200 It therefore may be 
very plausible that increased amounts of rFVIII contributed to increased thrombosis after shiga 
toxin-induced endothelial damage in the affected organs (especially intestines and brain). It is also 
known that hypertension can be responsible for cerebral involvement in HUS patients.201 Increased 
FVIII levels are significantly associated with intracranial hypertension202, and rFVIII administration 
could have contributed to the encephalopathy by this route as well. Bolus injections together with 
continuous infusion of rFVIII resulted in diverging FVIII levels (Figure 7.1A), which may have 
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The supraphysiological doses of rFVIII needed in the first days of disease to treat the underlying 
pathology of hemophilia A together with the release of increased secretion of vWF by the HUS 
pathology may have contributed further to the TMA. It is known that increased levels of FVIII in 
children can lead to acquired thrombophilia, a state of hypercoagulability.200 It therefore may be 
very plausible that increased amounts of rFVIII contributed to increased thrombosis after shiga 
toxin-induced endothelial damage in the affected organs (especially intestines and brain). It is also 
known that hypertension can be responsible for cerebral involvement in HUS patients.201 Increased 
FVIII levels are significantly associated with intracranial hypertension202, and rFVIII administration 
could have contributed to the encephalopathy by this route as well. Bolus injections together with 
continuous infusion of rFVIII resulted in diverging FVIII levels (Figure 7.1A), which may have 
compromised the disease. Therefore, only continuous infusion might be recommended to avoid a 
transient overdose of FVIII.  
 
The STEC serotype O26 found in this patient is one of the most common non-O157 STECs causing 
diarrhea and HUS.203 Neurological complications are seen often in O26-HUS, although case series 
disagree on their statistical significance. A study in Scotland showed a significant difference to the 
prejudice of O26 infection in disease severity and outcome204, while O26 patients in Austria and 
Germany did not have more neurological complications 203. Involvement of the basal ganglia is seen 
in the majority of the HUS patients with neurological complications and is frequently associated with 
good clinical outcome205, as is shown partly in our patient. Genetic aberrations, associated with the 
atypical form of HUS, were not identified in this patient.  
 
It is known that HUS patients with a combination on admission of dehydration, a longer period of 
oligoanuria, a WBC count of more than 20 x103/μL, and a hematocrit of more than 0.23 L/L, are at 
risk for a more severe disease course and even death.206 Furthermore, in HUS patients with 
hemorrhagic colitis, renal and neurological complications were more severe than in patients without 
HC.207 All above mentioned criteria were present in our patient (Table 7.1), which indicates that his 
severe condition could be due to all this as well. 
 
Here we have reported a hemophilia patient whom developed HUS after a STEC O26 infection, 
complicated by severe neurological and gastro-intestinal complications. His treatment schedule of 
rFVIII during the HUS period was a big challenge. Although the severe complications seen could be 
due to the specific STEC serotype, hemorrhagic colitis, or the combination of dehydration, 
oligoanuria, high WBC numbers, and high hematocrit, we cannot exclude that the administration of 
rFVIII also contributed to the severity of the HUS by enhancing the thrombotic microangiopathic 
process. 
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Abstract 
 
Atypical hemolytic uremic syndrome (aHUS) is associated with (genetic) alterations in the alternative 
complement pathway. Nevertheless, comprehensive evidence that the complement system in aHUS 
patients is more prone to activation is still lacking. Therefore, we performed a thorough analysis of 
complement activation in acute phase and in remission of this disease.  
Complement activation patterns of the aHUS patients in acute phase and in remission were 
compared to those of healthy controls. Background levels of complement activation products C3b/c, 
C3bBbP and TCC were measured using ELISA in EDTA plasma. In vitro triggered complement 
activation in serum samples was studied using zymosan-coating and pathway-specific assay. 
Furthermore, efficiencies of the C3b/c, C3bBbP, and TCC generation in fluid phase during 
spontaneous activation were analyzed.  
Patients with acute aHUS showed elevated levels of C3b/c (P<0.01), C3bBbP (P<0.0001) and TCC 
(P<0.0001) in EDTA plasma, while values of patients in remission were normal, compared to those of 
healthy controls. Using data from a single aHUS patient with complement factor B mutation, we 
illustrate normalization of complement activation during aHUS recovery. Serum samples from 
patients in remission showed normal in vitro patterns of complement activation and demonstrated 
normal kinetics of complement activation in the fluid phase. 
Our data indicate that while aHUS patients have clearly activated complement in the acute phase of 
the disease, this is not the case in remission of aHUS. This knowledge gives important insight into 
complement regulation in aHUS and may have an impact on monitoring of these patients, 
particularly when using complement inhibition therapy. 
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patients in remission showed normal in vitro patterns of complement activation and demonstrated 
normal kinetics of complement activation in the fluid phase. 
Our data indicate that while aHUS patients have clearly activated complement in the acute phase of 
the disease, this is not the case in remission of aHUS. This knowledge gives important insight into 
complement regulation in aHUS and may have an impact on monitoring of these patients, 
particularly when using complement inhibition therapy. 
 
Introduction 
 
Atypical hemolytic uremic syndrome (aHUS) is a severe renal illness with up to 50% of cases 
progressing to end stage renal disease (ESRD) and up to 25% of lethal outcomes in the acute phase 
of aHUS.3 Complement dysregulation, leading to glomerular endothelial cell damage is considered to 
be a central element in aHUS pathogenesis and complement inhibition therapy, reported to be 
successful, has recently been approved for aHUS treatment.104, 208, 209 
The complement system, a part of the innate immune system, can be activated via three pathways: 
the classical, the lectin and the alternative. These pathways converge at the cleavage and activation 
of the central complement component C3. This results in formation of the C3b fragment, which 
binds zymogen complement factor B (FB) and, in association with properdin, forms the alternative 
pathway C3 convertase (C3bBbP). C3bBbP cleaves and activates more C3 molecules, leading to 
formation of the terminal C5b-9 complement complex (TCC) and release of the potent 
anaphylatoxins C3a and C5a. To protect healthy host tissue, the C3 convertase activity is controlled 
by complement inhibitors, such as complement factor I (FI), complement factor H (FH) and 
membrane cofactor protein (CD46/MCP). As a result of C3 convertase inactivation, various C3 
degradation products are formed, such as iC3b, C3c and C3dg.66, 210  
Currently, alternative complement pathway deficiencies are identified in 50-60% of aHUS patients. 
Genetic variants affecting FH, FI, CD46, C3, and FB, as well as autoantibodies against FH (αFH) are 
associated with aHUS pathogenesis. Also aberrations affecting genes outside of the complement 
cascade, encoding thrombomodulin (THBD) and diacylglycerol kinase ε (DGKE) were reported.69-71, 73-
75, 80, 81, 83, 94, 143, 175, 211, 212 Etiological analysis of patients with aHUS is critically important, especially 
in renal transplantation, which is frequently required in this patient group. For example, patients 
that carry mutations in genes encoding FH, FI, or C3 are at higher risk of the disease recurrence in 
the graft (40-90%), whereas such probability is lower for the aHUS patients carrying CD46 mutations 
and αFH autoantibodies.
29, 78, 95, 213 Functional analysis of complement activation in aHUS patients 
remains very limited. C3 and C4 levels, which are used in clinical practice, often show normal values. 
Recently, a single study reported that C5a and TCC are higher in aHUS than in thrombotic 
thrombocytopenic purpura (associated not with complement aberrations, but with ADAMTS13 
deficiency).214 However, it is still not clear whether the complement system is more prone to 
activation in aHUS patients than in healthy individuals. 
In this study, we for the first time performed thorough analysis of complement activation in aHUS 
patients in the acute phase of the disease and in remission. Monitoring of complement activation 
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dynamics in EDTA plasma and serum samples may provide a simple and important tool in 
assessment of complement activation in aHUS patients, particularly when complement inhibition 
therapy is used. 
 
Materials and methods  
 
Study population  
The research population consisted of two groups of aHUS patients in acute phase (n=6) and in 
remission (n=11) of the disease. The acute phase was defined as the presence of hemolytic anemia, 
thrombocytopenia and acute renal failure. Patients in remission had their last aHUS episode more 
than one year ago. In addition, from a single aHUS patient with a p.Lys323Glu mutation in FB, 
samples were taken during two acute aHUS episodes, in following convalescence periods during 
plasmapheresis (PF) treatment, and in the remission phase at the time of the study. The patients 
were referred to the Pediatric Nephrology Department of the Radboud university medical center. 
The control group consisted of healthy adult volunteers. For the controls the following exclusion 
criteria were applicable: fever, bacterial/viral infection in previous two weeks, chronic illness, inborn 
or acquired immune disorders, immunosuppressive medication. The study was approved by the 
institutional review board and was performed in accordance with the appropriate version of the 
Declaration of Helsinki. Informed consent of all patients and/or their parents as well as of controls 
was obtained before analysis. 
 
Genetic analysis 
Genomic DNA was isolated from peripheral blood leukocytes as described by Miller et al.140 Coding 
fragments of CFH, CFI, MCP, C3, CFB, THBD, and DGKE genes were amplified from genomic DNA by 
means of PCR. Primer sequences are available upon request. The obtained PCR products included 
DNA sequences of the individual exons, flanked by the splice donor site and the splice acceptor site. 
The amplimers were subjected to double-stranded DNA sequence analysis on an ABI 3130 xl 
GeneticAnalyzer (Applied Biosystems, South San Francisco, CA, USA). Sequence analyses were 
performed using Sequencher 4.8 software (Gene Codes, Ann Arbor, MI USA). Anti-FH autoantibodies 
were detected as described before.72 
 
Sample collection 
EDTA blood and serum samples of patients and controls were collected and processed within one 
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Genomic DNA was isolated from peripheral blood leukocytes as described by Miller et al.140 Coding 
fragments of CFH, CFI, MCP, C3, CFB, THBD, and DGKE genes were amplified from genomic DNA by 
means of PCR. Primer sequences are available upon request. The obtained PCR products included 
DNA sequences of the individual exons, flanked by the splice donor site and the splice acceptor site. 
The amplimers were subjected to double-stranded DNA sequence analysis on an ABI 3130 xl 
GeneticAnalyzer (Applied Biosystems, South San Francisco, CA, USA). Sequence analyses were 
performed using Sequencher 4.8 software (Gene Codes, Ann Arbor, MI USA). Anti-FH autoantibodies 
were detected as described before.72 
 
Sample collection 
EDTA blood and serum samples of patients and controls were collected and processed within one 
hour after sampling. Samples were aliquoted and stored at -80°C. To avoid in vitro complement 
activation after sampling, EDTA plasma samples were used to compare complement activation in 
acute phase and in remission of aHUS. Serum samples were used in the in vitro complement 
activation experiments. 
 
Complement activation analyses 
The levels of complement activation products C3b and its degraded form C3c (C3b/c), the alternative 
complement pathway convertase C3bBbP, and the fluid phase terminal sC5b-9 complement 
complex (TCC) in EDTA plasma were quantified using enzyme-linked immunosorbent assay (ELISA) as 
described in detail previously by Bergseth et al.215 The international complement standard#2 (ICS#2) 
was used for quantification of activation products in complement activation units per ml 
(CAU/ml).215  
Zymosan-induced activation of serum was performed in 96-well plates coated using 2 μg/well of 
zymosan A from Saccharomyces cerevisiae (Sigma-Aldrich, St. Louis, MO, USA). Complement 
activation and detection of C3b and TCC deposition on the solid phase was performed as described 
before.216 
To analyze the classical, lectin and alternative pathway activation separately, a Wieslab® 
Complement system Screenkit (Euro Diagnostica, Malmö, Sweden) was used according to the 
manufacturer’s protocol.   
In a kinetic activation analysis, serum samples were diluted 1:2 in Dulbecco’s phosphate buffered 
saline with MgCl2 and CaCl2 (Sigma-Aldrich) and incubated at 37°C with gentle agitation, samples 
were collected at 0, 10, 20, 30 and 60 minutes of incubation and immediately placed on ice. To stop 
the complement activation, EDTA (Sigma-Aldrich) was added to a final concentration of 20 mM. 
Complement activation products were quantified as described above for EDTA plasma samples. 
 
Statistical analysis 
Statistical analysis was done using unpaired two-tailed t-test. Statistically significant differences with 
P<0.05 are indicated. 
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Results 
 
Genetic background of the aHUS patients 
For this study, samples from two groups of patients in the acute phase (n=6) and in remission (n=11) 
were available. The patients in both groups were screened for the presence of pathogenic genetic 
variations in genes encoding FH, FI, CD46, C3, FB, THBD, and DGKE; furthermore, presence of αFH 
autoantibodies was analyzed. In the acute phase aHUS group, two of the patients carried 
heterozygous genetic variants in C3 or CD46 and one had αFH autoantibodies, while three patients 
had aHUS of undefined etiology (Table 8.1). In the aHUS remission group, six patients carried 
heterozygous changes in CFH, CFI, C3 or THBD; in five patients no genetic aberrations or αFH 
autoantibodies were found (Table 8.2). Familial and idiopathic aHUS patients were present in both 
groups (Table 8.1 and Table 8.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1. Plasma complement activation products in patients with aHUS in acute phase and in remission. 
EDTA plasma samples of six aHUS patients in acute phase (A) and of 11 patients in remission phase (B) were 
analyzed for the levels of C3b/c, C3bBbP and TCC. The values were compared to those of 19 healthy controls. 
Data were quantified using the international complement standard#2 (ICS#2) in complement activation units per 
ml (CAU/ml) and are presented as mean+standard deviation. Values that were statistically different from those 
of healthy controls (P<0.05) are indicated. 
 
Complement activation in acute phase and in remission of aHUS 
First, we analyzed complement activation in the acute phase and in remission of aHUS. To this end, 
we measured concentrations of complement activation products C3b/c, C3bBbP, and TCC in EDTA 
plasma of aHUS patients and compared the values to those of healthy controls (n=19). These assays 
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Complement activation in acute phase and in remission of aHUS 
First, we analyzed complement activation in the acute phase and in remission of aHUS. To this end, 
we measured concentrations of complement activation products C3b/c, C3bBbP, and TCC in EDTA 
plasma of aHUS patients and compared the values to those of healthy controls (n=19). These assays 
reflect activation of the alternative complement pathway, which is implicated in aHUS pathogenesis. 
In the acute phase of the disease, we observed significantly elevated levels of C3b/c, C3bBbP, and 
TCC (Figure 8.1A). In four of the six patients in the acute phase, all three activation products were 
elevated; in the other two patients, two of the three activation product were elevated, indicating 
ongoing complement activation in all of these patients (Table 8.3). The values of C3bBbP and TCC 
were increased in all six patients, including the three patients with normal serum C3 levels in the 
acute phase. On the other hand, patients in remission showed C3b/c, C3bBbP, and TCC values that 
were completely comparable to those of healthy controls (Figure 8.1B).  
From a single female patient, carrying the well-characterized p.Lys323Glu mutation in FB74, samples 
taken during two acute aHUS episodes, following PF treatments, and in remission were available at 
the time of the study (Table 8.4). Increased concentrations of all three complement activation 
markers (first episode) and C3b/c and C3bBbP (second episode) were detected in the acute phase. 
Complement activation levels considerably decreased during PF treatments and were completely 
normalized in remission. 
Together, our data indicate that in acute aHUS episodes complement activation is taking place, but 
returns to the level of healthy controls during remission.  
 
Induced complement activation in serum samples of aHUS patients in acute phase 
Ongoing complement activation in the acute phase of aHUS may lead to complement consumption 
as partially seen from the C3 serum levels (Table 8.3). This may cause diminished capacity for 
complement activation. Next, we tested this hypothesis using a pathway-specific activation assay, 
widely used in clinical laboratories (Figure 8.2). Our results indicate that the classical and lectin 
pathway activation profiles are not different between the acute phase patients and healthy 
individuals. In the alternative pathway experiment, only one of the acute phase patients (P6a) 
demonstrated activation outside of the normal range.  
 
Induced complement activation in serum samples of aHUS patients in remission 
Next, we analyzed whether, when triggered, serum samples of aHUS patients in remission are able 
to reach higher complement activation levels than the samples of healthy controls. To this end, we 
performed complement activation on the zymosan-coated surface. Zymosan is able to directly 
activate the lectin and the alternative complement pathway and also activates the classical pathway 
when anti-zymosan antibodies are present in serum.217 We quantified C3b and TCC deposition on 
zymosan-coated surfaces in response to the activation of serum samples. No significant differences  
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Figure 8.2. Pathway-specific activation of serum samples from acute aHUS patients. Specific activation of the 
classical (CP), the lectin (LP) and the alternative (AP) pathway of complement was measured with TCC deposition 
as readout. Data are presented as percentage of activation of the positive control provided with the assay. Low 
alternative pathway activation value in sample of patient P6a is indicated. 
 
between remission phase aHUS samples and control samples were observed by using zymosan-
induced complement activation (Figure 8.3A).  
Furthermore, we performed pathway-specific analysis to quantify activation of the classical, lectin, 
and alternative pathway separately (Figure 8.3B). This analysis also did not reveal significant 
differences between complement activation in aHUS patients in remission and in healthy controls. 
These data indicate that complement activation in serum samples of aHUS patients in remission is 
not triggered to a higher level than in samples of healthy controls. 
 
Kinetics of complement activation in serum samples of aHUS patients in remission 
So far, no differences in complement activation between patients in remission and controls were 
observed. Finally, we analyzed whether serum samples of aHUS patients in remission have faster 
activation kinetics compared to samples of healthy controls. Thus, we studied the kinetics of 
spontaneous complement activation in fluid phase. Serum samples were incubated at 37°C to 
induce spontaneous alternative pathway complement activation, after which concentrations of 
C3b/c, C3bBbP and TCC were analyzed at various time points (Figure 8.4). No statistically significant 
differences between patients and controls were observed.  
These results indicate that there is no difference in complement activation kinetics between aHUS 
patients in remission and healthy controls. 
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Discussion  
 
Complement dysregulation is an established hallmark of aHUS. In this study we, to our best 
knowledge, for the first time present a comprehensive analysis of complement activation in blood of 
aHUS patients in the acute phase and in remission.   
 
We observed a clear activation of the alternative complement pathway in the acute phase group, as 
revealed by significant increases in C3b/c, C3bBbP, and TCC in EDTA plasma. The levels of these 
complement activation markers in aHUS patients in remission, however, were normal. Moreover, 
when analyzed in a single aHUS patient with a FB mutation, complement activation was clearly 
detected in both aHUS episodes, but not in remission. Therefore, we suggest that in remission, 
complement activation in blood of aHUS patients normalizes to the levels of healthy individuals. As 
our experiments included a limited number of patients, studies in larger cohorts should be 
performed in the future.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3. Induced complement activation of serum samples from aHUS patients in remission. (A) Serum 
samples of 11 patients in remission phase of aHUS and of 19 healthy controls were analyzed for complement 
activation in zymosan-coated wells, using C3b and TCC deposition as readout. Results are given as absorbance 
units of optical density (OD). (B) Specific activation of the classical (CP), the lectin (LP) and the alternative (AP) 
pathway of complement was measured with TCC deposition as readout. Data are presented as percentage of 
activation of the positive control provided with the assay. 
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Discussion  
 
Complement dysregulation is an established hallmark of aHUS. In this study we, to our best 
knowledge, for the first time present a comprehensive analysis of complement activation in blood of 
aHUS patients in the acute phase and in remission.   
 
We observed a clear activation of the alternative complement pathway in the acute phase group, as 
revealed by significant increases in C3b/c, C3bBbP, and TCC in EDTA plasma. The levels of these 
complement activation markers in aHUS patients in remission, however, were normal. Moreover, 
when analyzed in a single aHUS patient with a FB mutation, complement activation was clearly 
detected in both aHUS episodes, but not in remission. Therefore, we suggest that in remission, 
complement activation in blood of aHUS patients normalizes to the levels of healthy individuals. As 
our experiments included a limited number of patients, studies in larger cohorts should be 
performed in the future.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3. Induced complement activation of serum samples from aHUS patients in remission. (A) Serum 
samples of 11 patients in remission phase of aHUS and of 19 healthy controls were analyzed for complement 
activation in zymosan-coated wells, using C3b and TCC deposition as readout. Results are given as absorbance 
units of optical density (OD). (B) Specific activation of the classical (CP), the lectin (LP) and the alternative (AP) 
pathway of complement was measured with TCC deposition as readout. Data are presented as percentage of 
activation of the positive control provided with the assay. 
Table 8.3. Complement assessment of patients in the acute phase of aHUS. Values outside of the normal range 
are indicated in bold. 
Patient number C3 (700-1500) a C4 (100-400) a C3b/c (<15.8 ) b C3bBbP (<23.5) b TCC (<2.2) b 
P1a 1110 323 57.82 (↑) 148.7 (↑) 7.85 (↑) 
P2a 1130 300 18.15 (↑) 29.3 (↑) 15.16 (↑) 
P3a 639 (↓) 292 12.25 46.59 (↑) 5.39 (↑) 
P4a 657 (↓) 164 34.25 (↑) 67.48 (↑) 2.56 (↑) 
P5a 927 205 11.28 34.74 (↑) 4.84 (↑) 
P6a 620 (↓) 250 19.63 (↑) 99.95 (↑) 10.94 (↑) 
a Normal serum concentration range (mg/l) defined by the standard clinical protocol; b Normal concentration range (CAU/ml) 
defined by this study as mean+ 2 standard deviations of control values (n=19). 
 
Table 8.4. Complement assessment of a single female patient during two acute aHUS episodes. Samples were 
collected in convalescent periods after five (first episode) and 10 (second episode) plasmapheresis (PF) sessions 
and in remission at the time of the study. The patient recovered without need of a renal transplant and carries 
the pathogenic p.Lys323Glu mutation in FB74. Values outside of the normal range are indicated in bold. 
Disease phase  Age (years) C3b/c (<15.8) a C3bBbP (<23.5) a TCC (<2.2) a 
First acute episode 2.5 155.17  (↑) 61.58  (↑) 2.88  (↑) 
After 5 PF sessions 2.5 21.57  (↑) 19.87 1.3 
Second acute episode 3.5 116.16  (↑) 115.49  (↑) 0.74 
After 10 PF sessions 3.5 22.82  (↑) 10.82 0.67 
Remission phase 21 10.33 6.00 0.46 
a Normal concentration range (CAU/ml) defined by this study as mean+ 2 standard deviations of control values (n=19). 
 
activation might take place at the surface, but not close enough for the TCC to be inserted and 
thereby generating a fluid phase complex, as typically seen by artificial surfaces such as hemodialysis 
membrane.218, 219 
Our data do not exclude the possibility of ongoing complement activation on the cell surface in 
remission, that could be experimentally detected using sheep erythrocytes or endothelial cells and 
that was outside of scope of this study.  
 
We found that in a single aHUS patient with a FB mutation, complement activation was clearly 
detected in both aHUS episodes, but not in remission. Previously, complement activation in a single 
aHUS patient with the FH mutation p.Ser1191Leu was monitored before and after infusion of fresh 
frozen plasma.220 Only limited effect of plasma infusion on complement activation was observed 
using a hemolytic alternative pathway assay and no difference was observed in a pathway-specific 
screen. The assays used in this previous study reflect a resultant of several factors, including the 
amount of native components present, which not necessarily reflect the degree of ongoing 
activation. This is reflected by the activation product assays we have used. Consistently with these 
Complement activation patterns in atypical hemolytic uremic syndrome during acute phase and in remission
Table 8.3. Complement a se sment of patients in the acute phase of aHUS. Values outside of the normal range 
are indicated in bold. 
Patient number C3 (7 0-15 0) a C4 (1 0-4 0) a C3b/c (<15.8 ) b C3bBbP (<23.5) b T C (<2.2) b 
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P4a 657 (↓) 164 34.25 (↑) 67.48 (↑) 2.56 (↑) 
P5a 927 205 1.28 34.74 (↑) 4.84 (↑) 
P6a 620 (↓) 250 19.63 (↑) 9.95 (↑) 10.94 (↑) 
a Normal serum concentration range (mg/l) defined by the standard clinical protocol; b Normal concentration range (CAU/ml) 
defined by this study as mean+ 2 standard deviations of control values (n=19). 
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previous data, all but one patient in our acute phase group, demonstrated normal activation in 
pathway-specific assay, compared to a control group (Figure 8.2). 
 
Further, we analyzed whether complement activation in serum samples of remission patients can be 
triggered more efficiently than in samples of healthy controls. Our data indicate that both zymosan-
induced activation and pathway-specific activation of aHUS serum samples give results similar to 
those of healthy controls. Also results of kinetic analysis in the fluid phase appeared to be 
comparable in aHUS remission patients and in controls.  
 
These findings are indeed intriguing, as six out of 11 patients carry aHUS-predisposing genetic 
aberrations, which are expected to cause more efficient complement activation. Patient P1r and 
patient P2r carry the p.Arg1206Cys substitution in the CFH gene. Previously, the p.Arg1206Ala 
variant was characterized in functional studies using recombinant FH19-20 fragment.212 In this work, 
impaired binding of a FH19-20 fragment carrying p.Arg1206Ala to C3b/d and mouse glomerular 
endothelium was shown. We expect p.Arg1206Cys to have a similar effect on protein function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4. In vitro kinetics of spontaneous complement activation in the serum samples of aHUS patients in 
remission. Samples of 11 aHUS patients in remission and of 19 healthy controls were incubated at 37°C with 
gentle agitation. Samples were collected at 0, 10, 20, 30 and 60 minutes of incubation and levels of C3b/c (A), 
C3bBbP (B) and TCC (C) were analyzed. Data were quantified using international complement standard#2 (ICS#2) 
and are presented as complement activation units per ml (CAU/ml). 
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previous data, all but one patient in our acute phase group, demonstrated normal activation in 
pathway-specific assay, compared to a control group (Figure 8.2). 
 
Further, we analyzed whether complement activation in serum samples of remission patients can be 
triggered more efficiently than in samples of healthy controls. Our data indicate that both zymosan-
induced activation and pathway-specific activation of aHUS serum samples give results similar to 
those of healthy controls. Also results of kinetic analysis in the fluid phase appeared to be 
comparable in aHUS remission patients and in controls.  
 
These findings are indeed intriguing, as six out of 11 patients carry aHUS-predisposing genetic 
aberrations, which are expected to cause more efficient complement activation. Patient P1r and 
patient P2r carry the p.Arg1206Cys substitution in the CFH gene. Previously, the p.Arg1206Ala 
variant was characterized in functional studies using recombinant FH19-20 fragment.212 In this work, 
impaired binding of a FH19-20 fragment carrying p.Arg1206Ala to C3b/d and mouse glomerular 
endothelium was shown. We expect p.Arg1206Cys to have a similar effect on protein function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4. In vitro kinetics of spontaneous complement activation in the serum samples of aHUS patients in 
remission. Samples of 11 aHUS patients in remission and of 19 healthy controls were incubated at 37°C with 
gentle agitation. Samples were collected at 0, 10, 20, 30 and 60 minutes of incubation and levels of C3b/c (A), 
C3bBbP (B) and TCC (C) were analyzed. Data were quantified using international complement standard#2 (ICS#2) 
and are presented as complement activation units per ml (CAU/ml). 
Patients P4r and P5r carry the C3 variant p.Arg161Trp that was previously reported by us and others 
and has negative impact on FH and CD46 binding and increases the affinity to FB.94, 175 Furthermore, 
thrombomodulin, a component of the coagulation system, was previously reported to regulate 
inactivation of C3b in vitro. The p.Ala43Thr change (P6r) was shown to negatively affect this 
function.73 Particularly interesting is the FI mutation in patient P3r, which leads to a stop codon in 
the serine protease domain that is important for C3b and C4b inactivation. 
 
Absence of a phenotype in remission phase patients might be in line with relatively mild nature of 
often heterozygous aHUS changes. Penetrance (the chance to acquire aHUS) is estimated to be 
approximately 60% for aHUS variants. It is suggested that next to a genetic variant or αFH 
autoantibodies, presence of aHUS-predisposing single nucleotide polymorphisms and external 
stimuli, such as infections, surgeries or use of medication, is needed for development of aHUS.221 
 
In this study, low serum C3 levels were found only in three acute phase patients, indicating 
complement activation. Moreover, only one patient showed aberrant alternative pathway activation 
in a pathway-specific activation assay. However, the activation markers, which were elevated in all 
patients, may provide a more promising tool for the detection of complement activation in aHUS. 
 
The fact that the samples from patients in remission of aHUS display normal complement activation 
pattern in blood has an important clinical implication. This indicates that in remission phase, aHUS 
patients are likely to have the same low complement activation levels as that of healthy controls. 
Therefore, these assays may be used in early detection of relapse of aHUS in the future. Recently, 
the complement component C5 inhibitor eculizumab (Soliris®) was approved for treatment of 
aHUS.104, 208, 209 Patients in the acute phase of aHUS that undergo treatment with complement 
inhibition therapy can be monitored for the levels of complement activation markers (C3b/c, 
C3bBbP, and TCC). The value of these markers in patients undergoing eculizumab treatment will be 
studied in the near future, which may lead to the development of individualized therapy based on 
the levels of complement activation. 
 
In conclusion, we demonstrated that complement activation can be clearly shown in blood of aHUS 
patients during acute episodes of the disease and that levels of complement activation markers in 
the fluid phase completely return to normal during remission. No change in complement activation 
profile as compared with controls was seen when complement was triggered in vitro in the serum 
Complement activation patterns in atypical hemolytic uremic syndrome during acute phase and in remission
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samples of aHUS patients in remission. These assays may be very helpful in the diagnostic setting to 
monitor complement dysregulation during aHUS attacks, especially when using complement 
inhibition therapy.  
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Abstract 
 
The role of the complement system in the atypical form of HUS (aHUS) has been investigated 
tremendously in recent years. Genetic and acquired aberrations have been identified in aHUS 
patients, resulting in a dysregulation of the complement system. It is known that HUS-associated 
bacteria, like shiga-toxin producing Escherichia coli (STEC) and Streptococcus pneumoniae (SP), can 
evade the complement system by binding complement regulators. We hypothesize that a 
dysregulation of the complement system has an important role in the pathogenesis of STEC-HUS and 
SP-HUS as well.  
Serological and genetic profiles of the alternative complement pathway were prospectively 
determined in the acute and convalescent phase of disease in 38 HUS patients (27 STEC-HUS 
patients, 10 aHUS patients, and one SP-HUS patient). To compare the serological profiles to those of 
age-matched controls, 90 healthy children (aged 5 months – 18 years) were included in the study as 
well.  
In all HUS groups, the alternative pathway was activated in the acute phase of disease, but not in 
remission. The C3d/C3 ratio displayed the best discrepancy between acute and convalescent phase 
and between STEC-HUS and aHUS, and might therefore be used as a biomarker in diagnosis and 
disease monitoring. A genetic complement aberration or the presence of autoantibodies against 
Factor H was present in 40.5% of the patients, including STEC-HUS and SP-HUS patients. Both 
patients with and without proven genetic aberrations or autoantibodies had altered serological 
complement profiles in the acute and/or convalescent phase of disease. The reason for the 
identified complement activation in infection-induced HUS is not completely clear yet. A prospective 
study is needed to investigate differences in complement activation in the acute phase of disease 
and in remission between patients that develop HUS after an infection with STEC or SP and those 
that do not. 
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Abstract 
 
The role of the complement system in the atypical form of HUS (aHUS) has been investigated 
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patients, resulting in a dysregulation of the complement system. It is known that HUS-associated 
bacteria, like shiga-toxin producing Escherichia coli (STEC) and Streptococcus pneumoniae (SP), can 
evade the complement system by binding complement regulators. We hypothesize that a 
dysregulation of the complement system has an important role in the pathogenesis of STEC-HUS and 
SP-HUS as well.  
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patients with and without proven genetic aberrations or autoantibodies had altered serological 
complement profiles in the acute and/or convalescent phase of disease. The reason for the 
identified complement activation in infection-induced HUS is not completely clear yet. A prospective 
study is needed to investigate differences in complement activation in the acute phase of disease 
and in remission between patients that develop HUS after an infection with STEC or SP and those 
that do not. 
 
  
Introduction 
 
The hemolytic uremic syndrome (HUS) is a rare and severe thrombotic microangiopathy (TMA), 
characterized by the trias hemolytic anemia, thrombocytopenia, and acute renal failure.1 In most 
cases, HUS is seen in children between two and five years of age and is often preceded by watery or 
bloody diarrhoea. It is the most common cause of acute renal failure in infants and children in 
Western Europe.37 In more than 90% the disease is triggered by shiga-like toxin-producing 
Escherichia coli (STEC).133 The outcome of STEC-HUS is relatively good, with ~75% complete recovery 
and sequelae like proteinuria and hypertension in the remaining. Non-STEC-HUS is seen in 5% to 
10% of all pediatric HUS cases, can appear at any age and may be sporadic or familial. These patients 
have a less favourable prognosis: up to 50% of these so-called atypical cases progress to end-stage 
renal disease (ESRD) and 25% of the cases may result in death during the acute phase of the 
disease.29, 109 A wide variety of triggers for non-STEC-HUS have been identified, including 
dysregulation of the complement system (aHUS), various non-enteric infections (Streptococcus 
pneumonia), viruses (HIV), malignancies, drugs, transplantations, pregnancy, and other underlying 
medical conditions including systemic diseases.3, 171, 173  
 
The human complement system is part of innate immunity and consists of more than 40 plasma and 
membrane-associated proteins. The most important roles of the complement system are the 
recognition of pathogens (opsonization), the activation and chemotaxis of leukocytes, and the 
induction of cell lysis by incorporation of the membrane attack complex.66 Three activation 
pathways have been recognized: the classical pathway, the lectin pathway, and the alternative 
pathway. In the alternative pathway complement component C3 is spontaneously activated at a 
very low rate to C3a and C3b. Factor B can bind to C3b to form the C3 convertase C3bBb, which is 
stabilized by properdin and can cleave more C3 molecules. At the surface of normal host cells, 
complement activation is regulated by the inactivation of C3b and/or dissociation of C3 convertase 
by regulators in the fluid phase (complement factor H [FH] and factor I [FI]) or by membrane-bound 
regulators (membrane cofactor protein/CD46 [CD46] and complement receptor 1).66 
The dysregulation of the alternative pathway of the complement system plays an important role in 
the pathogenesis of aHUS. In the past years, DNA mutation analysis of genes encoding complement 
proteins in patients with aHUS have clearly demonstrated that in 50-60% of the patients mutations 
are found in FH, FI, CD46, FB, and C3.70-72, 74, 75, 94, 141 A subgroup of patients with aHUS has been 
described as having antibodies against FH (αFH) in combination with a polymorphic homozygous 
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deletion of complement factor H related proteins 1 and 3 (CFHR1/3).81, 82, 137 Next to the mentioned 
genes, mutations have been identified in three genes encoding coagulation proteins (THBD, DGKE, 
and PLG).73, 83, 85  
 
Recent in vitro studies have shown that the microbial pathogens associated with HUS or their toxins 
can activate the complement system and bind complement proteins, in particular the most 
important regulator factor H, thereby providing the organism with a mechanism to protect itself 
against complement activation.113, 116, 127 Based on the similarity of the clinical manifestations of 
complement-mediated and infection-induced HUS and the knowledge that bacteria can use 
complement regulators to survive in the host, we hypothesized that also in patients with HUS 
caused by an infection with Shiga-like toxin producing E. coli (STEC-HUS) and Streptococcus 
pneumonia (SP-HUS), a dysregulation of the complement system has an important place in the 
pathogenesis.  
 
Anecdotal reports showed low C3 levels and increased complement activation products in children 
with STEC-HUS and SP-HUS.65, 91, 110-112, 222 In 2009, a report was published about elevated plasma 
levels of complement fragments of the alternative pathway (only FB and TCC were measured) in 
STEC-HUS patients during the first month after onset of the disease, but a small research population 
was used (seventeen patients) and only four non-age-matched control patients were included.111 
These results were confirmed in a Swedish cohort of 10 STEC-HUS patients, in which C3a and TCC 
levels were increased in the acute phase of disease and normalized in remission.112 The use of the 
complement inhibitor eculizumab in STEC-HUS, however, is still questionable. Even though 
individual patients can respond rapidly with efficient recovery, in larger cohorts, no significant 
differences were seen on mortality or morbidity with the use of eculizumab in STEC-HUS patients.46, 
47, 119, 120 
 
To answer the question if alterations in the alternative complement pathway are common in 
patients with all forms of HUS, we prospectively determined genetic and serological complement 
profiles in serum and plasma of children with STEC-HUS, SP-HUS, or aHUS in the acute and in the 
convalescent phase of the disease. At the moment, in most studies, control ranges for adults are 
used to interpret results of serological complement tests in children, which is an important 
shortcoming in the correct interpretation of the results. There are only anecdotal reports of serum 
complement levels in healthy infants and children, of which most have been published more than 
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individual patients can respond rapidly with efficient recovery, in larger cohorts, no significant 
differences were seen on mortality or morbidity with the use of eculizumab in STEC-HUS patients.46, 
47, 119, 120 
 
To answer the question if alterations in the alternative complement pathway are common in 
patients with all forms of HUS, we prospectively determined genetic and serological complement 
profiles in serum and plasma of children with STEC-HUS, SP-HUS, or aHUS in the acute and in the 
convalescent phase of the disease. At the moment, in most studies, control ranges for adults are 
used to interpret results of serological complement tests in children, which is an important 
shortcoming in the correct interpretation of the results. There are only anecdotal reports of serum 
complement levels in healthy infants and children, of which most have been published more than 
two decades ago, using different in‐house and mostly outdated techniques.223-228 We therefore 
screened complement profiles in age-matched healthy Dutch infants and children, which have been 
collected in a strict protocolled way, to obtain reliable reference intervals for the interpretation of 
our studies in HUS children. 
 
Materials and methods 
 
Patients and controls 
Newly diagnosed children (0-18 years) with STEC-HUS, SP-HUS, or aHUS, referred to the pediatric 
nephrology ward of all eight academic hospitals in The Netherlands between August 2010 and 
September 2013, were eligible to enroll in the study. EDTA plasma and/or serum samples were 
collected before the initiation of therapy (acute phase sample) and 14-28 days later (convalescent 
phase sample), preferably when no signs of TMA were present anymore.  
To obtain a more reliable control population, 90 pediatric individuals of different ages were enrolled 
in the study to assess the correlation between the complement system and age. Exclusion criteria 
were: fever (>38.5°C), signs or symptoms of infection (bacterial or viral), chronic illness, immune 
suppressive medication, acquired or congenital immune deficiencies, younger than two days, 
intensive ventilation, surgical interventions in last three days. 
The study was approved by the Medical Ethical Committees of all academic hospitals in which 
patients were enrolled. The Medical Ethical Committee of the Radboud university medical centre 
approved the inclusion of control individuals (METC 2010/062). Informed consent for the sample 
collection was obtained before enrollment. 
 
Sample collection 
For serological complement profiling, EDTA blood samples were placed on ice immediately after 
collection and were processed within one hour (10 min, 2500g, 4°C); whole blood samples were 
allowed to coagulate for 45-60 minutes before processing (10 min, 2500g, 4°C). Serum and EDTA 
plasma samples were stored at -80°C in aliquots.  
For DNA analysis, genomic DNA was isolated from peripheral blood leukocytes according to 
established protocols. From one STEC-HUS patient, no material was available for genomic DNA 
isolation. 
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Genetic analysis of genes encoding 
Genomic DNA was amplified for CFH [National Centre for Biotechnology Information (NCBI) RefSeq 
NM_000186.3], CFI (NM_000204.3), CD46 (NM_002389.4), C3 (NM_000064.2), and CFB 
(NM_001710.5) by means of PCR, as described before.72 Primer data are available upon request. 
Fragments included DNA sequences of the individual exons and the splice donor and acceptor site. 
Amplimers were subjected to double-stranded DNA sequence analysis on an ABI 3130 xl Genetic 
Analyzer (Applied Biosystems). Sequence analysis was performed using Sequencher 4.8 software. 
Nonsynonymous aberrations were checked in literature and for presence in the Exome Variant 
Server (http://evs.gs.washington.edu/EVS/) and an in-house database, which both contain results of 
whole exome sequencing of >5000 individuals. 
 
Presence of autoantibodies against factor H and anti-O157 LPS antibodies 
Serum samples were tested for the presence of αFH by means of enzyme-linked immunosorbent 
assay (ELISA), as described previously.229 A positive control sample was obtained via Dr. Dragon-
Durey (Paris, France). ELISA tests were also performed on serum samples for the presence of anti-
O157 LPS antibodies, as described previously.230-232 LPS from Escherichia coli O157:H7 for coating 
was obtained via List Biological Laboratories (Campbell, CA, USA). 
 
Serological complement profiling of the alternative complement pathway 
The C3 concentration was determined by nephelometry (BN™ II System, Siemens Healthcare 
Diagnostics, Erlangen, Germany) using reagents from Beckman Coulter Inc (Brae, CA, USA); levels 
were standardized against the ERM‐DA470k/IFCC serum.233 Levels of FI and FH were determined by 
radial immunodiffusion. For FI, a goat antiserum raised against purified human factor I was used. 
Calibration was based on serial dilutions of a normal human serum and expressed as percentage of 
the value in this standard human serum (% NHS). For FH, a rabbit antiserum raised against purified 
human factor H was used. Calibration was based on serial dilutions of a normal human serum with a 
known concentration of FH (in mg/L). To analyze alternative complement pathway activity, a 
commercially available ELISA kit for total functional assessment of the alternative pathway (AP) was 
used according to the manufacturer’s protocol (Euro Diagnostica, Malmö, Sweden).   
Levels of the C3 degradation products C3d and C3b/c, and the alternative complement pathway 
convertase C3bBbP were quantified in EDTA plasma by means of ELISA, as previously described in 
detail.215, 234 As the initial C3 concentration may influence the C3d level, the C3d/C3 ratio was 
calculated as an extra marker of alternative complement activation independent of the 
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the value in this standard human serum (% NHS). For FH, a rabbit antiserum raised against purified 
human factor H was used. Calibration was based on serial dilutions of a normal human serum with a 
known concentration of FH (in mg/L). To analyze alternative complement pathway activity, a 
commercially available ELISA kit for total functional assessment of the alternative pathway (AP) was 
used according to the manufacturer’s protocol (Euro Diagnostica, Malmö, Sweden).   
Levels of the C3 degradation products C3d and C3b/c, and the alternative complement pathway 
convertase C3bBbP were quantified in EDTA plasma by means of ELISA, as previously described in 
detail.215, 234 As the initial C3 concentration may influence the C3d level, the C3d/C3 ratio was 
calculated as an extra marker of alternative complement activation independent of the 
concentrations of the individual molecules. For this matter, C3d levels were multiplied by 1000 and 
divided by C3 levels. The fluid phase terminal complement complex (TCC) was measured using a 
commercially available ELISA kit (Hycult Biotech, Uden, The Netherlands), according to the 
manufacturer’s protocol. 
 
Statistical analysis 
A linear regression analysis was performed for the control group to investigate the possible 
correlation between age and complement profiles. For each investigation, a D'Agostino-Pearson 
normality test was executed to assess whether the controls were sampled from a Gaussian 
distribution. When controls were normally distributed, a one-way ANOVA with a Dunnett post-test 
was executed to analyze differences between controls and independent patient groups; in case 
controls did not pass the normality test, a one-way ANOVA with a Dunns’ post-test was performed. 
A Mann-Whitney test was used to investigate the difference in age between STEC-HUS and aHUS 
patients and to compare between the acute and convalescent phase in these independent patient 
groups. To compare C3d/C3 ratio’s between patient groups in the acute phase of disease, a 
Pearson’s chi-square test was performed. All statistical analyses were performed using GraphPad 
PRISM software (version 5.03 for Windows, GraphPad Software), except for the Pearson’s chi-square 
test, which was executed in SPSS (version 20, IBM). 
As only one SP-HUS patient was included, no statistical analysis could be performed for this patient 
group. 
 
Results 
 
Clinical characteristics of included patients  
Thirty-eight patients from six university medical centers in The Netherlands were enrolled in this 
study between 2010 and 2013: 26 STEC-HUS patients, 11 aHUS patients, and one SP-HUS patient.  
Epidemiological features and genetic results for all patients and clinical characteristics (presenting 
symptoms, treatment, and outcome) for 35 patients (92.1%) are enlisted in Table 9.1. The clinical 
course of two patients (P1 and P6) has extensively been described before.235, 236 The mean age of all 
patients at presentation was 6.5 years old (6.6 years for STEC-HUS; 6.5 years for aHUS; 0.6 years for 
SP-HUS). No significant difference was seen in age at presentation between pediatric STEC-HUS and 
pediatric aHUS patients (P=0.9875; Figure 9.1). Even though in literature it is stated that STEC-HUS is 
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usually diagnosed in children than between 2 and 5 years of age, half of the STEC-HUS patients 
(13/26; 50.0%) was older than 5 years (range 0.4-17.8 years).  
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1. Age distribution of STEC-HUS, aHUS, and SP-HUS patients at time of diagnosis. No statistically 
significant difference is seen between STEC-HUS and aHUS patients. No statistics could be performed for SP-HUS 
(n=1). 
 
Over 60% of the STEC-HUS cases (16/26) was preceded by an infection with STEC O157; the 
remaining cases were infected with STEC O26, O5, or O104. In 4 patients (15.4%), culture and/or PCR 
was positive for STEC-infection, but no serotype could be identified; these patients were all negative 
for anti-O157 LPS antibodies. All STEC-HUS patients presented with (bloody) diarrhea and/or gastro-
intestinal complaints; one patient also had a upper respiratory tract infection. Neurological 
complications were seen in seven STEC-HUS patients (7/23; 30.4%). Two of these patients had other 
extra-renal complications as well: one patient suffered from chronic venous insufficiency thrombosis 
during the HUS episode and the other was diagnosed with sigmoid stenosis due to HUS three 
months after discharge, for which a sigmoid resection and end-to-end anastomosis was needed.235 
Dialysis was needed in 65.2% (15/23) of the STEC-HUS patients (average duration: 16 days); the 
other patients recovered without the need for renal replacement therapy. Two STEC-HUS patient 
were treated with plasmapheresis next to dialysis. In one of them, plasmapheresis was indicated 
because of anuria, symptoms of ileus, and severity of neurological condition; plasmatherapy was 
stopped when an STEC O26 infection was confirmed. Two STEC-HUS patients were treated with 
eculizumab: one STEC O104 patient was treated for eight weeks in the ad hoc off-label trial during 
the German outbreak, the other had such unusual presentation (12 years old, upper respiratory 
tract infection, no bloody diarrhea) that aHUS was suspected and one gift of eculizumab was given 
before anti-O157-LPS antibodies were identified. The majority of the STEC-HUS patients has a good  
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Table 9.1. Epidemiological and clinical features of included patients.  
Feature All patients STEC-HUS aHUS SP-HUS 
Number of patients 38 26 (68.4%) 11 (28.9%) 1 (2.6%) 
Gender 20 M : 18 F 13 M : 13 F 7 M : 4 F 1 F 
Age (yr) [Mean ± SD (range)] 6.5 ± 4.9  (0.4-17.8) 
6.6 ± 5.3  
(0.4-17.8) 
6.5 ± 3.8  
(0.5-12.6) 0.6 
Serotype  Not applicable O157: 16 (61.5%) Not applicable Not 
performed   O26: 4 (15.4%)  
  O5: 1 (3.8%)  
  O104: 1 (3.8%)  
  Not serotyped, but α-O157 negative: 4 (15.4%) 
Presentation      
Diarrhea 14 (35) 12 (23) 2 (11) 0 (1) 
Bloody diarrhea 9 (35) 9 (23) 0 (11) 0 (1) 
Gastro-intestinal symptoms without 
diarrhea 8 (35) 2 (23) 6 (11) 0 (1) 
Upper respiratory tract infection 4 (35) 1 (23) 3 (11) 0 (1) 
Oligo/anuria 14 (35) 8 (23) 6 (11) 0 (1) 
Acute renal insufficiency 1 (35) 0 (23) 1 (11) 0 (1) 
Headache 1 (35) 0 (23) 1 (11) 0 (1) 
Meningitis 1 (35) 0 (23) 0 (11) 1 (1) 
Extra-renal complications     
None 27 (35) 16 (23) 11 (11) 0 (1) 
Yes 8 (35) 7 (23) 0 (11) 1 (1) 
   Neurological 8 (35) 7 (23) 0 (11) 1 (1) 
   Intestinal (sigmoid stenosis, peritonitis) 2 (35) 1 (23) 0 (11) 1 (1) 
   Chronic venous insufficiency thrombosis 1 (35) 1 (23) 0 (11) 0 (1) 
Treatment     
Spontaneous remission 9 (35) 8 (23) 1 (11) 0 (1) 
Dialysis 14 (35) 13 (23) 0 (11) 1 (1) 
Plasma therapy 3 (35) 0 (23) 3 (11) 0 (1) 
Dialysis and plasma therapy 9 (35) 2 (23) 7 (11) 0 (1) 
Eculizumab 5 (35) 2 (23) 3 (11) 0 (1) 
Outcome     
Normal renal function 26 (34) 18 (23) 8 (10) 0 (1) 
Hypertensiona and proteinuriab 9 (34) 3 (23) 5 (10) 1 (1) 
Hypertensiona  2 (34) 1 (23) 1 (10) 0 (1) 
Proteinuriab  4 (34) 4 (23) 0 (10) 0 (1) 
Maintenance treatment with 
eculizumab  2 (34) 0 (23) 2 (10) 0 (1) 
Relapses after this episode 3 (34) 0 (23) 3 (10) 0 (1) 
Genetic or acquired complement aberrations (see Table 9.2) 
Total 15/37 (40.5%) 7/25 (28.0%) 7/11 (63.3%) 1/1 (100%) 
   CFH 2/37 (5.4%) 2/25 (8.0%) - - 
   CD46 2/37 (5.4%) - 2/11 (18.2%)  - 
   C3 3/37  (8.1%) 2/25 (8.0%) 1/11 (9.1%) - 
   C3 and αFH 1/37 (2.7%) - 1/11 (9.1%) - 
   αFH 7/37 (18.9%) 3/25 (12.0%) 3/11 (27.3%) 1/1 (100%) 
For the clinical features, the numbers of patients with data available are reported in parentheses. 
a Hypertension: a systolic and/ or diastolic pressure ≥ 2,0 Standard Deviation Scores compared to normal values for age, gender 
and height.  
b Proteinuria: > 2 y old:  > 0,2 mg / mg (> 22,6 mg/ mmol or 0,226 g/10 mmol); < 2 y old: > 0,5 mg/ mg (> 56,6 mg/mmol or 0,566 
g/10 mmol). 
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( . - .  
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Extra-renal complications    
None 27 (35) 1  ( )  ( ) 
Yes 8 (35) 7 ( )  ( ) 
   Neurological 8 (35) 7 (23)  ( ) 
   Intestinal (sigmoid stenosis, peritonitis) 2 (35) 1 (23)  ( ) 
   Chronic venous insu ficiency thrombosis 1 (35) 1 (23)  ( ) 
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Proteinuriab  4 (34) 4 ( )  ( ) 
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Relapses after this episode 3 (34) 0 ( )  ( ) 
Genetic or acquired co ple ent aberrations (see Table 9.2) 
Total 15/37 (40.5 ) 7/  ( . )  ( .  
   CFH 2/37 (5.4 ) 2/25 (8.0 ) -  
   CD46 2/37 (5.4 ) - /  ( . )   
   C3 3/37  (8.1 ) 2/25 (8.0 ) /  ( . )  
   C3 and αFH 1/37 (2.7 ) - /  ( . )  
   αFH 7/37 (18.9 ) 3/25 (12.0 ) /  ( . ) 
For the clinical features, the numbers of patients with data available are rep rte  i  r t s . 
a Hypertension: a systolic and/ or diastolic pressure ≥ 2,0 Standard eviatio  Sc r s c r  t  l l  
and height.  
b Proteinuria: > 2 y old:  > 0,2 mg / mg (> 22,6 g/ ol or 0,226 g/10 ol); <  y l :  ,    (  ,  
g/10 mmol). 
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outcome with normal renal function, although hypertension and/or proteinuria is still present in 
eight patients (8/23; 34.8%). 
Interestingly, more than 70% of the aHUS patients presented with diarrhea and/or gastro-intestinal 
complaints (e.g. stomach aches, vomiting), but no bloody diarrhea was seen. The other triggering 
events in aHUS were an upper respiratory tract infection in three patients and headache in one. No 
extra-renal complications were seen in these patients and the majority of the aHUS patients were 
treated with both dialysis (average duration: 9 days) and plasmatherapy (average amount of 
sessions: 14) to control renal failure. Sequelae are still present in 70% of aHUS patients, in most 
cases both hypertension and proteinuria. For three aHUS patients, the HUS episode at the time of 
the study was a recurrence. In one of these patients (P20) the first episode was thought to be 
induced by an STEC infection based on presentation with bloody diarrhea. Two aHUS patients (P6 
and P24) were enrolled in the pediatric eculizumab trial.104 In both, eculizumab treatment had to be 
discontinued when the trial ended, after which a relapse of disease occurred. These patients are 
now on maintenance treatment with eculizumab. 
 
Genetic and/or acquired complement aberrations in HUS patients 
All but one patient included in the study have been screened for mutations in the complement 
genes CFH, CFI, CD46, CFB, and C3, all associated with aHUS, and for the presence of αFH. In 40.5% 
(15/37) of the patients, including 7/25 STEC-HUS patients and the only SP-HUS patient, we identified 
a genetic and/or acquired complement abnormality. Characteristics of the identified mutations are 
depicted in Table 9.2.  
 
Correlation between serological complement profiles and age in healthy children 
We included 90 control patients (179 days to 18 years old) to define the correlation between 
complement levels / activity and age. The serological complement profiles for pediatric controls and 
the profiles seen in patients in the acute phase of disease are shown in Figure 9.2. No correlation 
was seen in healthy children between age and serological complement profiles except for C3d levels, 
which slightly decreased with increasing age (P=0.0017; R2=0.1086). All levels were within adult 
reference ranges, although FI levels for pediatric controls are around the lower limit of the adult 
reference interval. For the comparison of complement profiles between healthy individuals and 
patients, the results of the pediatric controls were grouped. 
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Table 9.2. Characteristics of genetic and acquired complement aberrations identified in the enrolled STEC-HUS, 
SP-HUS, and aHUS patients. 
 Disease Complement aberration EVS IHD Literature 
P9 STEC-HUS αFH N.A. N.A. Dragon-Durey, et al.
137 
Jozsi et al. 82 
P10 STEC-HUS αFH N.A. N.A. Dragon-Durey, et al.
137 
Jozsi et al. 82 
P14 STEC-HUS C3: p.Arg1219His 1/6503 (0.02%) 0/5036 (0.00%)  
P21 STEC-HUS CFH: p.Thr956Met 15/6503 (0.23%) 1/5036 (0.02%) Perez-Caballero et al.
149 
Perkins, Goodship.239 
P25 STEC-HUS C3: p.Lys155Gln 38/6503 (0.58%) 34/5036 (0.68%) Seddon et al.184 
P29 STEC-HUS CFH: p.Ser58Ala 2/6503 (0.03%) 0/5036 (0.00%)  
P32 STEC-HUS αFH N.A. N.A. Dragon-Durey, et al.
137 
Jozsi et al.82 
P17 SP-HUS αFH    
P3 aHUS αFH N.A. N.A. Dragon-Durey, et al.
137 
Jozsi et al.82 
P8 aHUS C3: p.Arg161Trp; αFH 0/6503 (0.00%) 6/5036 (0.12%) Roumenina et al.
175 
Volokhina et al.94 
P18 aHUS αFH N.A. N.A. Dragon-Durey, et al.
137 
Jozsi et al.82 
P20 aHUS CD46: p.Asp271_Ser272del 0/6503 (0.00%) 1/5036 (0.02%) Richards et al.
143 
Westra et al.72 
P31 aHUS αFH N.A. N.A. Dragon-Durey, et al.
137 
Jozsi et al.82 
P33 aHUS CD46: p.Cys35Tyr 0/6503 (0.0%) 2/5036 (0.04%) Caprioli et al.71 
P35 aHUS C3: p.Arg161Trp 0/6503 (0.00%) 6/5036 (0.12%) Roumenina et al.
175 
Volokhina et al.94 
EVS indicates ‘Exome variant server (http://evs.gs.washington.edu/EVS/)’; IHD ‘in-house database’; N.A. ‘not applicable’. 
 
Serological complement profiles in STEC-HUS, aHUS, and SP-HUS patients 
Levels of the individual complement proteins C3, FH, and FI, alternative complement pathway 
activity (AP), and the complement activation products C3d, C3bBbP, C3b/c, and TCC were measured 
in serum and EDTA plasma of HUS patients on admission and 14-28 days later and were compared 
to healthy pediatric controls. Levels of the investigated complement proteins in the acute and 
convalescent phase in all patient groups are shown in Figure 9.3. In the acute phase, patients had 
slightly decreased complement C3 levels compared to pediatric age-matched controls, although the 
alterations were not significantly different in all groups. These levels increased in remission in both 
STEC-HUS and aHUS patients. Levels of the complement regulator Factor I were significantly 
elevated in both the acute and the convalescent phase of the disease in all patient groups, as 
compared to the control population (P<0.001); for Factor H levels, this was only the case in STEC-
HUS patients (P<0.001 for the acute phase and P<0.01 for the convalescent phase; Figure 9.3). 
Serological and genetic analysis of the complement system in children with hemolytic uremic syndromes
Table 9.2. Characteristics of genetic and acquired co ple t rr ti  i tifi  i   
SP-HUS, and aHUS patients. 
 Disease Co ple ent aberration E S I  i
P9 STEC-HUS αFH . . . . i  l
P10 STEC-HUS αFH . . . . i  l
P14 STEC-HUS C3: p.Arg1219His 1/6503 (0. ) /  ( . )  
P21 STEC-HUS CFH: p.Thr956 et 15/6503 (0. ) /  ( . ) i  
P25 STEC-HUS C3: p.Lys155Gln 38/6503 (0. ) /  ( . )  
P29 STEC-HUS CFH: p.Ser58Ala 2/6503 (0. ) /  ( . )  
P32 STEC-HUS αFH . . . . i  l
P17 SP-HUS αFH    
P3 aHUS αFH . . . . i  l
P8 aHUS C3: p.Arg161Trp; αFH 0/6503 (0. ) /  ( . ) il i
P18 aHUS αFH . . . . i  l
P20 aHUS CD46: p.Asp271_Ser272del 0/6503 (0. ) /  ( . ) i   
P31 aHUS αFH . . . . i  l
P33 aHUS CD46: p.Cys35Tyr 0/6503 (0. ) /  ( . ) i li 
P35 aHUS C3: p.Arg161Trp 0/6503 (0. ) /  ( . ) il i
EVS indicates ‘Exome variant server (h tp://evs.gs. ashington.edu/EVS/)’; I  ‘i - s  t ’; . . ‘  li
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The mean alternative complement pathway activity in both phases was higher in patients than in 
controls, but this was not a significant difference for all patient groups (Figure 9.3). Individual AP 
activity, however, was comparable to respective age-matched controls (Figure 9.2). In the acute 
phase, the levels of the alternative pathway activation markers C3d (P<0.001 for STEC-HUS and 
aHUS), C3bBbP (STEC-HUS: P<0.01; aHUS: P<0.001), and C3b/c (STEC-HUS: n.s.; aHUS: P<0.01) were 
increased as well, as depicted in Figure 9.3. The terminal pathway activation marker TCC was only 
significantly increased in STEC-HUS patients (P<0.01; Figure 9.3). TCC levels in aHUS and SP-HUS 
patients, however, were above the mean of pediatric controls as well. In all patient groups, levels of 
complement activation markers normalized to about control levels in the convalescent phase of 
disease.  
As C3d levels were age-dependent, we calculated the C3d/C3 ratio as an extra marker of alternative 
complement pathway activation independent of initial C3 levels (Figure 9.3). This ratio did not show 
an age-dependent effect. In the acute phase of disease, the mean ratio in patients was more than 
three times higher than in controls (20.00 vs. 5.86), which was statistically significantly different 
(P=0.0003). No significant difference was seen between STEC-HUS and aHUS patients, but when a 
cut-off for the C3d/C3 ratio was arbitrarily set at 27.5, based on visual analysis of the data plot, 
atypical HUS patients were more likely to have a C3d/C3 ratio above this level than STEC-HUS 
patients (66.7% vs. 11.8%; P=0.021). The other alternative pathway activation markers displayed a 
significant difference between STEC-HUS and aHUS patients in the acute phase of disease as well 
(C3bBbP: P=0.011; C3b/c: P=0.027). 
The presence of a genetic aberration or αFH could not be linked to an altered serological 
complement profile: not all patients with a complement aberration displayed complement 
activation for the analyzed biomarkers in the acute and/or convalescent phase (Supplementary 
data). However, the power of this analysis was hampered by missing samples for analysis.  
 
Discussion 
 
To investigate the role of the alternative complement pathway in HUS in general (infection-induced 
HUS and aHUS), samples of 38 children with HUS of any etiology were collected in the acute phase 
of the disease and 14-28 days afterwards. Levels of individual complement proteins and 
complement activation markers were measured. It was demonstrated that in the acute phase of 
disease, the infection-induced HUS and aHUS patients had a trend towards decreased average C3 
levels and increased average AP activity, even though this was not statistically different in all patient 
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significant difference between STEC-HUS and aHUS patients in the acute phase of disease as well 
(C3bBbP: P=0.011; C3b/c: P=0.027). 
The presence of a genetic aberration or αFH could not be linked to an altered serological 
complement profile: not all patients with a complement aberration displayed complement 
activation for the analyzed biomarkers in the acute and/or convalescent phase (Supplementary 
data). However, the power of this analysis was hampered by missing samples for analysis.  
 
Discussion 
 
To investigate the role of the alternative complement pathway in HUS in general (infection-induced 
HUS and aHUS), samples of 38 children with HUS of any etiology were collected in the acute phase 
of the disease and 14-28 days afterwards. Levels of individual complement proteins and 
complement activation markers were measured. It was demonstrated that in the acute phase of 
disease, the infection-induced HUS and aHUS patients had a trend towards decreased average C3 
levels and increased average AP activity, even though this was not statistically different in all patient 
groups. The complement activation products C3bBbP, C3b/c, and C3d, and the C3d/C3 ratio were all 
significantly increased in all patients. This complement activation normalized to control levels in 
remission. Our results corroborate previous reports of complement activation in children with STEC-
HUS and SP-HUS.65, 91, 110-112, 222 
 
Thurman et al. mention that measurement of TCC might be useful in monitoring the course of the 
STEC-HUS and recent studies have shown that the activation products C3bBbP, C3b/c, and TCC can 
be used as biomarker for disease activity in aHUS patients.237 In this study, the same results were 
obtained in aHUS patients for C3bBbP and C3b/c, which all normalized in the convalescent phase of  
disease, but not for TCC. Volokhina et al. used remission samples of patients whom had their last 
aHUS episode more than one year ago, while our samples were already collected within one month 
after the disappearance of clinical HUS symptoms. It seems that in aHUS, the terminal pathway 
remains activated for a longer period than the alternative pathway.  
No significant difference was seen between acute and convalescent C3bBbP and C3b/c levels in 
STEC-HUS patients. In all patient groups, the C3d/C3 ratio gives the best discrepancy between the 
acute phase and the convalescent phase of disease in all patient groups (P<0.01 for STEC-HUS 
patients and P<0.001 for aHUS patients) and in our experience, the C3d/C3 ratio may therefore be 
the most promising biomarker to monitor disease activity. 
 
The finding of increased complement activation products in the circulation in the acute phase of 
aHUS indicate that in this patient group the alternative pathway might not only be dysregulated on 
the level of the glomerular endothelium, as was indicated in a recent study.98 Noris et al. only 
measured activation products of the terminal pathway (TCC and C5a), but we and Volokhina et al. 
also investigated the activation products of the alternative pathway.237 Our results with altered 
levels of C3bBbP, C3b/c and the C3d/C3 ratio, but not TCC, show that the fluid phase activation most 
probably occurs mostly at C3 level and not at C5 level. 
 
Based on clinical presentation, it sometimes can be difficult to distinguish between STEC-HUS and 
aHUS patients: no age differences were seen, many STEC-HUS cases were older than five years, and 
the majority of aHUS patients (70%) presented with gastro-intestinal problems and/or diarrhea. Not 
all STEC-HUS patients had (bloody) diarrhea and one aHUS patient presented with diarrhea, which 
has been described before.90, 93 This again clearly shows that postdiarrheal onset does not exclude 
the possibility of aHUS or that the absence of diarrhea excludes STEC-HUS. The C3d/C3 ratio at 
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admission was on average twice as high in aHUS patients than in infection-induced HUS patients, but 
this was not a statistically significant difference, most probably due to the low number of patients. 
At a more detailed inspection of individual ratios, two-third of the aHUS patients had a C3d/C3 ratio 
over 27.5, while 88% of the STEC-HUS patients had a ratio lower than 27.5. Levels of C3bBbP and 
C3b/c were also significantly higher in aHUS patient than in STEC-HUS patients. Based on our results, 
the investigated alternative pathway activation products may therefore be used as a biomarker to 
discriminate at admission between STEC-HUS and aHUS. As C3d is a more commonly performed 
measurement than C3bBbP and C3b/c, the C3d/C3 ratio is preferred and this ratio may be used to 
monitor disease activity as well. As the amount of patients in the current study of examination is 
very small, a prospective study is needed to determine sensitivity and specificity in a larger cohort 
before these assays are implemented in routine diagnostics. 
 
As the complement system is one of first parts of the innate immunity to be activated when micro-
organisms invade the human body, we cannot exclude that the observed activation in STEC-HUS and 
SP-HUS is only an infection-related phenomenon, for example due to produced endotoxins by the 
bacteria. In meningococcal infection, for instance, C3 activation and TCC are both increased with a 
strong correlation between complement activation and levels of endotoxins produced by N. 
meningitides.238 A prospective study is therefore needed to investigate differences in complement 
activation in acute and convalescent phase between patients that develop HUS after an infection 
with STEC or SP, those that do not, and patients with other severe life-threatening infections. 
 
We were surprised to see that in almost 30% of the STEC-HUS patients and in the SP-HUS patient a 
genetic complement aberration could be identified. Several case reports of STEC-HUS patients with 
complement mutations have been published, but so far no large cohorts were investigated.48, 50-52 
Most of the identified genetic variations were described before in other diseases associated with a 
dysregulated complement system (aHUS and/or age-related macular degeneration [AMD]) and 
functional studies that have been performed showed that these aberrations influence binding 
capacity of complement to C3b regulators or affect the inactivation of C3.71, 72, 94, 143, 180, 184, 239 All 
genetic aberrations we have identified were present in the EVS database and/or in the in-house 
database with exome data of >5000 individuals (Table 9.2). This is not remarkable, as an incomplete 
penetrance is seen in HUS: healthy family members can carry disease-causing mutations.29, 92 This 
indicates that additional triggers, genetic and/or environmental, are probably needed for the 
disease to develop. 
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the investigated alternative pathway activation products may therefore be used as a biomarker to 
discriminate at admission between STEC-HUS and aHUS. As C3d is a more commonly performed 
measurement than C3bBbP and C3b/c, the C3d/C3 ratio is preferred and this ratio may be used to 
monitor disease activity as well. As the amount of patients in the current study of examination is 
very small, a prospective study is needed to determine sensitivity and specificity in a larger cohort 
before these assays are implemented in routine diagnostics. 
 
As the complement system is one of first parts of the innate immunity to be activated when micro-
organisms invade the human body, we cannot exclude that the observed activation in STEC-HUS and 
SP-HUS is only an infection-related phenomenon, for example due to produced endotoxins by the 
bacteria. In meningococcal infection, for instance, C3 activation and TCC are both increased with a 
strong correlation between complement activation and levels of endotoxins produced by N. 
meningitides.238 A prospective study is therefore needed to investigate differences in complement 
activation in acute and convalescent phase between patients that develop HUS after an infection 
with STEC or SP, those that do not, and patients with other severe life-threatening infections. 
 
We were surprised to see that in almost 30% of the STEC-HUS patients and in the SP-HUS patient a 
genetic complement aberration could be identified. Several case reports of STEC-HUS patients with 
complement mutations have been published, but so far no large cohorts were investigated.48, 50-52 
Most of the identified genetic variations were described before in other diseases associated with a 
dysregulated complement system (aHUS and/or age-related macular degeneration [AMD]) and 
functional studies that have been performed showed that these aberrations influence binding 
capacity of complement to C3b regulators or affect the inactivation of C3.71, 72, 94, 143, 180, 184, 239 All 
genetic aberrations we have identified were present in the EVS database and/or in the in-house 
database with exome data of >5000 individuals (Table 9.2). This is not remarkable, as an incomplete 
penetrance is seen in HUS: healthy family members can carry disease-causing mutations.29, 92 This 
indicates that additional triggers, genetic and/or environmental, are probably needed for the 
disease to develop. 
As in other studies, we could not link an altered complement profile in both the acute and 
convalescent phase of the disease to the presence of a genetic or acquired complement aberration 
(mutation or αFH).
98 Both patients with and without identified mutations displayed similar 
complement abnormalities on protein level and not all patients with a complement aberration 
demonstrated complement activation for the analyzed biomarkers in the acute phase and/or in 
remission. 
 
The finding of mutations and αFH in STEC and SP-patients argues that there might be undiagnosed 
cases of aHUS triggered by an STEC or SP infection on a genetic background of impaired complement 
regulation. Different than in aHUS patients, the so-far investigated infection-induced HUS patients of 
our study with complement mutations or αFH had a good outcome and no recurrences. These 
patients, however, might be prone to develop a recurrence of disease. Indeed, one of the aHUS 
patients (P20) had a previous episode of HUS preceded by bloody diarrhea, but the recurrent 
episode had no evidence of a preceding STEC infection. In this patient, a CD46 mutation was 
identified (Table 9.2). The same occurred in  two Italian patients: they were first diagnosed with 
STEC-HUS, but after an HUS recurrence occurred, a complement mutation was identified.90  
 
For the investigated complement protein levels or activation products, except for C3d, no age-
dependent effect was seen in the control individuals we included in this study (age >5 months). It 
has been shown in neonatal infants at birth that complement levels are lower than in adults and rise 
towards adult levels within approximately 6 months.224, 228 To investigate the maturation of the 
alternative complement pathway more extensively, a new study to extend the collection of pediatric 
controls via a strict protocolled manner with children younger than 6 months is ungoing. 
 
Together, we conclude that in both infection-induced HUS and aHUS patients the complement 
system is activated in the fluid phase in the acute phase of disease, but not in remission. The C3d/C3 
ratio seems to display the best discrepancy between STEC-HUS and aHUS and between the acute 
and convalescent phase and may therefore be used as a biomarker for disease activity, but a larger 
cohort is needed to determine sensitivity and specificity of the assay. A genetic or acquired 
complement aberration was present in 40.5% of the patients, including STEC-HUS and SP-HUS 
patients, but both patients with and without complement aberrations showed altered complement 
profiles to a variable extent. As the complement system is the first part of the innate immune 
system that is activated after infection, we cannot exclude that the activation is purely infection-
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related. A international prospective study to investigate the role of the complement system, 
including the presence of complement mutations and/or autoantibodies against complement 
proteins, in a larger cohort with patients that do and do not develop HUS after infection is needed. 
 
Acknowledgements 
The authors thank patients, their parents, and healthy volunteers for participation in this study. This work was 
supported by the Dutch Kidney Foundation (C09.2313). We would like to thank Hycult Biotech (Uden, The 
Netherlands) and Euro Diagnostica (Malmö, Sweden) for the collaboration in this project and for making the TCC 
and Wielisa ELISA kits available. Corrie de Kat-Angelino and Marjo Beldhuis are thanked for their technical 
assistance in performing the AP and C3d assay.  
Su
pp
le
m
en
ta
ry
 d
at
a.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Se
ro
lo
gi
ca
l a
nd
 g
en
et
ic
 c
om
pl
em
en
t p
ro
fil
es
 o
f H
U
S 
pa
tie
nt
s 
in
 t
he
 a
cu
te
 a
nd
 c
on
va
le
sc
en
t p
ha
se
 o
f d
ise
as
e.
 L
ev
el
s 
ou
ts
id
e 
th
e 
co
nt
ro
l r
an
ge
s 
fo
r 
pe
di
at
ric
 c
on
tr
ol
s 
(d
ef
in
ed
 b
y 
th
is
 s
tu
d
y 
as
 m
ea
n
 ±
 2
 s
ta
n
d
ar
d
 d
ev
ia
ti
o
n
s)
 a
re
 s
h
o
w
n
 i
n
 b
o
ld
 a
n
d
 i
n
d
ic
at
ed
 w
it
h
 (
↑
) 
o
r 
(↓
).
 P
at
ie
n
t 
2
4
 w
as
 o
n
 e
cu
liz
um
ab
 in
 b
ot
h 
co
nv
al
es
ce
nt
 p
ha
se
s;
 
pa
tie
nt
 8
 a
nd
 2
4 
ha
d 
a 
se
co
nd
 e
pi
so
de
 o
f a
HU
S.
 
 
N
/D
 in
d
ic
at
es
 ‘n
o
t 
d
et
e
rm
in
e
d
’;
 N
/A
 ‘n
o
t 
ap
p
lic
ab
le
. 
 
 
AP
C
3
FH
FI
C
3d
C
3d
/C
3
C
3b
B
bP
C
3b
/c
TC
C
AP
C
3
FH
FI
C
3d
C
3d
/C
3
C
3b
B
bP
C
3b
/c
TC
C
(%
N
H
S
)
(m
g/
l)
(m
g/
l)
(%
N
H
S
)
(m
g/
l)
ra
tio
(A
U
/m
l)
(A
U
/m
l)
Hy
cu
lt
(%
N
H
S
)
(m
g/
l)
(m
g/
l)
(%
N
H
S
)
(m
g/
l)
ra
tio
(A
U
/m
l)
(A
U
/m
l)
Hy
cu
lt
P
1
M
2y
 7
m
S
TE
C
-H
U
S
O
26
90
,1
5
9
4
 (
↓
)
8
0
 (
↓
)
36
2
0
,7
8
 (
↑
)
3
4
,9
9
 (
↑
)
6,
67
1
7
,6
2
 (
↑
)
2
6
,8
4
 (
↑
)
10
6,
7
1
3
2
0
 (
↑
)
28
0
75
1
5
,8
6
 (
↑
)
1
2
,0
2
 (
↑
)
11
,6
6
3
8
,3
1
 (
↑
)
5,
23
no
 a
be
rr
at
io
ns
N
E
G
N
E
G
P
4
F
10
y 
2m
S
TE
C
-H
U
S
O
15
7
84
,7
N
/D
18
0
58
4
9
,0
7
 (
↑
)
N
/D
N
/D
N
/D
2
7
,1
4
 (
↑
)
94
,6
N
/D
11
0
30
N
/D
N
/D
2
8
,9
1
 (
↑
)
4
9
,6
9
 (
↑
)
4,
43
no
 a
be
rr
at
io
ns
N
E
G
PO
S
P
5
M
3y
 8
m
S
TE
C
-H
U
S
O
26
11
2,
7
93
7
24
0
93
N
/D
N
/D
N
/D
N
/D
N
/D
1
2
0
,0
  
(↑
)
1
4
4
0
 (
↑
)
32
0
90
7,
67
5,
33
6,
22
14
,0
1
4,
43
no
 a
be
rr
at
io
ns
N
E
G
N
E
G
P
7
F
2y
 3
m
S
TE
C
-H
U
S
O
15
7
1
1
7
,5
 (
↑
)
1
6
3
0
 (
↑
)
44
0
12
4
N
/D
N
/D
N
/D
N
/D
N
/D
82
,1
11
40
27
0
75
6,
89
6,
05
14
,0
3
2
0
,9
4
 (
↑
)
3,
43
no
 a
be
rr
at
io
ns
N
E
G
N
E
G
P
9
F
0y
 1
0m
S
TE
C
-H
U
S
O
10
4
91
,5
N
/D
15
0
50
N
/D
N
/D
N
/D
N
/D
N
/D
89
,5
1
5
6
0
 (
↑
)
28
0
79
8,
01
5,
13
15
,2
2
2
8
,8
6
 (
↑
)
5,
98
no
 a
be
rr
at
io
ns
PO
S
N
E
G
P
10
M
11
y 
7m
S
TE
C
-H
U
S
O
15
7
1
0
8
,8
 (
↑
)
11
60
24
0
79
1
3
,6
9
 (
↑
)
1
1
,8
1
 (
↑
)
17
,5
4
10
,7
3
2
3
,8
2
 (
↑
)
10
3,
3
11
80
19
0
69
4,
70
3,
98
7,
29
6,
03
3,
99
no
 D
N
A
 a
va
ila
b
le
PO
S
PO
S
P
12
M
8y
 6
m
S
TE
C
-H
U
S
O
15
7
95
,1
10
60
22
0
73
1
1
,1
5
 (
↑
)
10
,5
2
16
,3
9
7,
74
9
,7
6
 (
↑
)
69
,9
93
0
18
0
75
4,
13
4,
44
1
0
6
,8
8
 (
↑
)
3
8
,2
7
 (
↑
)
5,
68
no
 a
be
rr
at
io
ns
N
E
G
PO
S
P
13
M
7y
 7
m
S
TE
C
-H
U
S
O
15
7
90
,3
12
70
20
0
83
2
5
,0
8
 (
↑
)
1
9
,7
5
 (
↑
)
3
4
,6
9
 (
↑
)
6
5
,0
9
 (
↑
)
2,
48
no
 a
be
rr
at
io
ns
N
E
G
PO
S
P
14
F
2y
 8
m
S
TE
C
-H
U
S
O
5
25
,1
4
1
5
 (
↓
)
17
0
51
1
0
,9
8
 (
↑
)
2
6
,4
5
(↑
)
7,
48
7,
02
3
5
,8
5
 (
↑
)
10
3,
4
N
/D
36
0
99
3,
68
N
/D
10
,2
5
10
,1
1
4,
77
C3
: p
.A
rg
12
19
Hi
s
N
E
G
N
E
G
P
15
M
3y
 6
m
S
TE
C
-H
U
S
O
15
7
95
,1
76
4
12
0
59
3
8
,9
6
 (
↑
)
5
0
,9
9
 (
↑
)
17
,1
2
9,
33
4
7
,2
2
 (
↑
)
1
1
4
,5
 (
↑
)
12
70
29
0
10
1
5,
59
4,
40
15
,7
2
10
,3
2
4,
97
no
 a
be
rr
at
io
ns
N
E
G
N
E
G
P
16
F
2y
 0
m
S
TE
C
-H
U
S
N
T
1
0
4
 (
↑
)
70
9
13
0
61
1
2
,4
2
 (
↑
)
1
7
,5
2
 (
↑
)
10
,9
7
9,
89
8
,1
4
 (
↑
)
10
2,
1
92
8
19
0
59
1
2
,4
2
 (
↑
)
N
/D
2
1
,1
4
 (
↑
)
1
6
,1
5
 (
↑
)
3,
29
no
 a
be
rr
at
io
ns
N
E
G
N
E
G
P
19
F
8y
 4
m
S
TE
C
-H
U
S
N
T
97
,2
10
60
19
0
90
1
1
,6
5
 (
↑
)
1
0
,9
9
 (
↑
)
8,
85
8,
76
1,
48
no
 a
be
rr
at
io
ns
N
E
G
N
E
G
P
21
F
6y
 3
m
S
TE
C
-H
U
S
O
15
7
N
/D
12
30
24
0
97
7,
11
5,
78
N
/D
N
/D
0,
11
CF
H:
 p
.T
hr
95
6M
et
N
E
G
PO
S
P
22
M
0y
 6
m
S
TE
C
-H
U
S
O
15
7
93
,7
6
2
6
 (
↓
)
15
0
64
1
0
,5
4
 (
↑
)
1
6
,8
4
 (
↑
)
13
,7
3
13
,9
4
0,
77
no
 a
be
rr
at
io
ns
N
E
G
PO
S
P
23
M
1y
 3
m
S
TE
C
-H
U
S
O
15
7
74
,1
88
4
19
0
50
N
/D
N
/D
N
/D
N
/D
N
/D
no
 a
be
rr
at
io
ns
N
E
G
PO
S
P
25
F
2y
 0
m
S
TE
C
-H
U
S
O
15
7
8,
1
13
10
34
0
81
6,
44
4,
91
10
,8
7
9,
27
4,
79
C3
: p
.L
ys
15
5G
ln
N
E
G
PO
S
P
26
M
11
y 
4m
S
TE
C
-H
U
S
N
T
65
,0
11
40
20
0
63
1
3
,6
1
 (
↑
)
1
1
,9
3
 (
↑
)
2
4
,0
0
 (
↑
)
2
9
,4
5
 (
↑
)
1
5
,3
8
 (
↑
)
77
,5
10
40
22
0
39
4,
14
3,
98
4,
89
5,
38
6,
47
no
 a
be
rr
at
io
ns
N
E
G
N
E
G
P
27
F
0y
 5
m
S
TE
C
-H
U
S
N
T
88
,0
95
3
37
0
92
6,
78
N
/D
13
,5
2
11
,2
1
2,
40
66
,3
71
0
14
0
63
N
/D
N
/D
N
/D
N
/D
N
/D
no
 a
be
rr
at
io
ns
N
E
G
N
E
G
P
28
M
0y
 5
m
S
TE
C
-H
U
S
O
26
59
,5
46
2
18
0
39
N
/D
N
/D
N
/D
N
/D
N
/D
67
,6
81
3
25
0
48
7,
59
N
/D
11
,2
1
1
8
,6
7
 (
↑
)
0,
49
no
 a
be
rr
at
io
ns
N
E
G
N
E
G
P
29
F
9y
 4
m
S
TE
C
-H
U
S
O
26
90
,2
80
1
23
0
78
9,
09
N
/D
14
,3
6
13
,3
9
6,
02
42
,6
91
3
23
0
65
4,
64
5,
09
6,
88
9,
96
2,
97
CF
H:
 p
.S
er
58
Al
a
N
E
G
N
E
G
P
30
F
15
y 
3m
S
TE
C
-H
U
S
O
15
7
42
,7
75
0
14
0
48
1
7
,1
0
 (
↑
)
N
/D
3
6
,8
9
 (
↑
)
15
,3
6
3,
53
70
,8
10
30
26
0
67
3,
91
N
/D
11
,3
5
12
,4
6
2,
35
no
 a
be
rr
at
io
ns
N
E
G
PO
S
P
32
M
17
y 
9m
S
TE
C
-H
U
S
O
15
7
81
,2
11
20
19
0
71
N
/D
N
/D
N
/D
N
/D
N
/D
no
 a
be
rr
at
io
ns
PO
S
PO
S
P
33
M
6y
 4
m
S
TE
C
-H
U
S
N
T
62
,1
64
5
20
0
52
N
/D
N
/D
N
/D
N
/D
N
/D
CD
46
: p
.C
ys
35
Ty
r
N
E
G
N
E
G
24
-9
9
63
9-
13
12
>9
7
>1
9,
5
<9
,7
3
<1
9,
88
<1
5,
92
<7
,0
24
-9
9
63
9-
13
12
>9
7
>1
9,
5
<9
,7
3
<1
9,
88
<1
5,
92
<7
,0
%
N
H
S
m
g/
l
m
g/
l
%
N
H
S
m
g/
l
AU
/m
l
AU
/m
l
AU
/m
l
%
N
H
S
m
g/
l
m
g/
l
%
N
H
S
m
g/
l
AU
/m
l
AU
/m
l
AU
/m
l
<1
0,
82
<1
0,
82
C
on
tro
l r
an
ge
Pa
tie
nt
Ge
ne
tic
s
Se
ro
ty
pe
Di
se
as
e
Ag
e
Se
x
α
FH
α
O
15
7-
LP
S
Ac
ut
e 
ph
as
e
N
o 
m
at
er
ia
l a
va
ila
b
le
 in
 a
cu
te
 p
ha
se
 o
f d
is
ea
se
N
o 
m
at
er
ia
l a
va
ila
b
le
 in
 a
cu
te
 p
ha
se
 o
f d
is
ea
se
Co
nv
al
es
ce
nt
 p
ha
se
N
o 
m
at
er
ia
l a
va
ila
b
le
 in
 c
on
va
le
sc
en
t p
ha
se
 o
f d
is
ea
se
N
o 
m
at
er
ia
l a
va
ila
b
le
 in
 c
on
va
le
sc
en
t p
ha
se
 o
f d
is
ea
se
N
o 
m
at
er
ia
l a
va
ila
b
le
 in
 c
on
va
le
sc
en
t p
ha
se
 o
f d
is
ea
se
N
o 
m
at
er
ia
l a
va
ila
b
le
 in
 c
on
va
le
sc
en
t p
ha
se
 o
f d
is
ea
se
N
o 
m
at
er
ia
l a
va
ila
b
le
 in
 c
on
va
le
sc
en
t p
ha
se
 o
f d
is
ea
se
N
o 
m
at
er
ia
l a
va
ila
b
le
 in
 c
on
va
le
sc
en
t p
ha
se
 o
f d
is
ea
se
Chapter 9
 149
related. A international prospective study to investigate the role of the complement system, 
including the presence of complement mutations and/or autoantibodies against complement 
proteins, in a larger cohort with patients that do and do not develop HUS after infection is needed. 
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Chapter 10
Identification and functional characterization of potential com-
plement evasion factors secreted by STEC O157:H7
E.B. Volokhina1, D. Westra1, T.J.A.M. van der Velden1, N.C.A.J. van de Kar1, S. Rooijakkers3, 
J.A.G. van Strijp3, L.P. van den Heuvel1,2,4
Depts. of 1Pediatric Nephrology and 3Laboratory Medicine, Radboud university medical center, 
Nijmegen, The Netherlands; 2Dept. of Experimental Microbiology, University Medical Centre Utrecht, 
The Netherlands; 4Dept. of Pediatrics, University Hospital Leuven, Belgium.
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Abstract 
 
Hemolytic uremic syndrome (HUS) is one of the major causes of renal failure in childhood. Most 
cases of the disease are caused by infection with Shiga-toxin producing Escherichia coli (STEC). 
Available experimental evidence suggests that complement activation may play an important role in 
STEC-HUS pathogenesis, however the exact etiology of this disease is not yet fully understood.  
In this study, we used in silico genome analysis to select STEC-specific genes encoding secreted 
proteins that are not present in non-STEC E. coli genomes. In total, ten proteins were selected, of 
which five were successfully produced with a His-tag using recombinant technology and purified 
using TALON metal affinity resin. Complement activation was induced in normal human serum in the 
presence or absence of the STEC proteins. Binding to complement proteins and resulting 
complement activation was assessed by measuring C3b and TCC (C5b-9 and C6-9) levels using ELISA. 
None of the selected proteins were able to alter complement activation in human serum.  
These results indicate that a more robust approach is needed to analyze complement dysregulating 
properties of the STEC secretome, such as studies using the phage display library, which are 
currently being performed.  
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Abstract 
 
Hemolytic uremic syndrome (HUS) is one of the major causes of renal failure in childhood. Most 
cases of the disease are caused by infection with Shiga-toxin producing Escherichia coli (STEC). 
Available experimental evidence suggests that complement activation may play an important role in 
STEC-HUS pathogenesis, however the exact etiology of this disease is not yet fully understood.  
In this study, we used in silico genome analysis to select STEC-specific genes encoding secreted 
proteins that are not present in non-STEC E. coli genomes. In total, ten proteins were selected, of 
which five were successfully produced with a His-tag using recombinant technology and purified 
using TALON metal affinity resin. Complement activation was induced in normal human serum in the 
presence or absence of the STEC proteins. Binding to complement proteins and resulting 
complement activation was assessed by measuring C3b and TCC (C5b-9 and C6-9) levels using ELISA. 
None of the selected proteins were able to alter complement activation in human serum.  
These results indicate that a more robust approach is needed to analyze complement dysregulating 
properties of the STEC secretome, such as studies using the phage display library, which are 
currently being performed.  
 
Introduction 
 
The hemolytic uremic syndrome (HUS) is one of the major causes of acute renal failure in children. It 
is characterized by hemolytic anemia, thrombocytopenia and acute renal failure. More than 90% of 
cases (STEC-HUS) are preceded by watery or bloody diarrhea that are caused by an infection with 
Shiga toxin-producing Escherichia coli (STEC), which can be ingested with improperly cooked meat or 
contaminated water and vegetables.37 A STEC infection leads to HUS in approximately 15% of 
cases.35 The majority of STEC-HUS cases affects children and is associated with infection by the 
O157:H7 STEC serotype. In the intestine, HUS-causing STEC-strains produce Shiga toxins belonging to 
type Stx1 and/or type Stx2.240, 241 
Although Stx1 and Stx2 have been linked to protein synthesis inhibition, triggering of apoptosis, 
complement activation, and regulation of gene expression of cytokines and chemokines, the exact 
mechanisms of how Stx exposure leads to HUS is still not completely understood.242  
The complement system plays an important role in the innate immunity. It can be activated via three 
pathways: the classical, the lectin and the alternative.66, 210 The alternative complement pathway 
dysregulation, which is well-characterized in non-STEC-HUS3, 29, 158, may be important in STEC-HUS as 
well. Already in the 1980’s, increased levels of the breakdown products of C3 and complement 
factor B (FB) were demonstrated by our group in serum samples of children with diarrhea-associated 
HUS.65 In addition, a more recent study reported increased serum levels of Bb and serum C5b-9 in 
children in the acute phase of STEC-HUS.111 Complement activation was also shown on platelet-
leukocyte complexes and microparticles of HUS patients112. This complement activation in STEC-HUS 
might partially be attributed to Shiga toxin. In vitro Stx2 binds complement factor H (FH) and is able 
to activate alternative complement pathway.113 Furthermore, in vitro Stx1 triggers complement C3 
activation at the cell surface, which is mediated by P-selectin.116 Manipulation of complement 
activation is not reserved for the Shiga toxins. The STEC autotransporter E. coli secreted protein P 
(EspP) was shown to be able to cleave C3/C3b and C5 and impair complement activation in serum.117 
Furthermore, the zinc metalloprotease StcE found in STEC O157:H7 is able to downregulate the 
classical complement pathway (reviewed in S. Rooijakkers et al. 118). These examples illustrate that 
STEC is very well able to manipulate complement in multiple ways, as are other bacteria like 
Staphyloccus aureus, Borrelia Burgdorferi, and several streptococci.114, 118  
In this project, we aim to discover and functionally characterize novel complement evasion factors 
produced by STEC via well-established methods118, which might lead to the development of the new 
treatment strategies to protect renal function in the STEC-HUS patients in the future. 
Identification and functional characterization of potential complement evasion factors secreted by STEC O157:H7
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Materials and Methods  
 
Bacterial strains and growth conditions 
E. coli strains O157:H7 Sakai, DH5α (laboratory stock), and BL21(DE3) (Novagen) were grown at 37°C 
or 25°C in Luria-Bertani (LB) medium or on LB agar plates, supplemented, when required, with 100 
μg/ml of ampicillin (Sigma-Aldrich).  
 
Plasmid constructions 
DNA fragments, containing mature STEC proteins were obtained by PCR from genomic DNA of the 
O157:H7 Sakai strain (primers available upon request). The PCR products were cloned into the 
modified pET302/NT-His expression vectors (Invitrogen) using BamH I and Not I expression sites. In 
case of the ECs4562 gene, which contains an internal BamH I site, Bgl II was used. Combinations of 
different primers and vectors allowed to obtain constructs encoding various 6xHis-tagged variants as 
well as tag-free proteins (Figure 10.1). 
 
Expression of recombinant proteins 
Strain BL21(DE3) containing the obtained expression vectors was used to produce proteins. The 
BL21(DE3) cells were grown in 300 ml of total culture volume. When an optical density at 600 nm 
reached 0.7 OD, 100 μM of isopropyl-β-D-thiogalactopyranoside (IPTG) was added to induce the 
expression of the recombinant proteins. After 90 min of induction at 37°C (ECs2714 N-His FXa) or 
overnight induction at 25°C (all other preparations), the cells were harvested by centrifugation and 
frozen at –20°C.  
 
Protein isolation 
The BL21(DE3) bacteria with the expression vectors were subjected to osmotic shock in order to 
remove periplasmic fraction containing metal chelators.243 To this end, the cell pellets were 
resuspended in sucrose buffer (50 mM HEPES, 20% sucrose, 1mM EDTA, pH 7.9) at 5 ml/g and 
centrifuged (2100 g, 30 min, 4°C). The supernatant was removed and the pellet was resuspended in 
5 mM MgSO4 at 5 mL/g and incubated on ice for 10 min. The pellet was collected by centrifugation 
(2100 g, 30 min, 4°C) and stored at -20°C.  
Pellets obtained after the osmotic shock procedure were lysed in 45 ml CelLyticTM B (Sigma-Aldrich), 
supplemented with 1 tablet of EDTA-free protease inhibitor cocktail,  28 μg/ml of DNase I and RNase 
A (all from Roche diagnostics) and 100 μg/ml lysozyme (Sigma-Aldrich) and incubated for 30 min on  
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Figure 10.1. Cloning strategy for the recombinant production of proteins. (A) Schematic representation of the 
five primers: three forward (F1-F3) and two reverse (R1, R2); and three vectors: pEF110, pEF210 and pEF 111, 
used in this study are given. Locations of the BamH I (Bam) and Not I (Not) sites are shown. The N-terminal (N-
His) and C-terminal (C-His) positions of the sequences encoding polyhistidine tag (6xHIS) and start and stop 
codons (S) in the vectors are indicated. Sequences encoding cleavage sites for the removal of the polyhistidine 
tag specific for enterokinase (EK), factor Xa (FXa), and tobacco etch virus (TEV) protease are specified. (B) 
Combinations of the specific vectors and primers, required for the production of the six possible protein variants. 
(C) Schematic representation of the resulting six protein variants, including polyhistidine tags, protease cleavage 
sites, and additional amino acids (GS) encoded by the BamH I site that were introduced in the cloning process. 
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a shaker at room temperature. The inclusion bodies were collected by centrifugation (47800 g, 20 
min, 4°C); washed twice by resuspending in CelLyticTM B diluted 1:10 in H20, and centrifuging (47800 
g, 20 min, 4°C); and solubilized in denaturing buffer (8 M urea, 20 mM sodium phosphate buffer, 0.5 
M NaCl, pH 8.5). The remaining insoluble material was removed by centrifugation (47800 g, 20 min, 
4°C). 
 
Affinity purification and refolding 
The obtained preparations of the solubilized His-tagged proteins were purified using TALON metal 
affinity resin (Clontech) according to the manufacturer’s protocol for denaturing conditions. The 
proteins were eluted in elution buffer (8 M urea, 20 mM sodium phosphate buffer, 0.5 M NaCl, 300 
mM imidazole, pH 7.8). 
The purified proteins were dialyzed against the refolding buffer (50 mM Tris, 0.5 M L-argenine, pH 
10), and after that dialyzed against phosphate buffered saline (PBS; pH 8)  for complement assays. 
Protein preparations were analyzed using SDS-PAGE and Coomassie Brilliant Blue staining.  
 
Complement assays 
Complement activation of classical and alternative pathways was analyzed separately. Normal 
human serum (NHS) was diluted to create a concentration ranges of 0, 2.5, 5 and 10 % (classical 
pathway assay) and 0, 5, 25 and 50 % (alternative pathway assay) prior to complement activation. 
Generation of TCC reflected by C5b-9 and C6-9 levels, and of C3b was quantified in ELISA setting.210  
Binding of the purified proteins to complement factors was analyzed in ELISA setting. To this end, 
FH, FI, FD, FB, and C3b were coated overnight at 4°C on a 96-wells plate at concentrations of 1, 5 and 
10 μg/ml in carbonate buffer (15 mM Na2CO3, 25 mM NaHCO3, pH 9.6), and incubated with STEC 
proteins C diluted at a concentration of 10 µg/ml in dilution buffer (PBS, 1% bovine serum albumin, 
0.05% tween-20) for 60 min. at 37°. Immunodetection was performed using a primary mouse anti-
His antibody (Invitrogen) and a secondary horseradish peroxidase-labeled goat-anti-mouse antibody 
(Dako). 
 
Results 
 
Identification of possible complement evasion factors 
Comparative analysis of STEC and non-STEC E. coli genomes, was performed using the total genome 
and sequence analysis software Kodon (Applied Maths). In total 21 non-STEC and nine STEC 
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0.05% tween-20) for 60 min. at 37°. Immunodetection was performed using a primary mouse anti-
His antibody (Invitrogen) and a secondary horseradish peroxidase-labeled goat-anti-mouse antibody 
(Dako). 
 
Results 
 
Identification of possible complement evasion factors 
Comparative analysis of STEC and non-STEC E. coli genomes, was performed using the total genome 
and sequence analysis software Kodon (Applied Maths). In total 21 non-STEC and nine STEC 
genomes were compared (Table 10.1); only two of these STEC strains have directly been involved in 
an HUS outbreak (Sakai and TW14359). The ten proteins that were STEC-specific, annotated as 
secreted, had a low molecular weight (<25 kDa) and a high isoelectric point (>8), are secreted via the 
type 3 secretion system of STEC, and were encoded by genes that are located on mobile elements, 
were chosen for further production and analysis (Table 10.2). All selected genes are present in 
O157:H7 Sakai strain, a well-described HUS-causing STEC strain, and.244, 245 
 
Table 10.1. Escherichia coli genomes used in comparative analysis. 
None STEC-strains STEC strains 
Escherichia coli ‘BL21-Gold(DE3)pLysS AG’ Escherichia coli O103:H2 str. 12009 
Escherichia coli 536 Escherichia coli O111:H- str. 11128 
Escherichia coli 55989 Escherichia coli O127:H6 str. E2348/69 
Escherichia coli APEC O1 Escherichia coli O157:H7 EDL933 
Escherichia coli ATCC 8739 Escherichia coli O157:H7 str. EC4115 
Escherichia coli B str. REL606 Escherichia coli O157:H7 str. Sakai 
Escherichia coli BW2952 Escherichia coli O157H7 str. TW14359 
Escherichia coli CFT073 Escherichia coli O26:H11 str. 11368 
Escherichia coli E24377A Escherichia coli O55:H7 str. CB9615 
Escherichia coli ED1a   
Escherichia coli HS  
Escherichia coli IAI1  
Escherichia coli IAI39  
Escherichia coli S88  
Escherichia coli SE11   
Escherichia coli SMS-3-5  
Escherichia coli UMN026  
Escherichia coli UTI89  
Escherichia coli str. K-12 substr. DH10B  
Escherichia coli str. K-12 substr. MG1655  
Escherichia coli str. K-12 substr. W3110  
 
Table 10.2. Possible novel complement evasion factors of the E. coli strain O157:H7 Sakai, selected by 
comparative genome analysis. The isoelectric point (pI) and molecular weight (Mw) values are given for the tag- 
free wild type variants. ECs2715 and ECs1126 are also known as TccP and TccP2, respectively.246, 252 
 pI MW (kDa) 
ECs1825 (EspM1) 9.1 21.9 
ECs3485 (EspM2) 8.7 22.5 
ECs4562 (Map) 9.7 22.9 
ECs2714 (EspJ) 9.5 24.7 
ECs4550 (EspF1) 10.4 25.3 
ECs2715 (EspF2-2) 10.1 37.2 
ECs1126 (EspF2-1’) 6.4 21 .0 
ECs4564 (EspH) 9.8 19.3 
ECs1567 (EspO1-1) 9.1 10.3 
ECs1821 (EspO1-2) 8.6 10.4 
Identification and functional characterization of potential complement evasion factors secreted by STEC O157:H7
genomes were compared (Table 10.1); only two of these STEC strains have directly been involved in 
an HUS outbreak (Sakai and TW14359). The ten proteins that were STEC-specific, annotated as 
secreted, had a low molecular weight (<25 kDa) and a high isoelectric point (>8), are secreted via the 
type 3 secretion system of STEC, and were encoded by genes that are located on mobile elements, 
were chosen for further production and analysis (Table 10.2). All selected genes are present in 
O157:H7 Sakai strain, a well-described HUS-causing STEC strain, and.2 4, 245 
 
Table 10.1. Escherichia coli genomes used in comparative analysis. 
None STEC-strains STEC strains 
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Escherichia coli HS  
Escherichia coli IAI1  
Escherichia coli IAI39  
Escherichia coli S 8  
Escherichia coli SE 1   
Escherichia coli SMS-3-5  
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Table 10.2. Po sible novel complement evasion factors of the E. coli strain O157:H7 Sakai, selected by 
comparative genome analysis. The isoelectric point (pI) and molecular weight (Mw) values are given for the tag- 
fr e wild type variants. ECs2715 and ECs 126 are also known as T cP and T cP2, respectively.246, 252 
 pI MW (kDa) 
ECs1825 (EspM1) 9.1 21.9 
ECs3485 (EspM2) 8.7 2.5 
ECs4562 (Map) 9.7 2.9 
ECs2714 (EspJ) 9.5 24.7 
ECs4 50 (EspF1) 10.4 25.3 
ECs2715 (EspF2-2) 10.1 37.2 
ECs 126 (EspF2-1’) 6.4 21 .0 
ECs4564 (EspH) 9.8 19.3 
ECs1567 (EspO1-1) 9.1 10.3 
ECs1821 (EspO1-2) 8.6 10.4 
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Production and purification of recombinant protein 
Potential STEC complement evasion factors were produced in recombinant form with a His-tag and 
purified using affinity chromatography, as described in Materials and Methods. For one gene 
(ECs1126), it was not possible to obtain a PCR product due to high frequency of short homologues 
repeats in the locus of the gene. 
To optimize the yields of protein expression, IPTG concentrations (50, 100, 300 μM) and expression 
temperature and time (37˚C for 90 min or 25˚C overnight) were varied. Furthermore, the genes 
were cloned as tag-free variants and with various His-tag constructs: a N-terminal His-tag (cleavable 
and not cleavable) and a C-terminal His-tag (Figure 10.1). The best obtained preparations are 
illustrated in Figure 10.2. For the proteins ECs1825, ECs4564, ECs1567 and ECs1821 only low yields 
of expression were obtained despite the thorough optimization attempts. 
 
 
 
 
 
 
 
 
 
Figure 10.2.  The obtained final preparations of the five recombinant STEC proteins. Samples were analyzed 
using SDS-PAGE and Coomassie Brilliant Blue staining. A molecular weight standard is indicated on the left. Bands 
corresponding to the molecular weights of proteins are indicated (*).  
 
Functional analysis of possible complement evasion factors 
Next we analyzed possible effect of produced recombinant STEC proteins on complement activation 
in the fluid phase. Proteins ECs3485, ECs4562, ECs2714, ECs4550 and ECs2715 yielded enough 
amount for these experiments (Figure 10.2, Figure 10.3). None of the proteins affected levels of 
complement activation in NHS. The ECs4550 protein appeared to increase efficiency of C5b-9 
generation in alternative complement pathway activation in one of the experiments (Figure 10.3A). 
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Production and purification of recombinant protein 
Potential STEC complement evasion factors were produced in recombinant form with a His-tag and 
purified using affinity chromatography, as described in Materials and Methods. For one gene 
(ECs1126), it was not possible to obtain a PCR product due to high frequency of short homologues 
repeats in the locus of the gene. 
To optimize the yields of protein expression, IPTG concentrations (50, 100, 300 μM) and expression 
temperature and time (37˚C for 90 min or 25˚C overnight) were varied. Furthermore, the genes 
were cloned as tag-free variants and with various His-tag constructs: a N-terminal His-tag (cleavable 
and not cleavable) and a C-terminal His-tag (Figure 10.1). The best obtained preparations are 
illustrated in Figure 10.2. For the proteins ECs1825, ECs4564, ECs1567 and ECs1821 only low yields 
of expression were obtained despite the thorough optimization attempts. 
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Functional analysis of possible complement evasion factors 
Next we analyzed possible effect of produced recombinant STEC proteins on complement activation 
in the fluid phase. Proteins ECs3485, ECs4562, ECs2714, ECs4550 and ECs2715 yielded enough 
amount for these experiments (Figure 10.2, Figure 10.3). None of the proteins affected levels of 
complement activation in NHS. The ECs4550 protein appeared to increase efficiency of C5b-9 
generation in alternative complement pathway activation in one of the experiments (Figure 10.3A). 
However, this finding was not supported by the measurements of C3b and C6-9 levels (Figure 10.3B 
and 10.3C). 
Moreover, we performed binding studies to analyze possible interactions between the STEC proteins 
and human complement proteins (FH, FI, FD, FB, and C3b). For these assays amounts obtained for all 
nine produced STEC proteins were sufficient. No binding between complement factors and the 
produced STEC proteins was observed in these experiments (data not shown). 
 
 
Figure 10.3. Results of the complement activation experiments. Complement activation was induced in diluted 
NHS in the absence (blanco sample) or presence of recombinant STEC proteins. Samples were collected and 
complement activation was assessed by measuring levels of C5b-9 (A), C6-9 (B) and C3b (C), generated during 
specific activation of the classical and alternative pathways. C5b-9 and C6-9 both reflect levels of the terminal 
complement component (TCC). 
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Discussion 
 
In the light of the complement evading properties of other bacteria, we aimed to discover and 
characterize novel evasion factors produced by STEC, next to Stx, EspP, and StcE.113, 115-118 We 
selected, recombinantly produced, refolded, and analyzed potentially pathogenic STEC proteins. Ten 
proteins have been selected using genome comparison and five proteins were eventually produced 
in sufficient quantities to perform more extensive complement binding experiments. None of the 
produced proteins had an effect on complement activation in the in vitro studies. 
A comparative in silico analysis was used to select proteins encoded by genes that are only present 
in STEC and not in other E. coli genomes. For eight of the ten selected proteins, the expression and 
secretion was previously confirmed by other experiments.246 Only for ECs1821 and ECs1126, no 
experimental confirmation for secretion was available.  
Five of the selected proteins were produced recombinantly and used in complement activation and 
binding assays. However, none of these proteins showed effect on complement activation in human 
serum. In non-STEC-HUS, which is associated with mutation in genes encoding complement 
proteins, it is thought that complement activation occurs mostly at the endothelial surface and not 
just in the fluid phase.98 This could be the case for these STEC proteins as well.  
 
Future perspecitives 
An  important limitation of this study is the use of the candidate-gene approach, where genes that 
are not selected during the in silico step will never be tested in the laboratory. In the next step of 
this project, we are therefore going to use a different approach. We will create a STEC genome 
phage display library, where all STEC proteins will be expressed and tested for interaction with 
different complement components (Figure 10.4). Phage display technology is a high throughput and 
unbiased technique for identification of novel complement evasion molecules. During phage display, 
proteins of choice are expressed fused to capsid proteins on the surface of a filamentous Ff-phage, a 
virus that specifically infects the Gram-negative bacterium E. coli carrying F- pili. A phage library 
contains a large amount of different phage clones randomly displaying different proteins resulting in 
a heterogeneous mixture of phages. The chromosomal DNA of the pathogenic STEC strains Sakai and 
EDL933 will be randomly sheared and inserted into a phagemid vector lacking a native signal 
sequence. The presence of a signal sequence or membrane targeting motif within the fusion protein 
construct is essential for protein display. In a secretome phage display, the membrane targeting 
motif in the inserted fragment is used to specifically display secretome proteins.247-249 The 
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secretion was previously confirmed by other experiments.246 Only for ECs1821 and ECs1126, no 
experimental confirmation for secretion was available.  
Five of the selected proteins were produced recombinantly and used in complement activation and 
binding assays. However, none of these proteins showed effect on complement activation in human 
serum. In non-STEC-HUS, which is associated with mutation in genes encoding complement 
proteins, it is thought that complement activation occurs mostly at the endothelial surface and not 
just in the fluid phase.98 This could be the case for these STEC proteins as well.  
 
Future perspecitives 
An  important limitation of this study is the use of the candidate-gene approach, where genes that 
are not selected during the in silico step will never be tested in the laboratory. In the next step of 
this project, we are therefore going to use a different approach. We will create a STEC genome 
phage display library, where all STEC proteins will be expressed and tested for interaction with 
different complement components (Figure 10.4). Phage display technology is a high throughput and 
unbiased technique for identification of novel complement evasion molecules. During phage display, 
proteins of choice are expressed fused to capsid proteins on the surface of a filamentous Ff-phage, a 
virus that specifically infects the Gram-negative bacterium E. coli carrying F- pili. A phage library 
contains a large amount of different phage clones randomly displaying different proteins resulting in 
a heterogeneous mixture of phages. The chromosomal DNA of the pathogenic STEC strains Sakai and 
EDL933 will be randomly sheared and inserted into a phagemid vector lacking a native signal 
sequence. The presence of a signal sequence or membrane targeting motif within the fusion protein 
construct is essential for protein display. In a secretome phage display, the membrane targeting 
motif in the inserted fragment is used to specifically display secretome proteins.247-249 The 
membrane targeting motif in the inserted fragment addresses the encoded bacterial protein in 
fusion with a phage capsid protein PIII to the E. coli cytoplasmic membrane, where it is assembled 
into the phage particle. The displayed STEC fusion protein retains its native conformation and 
activity, which allows for affinity selection. 
 
 
 
Figure 10.4. Schematic representation of the work flow in the follow-up project involving the phage display 
screening of mature (full length) proteins originating from the complete STEC proteome. 
 
Phage selection will be performed by panning the phage library on different complement 
components: FH, FI, CD46, C3, FB, C1-C9, FD, total TCC, etc. For each complement protein, only 10 
μg will be sufficient. Thus the initial screening of the phage display library for binding to complement 
component will be independent of the successful production of purification of proteins in high yields 
(mg amounts), as was the case in this study. STEC proteins that demonstrate complement binding, 
will be produced or purified from the STEC secretome in high quantities in order to perform more 
extensive complement activation tests in vitro. Moreover, they also will be tested in vivo in wild type 
mice and transgenic mouse models for the ability to induce HUS phenotype in the presence or 
absence of shiga toxins.250, 251 
Therefore, this project will be continued using a more promising strategy for the selection of novel 
possible STEC virulence factors. The platform to produce and purify recombinant STEC proteins that 
was created during this project will be used in the follow-up study and will facilitate more efficient 
experimental testing. 
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Abstract 
 
Infection with Streptococcus pneumoniae (SP) is one of the causes of the hemolytic uremic 
syndrome (HUS), a rare but severe renal disorder that is thought to be caused by glomerular 
endothelial damage due to desialylation of glycoproteins by the pneumococcal neuraminidase. 
Defective complement regulation, as seen in other HUS patients, might be an important risk factor.  
Wild-type mice (FH+/+) and mice deficient in the complement regulator factor H (FH-/-) were infected 
with SP. Bacterial virulence factors putatively involved in SP-HUS pathogenesis or in complement 
evasion and activation (pspC, pneumolysin [ply], and neuraminidase A [nanA]) were inactivated to 
determine if a temporally complement deficiency due to SP infection is enough to develop HUS.  
Bacterial counts in blood were higher in FH-/- mice and these animals showed more signs of disease, 
higher acute kidney injury markers in urine, and a higher inflammatory response after infection. 
Fibrin(ogen) staining, as a marker for the presence of thrombotic microangiopathy, however, was 
present in similar levels in both FH+/+ and FH-/- mice. The mutant bacteria ΔpspC and ΔnanA acted 
similar as wild-type bacteria; Δply bacteria were less virulent. 
While no influence of factor H and secondary C3 deficiency was found on the level of thrombotic 
microangiopathy, its deficiency clearly resulted in a decreased host resistance against pneumococcal 
infection, as shown by higher bacterial load in blood of FH-/- mice. Therefore, complement deficiency 
might lead to higher bacteria load in patients, thereby increasing the risk for the development of 
HUS.  
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Introduction 
 
The hemolytic uremic syndrome (HUS) is one of the main causes of acute renal failure in childhood. 
This thrombotic microangiopathy (TMA) manifests as hemolytic anemia, thrombocytopenia, and 
acute renal failure. Patients are classified according to their etiology, which can be infection induced, 
a disorder of the complement system, or a rare cause associated with HUS (medication, systemic 
diseases, pregnancy, etc.).1, 109 In most cases in childhood, the disease is triggered by an infection 
with Shiga-like toxin producing Escherichia coli (STEC); non-STEC-HUS is seen in 5-10% of the 
patients.  
One of the causes of non-STEC-HUS is an infection with Streptococcus pneumoniae (SP-HUS).48 A 
higher morbidity (25-50%) and mortality (5-25%) rate has been reported over the years for this type 
of HUS as compared to STEC-HUS.50, 58 In literature, these cases are associated with pneumonia and  
meningitis.53 The high incidence of empyema, which is found in 51% of SP-HUS cases associated with 
pneumonia, suggests that a high bacterial load may increase the risk of HUS in the setting of 
pulmonary infection.50 The current hypothesis of the pathogenesis of SP-HUS is desialylation of 
glycoproteins of red blood cells, thrombocytes, and endothelial cells by the bacteria’s neuraminidase 
(NanA), leading to the exposure of the Thomson Friedenreich cryptantigen (T-antigen).48, 49 Naturally 
occurring circulating IgM antibodies against this T-antigen, which are present in the plasma of most 
people, can bind to the exposed T-antigen, resulting in the agglutination of red blood cells in vitro. 
The exact role of these anti-T-antigen antibodies in the pathogenesis of SP-HUS is not known: T-
antigen activation can be caused by more than 77 well-defined serotypes, but most of them are not 
associated with pneumococcal HUS.51 Furthermore, no difference was seen in overall neuraminidase 
activity between SP-HUS isolates and control isolates.253 This indicates that other important 
susceptibility factors, like a defective complement regulation seen in other non-STEC-HUS patients, 
have to be considered in the pathogenesis of SP-HUS. 
Previously, a significant role of the alternative complement pathway has been shown in 
pneumococcal infection in mice deficient in C3 and factor B.123 These mice were unable to form C3 
convertases and therefore had hardly any hemolytic activity, resulting in more severe pneumococcal 
disease. Patients with HUS due to an alternative complement pathway disorder can still produce C3 
convertases, but have an impaired complement regulation in the fluid phase and/or on the cell 
surface. This results in a hyperactive complement system. Increased alternative pathway activity 
may result in complement factor consumption and secondary deficiencies. In ~30% of these 
patients, a genetic aberration is found in the alternative pathway regulator FH.29, 78 Although mice 
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deficient in FH still had a normal renal function after two months, within eight months they 
spontaneously developed dense deposit disease, another complement-mediated glomerular disease 
strongly associated with FH mutations.250 A conditional trigger of the complement system might be 
needed to develop HUS in these mice, as is observed in patients.71, 93 
This hypothesis has been investigated previously: Shiga toxin (Stx) was administered to mice with a 
heterozygous deficiency of factor H to induce STEC-HUS, but this resulted in renal tubular but not 
glomerular injury.251 This is probably due to the location of the Gb3-receptor that is targeted by Stx: 
in mice, this receptor is only expressed in the renal tubules and not in glomeruli.254 So, shiga toxin is 
not the right trigger to induce glomerular TMA in mice, but S. pneumoniae could be. Streptococcus 
pneumoniae does not bind mouse factor H, thus studies in FH-/- mice allow to study the effect of FH 
on overall complement activity, not influenced by FH complement interactions on the pneumococcal 
surface. 
In earlier studies, it has been shown that pneumococci have the capacity to bind one of the main 
complement regulators in humans, complement factor H (FH), by the pneumococcal surface protein 
C (PspC), thereby improving survival in the host.125-127 In addition, during autolysis of the bacteria, 
pneumolysin is released, an important virulence factor that activates the complement system, 
leading to complement depletion and reduced opsonisation.131 Infection with S. pneumoniae might 
therefore lead to temporally complement deficiency, by means of evasion or activation, and loss of 
complement regulation. This in turn could result in less protection of the host cells to complement 
activation and, together with the bacteremia in the patient, in vascular injury and the symptoms of 
HUS.  
To test the hypothesis that a defective host complement regulation is involved in the pathogenesis 
of SP-HUS, wild-type mice (FH+/+) and mice deficient in complement factor H (FH-/-) were infected 
with Streptococcus pneumoniae bacteria. The role of complement evasion and/or activation by the 
bacteria itself is further studied by infection with mutant bacteria lacking virulence factors 
associated with SP-HUS or complement [PspC (ΔpspC), neuraminidase A (ΔnanA), or pneumolysin 
(Δply)]. 
 
Materials and methods 
 
Bacterial strains and growth conditions 
S. pneumoniae TIGR4 (serotype 4)255 and its respective mutants were routinely grown in Todd-
Hewitt broth supplemented with 5 g/l yeast extract (THY) or on Colombia blood agar plates (Oxoid) 
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complement regulation. This in turn could result in less protection of the host cells to complement 
activation and, together with the bacteremia in the patient, in vascular injury and the symptoms of 
HUS.  
To test the hypothesis that a defective host complement regulation is involved in the pathogenesis 
of SP-HUS, wild-type mice (FH+/+) and mice deficient in complement factor H (FH-/-) were infected 
with Streptococcus pneumoniae bacteria. The role of complement evasion and/or activation by the 
bacteria itself is further studied by infection with mutant bacteria lacking virulence factors 
associated with SP-HUS or complement [PspC (ΔpspC), neuraminidase A (ΔnanA), or pneumolysin 
(Δply)]. 
 
Materials and methods 
 
Bacterial strains and growth conditions 
S. pneumoniae TIGR4 (serotype 4)255 and its respective mutants were routinely grown in Todd-
Hewitt broth supplemented with 5 g/l yeast extract (THY) or on Colombia blood agar plates (Oxoid) 
at 37ºC and 5% CO2. Prior to infection, the TIGR4 wild-type and mutant strains were passaged in 
mice to maintain virulence as described previously.256 Cultures of mouse-passaged S. pneumoniae 
TIGR4 strains were grown to an optical density at 620 nm of 0.2, were aliquoted, and stored at -80ºC 
in 15% glycerol.  
 
Construction of pneumococcal mutants 
Directed deletion mutants of S. pneumoniae TIGR4 lacking pneumococcal surface protein C (ΔpspC), 
pneumolysin (Δply) and neuraminidase A (ΔnanA) were constructed by allelic replacement of the 
target gene with an antibiotic resistance marker as described previously.257 Briefly, overlap 
extension PCR was used to insert the spectinomycin resistance cassette of the pR412 plasmid 
between the two 500-bp flanking sequences adjacent of the target gene. The resulting PCR products 
were introduced by competent stimulating peptide (CSP-2)-induced transformation into TIGR4. 
Directed mutants were obtained by selective plating and were checked for correct integration of the 
antibiotic resistance cassette into the target gene by PCR using  control primers located inside the 
gene. Subsequently, the TIGR4 WT strain was transformed with chromosomal DNA isolated from the 
mutants to prevent the accumulation of inadvertent mutations elsewhere on the chromosome. In 
addition, inactivation of the target gene was confirmed by qPCR.  The primers (Biolegio, Nijmegen, 
Netherlands) used in this study are listed in Table 1. 
 
Animals 
FH+/+ and FH-/- mice with a C57BL/6 genetic background were generated as described before.250 
Genomic DNA was extracted from mouse tissue (tail or ear snips) and analyzed for the presence of 
complement factor H by means of PCR. Three different primers were used: one is located in exon 2 
(mFH/2+; 5’-GTAAAGGTCCTCCTCCAAGAG-3’) present in all mice; the others are situated in exon 3 of 
the normal gene (mFH/3-; 5’- GGTATAAACAACCTTTGCACC-3’) or in a sequence specific for the 
mutant gene (neo/3-; 5’- GGGGATCGGCAATAAAAAGAC-3’). This resulted in a WT band of 600 bp and 
a recombinant band of 400 bp. Further details have been published previously.258 
 
Measurement of disease score  
During the experiment, mice were monitored twice a day and were scored according to their 
condition. Used parameters were weight, ruffled coat, hunched back, reduced mobility, body 
temperature, and a moribund state (Table 2). Mice were sacrificed when reaching humane 
endpoints: i.e. an overall score of more than 15 and/or a moribund state and/or weight loss >20%  
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from starting weight and/or a body temperature below 35ºC was used as an indication for 
euthanasia. 
 
Mouse bacteremia model 
All animal procedures were performed in accordance with local and national ethical approval and 
guidelines. Bacteremia experiments were conducted in six-to-eight week old male mice. Mice were 
infected intravenously in the tail vein with 1x107 colony forming units (CFU) in 100 µl sterile 
phosphate-buffered saline (PBS). Before infection, blood was collected via a cheek puncture and also  
urine secreted by the animals during fixation was collected. Mice were sacrificed 19 hours after 
infection, when several mice reached humane endpoints as described above. 
 
Table 11.1. Primers used in the construction of directed deletion mutants of S. pneumoniae TIGR4 lacking 
pneumococcal surface protein C (ΔpspC), pneumolysin (Δply) and neuraminidase A (ΔnanA). 
Primers for mutant generation: 
spn1923_L1 Spn -1923 ply 5’-GAAGACTTGGTCAATCCTGTC-3’ 
spn1923_L2 Spn -1923 ply 5’-CCACTAGTTCTAGAGCGGCCCTGATGGGTCAAGAGTTTC-3’ 
spn1923_R1 Spn -1923 ply 5’-AAGCTAGCCTCAGGTTGCTC-3’ 
spn1923_R2 Spn -1923 ply 5’-GCGTCAATTCGAGGGGTATCACCGATTTGCCACTAGTGCG-3’ 
spn1923_C Spn -1923 ply 5’-CGAGAAGTGCTCCAGGATAG-3’ 
spn1693_L1_nanA   Spn -1693 nanA 5’-GTTCGATAAGGATTGAGCAGG-3’ 
spn1693_L2_nanA   Spn -1693 nanA 5’-CCACTAGTTCTAGAGCGGCCGTTCCAAATACCACTGCTC-3’ 
spn1693_R1_nanA   Spn -1693 nanA 5’-GGATCGAAAGTCTCATGAATAC-3’ 
spd1504_R2 Spn - 1693 nanA 5’-GCGTCAATTCGAGGGGTATC-GCTTCACTAGGACTAACAGC-3’ 
spd1504_C Spn - 1693 nanA 5’-TGGCATCTGGCTTAAACTCC-3’ 
spn2190_L1 Spn -2190 pspC 5’-TTG AGG CAA TGG TGC ACA AG-3’ 
EMspn2190_L2 Spn -2190 pspC 5’-CCACTAGTTCTAGAGCGGCTACACTAGCTACTCCAACAC-3’ 
EMspn2190_R1 Spn -2190 pspC 5’-CAAGATGAAGATCGCCTACG-3’ 
EMspn2190_R2a Spn -2190 pspC 5’-GCGTCAATTCGAGGGGTATCGCTATGGAGTCAATGCCAAT-3’ 
EMspn2190_C Spn -2190 pspC 5’-TCGTTCTCTGTCGCATGAAC-3’ 
Primers for qPCR: 
2190pspC_Fw_qpcr    Spn 2190 pspC 5’-CATCTTCTTCGTCAAGTTCAGACTCT-3’ 
spn_2190pspC_Rev_qpcr    Spn 2190 pspC 5’-CTGGTTCTGTCGGCTTGTTTG-3’ 
HB_Sp_plyF Spn -1923 ply 5’-TCGTAGTGGATGAGACCTTGTTAGA-3’ 
HB_Sp_plyR Spn -1923 ply 5’-GCCAAACCAGGCAAATCAAT-3’ 
HB_Sp_nanAF Spn - 1693 nanA 5’-TTGGAACGTCTCCTGTTTTAGCT-3’ 
HB_Sp_nanAR Spn - 1693 nanA 5’-CCCCGAAAGTTGAGTTTCATTT-3’ 
HBgyrAF Spn – 1219 GyrA 5’-AATGAACGGGAACCCTTGGT-3’ 
HBgyrAR Spn – 1219 GyrA 5’-CCATCCCAACCGCGATAC-3’ 
PBMrTn9 Specres cassette 5’-CAATGGTTCAGATACGACGAC-3’ 
PBpR412_L Specres cassette 5’-GCCGCTCTAGAACTAGTGG-3’ 
PBpR412_R Specres cassette 5’-GATACCCCTCGAATTGACGC-3’ 
Abbreviations: Spec, spectinomycin resistance cassette; L1 and L2, primers downstream of the open reading frame of the target 
gene; R1 and R2, primers upstream of the open reading frame of the target gene; C, control primer within the target gene.  Ply, 
pneumolysin; nanA; Neuraminidase A; pspC, pneumococcal surface protein C.  
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HB_Sp_plyF Spn -1923 ply 5’-TCGTAGTGGATGAGACCTTGTTAGA-3’ 
HB_Sp_plyR Spn -1923 ply 5’-GCCAAACCAGGCAAATCAAT-3’ 
HB_Sp_nanAF Spn - 1693 nanA 5’-TTGGAACGTCTCCTGTTTTAGCT-3’ 
HB_Sp_nanAR Spn - 1693 nanA 5’-CCCCGAAAGTTGAGTTTCATTT-3’ 
HBgyrAF Spn – 1219 GyrA 5’-AATGAACGGGAACCCTTGGT-3’ 
HBgyrAR Spn – 1219 GyrA 5’-CCATCCCAACCGCGATAC-3’ 
PBMrTn9 Specres cassette 5’-CAATGGTTCAGATACGACGAC-3’ 
PBpR412_L Specres cassette 5’-GCCGCTCTAGAACTAGTGG-3’ 
PBpR412_R Specres cassette 5’-GATACCCCTCGAATTGACGC-3’ 
Abbreviations: Spec, spectinomycin resistance cassette; L1 and L2, primers downstream of the open reading frame of the target 
gene; R1 and R2, primers upstream of the open reading frame of the target gene; C, control primer within the target gene.  Ply, 
pneumolysin; nanA; Neuraminidase A; pspC, pneumococcal surface protein C.  
  
Bacteria were cultured from blood obtained by retro-orbital puncture. One kidney was used for 
histology; half of it was fixed in 10% buffered formalin and embedded in paraffin for light 
microscopy, the other half was snap-frozen for immunofluorescence studies. Urine was collected 
from the bladder of the animals. For bacterial quantification, obtained blood was serially diluted by 
10-fold in sterile PBS and plated onto blood agar plates. Following overnight incubation at 37ºC and 
5% CO2, CFU were counted. 
 
Measurement of renal injury markers 
Kidney injury marker 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) were 
measured as markers for acute kidney injury in pre- and post-infection urine samples. Commercially 
available ELISA assays were used (R&D Systems). As one of the signs of invasive pneumococcal 
disease in mice is the loss of urine production due to reduced fluid intake, it was not possible to 
obtain post-infection urine from all animals. Therefore, urine samples were pooled per category. No 
urine was available at all for FH+/+ mice infected with WT bacteria. 
 
Measurement of IL-6 and MIP-2 as inflammation marker 
To investigate the immune response in mice infected with S. pneumoniae TIGR4, the general 
inflammatory markers interleukin 6 (IL-6) and macrophage inflammatory protein 2 (MIP-2) were  
 
Table 11.2.  Legend for disease scores. An overall score of more than 15 and/or a moribund state and/or weight 
loss >20% from starting weight and/or a body temperature below 35.5ºC is an indication for euthanasia. 
 
Condition Score Description 
Normal 0 No signs of disease 
 1 Showing signs of a ruffled coat 
Ruffled coat 2 Dull ruffled coat, mildly seen around neck and back 
 3 Ruffled coat 
Hunched back 2 Hunched back, mildly seen 
 3 Hunched back 
Temp. <35.5ºC 5  
Reduced 
mobility 3 Less mobile but still being active and reacts to any handling 
 4 Back legs are walking weird and slower 
 5 Not walking around much, needs to be pushed to get going 
Weight loss 2 >5% body weight loss from T=0 
 3 >10% body weight loss from T=0 
 5 >15% body weight loss from T=0 
 15 >20% body weight loss from T=0 
Moribund state 15  
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from starting weight and/or a body temperature below 35ºC was used as an indication for 
euthanasia. 
 
Mouse bacteremia model 
All animal procedures were performed in a cordance with local and national ethical approval and 
guidelines. Bacteremia experiments were conducted in six-to-eight week old male mice. Mice were 
infected intravenously in the tail vein with 1x107 colony forming units (CFU) in 100 µl sterile 
phosphate-bu fered saline (PBS). Before infection, blood was collected via a cheek puncture and also  
urine secreted by the animals during fixation was collected. Mice were sacrificed 19 hours after 
infection, when several mice reached humane endpoints as described above. 
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pneumoco cal surface protein C (ΔpspC), pneumolysin (Δply) and neuraminidase A (ΔnanA). 
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gene; R1 and R2, primers upstream of the open reading frame of the target gene; C, control primer within the target gene.  Ply, 
pneumolysin; nanA; Neuraminidase A; pspC, pneumoco cal surface protein C.  
  
Bacteria were cultured from blood obtained by retro-orbital puncture. One kidney was used for 
histology; half of it was fixed in 10% bu fered formalin and embedded in para fin for light 
microscopy, the other half was snap-frozen for immunofluorescence studies. Urine was collected 
from the bladder of the animals. For bacterial quantification, obtained blood was serially diluted by 
10-fold in sterile PBS and plated onto blood agar plates. Following overnight incubation at 37ºC and 
5% CO2, CFU were counted. 
 
Measurement of renal injury markers 
Kidney injury marker 1 (KIM-1) and neutrophil gelatinase-a sociated lipocalin (NGAL) were 
measured as markers for acute kidney injury in pre- and post-infection urine samples. Commercially 
available ELISA a says were used (R&D Systems). As one of the signs of invasive pneumoco cal 
disease in mice is the lo s of urine production due to reduced fluid intake, it was not po sible to 
obtain post-infection urine from all animals. Therefore, urine samples were pooled per category. No 
urine was available at a l for FH+/+ mice infected with WT bacteria. 
 
Measurement of IL-6 and MIP-2 as inflammation marker 
To investigate the immune response in mice infected with S. pneumoniae TIGR4, the general 
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Table 1.2.  Legend for disease scores. An overall score of more than 15 and/or a moribund state and/or weight 
lo s >20% from starting weight and/or a body temperature below 35.5ºC is an indication for euthanasia. 
 
Condition Score Description 
Normal 0 No signs of disease 
 1 Showing signs of a ru fled coat 
Ru fled coat 2 Dull ru fled coat, mildly s en around neck and back 
 3 Ru fled coat 
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 3 Hunched back 
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Reduced 
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 15 >20% body weight lo s from T=0 
Moribund state 15  
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measured in post-infection serum samples using commercially available ELISA assays (Mouse IL-6 
ELISA, eBioscience; Mouse CXCL2/MIP-2 Quantikine ELISA Kit, R&D Systems).  
 
Histological studies 
Immunostainings were performed in a standard manner.259 To identify glomerular inflammation, the 
following primary antibodies were used: anti-mouse Ly-6G and Ly-6C (Pharmingen, Erembodegem, 
Belgium), F4/80 (Serotec, Oxford, UK), and anti-CD3 (Thermo Fisher Scientific, Rockford, IL, USA). 
The presence of apoptosis was investigated with an anti-active caspase 3 antibody (Cell Signaling 
Technology, Beverly, MA, USA). Glomerular complement deposition was demonstrated with an anti-
C3c antibody (Dako, Glostrup, Denmark). The deposition of fibrin(ogen), and therefore the existence 
of glomerular thrombotic microangiopathy, was examined with an anti-mouse fibrin(ogen) antibody 
(Accurate Chemical & Scientific, Westbury, NY, USA) as described before.259  
Fibrin(ogen) and C3 deposition were scored in 50 glomeruli by a pathologist without knowledge of 
the genotype of mice and treatment on a scale of 0 to 3 (0, absent; 0.5, mild; 1, moderate; 2, severe; 
3, very severe). The total deposition score per mouse was expressed as the mean of the individual 
glomerular scores. 
 
Statistical analysis 
We used a Mann-Whitney test, with a Bonferroni correction to correct for multiple testing, to 
analyze bacterial counts, signs of disease, and IL-6 levels. An unpaired t-test was used to analyze 
KIM-1 and NGAL levels in urine samples.  
 
Results 
 
Mice deficient in factor H show more signs of disease and have higher bacterial counts in blood 
To assess the influence of the most important complement regulator, factor H, on the host defense 
against pneumococcal infection, FH+/+ and FH-/- mice were infected with S. pneumoniae TIGR4 wild-
type bacteria or its mutants (ΔpspC, ΔnanA, and Δply). Wild-type animals showed less signs of 
disease 19 hours after infection (ruffled coat, hunched back, reduced mobility, and/or weight loss; 
Figure 11.1A) and had lower bacterial counts (3- tot 280-fold less) in blood (Figure 11.1B) than FH-/- 
animals, irrespective of the pneumococcal variant used bacteria  
The influence of the virulence factors PspC, neuraminidase and pneumolysin on infection of FH+/+ 
and FH-/- mice was investigated in the same experiment. In both FH+/+ and FH-/- mice, Δply bacteria  
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We used a Mann-Whitney test, with a Bonferroni correction to correct for multiple testing, to 
analyze bacterial counts, signs of disease, and IL-6 levels. An unpaired t-test was used to analyze 
KIM-1 and NGAL levels in urine samples.  
 
Results 
 
Mice deficient in factor H show more signs of disease and have higher bacterial counts in blood 
To assess the influence of the most important complement regulator, factor H, on the host defense 
against pneumococcal infection, FH+/+ and FH-/- mice were infected with S. pneumoniae TIGR4 wild-
type bacteria or its mutants (ΔpspC, ΔnanA, and Δply). Wild-type animals showed less signs of 
disease 19 hours after infection (ruffled coat, hunched back, reduced mobility, and/or weight loss; 
Figure 11.1A) and had lower bacterial counts (3- tot 280-fold less) in blood (Figure 11.1B) than FH-/- 
animals, irrespective of the pneumococcal variant used bacteria  
The influence of the virulence factors PspC, neuraminidase and pneumolysin on infection of FH+/+ 
and FH-/- mice was investigated in the same experiment. In both FH+/+ and FH-/- mice, Δply bacteria  
were less able to survive in the bloodstream, as shown by lower bacterial counts in blood (Δply vs 
WT: P<0.0125).  
 
C57Bl/6 mice show acute kidney injury after invasive infection with S. pneumoniae 
KIM-1 and NGAL are early indicators of acute kidney injury (AKI), with an earlier detection of AKI 
than for instance serum creatinine.260 All mice, irrespective of the factor H level, showed increased 
NGAL and KIM-1 levels after infection with wild-type or mutant S. pneumoniae, except for KIM-1 
levels in the FH+/+ mice infected with Δply (Figure 11.2). After infection with wild-type or mutant 
TIGR4, NGAL is significantly more increased in FH-/- mice, but no clear trend is seen in KIM-1 levels. 
Both KIM-1 and NGAL are significantly lower in FH+/+ and FH-/- mice after infection with Δply 
compared to the other bacteria (P<0.01).  
 
Higher levels of inflammatory cytokines in FH deficient mice after invasive S. pneumoniae infection  
To investigate the role of FH deficiency in the immunological response after S. pneumoniae 
infection, the cytokines IL-6 and MIP-2 were measured (Figure 11.3). In mice infected with WT TIGR4 
and Δply, both IL-6 and MIP-2 levels were higher in FH-/- mice than in FH+/+ mice 19 hours after 
infection; in ΔnanA infected mice, this was only the case for IL-6. Both inflammatory cytokines were 
not significantly different in ΔpspC infected mice. Mice infected with Δply had significantly lower IL-6 
and MIP-2 levels after infection, irrespective of their factor H status (P<0.05). 
 
 
Figure 11.1. Disease scores (A) and bacterial load in the blood (B) of mice 19 hours after intravenous infection 
with 1x107 CFU of wild-type S. pneumoniae or its respective ΔpspC, ΔnanA, or Δply mutant. Each point depicted 
indicates one mouse; the horizontal line represents the mean. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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Figure 11.2. Levels of acute kidney injury markers NGAL (A) and KIM-1 (B) in pooled pre-infectious (striped bars) 
and pooled post-infection urine samples in FH+/+ (grey bars) and FH-/- mice (black bars) mice infected wild-type S. 
pneumoniae or its respective ΔpspC, ΔnanA, or Δply mutant. Post-infection urine samples were collected 19 
hours after infection. No urine samples were available from FH-/- mice infected with wild-type bacteria. *, P < 
0.05; **, P < 0.01; ***, P < 0.001. 
 
Figure 11.3. Post-infection levels of inflammatory cytokines IL-6 (A) and MIP-2 (B) in serum samples of FH+/+ 
(open bars) and FH-/- (black bars) mice infected wild-type S. pneumoniae or its respective ΔpspC, ΔnanA, or Δply 
mutant. Post-infection serum samples were collected 19 hours after infection. *, P < 0.05; **, P < 0.01; ***, P < 
0.001. 
 
C57Bl/6 mice develop thrombotic microangiopathy after invasive streptococcal infection 
The influx of granulocytes, T-cells, or macrophages into the glomerulus and the presence of 
apoptosis was not influenced by FH status or virulence factor (data not shown). Initial complement 
C3 levels and C3 deposition in glomeruli of FH-/- mice and not in FH+/+ mice was comparable with 
that observed in previous experiments (data not shown).250 This deposition was not influenced by 
the depletion of the different TIGR4 virulence factors (data not shown). To evaluate the presence of 
glomerular thrombotic microangiopathy, renal tissue was examined for the presence of fibrin(ogen), 
the endpoint of the coagulation cascade after endothelial damage. Antifibrin(ogen) immunostaining 
BA
Pre +/+ +/+ -/- +/+ -/- +/+ -/-
1
10
100
1000
10000
100000 *********
WT ∆pspC ∆nanA ∆ply
N
G
AL
 in
 u
rin
e 
(n
g/
m
L)
Pre +/+ +/+ -/- +/+ -/- +/+ -/-
1
10
100
1000
WT ∆pspC ∆nanA ∆ply
* *
K
IM
-1
 in
 u
rin
e 
(n
g/
m
L)
A B
+/+ -/- +/+ -/- +/+ -/- +/+ -/-
0
1
2
3
4
5
6
7
WT ∆pspC ∆nanA ∆ply
** * ***
IL
-6
 in
 s
er
um
 (l
og
10   
pg
/m
l)
+/+ -/- +/+ -/- +/+ -/- +/+ -/-
0
1
2
3
4
5
6
7
WT ∆pspC ∆nanA ∆ply
** **
M
IP
-2
 in
 s
er
um
 (l
og
10   
pg
/m
l)
Chapter 11
 175
Figure 11.2. Levels of acute kidney injury markers NGAL (A) and KIM-1 (B) in pooled pre-infectious (striped bars) 
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C57Bl/6 mice develop thrombotic microangiopathy after invasive streptococcal infection 
The influx of granulocytes, T-cells, or macrophages into the glomerulus and the presence of 
apoptosis was not influenced by FH status or virulence factor (data not shown). Initial complement 
C3 levels and C3 deposition in glomeruli of FH-/- mice and not in FH+/+ mice was comparable with 
that observed in previous experiments (data not shown).250 This deposition was not influenced by 
the depletion of the different TIGR4 virulence factors (data not shown). To evaluate the presence of 
glomerular thrombotic microangiopathy, renal tissue was examined for the presence of fibrin(ogen), 
the endpoint of the coagulation cascade after endothelial damage. Antifibrin(ogen) immunostaining 
showed moderate fibrin(ogen) deposition (score >1) in the glomeruli of 7 FH+/+ mice and 6 FH-/- mice 
infected with different bacteria (Figure 11.4). Although FH-/- mice infected with ΔpspC had 
significantly less fibrin(ogen) staining than FH+/+ mice, this was not statistically significantly different 
compared to mice infected with wild-type bacteria. 
 
Discussion 
 
To investigate the role of the complement system in the pathogenesis of SP-HUS, we induced 
pneumococcal infection in wild-type mice (FH+/+) and in mice deficient in the complement regulator 
factor H (FH-/-). Several virulence factors of S. pneumoniae involved in SP-HUS pathogenesis or in 
complement evasion and activation (PspC, pneumolysin, and neuraminidase) were inactivated, to 
determine if a temporally complement deficiency due to S. pneumoniae infection is leading to the 
development HUS. 
Mice deficient in factor H with secondary C3 deficiency were less capable in clearing bacteria, 
showed more acute kidney injury, and had a stronger immunological response after infection than 
wild-type mice. The observed thrombotic microangiopathy in 23% of the mice, however, was not 
associated with complement deficiency. Infection with the knock out mutants ΔpspC and ΔnanA 
resulted in similar disease phenotype as wild-type pneumococci, while Δply was less virulent in both 
FH+/+ and FH-/- mice. 
 
After infection of FH+/+ and FH-/- mice with S. pneumoniae, it was shown that a defective host 
complement regulation influences the host response against pneumococcal infection. Bacterial 
counts were higher in FH-/- mice and these animals showed more signs of disease (Figure 11.1). 
Previously, C57Bl/6 mice deficient in factor B had increased susceptibility S. pneumoniae as well.261 
FH levels had no influence on phagocyte and/or lymfocyte influx in the glomerulus of the mice, but 
the acute kidney injury marker NGAL was higher after infection in FH-/- mice; no trend was visible for 
KIM-1 levels. This might be due to the time it was measured: in humans with postoperative AKI, the 
concentration of NGAL is highest within 2 hours after surgery, while KIM-1 has only significantly 
increased after 18 hours.260, 262  
 
The presence of fibrin(ogen) was seen in 23% (13/57) of the mice after infection with wild-type or 
mutant bacteria, but this was not associated with the presence of absence of FH: both FH+/+ and FH-/- 
mice infected with the different pneumococcal variants were diagnosed with renal TMA (Figure
Invasive pneumococcal disease results in renal thrombotic microangiopathy in mice
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Figure 11.4. Thrombotic 
microangiopathy is present in the 
glomeruli of mice infected with S. 
pneumoniae. Renal sections were 
stained (A) and semiquantitatively 
scored (B) for the presence of 
fibrinogen. In figure 11.4B, each point 
depicted indicates one mouse; the 
horizontal line represents the mean. *, 
P < 0.05. AU, arbitrary units. 
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11.4). Mice deficient in factor H that were not infected with pneumococci did not show TMA, 
indicating that this is likely a result of the infection.250 Renal histological studies in mice models of 
pneumococcal infection are scarce. In one study, both wild-type C57Bl/6 mice and mice deficient in 
selectin, involved in leukocyte rolling along the endothelium but with a normal complement 
activation, did show thrombosis in spleen and liver, but not in kidney.263 In another study examining 
the effect of complement deficiency on  pneumococcal infection associated coagulation, the spleen 
of wild-type and C1q-/- mice did show multiple (micro)thrombi after infection with serotype 6A, 
while in C2/FB-/- mice, with no complement activity at all, no thrombi were formed; unfortunately, 
this study did not include renal histology.264 These results indicate that the alternative complement 
pathway contributes to the formation of splenic TMA after pneumococcal infection. Our factor H 
deficient mice did not show alternative pathway activity in a hemolysis assay (data not shown), like 
the C2/FB-/- mice, which is likely due to a hyperactive complement system. It is known that the C3 
convertase C3bBbP and the membrane attack complex (sC5b-9) are involved in the cleavage of pro-
thrombin into active thrombin, which is needed for the formation of a stable fibrin clot.265, 266 These 
convertases will not be present in serum of FB deficient mice, in contrast to serum of FH-/- mice. 
Additionally, atypical HUS patients with FH mutations, resulting in a dysregulated alternative 
complement pathway, have increased levels of C3BbP and sC5b-9 in the acute phase of disease.237  
 
Based on the results of the infection experiments with the mutant bacteria, we cannot elucidate on 
the role of complement evasion and/or activation by S. pneumoniae. Pneumolysin seems to be a 
more important general virulence factor than neuraminidase or PspC, but as the decreased survival 
of Δply bacteria was alike in FH+/+ and FH-/- mice, the pathogenic mechanism is probably not via the 
binding of the alternative pathway regulator.  
 
The current hypothesis of SP-HUS pathogenesis involves T-activation due to desialysation of 
glycoproteins by pneumococcal neuraminidase, leading to in vitro hemagglutination, but we did not 
observe decreased TMA formation in mice infected with ΔnanA pneumococci. The role of T-
activation in pneumococcal infection in mice is not fully understood, but neuraminidase can expose 
cryptic T-antigens on murine lymphocytes.267 It is known that TIGR4 can produce at least one other 
neuraminidase (NanB), which in other serotypes can compensate for the absence of NanA.268 A third 
neuraminidase, NanC, has been associated with SP-HUS as well269, but this gene has not been 
identified in S. pneumoniae TIGR4 yet. It would be interesting to perform the same experiments with 
S. pneumoniae without any of the neuraminidases. 
Invasive pneumococcal disease results in renal thrombotic microangiopathy in mice
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In contrast to a previous study, we did not observe a significant reduction of ΔpspC bacteria in the 
bloodstream of C57Bl/6 mice.270 However, in this study mice were infected with lower numbers of 
bacteria (1x104 CFU), while we used a significantly higher infectious dose (1x107 CFU), which makes 
it difficult to compare the results. BALB/c mice infected with comparable, higher, amounts of 
bacteria of pneumococcal strain D39 lacking PspC displayed similar bacterial levels as wild-type D39 
as well.271, 272 PspC is considered to be the most important human factor H binding protein of 
Streptococcus pneumoniae, but there are contradictory opinions about the binding capacity to 
mouse factor H.270, 271 It is known that human factor H interacts via two contact sites with PspC 
located in SCR8-11 and SCR19-20.127, 273 These SCRs are not homologous to mouse factor H: four out 
of six residues in SCR20 involved in human FH binding by S. pneumoniae  are not identical (human: 
R1182, R1203, R1206, R1210; mouse: K1182, Y1203, Y1206, D1210).273 Indeed, none of the 11 
different capsular serotypes tested in the past showed detectable binding to mouse FH, although 
TIGR4 was not examined.271 To study the interactions of PspC with human FH in vivo, and thereby its 
role in host response and in the pathogenesis of SP-HUS, a transgenic mouse model is needed, with 
the human binding sites for PspC and murine complement regulatory and surface-binding domains 
to preserve complement regulation. 
 
The alternative complement pathway indeed seems to be important in the clearance of 
pneumococci, as shown by increased bacterial blood counts in FH-/- mice. However, this higher 
bacterial blood count was not associated with TMA in mice. The factor H deficiency in FH-/- mice 
might have resulted in reduced complement-mediated tissue inflammation hence kidney injury 
similar to wild-type mice despite higher bacterial counts. This might be different in humans, as 
patients with pneumonia and empyema, and therefore a higher bacterial load, have a higher risk to 
develop HUS.50 An impaired host response due to a factor H deficiency, as shown in our 
experiments, might therefore result in increased SP-HUS risk. Indeed, we and others91 identified 
genetic and/or acquired complement abnormalities in SP-HUS patients that are associated with a 
dysregulated complement system, thereby possibly contributing to the development of the disease. 
 
In summary, invasive Streptococcus pneumoniae infection alone is capable to induce glomerular 
thrombotic microangiopathy. This was not associated with a dysregulated complement system due 
to a factor H deficiency: both FH+/+ and FH-/- mice were diagnosed with glomerular TMA. The tested 
virulence factors pneumolysin, neuraminidase A, and PspC had no clear effect on the thrombotic 
microangiopathy. The role of other virulence factors, including other neuraminidases than NanA, 
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In contrast to a previous study, we did not observe a significant reduction of ΔpspC bacteria in the 
bloodstream of C57Bl/6 mice.270 However, in this study mice were infected with lower numbers of 
bacteria (1x104 CFU), while we used a significantly higher infectious dose (1x107 CFU), which makes 
it difficult to compare the results. BALB/c mice infected with comparable, higher, amounts of 
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Streptococcus pneumoniae, but there are contradictory opinions about the binding capacity to 
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of six residues in SCR20 involved in human FH binding by S. pneumoniae  are not identical (human: 
R1182, R1203, R1206, R1210; mouse: K1182, Y1203, Y1206, D1210).273 Indeed, none of the 11 
different capsular serotypes tested in the past showed detectable binding to mouse FH, although 
TIGR4 was not examined.271 To study the interactions of PspC with human FH in vivo, and thereby its 
role in host response and in the pathogenesis of SP-HUS, a transgenic mouse model is needed, with 
the human binding sites for PspC and murine complement regulatory and surface-binding domains 
to preserve complement regulation. 
 
The alternative complement pathway indeed seems to be important in the clearance of 
pneumococci, as shown by increased bacterial blood counts in FH-/- mice. However, this higher 
bacterial blood count was not associated with TMA in mice. The factor H deficiency in FH-/- mice 
might have resulted in reduced complement-mediated tissue inflammation hence kidney injury 
similar to wild-type mice despite higher bacterial counts. This might be different in humans, as 
patients with pneumonia and empyema, and therefore a higher bacterial load, have a higher risk to 
develop HUS.50 An impaired host response due to a factor H deficiency, as shown in our 
experiments, might therefore result in increased SP-HUS risk. Indeed, we and others91 identified 
genetic and/or acquired complement abnormalities in SP-HUS patients that are associated with a 
dysregulated complement system, thereby possibly contributing to the development of the disease. 
 
In summary, invasive Streptococcus pneumoniae infection alone is capable to induce glomerular 
thrombotic microangiopathy. This was not associated with a dysregulated complement system due 
to a factor H deficiency: both FH+/+ and FH-/- mice were diagnosed with glomerular TMA. The tested 
virulence factors pneumolysin, neuraminidase A, and PspC had no clear effect on the thrombotic 
microangiopathy. The role of other virulence factors, including other neuraminidases than NanA, 
warrants further investigation. Factor H deficiency does result in an impaired host defence response, 
as shown in our experiments by higher bacteria load in blood of in FH-/- mice. Complement 
deficiency might lead to higher pneumococcal load in patients as well, thereby increasing the risk for 
SP-HUS.  
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Since the first use of the term hemolytic uremic syndrome (HUS) for children with renal failure, 
hemolytic anemia, and thrombocytopenia, the pathogenesis of the disease has been studied 
extensively. In the mid eighties of the twentieth century, an infection with shiga-like toxin producing 
Escherichia coli (STEC) was identified as the main cause of diarrhea-associated HUS. Twenty years 
later, the role of the complement system as etiology in atypical HUS (aHUS) was clearly 
demonstrated. In childhood, STEC-HUS and complement-mediated HUS, the latter here called aHUS, 
are the main causes of HUS, together with HUS induced by an Streptococcus pneumoniae infection 
(SP-HUS).  
 
Since the discovery of mutations in complement factor H in aHUS patients in 1998, five other 
complement genes have been associated with the disease, which all resulted in an impaired 
regulation of the alternative complement pathway. Mutation in three genes ecoding proteins of the 
coagulation system have been found in aHUS patients as well. Nowadays, in more than 50% of the 
aHUS patients mutations in complement genes or the presence of autoantibodies against factor H 
(αFH) have been identified. The role of the complement system in infection-induced HUS has not 
been fully elucidated yet, but microbiology studies have shown that both bacteria that are 
associated with the disease, STEC and Streptococcus pneumoniae, can protect themselves against 
the complement system by binding complement regulators and their toxins are able to activate the 
complement system.  
The purpose of this thesis was to further elucidate the role of the complement system, in particular 
the alternative pathway, in the pathogenesis of STEC-HUS, SP-HUS, and aHUS. We showed that, 
compared to age-matched controls, the complement system is indeed activated in the acute phase 
of disease in all HUS subgroups: the alternative pathway activation markers C3bBbP, C3b/c, and the 
C3d/C3 ratio were increased in the acute phase of disease and normalized in remission. The 
activation products were more increased in aHUS patients than in infection-induced HUS patients. 
Therefore, these markers probably may not only be used for monitoring disease activity, but can be 
used to distinguish between different HUS etiologies at time of presentation as well. Mutations in 
aHUS associated genes and/or αFH were present in STEC-HUS and SP-HUS patients as well, albeit in 
a lesser amount. The influence of these complement aberrations on the disease course and outcome 
in STEC-HUS and SP-HUS needs to be investigated in larger cohorts. 
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12.1. The complement system and aHUS 
 
With the identification of mutations in complement (regulating) genes in familial and sporadic aHUS 
patients, the pathogenic mechanisms of disease can nowadays be explained in more than 50% of 
these aHUS patients. Our aHUS cohort with 70 patients was screened for potentially pathogenic 
genetic aberrations in the associated genes CFH, CFI, CD46, CFB, C3, CFHR5, THBD, and DGKE, and 
for the presence of αFH (see Chapter 2, Chapter 3, Chapter 4, and Chapter 6 of this thesis).
72, 77, 93, 94 
In 52,8% (37/70) of the patients a potential disease causing nonsynonymous rare variant or αFH 
have been identified. For the first time to our knowledge, we showed the presence of mutations in 
more than one associated gene in aHUS patients (CFI and CD46: 2 patients; CFI and αFH: one 
patient)72, a finding that has been confirmed by others.76, 78 In the remaining patients, aHUS could 
not be explained by a mutation in any of the screened genes. 
 
The association of aHUS with new genes encoding proteins that are not solely involved in the 
complement system, but also in the coagulation system, implicate that not only the complement 
system is an important contributor in the pathogenesis of aHUS. In DGKE-associated HUS, the 
thrombotic microangiopathy even seems to result from impaired proliferation and repair of 
endothelial cells and impaired angiogenesis rather than from complement-mediated cell damage.274 
So far, mutations have been identified in three coagulation genes (DGKE, THBD, and PLG), but 
isolated mutations in the last two genes are rare: for instance, in a French cohort of 214 patients, 
none had a mutation in only THBD, and in PLG, three out of four patients with a mutation had a 
deleterious nonsynonymous rare variant in a complement gene as well.76, 85, 275 All described 
patients with mutations in DGKE were diagnosed with aHUS within the first year of their live and in 
all but one patient hypertension, microhematuria, and proteinuria (even nephrotic syndrome) 
persisted after renal function recovery, hereby distinguishing this specific subgroup of patients from 
patients with complement mutations.83, 84 Interestingly, all DGKE patients originated from countries 
around the Mediterranean Sea (Spain, Northern Africa, Turkey, Italy), possibly suggesting a founder 
effect. In our aHUS cohort, including eight patients with an early-infantile onset of disease, we could 
not find any potentially pathogenic sequence variations in DGKE and only one in THBD. We did not 
screen PLG in all our patients yet; anyhow, the coverage on a HiSeq2000 sequencer commonly used 
in whole exome sequencing (see Chapter 5) was too low to exclude the presence of mutations in 
PLG in that patient group (a horizontal coverage of 68.4%; 13 out of 19 coding exons vertically 
covered with >10 reads throughout the exon). 
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So far, mutations have been found in aHUS patients in almost ten genes encoding proteins of both 
the complement system and the coagulation pathway. Genetic screening of all associated genes and 
haplotypes via regular methods (PCR and Sanger sequencing) is labor intensive, costly, and time 
consuming. Next generation sequencing has already resulted in two new genes that could be 
associated with the disease (DGKE83, 84 and PLG85), but in our experience, the sole application of 
whole exome sequencing does not result in a higher diagnostic yield than conventional sequencing, 
as shown in Chapter 5, as exon 23 of CFH and most coding regions of the CFHR genes are not fully 
covered. At this moment, next generation sequencing in combination with conventional amplicon 
based (Sanger) sequencing of the missing CFH region and the deep intronic SNPs of aHUS associated 
haplotypes and multi-ligand probe amplification for detection of CFH/CFHR rearrangements and 
deletions can be used to maintain or even improve current diagnostic yields in a more efficient 
manner. 
 
The incomplete penetrance rate of ~60% seen in aHUS patients indicates that additional triggers, 
genetic and/or environmental, are probably needed for the disease to developed.29 The presence of 
associated risk haplotypes in CFH79 and/or CD4680 have been associated with the penetrance of 
disease in HUS families. Goicoechea de Jorge et al. (2007) showed that all HUS patients in a family 
with a CFB mutation (p.Phe286Leu) also presented the CD46ggaac haplotype, while in the healthy 
carriers only one individual, who is probably still at risk for development of HUS, harbored the CD46 
haplotype.74 In three families with a CFH mutation (p.Arg1215Gly), Sansbury et al. found that the 
CFH haplotype on the allele not carrying the CFH mutation had a significant effect on disease 
penetrance.92 These results and the presence of combined mutations indicate that a thorough 
mutational screening of all associated genes, including the associated risk SNP haplotypes, is needed 
to be able to give family members a proper genetic advice about the chances to get the disease as 
well. This is nicely shown in an aHUS patient that was diagnosed with three recurrence within 10 
years, including in two renal grafts.157 Genetic screening of the genes encoding FH, FI, and CD46, the 
aHUS associated genes at time of investigation, revealed a familial heterozygous pathogenic 
mutation in CFI (c.1019T>C; p.Ile340Thr)158, as depicted in Figure 12.1. None of the other family 
member ever showed any aHUS symptoms. After the discovery of new aHUS genes and haplotypes, 
the genetic screening of all family members was extended. Next to the CFI mutation, the aHUS 
predisposing missense variation p.Arg161Trp in C3 94, 175 was identified in both the father and the 
index patient. The CFH haplotype71 was present in all family members, but not in the mother; the 
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none had a mutation in only THBD, and in PLG, three out of four patients with a mutation had a 
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persisted after renal function recovery, hereby distinguishing this specific subgroup of patients from 
patients with complement mutations.83, 84 Interestingly, all DGKE patients originated from countries 
around the Mediterranean Sea (Spain, Northern Africa, Turkey, Italy), possibly suggesting a founder 
effect. In our aHUS cohort, including eight patients with an early-infantile onset of disease, we could 
not find any potentially pathogenic sequence variations in DGKE and only one in THBD. We did not 
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PLG in that patient group (a horizontal coverage of 68.4%; 13 out of 19 coding exons vertically 
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CD46 haplotype80 was seen in the mother, the two elder sisters, and the index patient (Figure 12.1). 
A cousin of the father (daughter of his father’s sister) died of HUS at the age of 25, but no DNA 
material was available to investigate. Interestingly, only the index patient carried all four genetic 
aberrations. This indicates that the presence of all four genetic changes, including the aHUS 
associated haplotypes, seems to be needed within this family to develop aHUS. This risk probably 
will be smaller in family members with for instance two out of four genetic aberrations, although it 
can still be that a trigger with an extreme complement activation as a result (i.e. pregnancy, certain 
drugs) could induce the disease, as complement regulation is impaired due to the CFI mutation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.1. Results of genetic screening of all associated genes and SNP haplotypes79, 80 in a family with 
familial aHUS. The index patient, indicated with an arrow, is the only family member that carries all four genetic 
aberrations (missense variations in CFI and C3 and both haplotypes in CFH and CD46 associated with disease). 
 
Extra predisposing genetic factors that increase the risk for developing aHUS might not only be 
present in for instance complement haplotypes or complotypes, but also in changes in the 
endothelial glycocalyx, via which the complement regulator factor H bind to host cells. Proper 
binding of FH to the glycosaminoglycan heparin sulphate is required for optimal C3b regulation and 
it was shown that mutations in the C-terminus of FH can alter the binding properties.212, 276 
Mutations or polymorphisms in the gene encoding heparan sulphate itself (HPSG2) could have the 
same effect.277, 278 In ten patients with familial HUS, however, no potentially pathogenic sequence 
variations were identified by means of WES in HPSG2 or any other endothelial matrix component on 
the candidate list (see Chapter 5), but a larger cohort needs to be screened to further investigate 
this hypothesis.  
 
The role of mutations in genes encoding complement (regulating) proteins in the pathogenesis of 
aHUS has clearly been established. Resulting complement dysregulation, leading to glomerular 
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endothelial cell damage, seems to be the central element. Recently it has been shown that this 
dysregulation mostly occurs on the level of the glomerular endothelium98, but the presence of 
complement activation products in the circulation indicate that activation is also present in the fluid 
phase (Chapter 8).237 Functional analysis of serological complement activation in aHUS patients, 
however, remains very limited. C3 and C4 levels, regularly used in clinical practice, can be normal, 
just like the activity of the alternative and classical complement pathway and levels of factor H and 
factor I (see Chapter 6 and Chapter 9). We performed a comprehensive analysis of complement 
activation in aHUS patients in the acute phase of disease and in remission. The alternative pathway 
activation markers C3d (especially the C3d/C3 ratio), C3bBbP, and C3b/c were increased in the acute 
phase of disease, but not in the remission phase (see Chapter 8 and Chapter 9). This normalization 
of alternative pathway activation existed even in patients with a clear complement dysregulation 
due to genetic aberrations, as shown in Chapter 8. The proposed method to monitor the deposition 
of C3 and C5b-9 on unstimulated human microvascular endothelial cells (HMVEC)98 is labor intensive 
and technically complex. The assays detecting fluid phase complement activation we investigated, 
especially the C3d/C3 ratio, are more standard and easy to use and could therefore be used in early 
detection of a relapse of aHUS, especially in patients undergoing complement inhibition therapy. 
 
12.2. The complement system and STEC-HUS 
 
In the past, complement activation has been shown in patients with STEC-HUS in the acute phase of 
the disease.64, 65, 110-112, 279, 280 Complement levels in these patients have been compared to adult 
controls in most cases, or to only a very small amount of pediatric controls that were not age-
matched. The results in Chapter 9 of this thesis corroborate these anecdotal reports: we 
demonstrated that, compared to age-matched controls that had been collected in a strict and 
protocolled manner, the complement system is indeed activated in a large cohort of almost 30 STEC-
HUS patients in the acute phase of disease, but not in the convalescent phase. As in aHUS patients, 
the C3d/C3 ratio gives the best discrepancy between the acute and convalescent phase in infection-
induced HUS and could be therefore be used as a marker to monitor disease activity in HUS of any 
etiology. Furthermore, the investigated alternative pathway activation products C3d/C3 ratio, 
C3bBbP, and C3b/c were significantly more increased in aHUS patients than in STEC-HUS patients 
and may be used as a biomarker to distinguish at admission between these two diseases, which 
sometimes can be difficult solely based on clinical symptoms. 
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same effect.277, 278 In ten patients with familial HUS, however, no potentially pathogenic sequence 
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this hypothesis.  
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In Chapter 9, we showed that not only in aHUS patients a genetic or acquired complement 
aberration is present in an associated complement protein, but also in 28.0% (7/25) of the 
investigated STEC-HUS patients (CFH: n=2; CD46: n=1; C3: n=2; αFH: n=3). Some case reports on 
STEC-HUS patients with complement mutations have been published in the past, but these reports 
usually describe one or two patients with a severe disease course87-90, 281; no larger cohorts have 
been published so far. The high mutation rate seen in 27 STEC-HUS patients investigated in Chapter 
9 therefore needs to be confirmed in other patient cohorts and detailed clinical follow-up data are 
needed to determine the influence of complement aberrations on disease course and outcome in 
STEC-HUS. The presence of complement aberrations might partly explain why only 5-15% of the 
people infected with STEC eventually develop HUS. A perfect cohort to test this hypothesis is the 
cohort of patients in the German outbreak: more than 4000 individuals were infected with STEC 
O104, but eventually less than 1000 of them developed HUS. 
The outcome of disease in STEC-HUS patients with mutations or αFH in our cohort was good and the 
disease course was not different as in other STEC-HUS patients. However, it needs to be examined if 
patients carrying complement aberrations indeed have a higher risk for a more severe disease 
course, more sequelae, or recurrences, as they might be more susceptible anyhow to develop HUS 
based on their complement aberration. In several STEC-HUS patients whom had a recurrence in 
their native kidneys or after transplantation, which is usually not seen in STEC-HUS, complement 
aberrations have been identified.87, 90 Based on our results, it is therefore advised to also screen 
STEC-HUS patients for complement aberrations to understand its role in pathology. 
 
The alternative pathway activation we identified in STEC-HUS patients could be caused by 
complement binding or activation by the bacteria’s toxins: it has been shown that Stx1 can activate 
C3 and Stx2 can bind the main complement regulator Factor H.113, 116 The used Stx concentration 
used in these experiment, though, were much higher than the levels ever documented in STEC-HUS 
patients.14 Several proteins expressed by STEC have been associated with complement activation as 
well, but the carefully selected ten STEC O157:H7 proteins investigated in Chapter 10 did not show 
this capacity. No interaction between complement proteins and produced STEC proteins was 
observed and none of the recombinant proteins could show complement activation in normal 
human serum. As the proteins that were not identified in the in silico selection procedure could still 
influence the complement system, a more robust approach is needed to analyze complement 
dysregulating properties of the STEC secretome. Expressing all mature proteins in the complete STEC 
genome using a STEC phage display library and test them for interaction with complement 
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components is efficient way to analyze the influence of STEC on complement activation in both the 
fluid phase and on the endothelial cell surface. The platform to produce and purify recombinant 
STEC proteins that was created in Chapter 10 can be used in this STEC phage display library study. 
 
As the direct and indirect action of Stx on glomerular endothelial cells remains the most important 
factor in the pathogenesis of STEC-HUS at this moment, Stx is being targeted in the development of 
new treatment options. The most promising drug seems to be Shigamabs™ (Thallion 
Pharmaceuticals/BELLUS Health Inc., Quebec, Canada), which consists of two monoclonal antibody 
against Stx1 and the A subunit of Stx2, respectively, thereby blocking the inhibition of protein 
synthesis in the ribosome in vitro and altering the overall cellular distribution of Stx2.282 The first 
phase II trial with 22 patients with STEC infection showed a good safety and tolerability profile and a 
potential benefit in preventing complications, including the development of STEC-HUS: only one 
patient (4.5%) progressed to HUS.283 A phase III efficacy trial is being planned.  
 
12.3. The complement system and SP-HUS 
 
The pathogenesis of SP-HUS is not as extensively investigated as that of STEC-HUS and aHUS. The 
current hypothesis involves T-antigen exposure on erythrocytes, platelets, and glomerular 
endothelial cells by the pneumococcal neuraminidase, in particular neuraminidase A (NanA).284 
However, neuraminidase activity is also seen in patients with pneumococcus-associated anemia and 
uncomplicated invasive pneumococcal disease.285 In one SP-HUS patient, no anti-T-antigen 
antibodies could be shown throughout the disease at all.286 As the exact role of T-activation by 
neuraminidase in vivo is not clear and as we could not link NanA to the development of TMA in mice 
with and without FH, as shown in Chapter 11, this implicates that T-activation is most probably 
required but not sufficient to induce TMA and SP-HUS: other environmental and/or genetic factors 
in host or micro-organism have to be present as well, for instance an altered complement activity as 
seen in aHUS patients. In the set-up of our mice experiments (Chapter 11), we could not show a 
relation between the pneumococcal pneumolysin or PspC expression, associated with complement 
activation131 or dysregulation127, and the formation of thrombotic microangiopathy (TMA) in murine 
glomeruli. 
 
Next to T-activation, other mechanisms for neuraminidase in the pathogenesis of SP-HUS have been 
proposed as well. Polyanions on the cell membrane of host cells, including sialic acids, are crucial for 
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observed and none of the recombinant proteins could show complement activation in normal 
human serum. As the proteins that were not identified in the in silico selection procedure could still 
influence the complement system, a more robust approach is needed to analyze complement 
dysregulating properties of the STEC secretome. Expressing all mature proteins in the complete STEC 
genome using a STEC phage display library and test them for interaction with complement 
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the regulation of the complement system and the cleavage of these sialic acids by neuraminidase 
might interrupt the binding of factor H to host cell membranes.277, 287 Complement components 
themselves are glycosylated as well and, for instance, the interactions of factor I with C3b and factor 
H are regulated in part by these glycans.288 Removal of the sialic acid group from these glycoproteins 
by neuraminidase can alter these interactions, thereby dysregulating the complement system. In a 
patient with a COG7 deficiency, in which the glycosylation of proteins was impaired due to a defect 
in retrograde vesicular transport of the Golgi apparatus, thrombocytopenia, anemia, and mild 
proteinuria were seen.289 Macrothrombycytopenia, hemolytic anemia, and renal failure (most 
probably due to tubular necrosis) were recently identified in a patient with a CMP-sialic acid 
transporter defect that results in reduced biosynthesis of sialylated proteins as well.290 It is not 
known if the symptoms resembling those in HUS in these congenital disorders of glycosylation 
(CDG), were caused by deglycosylation of complement proteins. More research is needed to 
examine the role of desialylated complement proteins in the pathogenesis of SP-HUS. 
 
A few reports on complement activation in SP-HUS patients have been published: C3 levels were low 
in the acute phase of the disease, but levels normalized within a few days.91, 222 This indication for 
complement activation was also shown in Chapter 9 in the SP-HUS patient with autoantibodies 
against FH: the C3d/C3 ratio depicting complement consumption was increased in the acute phase 
and normalized to control ranges in remission, as in STEC-HUS and aHUS patients. In our hospital, 
four other SP-HUS patients were treated in the last decade. Unfortunately, serological complement 
levels in the acute phase of the disease were only obtained in one of them. This patient also 
displayed normal C3 and C4 levels, but increased C3d levels. and one of our patients was positive for 
autoantibodies against FH (Chapter 9), which has not been described before in SP-HUS. No 
mutations were identified in one of the screened complement genes (FH, FI, and CD46 in all 
patients, extended with FB and C3 in one patient); none of the patients were screened for the 
presence of αFH. 
 
Although no large cohorts have been screened, the presence of complement mutations might not 
directly influence the course or outcome of SP-HUS. In a case series of five patients, genetic 
screening revealed complement aberration in three of them.91 These three patients, however, had a 
relatively good outcome with no sequelae or recurrence, while the two remaining patients without 
mutations died due to severe intracranial hemorrhages during the acute phase of disease. The 
mortality of SP-HUS in the first episode is high, but the potential disease recurrence in SP-HUS seems 
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low: about 100 cases have been reported with outcome and follow-up data, but no recurrences 
have been reported so far.91 It is not known for how many of these patients genetic workup of the 
complement system has been performed.  
 
Results of mutational screening of associated HUS genes will most probably not affect therapeutic 
decision making, but can give more information on the role of the patient’s genetic background in 
the pathogenesis of the disease. Patients with a genetic or acquired complement aberration 
resulting in a dysregulated complement system might have an altered host response. In Chapter 11, 
we showed that factor H deficient mice have higher bacterial counts in blood, more disease 
symptoms, and increased acute injury markers after Streptococcal pneumoniae infection. 
Complement deficiency did not influence the formation of glomerular TMA in mice; this was 
probably a result of the pneumococcal infection in general. The observed decreased host response, 
however, may result in increased bacterial load in patients as well, which is associated with 
increased HUS risk: a high incidence of empyema is seen in SP-HUS cases in several cohorts.50, 56, 291 
Patients with a dysregulated complement system might therefore be more prone to develop HUS 
after Streptococcus pneumoniae infection.  
 
12.4. Future perspectives 
 
This thesis has clearly shown that the complement system is involved in the disease course of HUS 
secondary to an infection: patients had increased complement activation markers in the acute phase 
of the disease and mutations and/or autoantibodies against FH were present in STEC-HUS and SP-
HUS patients as well. As the complement system is one of first parts of the innate immunity to be 
activated when micro-organisms invade the human body, we cannot exclude that the observed 
activation in STEC-HUS and SP-HUS is only an infection-related phenomenon, for example due to 
produced endotoxins by the bacteria. No study has compared levels of complement activation 
products in patients with STEC-HUS and patients undergoing infection with E. coli whom did not 
develop HUS, and therefore we cannot exclude that the complement activation is an infection-
related phenomenon due to for instance bacterial LPS. A prospective study is needed to investigate 
this. 
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12.4.1. Diagnosis of the hemolytic uremic syndrome 
Based on clinical presentation, it sometimes is difficult to distinguish between individual STEC-HUS 
and aHUS patients: no age difference is seen and both STEC-HUS and aHUS present with gastro-
intestinal problems, including diarrhea (Chapter 6 and Chapter 9).93 This again clearly shows that 
postdiarrheal onset does not exclude the possibility of aHUS or that the absence of diarrhea 
excludes STEC-HUS. This makes differentiating between etiologies for the general pediatrician, 
whom not often see HUS patients due to the low incidence rate, sometimes even more difficult and 
this may result in a delay of adequate treatment in these patients. Measurement of serological 
alternative pathway activation products, might simplify this process: levels of C3bBbP, C3b/c and the 
C3d/C3 ratio were all higher in aHUS patients than in STEC-HUS patients. As C3d is a more commonly 
performed measurement than C3bBbP and C3b/c, the C3d/C3 ratio is preferred, especially because 
this ratio can be used to monitor disease activity in all HUS forms as well. An international cohort, 
however, is required to achieve sufficient number of patients and the throughput time of the 
analyses needs to be improved before this diagnostic tool can be added to the current guidelines in 
diagnosing and monitoring the hemolytic uremic syndrome. 
 
In case STEC-HUS is suspected, a fecal and a rectal swab culture on specific culture plates (sorbitol-
MacConkey agar) and simultaneous testing by PCR and/or EIA for the presence of Stx1 and Stx2 is 
advised. More importantly, serological investigation for antibodies against LPS of the most common 
STEC serogroups can accelerate the process of discovering the disease background. In several 
patients included in the study in Chapter 9, the pathological STEC species could not be serotyped by 
means of fecal culture, but serological screening within the first days after admission revealed anti-
O157 LPS antibodies and specific therapy could be started for STEC-HUS. Retrospective analysis of 
both fecal and serology tests in 50 STEC-HUS patients performed in our institution  revealed an 
increase in STEC diagnosis of 12% with using serology techniques (unpublished data). Therefore, 
anti-LPS antibody detection needs to be implemented in standard STEC-HUS diagnosis algorithms. At 
this moment, it is not known how many STEC-HUS patients are culture-negative, but do possess 
serological antibodies against STEC-LPS, but a retrospective and prospective study in an 
(inter)national cohort could answer this question. 
 
Even though literature states that ~40% of the non-STEC-HUS cases is preceded by an pneumococcal 
infection, we could include only one SP-HUS patient in a time-period of four years (1/11; 9%). The 
lack of familiarity with SP-HUS by the general pediatrician and other pediatric specialists might have 
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caused that they have overlooked the diagnosis: the similarity to disseminated intravascular 
coagulation often seen in sepsis, in which thrombocytopenia, hemolytic anemia, and multiorgan 
failure are seen as well, make the diagnosis of SP-HUS challenging. Awareness for SP-HUS by the 
pediatricians therefore remains important. 
 
12.4.2. Monitoring of the hemolytic uremic syndrome 
Monitoring of complement activation will become more and more important with the 
implementation of complement inhibition therapy in aHUS and sophisticated methods are needed 
as routine methods regularly used in clinical setting (AP/CP activity, C3/C4 levels) can give results 
similar to healthy controls (see Chapter 6 and Chapter 9). Even though the complement 
dysregulation in aHUS mostly occurs on the level of the glomerular endothelium, the proposed 
method to monitor the deposition of C3 and C5b-9 on unstimulated HMVEC is labor intensive and 
technically complex and can certainly not be performed in every clinic.98 We performed a 
comprehensive analysis of complement activation in aHUS patients in the acute phase of disease 
and in remission to identify new biomarkers in the fluid phase for disease activity that could be 
measured fast and easy via ELISA. The complement activation markers C3d (especially the C3d/C3 
ratio), C3bBbP, C3b/c were increased in the acute phase of disease (see Chapter 8 and Chapter 9), 
but not in the remission phase. This normalization of alternative pathway activation existed even in 
patients with a clear complement dysregulation due to genetic aberrations, as shown in Chapter 8. 
Therefore, these fast complement activation assays could be used in early detection of a relapse of 
aHUS, especially in patients undergoing complement inhibition therapy. In Chapter 9, we showed 
that the same activation markers also discriminated between the acute and convalescent phase of 
STEC-HUS and SP-HUS and may therefore be implicated in monitoring disease activity of HUS of any 
etiology.  
 
12.4.3. Genetic screening in the hemolytic uremic syndrome 
Genetic and acquired complement aberrations patients can influence the outcome of aHUS, the 
success rate of different treatment options such as renal transplantation and eculizumab 
administration, and the recurrence risk. As mutations are also identified in STEC-HUS and SP-HUS 
patients, all HUS patients of any etiology should be screened for complement mutations and 
autoantibodies against factor H.  
So far, mutations have been found in aHUS patients in approximately ten genes encoding proteins of 
both the complement system and the coagulation pathway, and in several patients, mutations have 
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been identified in more than one associated gene. A next generation based gene panel that targets 
all genes involved in the complement system, the coagulation system, and the endothelial glycocalyx 
simultaneously needs to be implemented in the diagnostic routing, as it can maintain or even 
improve current diagnostic yields in a more efficient manner. Also functional genomics will become 
more and more important to unravel the functional consequences of identified genetic aberrations. 
Predicting the likely functional impact of identified sequence variation can be performed by in silico 
prediction software, but these are not always accurate. Prediction programs like Polyphen-2, which 
predicts the possible functional effects of human non-synonymous variants, extract annotations that 
are already present in for instance the dbSNP database of the National Centre of Biotechnology 
Information.292 Several established mutations identified in aHUS patients nowadays have dbSNP 
numbers as they have been identified in next generation sequencing projects. The p.Arg1210Cys 
variant in CFH, which has a frequency in the European population of only 0.03%, is annotated in the 
dbSNP database (rs121913059) and based on that would not be predicted as pathogenic by 
prediction software, even though it clearly influences the binding of FH to C3b152. For most 
functional analysis methods that are nowadays available, such as crystallography, Biacore, and 
ELISAs, recombinant protein production and purification is needed, a time-consuming matter. 
Preferably, one would isolate the mutant protein from the patient’s blood to execute binding assays 
to individual proteins, but as many mutations are found heterozygously, i.e. on only one allele, 
isolation is complicated. An assay to analyze the functional activity of the complement convertases 
and the membrane attack complex separately in patient serum without the need of protein 
purification has recently been developed.129 This allows one to study the functional consequences of 
mutations in a situation in whole serum, the natural environment of complement activation in vivo. 
In the current design, this assay cannot point out the exact effect mechanism of the present 
mutation, but modifications such as the addition of individual purified proteins or its inhibitors can 
be used to pin-point the site of action. Standardization of this assay still needs to be performed 
before it can be used in diagnostics. 
 
12.4.4. Establishment of an independent international registry for hemolytic uremic syndrome 
Several HUS registries have been set up in the last decade (i.e. the Austrian registry in Innsbruck, the 
Oklahoma TTP-HUS registry, and the Italian international registry of recurrent and familial HUS and 
TTP in Bergamo), but all registries focus on STEC-HUS or aHUS and never on both diseases. Only with 
an extensive database with both genotype and phenotype, we can further improve our insights into 
the pathogenesis of the different rare HUS forms, which will improve diagnosis, care, and treatment 
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of HUS in general. Therefore, an international registry with clinical information on initial 
presentation, disease course, outcome, long-term follow-up, and diagnostic results (microbiology, 
serology, and genetics) for every patient diagnosed with HUS (STEC-HUS, SP-HUS, aHUS) of any age 
is indispensable. This registry preferably remains independent from pharmaceutical companies and 
is owned by the collaborating clinicians.  
Along with this registry, a new proposal for the nomenclature of different HUS subgroups is needed. 
The current nomenclature used by researchers and clinicians can be confusing. Patients with 
hemolytic anemia, thrombocytopenia, and acute renal failure are divided in two groups: typical or 
diarrhea-positive (D+) HUS due to a STEC infection, and atypical or diarrhea-negative (D-) HUS. As 
diarrhea can also be a prodrome in patients with atypical HUS93, this terminology is not able to 
distinguish between typical and atypical HUS. Furthermore, aHUS is nowadays mostly used for 
complement-mediated HUS, but in the current terminology, all non-STEC-HUS etiologies, including 
SP-HUS and for instance pregnancy-induced HUS, are part of this subdivision. The best way to divide 
HUS subgroups is based on etiology, i.g. STEC-HUS, SP-HUS, complement-mediated HUS (in which no 
preceding infection with STEC or SP is seen), pregnancy-induced HUS, and idiopathic HUS for ultra-
rare cases associated with viruses, medication, or systemic diseases. 
 
12.4.5. Treatment of the hemolytic uremic syndrome with complement inhibitors 
The approval in 2012 of the complement inhibiting monoclonal antibody eculizumab for the 
treatment of atypical HUS has indicated a new era. Since the first successful reports of eculizumab 
treatment in aHUS patients, many reports have followed, describing aHUS and STEC-HUS patients 
that received eculizumab to rescue their native kidneys or to prevent a recurrence after kidney 
transplantation.78, 103, 120, 293  
 
Only one systematic review to determine the efficacy and safety of eculizumab treatment in aHUS 
patients has been performed, but just small, uncontrolled clinical trials of the pharmaceutical 
company have been included.294 No meta-analyses have been published yet. The authors of the 
systematic review state that further research is needed to evaluate eculizumab, ideally using 
patient-related clinical outcomes. No such clinical trials are enrolling aHUS patients at this moment; 
neither is eculizumab mentioned in the Cochrane Library (a database with i.e. systemic reviews and 
health technology assessments; www.cochrane.org) in relation to aHUS. At the moment, there is no 
consensus document for the treatment of adult aHUS patients in Europe, although both a French 
and a Spanish study group recently published a diagnostic algorithm including treatment options for 
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aHUS.293, 295 They state that eculizumab treatment should be life-long, but also mention that in some 
patients groups withdrawal of eculizumab might be an option. In 2009, The European Study Group 
for atypical HUS published guidelines for the initial assessment and early management of children 
with aHUS, in which of course eculizumab treatment was not implemented.96 In the audit analysis of 
this guideline, the benefits and risks for this therapy in children could not be evaluated, as the 
results of the prospective pediatric trials with eculizumab for aHUS were not published yet.296 These 
results have recently been presented at several international conferences (European Society of 
Pediatric Nephrology 2014, American Society of Hematology 2014, American Society of Nephrology 
2014): it clearly has been shown that early intervention with eculizumab improved hematologic and 
renal parameters, 82% of the patients discontinued dialysis, and no patient has to start dialysis 
during the study period of 26 weeks.  
 
The results of the prospective trials make that eculizumab is now recommended as the first-line 
treatment in both children and adult aHUS patients. Eculizumab, however, is extremely expensive: 
costs per year vary from €82,000 for a 1-year old child up to €500,000 for an adult aHUS patient 
(average cost for usual care per patient: €360,000), which makes it difficult to implement in our 
health care system. 
 
In  post-transplantation settings, eculizumab is stated in the published algorithms as first-line 
therapy in cases of aHUS recurrence.293, 295 We showed that kidney transplantation in adult patients, 
even those at high risk for recurrence of disease in the graft due to a CFH mutation, can be 
successful without prophylactic eculizumab.297 A protocol that minimizes cold ischemia time, 
reduces the risk of rejection  and provides endothelial protection was used in four adult aHUS 
patients and after 16-21 months of follow-up, none of the patients developed a recurrent aHUS or a 
rejection.297  
 
In recent years, the role of the complement system has become more and more important in not 
only the hemolytic uremic syndrome, but also in for instance age-related macular degeneration 
(AMD), ANCA vasculitis, ischemia/reperfusion injury, rheumatoid arthritis, and different 
transplantation settings.298 Alexion Pharmaceuticals, the producer of eculizumab (Soliris®), is 
therefore exploring the use of eculizumab in other, mostly ultra-rare, diseases. In Table 12.1, the 
diseases for which a clinical trial has been conducted are shown. The most recently reported disease 
in which eculizumab might be a treatment option is thrombotic microangiopathy associated with  
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aHUS.293, 295 They state that eculizumab treatment should be life-long, but also mention that in some 
patients groups withdrawal of eculizumab might be an option. In 2009, The European Study Group 
for atypical HUS published guidelines for the initial assessment and early management of children 
with aHUS, in which of course eculizumab treatment was not implemented.96 In the audit analysis of 
this guideline, the benefits and risks for this therapy in children could not be evaluated, as the 
results of the prospective pediatric trials with eculizumab for aHUS were not published yet.296 These 
results have recently been presented at several international conferences (European Society of 
Pediatric Nephrology 2014, American Society of Hematology 2014, American Society of Nephrology 
2014): it clearly has been shown that early intervention with eculizumab improved hematologic and 
renal parameters, 82% of the patients discontinued dialysis, and no patient has to start dialysis 
during the study period of 26 weeks.  
 
The results of the prospective trials make that eculizumab is now recommended as the first-line 
treatment in both children and adult aHUS patients. Eculizumab, however, is extremely expensive: 
costs per year vary from €82,000 for a 1-year old child up to €500,000 for an adult aHUS patient 
(average cost for usual care per patient: €360,000), which makes it difficult to implement in our 
health care system. 
 
In  post-transplantation settings, eculizumab is stated in the published algorithms as first-line 
therapy in cases of aHUS recurrence.293, 295 We showed that kidney transplantation in adult patients, 
even those at high risk for recurrence of disease in the graft due to a CFH mutation, can be 
successful without prophylactic eculizumab.297 A protocol that minimizes cold ischemia time, 
reduces the risk of rejection  and provides endothelial protection was used in four adult aHUS 
patients and after 16-21 months of follow-up, none of the patients developed a recurrent aHUS or a 
rejection.297  
 
In recent years, the role of the complement system has become more and more important in not 
only the hemolytic uremic syndrome, but also in for instance age-related macular degeneration 
(AMD), ANCA vasculitis, ischemia/reperfusion injury, rheumatoid arthritis, and different 
transplantation settings.298 Alexion Pharmaceuticals, the producer of eculizumab (Soliris®), is 
therefore exploring the use of eculizumab in other, mostly ultra-rare, diseases. In Table 12.1, the 
diseases for which a clinical trial has been conducted are shown. The most recently reported disease 
in which eculizumab might be a treatment option is thrombotic microangiopathy associated with  
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severe hematopoietic stem cell transplantation; however, no clinical trial for eculizumab in HSCT is 
being conducted.299 The use of eculizumab in STEC-HUS is still questionable. Even though individual 
patients can respond rapidly with efficient recovery, no significant differences were seen in larger 
cohorts on mortality or morbidity with the use of eculizumab in STEC-HUS patients.46, 47, 119, 120 A 
randomized controlled trial is needed in which eculizumab is administered at a time point early after 
diagnosing the patient with STEC-HUS and not only to the most severely ill patients.  
 
Next to eculizumab for PNH and aHUS, only one other complement inhibitor has been approved by 
the FDA and the EMA for clinical use (recombinant C1 inhibitor for hereditary angioedema). 
However, many drug candidates are in the pipeline, as depicted in Figure 12.2.300 As complement 
dysregulation in HUS occurs at both the alternative and terminal pathway, complement inhibiting 
strategies at C3 level might be just as specific for aHUS than eculizumab treatment. At this moment, 
the C3 inhibiting peptide compstatin and its analogs are tested in a clinical phase 2 trial in age-
related macular degeneration (AMD) and in preclinical phases in for instance aHUS, PNH, and 
transplantation.300 Compstatin can block the activation of C3, thereby blocking C3b opsonization, 
the amplification loop of the alternative pathway, the activation of the terminal complement 
pathway, and the formation of the anaphylatoxins C3a and C5a.301, 302 To prevent the formation of 
C3 convertases, antibodies against factor B, factor D, properdin, and C3b have been disclosed, but 
not for clinical trials in aHUS so far.303-308 The natural complement inhibitors present in the human 
body are object for therapeutic complement inhibitor development as well. Soluble CR1, which is a 
cofactor for FI in the regulation of the alternative pathway, has successfully been used in one patient 
with dense deposit disease, but a longer trial in a larger patient population still has to be 
performed.309 Recombinant factor H has been considered, but no clinical trials are being conducted 
at the moment. The manufacturer of eculizumab, Alexion, is currently evaluating the protein TT30 
that combines SCR1-5 of FH with the N-terminal four domains of CR2, which can bind C3 
degradation products on sites of ongoing complement activation310; TT30 is being tested for the use 
in PNH in a phase 1 trial. A FH derivate that still has the regulatory and target domains, mini-FH, 
gives promising results in PNH models.311 Peptides that can recruit and bind host factor H are being 
evaluated as well.75 As the incidence rate of HUS is very low (1 in 2 million for aHUS), trials to 
investigate new complement inhibitors are very expensive and multi-centre, multi-national cohorts 
are needed. A international, independent registry could facilitate these trials. 
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Figure 12.2. Schematic overview of the alternative and terminal pathway of the complement system. The 
central complement component C3 is spontaneously activated at very low rate to form C3b, which is able to 
attach to the surfaces of pathogens and host cells. There it binds complement factor B (FB), which is 
proteolytically activated by Factor D (FD). The resulting C3bBb complex is stabilized by properdin (FP) and this C3 
convertase can cleave and activate more C3 molecules. This activation leads to amplification of the complement 
cascade via the C5 convertase, to the formation of the membrane attack complex (C5b-9), and, eventually, to cell 
lysis. The complement inhibiting therapeutics acting on the level of C3 and C5 that are currently approved or in 
development are depicted at the level of action. 
 
As long as no other complement inhibiting therapeutics are on the market, eculizumab remains the 
best option in aHUS patients. Due to the extreme costs of eculizumab, however, the treatment is not 
readily available for all patients. One way to optimize cost-efficacy involved in the treatment is by 
adapting the treatment to the individual. Recently reported and preliminary data indeed indicate 
that we may be exceeding the pharmacodynamic target and that even despite the severity of 
disease, we may need less drug for effective treatment in some patients. The dose regimen used in 
the trials for registration of eculizumab in aHUS were targeted at eculizumab trough levels above 50-
100 ug/ml to ensure complete complement blockade. Pharmacokinetic data in the trials revealed 
levels of eculizumab ranging between 93-342 μg/ml and 113-431 μg/ml in adults and 104-392 and 
109-414 μg/ml in adolescents, and thus more than twice as high as reported by EMA to achieve a 
complement inhibition.104 Furthermore, different experiences show that increased intervals 
between doses, or even therapy discontinuation, is possible in some patients without 
reactivation.312 Ardissino et al. recently reported the discontinuation of eculizumab treatment in 10 
aHUS patients. Seven patients did not experience a recurrence of disease; the remaining three 
patients had a recurrence of disease within 6 weeks after the treatment was stopped.313  
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being conducted.299 The use of eculizumab in STEC-HUS is still questionable. Even though individual 
patients can respond rapidly with efficient recovery, no significant differences were seen in larger 
cohorts on mortality or morbidity with the use of eculizumab in STEC-HUS patients.46, 47, 119, 120 A 
randomized controlled trial is needed in which eculizumab is administered at a time point early after 
diagnosing the patient with STEC-HUS and not only to the most severely ill patients.  
 
Next to eculizumab for PNH and aHUS, only one other complement inhibitor has been approved by 
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However, many drug candidates are in the pipeline, as depicted in Figure 12.2.300 As complement 
dysregulation in HUS occurs at both the alternative and terminal pathway, complement inhibiting 
strategies at C3 level might be just as specific for aHUS than eculizumab treatment. At this moment, 
the C3 inhibiting peptide compstatin and its analogs are tested in a clinical phase 2 trial in age-
related macular degeneration (AMD) and in preclinical phases in for instance aHUS, PNH, and 
transplantation.300 Compstatin can block the activation of C3, thereby blocking C3b opsonization, 
the amplification loop of the alternative pathway, the activation of the terminal complement 
pathway, and the formation of the anaphylatoxins C3a and C5a.301, 302 To prevent the formation of 
C3 convertases, antibodies against factor B, factor D, properdin, and C3b have been disclosed, but 
not for clinical trials in aHUS so far.303-308 The natural complement inhibitors present in the human 
body are object for therapeutic complement inhibitor development as well. Soluble CR1, which is a 
cofactor for FI in the regulation of the alternative pathway, has successfully been used in one patient 
with dense deposit disease, but a longer trial in a larger patient population still has to be 
performed.309 Recombinant factor H has been considered, but no clinical trials are being conducted 
at the moment. The manufacturer of eculizumab, Alexion, is currently evaluating the protein TT30 
that combines SCR1-5 of FH with the N-terminal four domains of CR2, which can bind C3 
degradation products on sites of ongoing complement activation310; TT30 is being tested for the use 
in PNH in a phase 1 trial. A FH derivate that still has the regulatory and target domains, mini-FH, 
gives promising results in PNH models.311 Peptides that can recruit and bind host factor H are being 
evaluated as well.75 As the incidence rate of HUS is very low (1 in 2 million for aHUS), trials to 
investigate new complement inhibitors are very expensive and multi-centre, multi-national cohorts 
are needed. A international, independent registry could facilitate these trials. 
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Although eculizumab certainly has changed the future perspectives of patients with aHUS, many 
unsolved questions remain: who should receive the drug, what treatment schedules should be used, 
and how long should therapy be continued. As proven by several case reports, it might possible to 
settle with less amount of drug or even stop the treatment after a certain amount of time in more 
patients. The relationship between pharmacokinetics and pharmacodynamics and tailored therapy 
needs to be demonstrated in a robust and controlled fashion. Adapting dosage schemes by means of 
therapeutic drug monitoring based on eculizumab levels and for instance the alternative pathway 
biomarkers investigated in this thesis, will improve the quality of live for patients and their family 
members, as the burden of traveling to the hospital every two weeks for eculizumab therapy is very 
high. Furthermore, as therapeutic drug monitoring can possibly result in a 50% reduction of the 
amount of drug to be used and thus a saving of €180,000 for an average patient, this will result in an 
extreme cost reduction of at least €1,5 million a year in the Netherlands. The Netherlands 
Organisation for Health Research and Development (ZonMw) has recently granted this study in their 
‘Goed Geneesmiddelen Gebruik’ program.  
 
12.5. Concluding remarks 
 
We have demonstrated that the complement system is involved in all forms of the hemolytic uremic 
syndrome. In both infection-induced HUS and aHUS patients, the complement system is activated in 
the acute phase of the disease and not in the convalescent phase. Measuring alternative pathway 
activation products, in particular the C3d/C3 ratio, might help in motoring disease activity and in 
distinguishing between the different HUS etiologies. Interestingly, genetic and/or acquired 
complement aberrations (mutations and/or autoantibodies) were not only identified in aHUS 
patients, but also in STEC-HUS and SP-HUS. This indicates that genetic screening is advised in these 
patients as well. The exact role of altered complement activation in the pathogenesis of STEC-HUS 
and SP-HUS has not been fully elucidated with this project and more research is needed before 
complement inhibiting therapeutics may be included in the treatment guidelines of infection-
induced HUS. 
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Summary 
 
The hemolytic uremic syndrome (HUS) is a rare and severe thrombotic microangiopathy 
characterized by hemolytic anemia, thrombocytopenia, and acute renal failure. In more than 90% of 
the cases in childhood, the disease is triggered by an infection with Shiga-like toxin producing 
Escherichia coli (STEC). The most important causes seen in the remaining 5-10% of the HUS cases are 
dysregulation of the alternative pathway of the complement system due to genetic mutations (here 
called atypical HUS or aHUS) and an non-enteric infection with Streptococcus pneumoniae (SP-HUS). 
The complement system is part of the innate immunity. It induces cell lysis by the incorporation of 
the membrane attack complex and activates and attracts leukocytes. The complement system, 
however, does not discriminate between pathogens and host cells. To protect our own cells the 
system is therefore tightly regulated on both the cell surface and in the fluid phase. Non-host 
surfaces that lack these regulators are attacked and damaged by the complement system. A 
mutation in one of the regulators will lead to uncontrolled activation of the complement system on 
host cells resulting in cell damage, especially to those in the microcirculation of the kidney. These 
mutations, mostly seen in the alternative pathway of the complement system, are described in ~50-
60% of the aHUS patients. 
It has been shown that both STEC and S. pneumoniae can protect themselves against complement 
activation. This knowledge, the fact that dysregulation of the alternative complement pathway due 
to mutations is believed to play an important role in the pathogenesis of aHUS, and the similarity of 
the clinical manifestations, lead to the aim of this thesis: to study and define the role of the 
complement system in three forms of HUS (STEC-HUS, SP-HUS, and aHUS). 
 
The first part if this thesis is focused on genetic studies in aHUS patients as the presence of 
mutations can be of prognostic value for the outcome of disease and for treatment options. For 
instance, patients with a mutation in the CFH or CFI gene have a worse outcome after renal 
transplantation (recurrence: 80-100%) than patients with a CD46 mutation (recurrence 0–20%). In 
Chapter 2, Chapter 3, Chapter 4, and Chapter 6, we screened a group of 70 aHUS patients for 
mutations in genes encoding associated complement (regulating) proteins. In just over 50% of these 
patients, a potential disease causing genetic aberrations or the presence of autoantibodies against 
the key regulator Factor H was identified. In the remaining patients, however, aHUS could not be 
explained by a mutation in any of the screened genes. Genetic screening of all associated genes via 
regular methods (PCR and Sanger sequencing) is labor intensive, costly, and time consuming. The 
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application of next generation sequencing might be an attractive alternative routing for mutation 
scanning in aHUS patients, but in Chapter 5 we have shown that the mutation hotspot in CFH is not 
fully covered with the current whole exome sequencing technique. Therefore, at this moment next 
generation sequencing can only be applied when combined with conventional amplicon based 
(Sanger) sequencing for the missing CFH region and the deep intronic SNPs of aHUS associated 
haplotypes. Genetic or acquired complement aberrations are not only present in aHUS patients, but 
also in more than 30% (8/26) of the investigated STEC-HUS and SP-HUS patients in Chapter 9. This 
high mutation rate needs to be confirmed in other large patient cohorts and detailed clinical follow-
up data are needed to determine the influence of these mutation on disease course and outcome in 
STEC-HUS and SP-HUS. Based on these results, it is advised to not only screen aHUS patients for 
complement aberrations, but also STEC-HUS and SP-HUS patients. In that way, the knowledge on 
their role in pathology can be further extended. 
The therapeutic management of HUS can be very difficult, especially when other diseases are 
present in the patient. This is shown in Chapter 7, where a patient is described with both STEC-HUS 
and hemophilia A. The administration of recombinant coagulation factor VIII was needed to control 
hemorrhagic colitis and to prevent severe neurological complication, but might have enhanced to 
thrombotic microangiopathic process. 
 
The second part of the thesis is focused on biomarkers for complement activation in HUS patients, 
on complement evasion by STEC O157:H7, and on host response due to complement dysregulation. 
Functional analysis of serological complement levels in HUS patients remains very limited. We 
therefore performed a comprehensive study of complement activation in both the acute and 
convalescent phase of the disease, first in aHUS patients (Chapter 8) and later in STEC-HUS and SP-
HUS patients as well (Chapter 9). We demonstrated that the alternative pathway activation markers 
C3d, C3bBbP, and C3b/c were increased in all patient groups in the acute phase, but not in 
remission. The C3d/C3 ratio gives the best discrepancy between the acute and convalescent phase 
and could therefore be used as a marker to monitor disease activity in HUS of any etiology. 
Furthermore, all above-mentioned alternative pathway activation products were significantly more 
increased in the acute phase of disease in aHUS patients than in STEC-HUS patients and may be used 
as a biomarker to distinguish at admission between these two diseases. We could not link any of ten 
STEC O157:H7 proteins investigated in Chapter 10 to the identified complement activation seen in 
STEC-HUS patients; nor could we link the streptococcal proteins neuraminidase A, pneumolysin or 
PspC to the development of thrombotic microangiopathy in mice (Chapter 11). We did, however, 
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and could therefore be used as a marker to monitor disease activity in HUS of any etiology. 
Furthermore, all above-mentioned alternative pathway activation products were significantly more 
increased in the acute phase of disease in aHUS patients than in STEC-HUS patients and may be used 
as a biomarker to distinguish at admission between these two diseases. We could not link any of ten 
STEC O157:H7 proteins investigated in Chapter 10 to the identified complement activation seen in 
STEC-HUS patients; nor could we link the streptococcal proteins neuraminidase A, pneumolysin or 
PspC to the development of thrombotic microangiopathy in mice (Chapter 11). We did, however, 
observe a decreased host response in Factor H deficient mice that lead to a higher bacterial load. In 
patients, this is associated with increased risk to develop HUS, and patients with a dysregulated 
complement system due to genetic or acquired aberrations might therefore be more prone to 
develop SP-HUS. 
 
The complement inhibitor eculizumab has certainly changed the future perspectives of patients with 
aHUS, but many unsolved questions remain: who should receive the drug, which optimal treatment 
schedules should be used, and how long should therapy be continued. It is even undecided if 
prophylactic treatment is needed in transplantation settings. As eculizumab is very expensive (up to 
€500,000 per treatment year), cost effectiveness in both standard and new treatment algorithms 
should be evaluated in carefully conducted prospective cohort studies. For this, new complement 
assays and biomarkers will be obligatory. 
An important role of the complement system in the pathogenesis of infection-induced HUS has not 
been fully verified so far, and more research is needed before complement inhibitors are 
implemented as treatment options in these HUS etiologies. 
 
In this thesis, we aimed to further elucidate the role of the complement system in the pathogenesis 
of STEC-HUS, SP-HUS, and aHUS. In Chapter 12, we discuss the implications of the results. 
Investigation in a larger cohort is needed, but based on our results, the alternative pathway 
activation markers C3bBbP, C3b/c, and in particular the C3d/C3 ratio may be used to monitor 
disease activity and to distinguish between different HUS etiologies at time of presentation. As we 
also identified genetic and/or acquired complement aberrations in patients with both complement-
mediated and infection-related HUS, genetic screening is not only advised in aHUS, but in STEC-HUS 
and SP-HUS as well. The establishment of an independent international registry for HUS with both 
clinical information and diagnostic results (microbiology, serology, and genetics) will further improve 
our insights into the pathogenesis of the different HUS forms. 
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Nederlandse samenvatting 
 
Het hemolytisch uremisch syndroom (HUS) is een zeldzame, maar ernstige nierziekte. De ziekte 
wordt gekarakteriseerd door hemolytische anemie (een abnormale afbraak van rode bloedcellen), 
trombocytopenie (een tekort aan bloedplaatjes) en acuut nierfalen. In meer dan 90% van de 
gevallen op kinderleeftijd wordt de ziekte voorafgegaan door een infectie met de Shiga-like toxine 
producerende Escherichia coli (STEC) bacterie. De belangrijkste oorzaken in de overige 5-10% zijn 
een verkeerde regulatie van het complementsysteem door genetische afwijkingen (hier atypisch 
HUS of aHUS genoemd) en een infectie met de Streptococcus pneumoniae bacterie (SP-HUS). Het 
complementsysteem is onderdeel van het aangeboren immuunsysteem en zorgt voor de eerste 
afweer tegen indringers. Het induceert cellysis door het inbouwen van het membrane attack 
complex in het celmembraan van bijv. bacteriën en het activeert leukocyten om te infectie op te 
ruimen. Het complementsysteem ziet echter geen verschil tussen indringers en eigen cellen. Om de 
eigen cellen te beschermen wordt het complementsysteem daarom strikt gereguleerd op zowel het 
celoppervlak als in de bloedbaan. Indringers die deze beschermmechanismen niet hebben, worden 
aangevallen en beschadigd. Een genetische afwijking of mutatie in één van de regulatoren zal leiden 
tot een ongecontroleerde activatie van het complementsysteem op eigen cellen met celschade als 
gevolg, vooral aan de cellen in de microcirculatie van de nieren. Deze mutaties, die meestal worden 
gevonden in genen die coderen voor onderdelen van de alternatieve route van het 
complementsysteem, worden beschreven in ~50-60% van de aHUS patiënten. 
Het is bekend dat zowel STEC als S. pneumonaie zichzelf kunnen beschermen tegen 
complementactivatie. Deze wetenschap, het feit dat een dysregulatie van de alternatieve route van 
het complementsysteem een belangrijke rol lijkt te spelen in de pathogenese van aHUS, en de 
overeenkomsten in de klinische symptomen heeft geleid tot het doel van dit proefschrift: het verder 
ontrafelen van de rol van het complementsysteem in de drie verschillende vormen van HUS (STEC-
HUS, SP-HUS en aHUS). 
 
In het eerste deel van dit proefschrift worden de genetische studies in aHUS patiënten beschreven. 
De aanwezigheid van mutaties kan van invloed zijn op het ziektebeloop en op de verschillende 
behandelopties. Patiënten met een mutatie in CFH of CFI hebben bijvoorbeeld een hoge kans op 
terugkeer van ziekte na een niertransplantatie (80-100%), terwijl in patiënten met alleen een CD46 
mutatie die kans 0-20% is. In Hoofdstuk 2, Hoofdstuk 3, Hoofdstuk 4 en Hoofdstuk 6 hebben we 
een groep van 70 aHUS patiënten gescreend op de aanwezigheid van mutaties in genen die coderen  
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een groep van 70 aHUS patiënten gescreend op de aanwezigheid van mutaties in genen die coderen  
voor complementeiwitten en geassocieerd zijn met de ziekte. In iets meer dan 50% van de patiënten 
hebben we een mogelijke ziekteveroorzakende verandering of de aanwezigheid van 
autoantilichamen tegen Factor H, de belangrijkste regulator van de alternatieve route, gevonden. In 
de overige patiënten is echter geen mutatie gevonden in één van de gescreende genen die het 
ontstaan van aHUS kan verklaren. De genetische screening van alle geassocieerde genen via 
reguliere methoden (PCR en Sanger scequencing) is arbeidsintensief, kostbaar en tijdrovend. Het 
toepassen van next generation sequencing technieken zou daarom een mogelijk interessante 
alternatieve manier zijn om aHUS patiënten te screenen op mutaties. In Hoofdstuk 5 hebben wij 
echter laten zien dat de hotspot voor mutaties in CFH niet volledig wordt gedekt met de huidige 
whole exome technieken, waardoor in 7,5% van de patiënten de mutatie wordt gemist. Daarom kan 
op dit moment next generation sequencing alleen worden toegepast wanneer het wordt 
gecombineerd met traditionele Sanger sequencing voor de niet-gedekte CFH gebieden en voor diep-
intronische SNPs in haplotypes geassocieerd met aHUS. Genetische en verworven afwijkingen, zoals 
de autoantilichamen tegen Factor H, in het complementsysteem zijn niet alleen aanwezig in aHUS 
patiënten, maar ook in meer dan 30% (8/26) van de onderzochte STEC-HUS en SP-HUS patiënten in 
Hoofdstuk 9. Dit hoge percentage mutaties moet bevestigd worden in grotere patiëntcohorten en 
gedetailleerde data over klinische follow-up zijn nodig om de invloed van deze mutaties op het 
ziekteverloop en de gevolgen in STEC-HUS en SP-HUS te bepalen. Gebaseerd op onze resultaten 
wordt aangeraden niet alleen aHUS patiënten te screenen op complementafwijkingen, maar ook 
STEC-HUS en SP-HUS patiënten, om zo de kennis over de rol van mutaties in de pathogenese van de 
ziekte te vergroten. 
De behandeling van HUS patiënten kan erg uitdagend zijn, met name wanneer de patiënt ook nog 
andere ziektes heeft. Dit wordt duidelijk in Hoofdstuk 7 waar een patiënt wordt beschreven met 
zowel STEC-HUS als hemofilie A. De toediening van recombinant factor VIII om hemorrhagische 
colitis onder controle te krijgen en ernstige neurologische complicaties te voorkomen, zou het 
thrombotisch microangiopathisch proces van de HUS hebben kunnen bevorderd. 
 
Het tweede deel van dit proefschrift is gefocust op het vinden van biomarkers voor 
complementactivteit in HUS patiënten, op complementevasie door STEC O157:H7 en op de 
gastheerresponse bij complementdysregulatie. De mogelijkheid tot het meten van 
complementeiwitten en de complementactiviteit in het bloed van HUS patiënten is beperkt. Daarom 
hebben wij de complementactiviteit uitgebreid bestudeerd in de acute fase en de herstelfase van de 
ziekte, eerst aHUS patiënten (Hoofdstuk 8) en later ook in STEC-HUS en SP-HUS patiënten 
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(Hoofdstuk 9). Wij hebben laten zien dan de activatieproducten van de alternatieve route (C3d, 
C3bBbP en C3b/c) verhoogd waren in alle patiëntengroepen in de acute fase, maar niet in remissie. 
De C3d/C3 ratio geeft het duidelijkst verschil tussen de acute fase en de herstelfase en kan daardoor 
mogelijk gebruikt worden als een biomarker voor ziekteactiviteit in alle HUS vormen. Verder waren 
alle activatieproducten in de acute fase significant meer verhoogd in aHUS patiënten dan in STEC-
HUS patiënten en kunnen deze gebruikt worden als mogelijk toekomstige biomarker om bij opname 
onderscheid te maken tussen deze twee etiologiën. De gevonden complementactivatie in STEC-HUS 
patiënten kon niet verklaard worden door verandering in complementregulatie door één van de tien 
STEC O157:H7 eiwitten die zijn bestudeerd in Hoofdstuk 10. Ook konden we streptokokkeneiwitten 
neuraminidase A, pneumolysine of PspC niet linken aan het ontstaan van thrombotische 
microangiopatie in muizen (Hoofdstuk 11). We zagen echter wel een veranderde afweer tegen 
Streptococcus pneumoniae in muizen deficiënt voor Factor H wat resulteerde in een meer bacteriën 
in de bloedbaan. In patiënten is deze zogenoemde hogere bacterieload geassocieerd met een hoger 
risico op het ontwikkelen van HUS. Patiënten met een verstoorde complementregulatie door 
genetische of verworven afwijkingen zouden daardoor mogelijk vatbaarder zijn voor het 
ontwikkelen van SP-HUS. 
 
De behandeling met de complementremmer eculizumab heeft de toekomst van aHUS patiënten 
zeker veranderd, maar er zijn nog steeds veel onbeantwoorde vragen. Welke patiënten moeten het 
medicijn ontvangen of kunnen zij ook met andere methodes behandeld worden; wat is het beste 
behandelschema; moet het medicijn inderdaad levenslang gegeven worden, zoals de farmaceut 
zegt, of kan er ook afgebouwd worden; moeten patiënten die een niertransplantatie ondergaan 
inderdaad altijd rond de transplantatie eculizumab ontvangen? Om bovenstaande vragen te kunnen 
beantwoorden en omdat eculizumab een erg kostbaar medicijn is (tot €500.000,- per behandeljaar), 
moet het huidige behandelschema vergeleken worden met nieuwe schema’s in een prospectieve 
cohortstudie. Hiervoor zijn nieuwe complement assays en biomarkers essentieel. 
Met de resultaten uit dit proefschrift is de exacte rol van het complementsysteem in de 
pathogenese van infectiegerelateerde HUS niet bevestigd. Voordat complementremmers ook een 
rol krijgen in de behandeling van deze HUS vormen is eerst nog meer onderzoek nodig. 
 
In dit proefschrift hebben we geprobeerd de rol van het complementsysteem in de pathogenese van 
STEC-HUS, SP-HUS en aHUS verder te ontrafelen. In Hoofdstuk 12 bediscussiëren we de 
consequenties van de resultaten. De activatieproducten van de alternatieve route van het 
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(Hoofdstuk 9). Wij hebben laten zien dan de activatieproducten van de alternatieve route (C3d, 
C3bBbP en C3b/c) verhoogd waren in alle patiëntengroepen in de acute fase, maar niet in remissie. 
De C3d/C3 ratio geeft het duidelijkst verschil tussen de acute fase en de herstelfase en kan daardoor 
mogelijk gebruikt worden als een biomarker voor ziekteactiviteit in alle HUS vormen. Verder waren 
alle activatieproducten in de acute fase significant meer verhoogd in aHUS patiënten dan in STEC-
HUS patiënten en kunnen deze gebruikt worden als mogelijk toekomstige biomarker om bij opname 
onderscheid te maken tussen deze twee etiologiën. De gevonden complementactivatie in STEC-HUS 
patiënten kon niet verklaard worden door verandering in complementregulatie door één van de tien 
STEC O157:H7 eiwitten die zijn bestudeerd in Hoofdstuk 10. Ook konden we streptokokkeneiwitten 
neuraminidase A, pneumolysine of PspC niet linken aan het ontstaan van thrombotische 
microangiopatie in muizen (Hoofdstuk 11). We zagen echter wel een veranderde afweer tegen 
Streptococcus pneumoniae in muizen deficiënt voor Factor H wat resulteerde in een meer bacteriën 
in de bloedbaan. In patiënten is deze zogenoemde hogere bacterieload geassocieerd met een hoger 
risico op het ontwikkelen van HUS. Patiënten met een verstoorde complementregulatie door 
genetische of verworven afwijkingen zouden daardoor mogelijk vatbaarder zijn voor het 
ontwikkelen van SP-HUS. 
 
De behandeling met de complementremmer eculizumab heeft de toekomst van aHUS patiënten 
zeker veranderd, maar er zijn nog steeds veel onbeantwoorde vragen. Welke patiënten moeten het 
medicijn ontvangen of kunnen zij ook met andere methodes behandeld worden; wat is het beste 
behandelschema; moet het medicijn inderdaad levenslang gegeven worden, zoals de farmaceut 
zegt, of kan er ook afgebouwd worden; moeten patiënten die een niertransplantatie ondergaan 
inderdaad altijd rond de transplantatie eculizumab ontvangen? Om bovenstaande vragen te kunnen 
beantwoorden en omdat eculizumab een erg kostbaar medicijn is (tot €500.000,- per behandeljaar), 
moet het huidige behandelschema vergeleken worden met nieuwe schema’s in een prospectieve 
cohortstudie. Hiervoor zijn nieuwe complement assays en biomarkers essentieel. 
Met de resultaten uit dit proefschrift is de exacte rol van het complementsysteem in de 
pathogenese van infectiegerelateerde HUS niet bevestigd. Voordat complementremmers ook een 
rol krijgen in de behandeling van deze HUS vormen is eerst nog meer onderzoek nodig. 
 
In dit proefschrift hebben we geprobeerd de rol van het complementsysteem in de pathogenese van 
STEC-HUS, SP-HUS en aHUS verder te ontrafelen. In Hoofdstuk 12 bediscussiëren we de 
consequenties van de resultaten. De activatieproducten van de alternatieve route van het 
complementsysteem C3bBbP, C3b/c en vooral de C3d/C3 ratio zouden als biomarkers gebruikt 
kunnen worden om ziekteactiviteit te monitoren en om onderscheid te maken tussen verschillende 
oorzaken bij opname van de patiënten, maar dit resultaat moet bevestigd worden in een groter 
cohort. Het screenen naar afwijkingen in het complementsysteem, zowel genetische als verworven, 
wordt niet alleen aangeraden in aHUS patiënten, maar ook in STEC-HUS en SP-HUS, aangezien wij 
ook in die groepen afwijkingen hebben gevonden. Door een onafhankelijke internationale database 
op te zetten voor HUS waarin zowel klinische informatie en diagnostische resultaten (op 
microbiologisch, serologisch en genetisch niveau) worden verzameld, zullen de inzichten wat betreft 
de pathogenese van de verschillende HUS vormen vergroot worden. 
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Dankwoord 
 
Eindelijk kan ik dan aan het dankwoord beginnen: het meest gelezen, en dus misschien wel het 
belangrijkste hoofdstuk van mijn proefschrift. Ik wil iedereen danken die op enige wijze betrokken is 
geweest bij de totstandkoming van dit boekje, op inhoudelijk gebied, met praktische zaken, of door 
gewoon aanwezig te zijn in de afgelopen jaren. Een aantal mensen wil ik graag in het bijzonder 
bedanken. 
 
Allereerst natuurlijk mijn promotor, prof. dr. Bert van den Heuvel. Beste Bert, dank je wel dat ik in 
2007 die eerste bachelorstage onder jouw leiding heb mogen uitvoeren en dat je me daarna de kans 
hebt gegeven om het onderzoek voort te zetten. Ondanks je volle agenda door alle verschillende 
groepen die je leiding moet geven, in Nijmegen en Leuven, en de vele congressen in binnen- en 
buitenland, kon er altijd wel ergens tijd vrij worden gemaakt om even de voortgang van het project 
door te nemen of een manuscript te lezen en door te spreken. Dank ook dat je je medewerkers niet 
alleen ziet als werknemers, maar ook hun persoonlijke sores in de gaten probeert te houden. 
 
Dan mijn eerste co-promotor, dr. Nicole van de Kar. Lieve Nicole, wat ben ik blij dat ik jouw eerste 
promovendus mag zijn! Nog steeds vind ik het verwonderlijk hoe stellig jij aan het eind van mijn 
bachelorstage kon zeggen dat ik de juiste kandidaat zou zijn voor een promotie-onderzoek binnen 
de HUS groep, terwijl ik eerst nog twee jaar zou moeten studeren. En zie hier het resultaat van die 
stelligheid! Ik zal al onze uitstapjes naar de vele congressen in binnen- en buitenland nooit vergeten: 
na een nacht in het heerlijk slapende prinsessenbed van Janne 8 uur in de auto om naar Jena te 
gaan; vliegen naar Innsbruck vanaf Frankfurt, maar het vliegtuig missen omdat het verkeerde 
vliegveld ingesteld stond op de TomTom; al dansend in het Kasnapolsky het succes van VTEC2012 
vieren; enz, enz. Ook dank voor al je persoonlijke belangstelling, het meedenken over mijn 
toekomst, en de soms zelfs nachtelijk Whatsapp-gesprekken! 
 
Ook mijn tweede co-promotor mag niet vergeten worden, dr. Elena Volokhina. Beste Elena, toen jij 
in de HUS groep kwam, zat ik daar al als masterstudent. In het begin was het een beetje lastig om de 
juiste omgang te vinden (ik de wat betweterige student die al veel wist van HUS en het 
complementsysteem, jij de gepromoveerde onderzoeker met veel meer praktische ervaring), maar 
volgens mij ging dat de laatste jaren prima. Ik heb altijd veel van je kunnen leren op het vlak van de 
biochemische technieken, dank je wel daarvoor! 
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Beste manuscriptcommissie, beste prof. dr. Wetzels, prof. dr. van Kooten en prof. dr. den Hollander. 
Dank jullie wel voor de bereidheid tot het doorlezen van mijn manuscript zo vlak na de kerst. Jack, 
ook dank voor al je kennis in de afgelopen jaren en de prettige discussies die we hebben gehad over 
behandeling van en onderzoek naar glomerulaire ziekten. Cees, dank je wel dat ik bij jou de TCC 
assays heb mogen uitvoeren. Helaas is het geen artikel geworden en heeft het dit proefschrift ook 
niet gehaald, maar ik denk nog steeds dat het een heel mooi verhaal is. 
 
Beste paranimfen, lieve Thatjana en Inge. Wat ben ik blij dat jullie achter mij willen staan met mijn 
promotie! Thatjana, al sinds die eerste zondag van de introductie in het Kronenburgerpark was er 
een band. Tijdens de studie zijn we elkaar helaas een beetje uit het oog verloren, maar wat was het 
leuk om mijn mentorzusje opeens weer op het lab tegen te komen. Meteen was het alsof we elkaar 
niet al een aantal jaar niet hadden gezien en toen we ook nog eens tegelijkertijd zwanger waren, 
werd het alleen maar leuker. Nu ook nog eens samen bij Genetica, volgens mij komen we niet meer 
van elkaar af, gelukkig maar! Inge, wat hebben wij al veel gedeeld de afgelopen 12 jaar: hockey tot 
en met, een geweldig bestuursjaar, vele etentjes, de nodige biertjes, wijntjes en tegenwoordig 
kopjes thee, stapavonden, sleep-overs in Nijmegen of Vught, goede gesprekken, zwangerschappen 
en nog veel meer. Dank je wel daarvoor en het leek me niet meer dan logisch om dit moment ook 
met jou te delen!  
 
Lieve mede-promovendi, dank voor het luisterend oor als we er allemaal even doorheen zaten en 
ook voor het delen van alle successen. Daardoor weten we dat het uiteindelijk altijd wel een keer 
goed komt. Succes allemaal met het afronden van jullie boekjes: je ziet het, op een bepaald 
moment, hoe lang het ook kan duren, staan ook jullie hier! In het bijzonder wil ik mijn meest directe 
collegaatjes nog noemen. Ruud, dank je wel voor al je kennis op het gebied van dierenstudies en 
statistiek. Volgens mij was die muizenstudie zonder jou echt nergens op uitgelopen, want dan had ik 
niet eens een fatsoenlijke DEC aanvraag kunnen schrijven… Carolien, dank je wel voor je grote 
enthousiasme, ook als jij in een dipje zat en ik weer eens aankwam met weer een geaccepteerd 
artikel. Ik zal onze reis naar de ASN in San Diego nooit vergeten: 27 uur in een vliegtuig als je ziek 
bent is geen pretje. Gelukkig hebben we het daarna goed kunnen maken met een vliegdekschip, een 
veel te duur bezoekje aan de dierentuin en de allerlekkerste en daarna de allervieste sushi ever! 
Evelien, dank je wel voor de heerlijke kopjes koffie waarbij we onze zorgen konden delen. Ik weet 
zeker dat je goed terecht gaat komen, of het nu wel in de wetenschap is of juist heel ver daar 
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vandaan! Roel Kurvers en Kioa, heel veel succes met jullie onderzoek naar complementgemediëerde 
glomerulaire ziekten: het is goed om ook weer eens klinisch onderzoekers in de groep te hebben! 
 
Dan de mensen op het lab. Moet ik jullie nu LKN, LGEM of TML noemen, ik weet het niet meer met 
al die namen die de revue zijn gepasseerd… Dank voor alle gezelligheid op het lab, tijdens de 
koffiepauzes, bij de TGIFs, de dagjes uit, kortom: in de afgelopen zoveel jaar. Jullie dachten 
misschien nooit meer van me af te komen en ik vind het ook erg jammer dat ik dit alles nu moet 
missen. Gelukkig is de koffiekamer dichtbij!  
 
Uiteraard moeten er ook wat mensen van het lab speciaal in het zonnetje worden gezet. Allereerst 
de analisten van de HUS groep: Thea, Annelies, Annemieke en Joop. Thea, dank je wel voor al je 
gezelligheid, gezang en kritische noten op het lab. ELISA’s draaien zoals jij kan volgens mij niemand! 
Annelies, je bent altijd in voor een gesprekje over van alles en nog wat en dat was altijd fijn als ik 
even niet met werk bezig wilde zijn. Annemieke, ook al was je er niet lang, jouw gedrevenheid heeft 
diepe indruk op me gemaakt! Joop, dank je wel voor die laatste ELISA’s die je nog op het eind voor 
mij wilde draaien. Met jou in de groep maak ik me totaal geen zorgen over alle diagnostische assays 
die opgezet en geïmplementeerd moeten worden. Verder moet de DNA groep ook even genoemd 
worden, vooral Roel en Inge. Roel, dank je wel dat jij mij 8 jaar geleden hebt leren pipetteren en 
sequencen. Ik denk dat ik zonder jouw kennis niet was gekomen tot waar ik nu sta. Inge, bedankt 
voor al die DNAtjes die je hebt geïsoleerd en voor je altijd snelle antwoord als ik weer eens een 
vraag moest doorspelen uit de kliniek kwam over welk gen er nu wel of niet gerund was. 
 
Beste LKI’ers, jullie mogen niet vergeten worden met jullie belangrijke rol in het muizenstuk. Fred, 
dank je wel voor al die gezellige, persoonlijke gesprekken die we hebben gehad terwijl we in de 
flowkast bezig waren met de muizen. Saskia, zonder jou was de DEC aanvraag en alle 
werkprotocollen helemaal niets geworden. Marien, dank voor je inhoudelijke input die je opeens 
moest gaan leveren in mijn project toen Peter wegging. Erika, heel veel succes met je eigen 
onderzoek; ik hoop dat we onze gezamenlijke stukken heel snel gepubliceerd krijgen! 
 
Alle studenten die ik in de afgelopen jaren (mede) heb mogen begeleiden (Eefje, Maarten, Ellen, 
Linda, Ntsiki, Maartje, Renske, Nieke, Ymke, Roy, Freek, Peran, Stephan): dank jullie wel voor al die 
sequenties die jullie hebben gerund en geanalyseerd. Zonder jullie werk was heel Section I van dit 
proefschrift er niet geweest! 
 
Beste manuscriptcommissie, beste prof. dr. Wetzels, prof. dr. van Kooten en prof. dr. den Hollander. 
Dank jullie wel voor de bereidheid tot het doorlezen van mijn manuscript zo vlak na de kerst. Jack, 
ook dank voor al je kennis in de afgelopen jaren en de prettige discussies die we hebben gehad over 
behandeling van en onderzoek naar glomerulaire ziekten. Cees, dank je wel dat ik bij jou de TCC 
assays heb mogen uitvoeren. Helaas is het geen artikel geworden en heeft het dit proefschrift ook 
niet gehaald, maar ik denk nog steeds dat het een heel mooi verhaal is. 
 
Beste paranimfen, lieve Thatjana en Inge. Wat ben ik blij dat jullie achter mij willen staan met mijn 
promotie! Thatjana, al sinds die eerste zondag van de introductie in het Kronenburgerpark was er 
een band. Tijdens de studie zijn we elkaar helaas een beetje uit het oog verloren, maar wat was het 
leuk om mijn mentorzusje opeens weer op het lab tegen te komen. Meteen was het alsof we elkaar 
niet al een aantal jaar niet hadden gezien en toen we ook nog eens tegelijkertijd zwanger waren, 
werd het alleen maar leuker. Nu ook nog eens samen bij Genetica, volgens mij komen we niet meer 
van elkaar af, gelukkig maar! Inge, wat hebben wij al veel gedeeld de afgelopen 12 jaar: hockey tot 
en met, een geweldig bestuursjaar, vele etentjes, de nodige biertjes, wijntjes en tegenwoordig 
kopjes thee, stapavonden, sleep-overs in Nijmegen of Vught, goede gesprekken, zwangerschappen 
en nog veel meer. Dank je wel daarvoor en het leek me niet meer dan logisch om dit moment ook 
met jou te delen!  
 
Lieve mede-promovendi, dank voor het luisterend oor als we er allemaal even doorheen zaten en 
ook voor het delen van alle successen. Daardoor weten we dat het uiteindelijk altijd wel een keer 
goed komt. Succes allemaal met het afronden van jullie boekjes: je ziet het, op een bepaald 
moment, hoe lang het ook kan duren, staan ook jullie hier! In het bijzonder wil ik mijn meest directe 
collegaatjes nog noemen. Ruud, dank je wel voor al je kennis op het gebied van dierenstudies en 
statistiek. Volgens mij was die muizenstudie zonder jou echt nergens op uitgelopen, want dan had ik 
niet eens een fatsoenlijke DEC aanvraag kunnen schrijven… Carolien, dank je wel voor je grote 
enthousiasme, ook als jij in een dipje zat en ik weer eens aankwam met weer een geaccepteerd 
artikel. Ik zal onze reis naar de ASN in San Diego nooit vergeten: 27 uur in een vliegtuig als je ziek 
bent is geen pretje. Gelukkig hebben we het daarna goed kunnen maken met een vliegdekschip, een 
veel te duur bezoekje aan de dierentuin en de allerlekkerste en daarna de allervieste sushi ever! 
Evelien, dank je wel voor de heerlijke kopjes koffie waarbij we onze zorgen konden delen. Ik weet 
zeker dat je goed terecht gaat komen, of het nu wel in de wetenschap is of juist heel ver daar 
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De kindernefrologen van het Radboud wil ik bedanken voor al die buisjes bloed die afgenomen 
moesten worden bij de HUS patiëntjes. Moest het nou een rode of een paarse buis zijn, wel of niet 
op ijs, waar ligt die trialbon: sorry voor de onduidelijkheid soms! Michiel, dank je wel dat jij uit jezelf 
een soort van mentorrol op je nam en in de auto op de terugweg van de Nefrologiedagen tegen me 
zei dat ik moest gaan nadenken over waar ik wilde staan over 5 jaar. Dankzij die tip zit ik waar ik nu 
zit, ondanks dat dat betekende dat ik de HUS groep vaarwel moest zeggen. Ook wil ik Jacqueline, 
Karen en Mariëtte bedanken voor al die controlesamples die zij hebben verzameld. Zonder jullie 
waren we nooit tot over die 100 gekomen! 
 
De kindernefrologen in de rest van het land, dank voor het insturen van al die samples die wij aan 
jullie vroegen. Ook vond ik het altijd erg gezellig op alle congressen waar we elkaar tegen kwamen.  
Alle patiënten die hebben mee willen werken aan de verschillende onderzoeken: zonder jullie was 
dit proefschrift nergens geweest! Duizendmaal dank! 
 
All collaborators are being thanked for all the work we could perform together. Prof. dr. Pickering, 
thank you for the Cfh-/- mouse and for the opportunity to have a week in your lab in London for the 
CFHR5 article. Dr. Gershagen and mrs. Anderson from Eurodiagnostica in Sweden, Sten and Felicia, 
thank you for all the trouble shooting in Sweden and in Nijmegen with the Wielisa assay. Dr. van der 
Molen, Renate, dank je wel dat ik bij LMI al die C3d en AP/CP ELISA’s mocht komen runnen. Ik hoop 
dat het complementsysteem een speerpuntje van je blijft, we hebben een medisch immunoloog 
nodig! Dr. Roos, Anja, wat fijn dat we de kwantitatieve Factor H en Factor I assay via jou hebben 
kunnen regelen ondanks al je verhuizingen in het land. Dat artikel wordt vast snel geaccepteerd! 
Prof. dr. Florquin, Sandrine, wat was het handig de TMA specialist op (muizen)niergebied opeens in 
het Radboud te hebben. Dank voor alle kleuringen die we op korte termijn via jou hebben kunnen 
laten doen. 
 
Het leven draait niet alleen maar om werk, zeker niet en gelukkig niet! Allereerst wil ik de meiden 
bedanken die mij in staat stelden om iedere week mijn frustraties kwijt te raken op het hockeyveld. 
Vanaf het eerste jaar in Nijmegen zijn we samen volwassen geworden, hebben we inmiddels de 
nodige huwelijken en zwangerschappen meegemaakt en nog steeds staan we met een hele grote 
groep wekelijks veel te fanatiek te wezen. Volgens mij blijven wij tot in den treuren samen op dat 
veld staan!  
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Familie, dank jullie wel voor de interesse in mijn onderzoek, ook al zei het jullie vaak helemaal niets. 
Wat leuk dat een deel van jullie bij de promotieplechtigheid kan zijn! Fred, bedankt dat je de 
familietraditie voor het maken van de layout van een proefschrift hebt willen voortzetten: het is 
prachtig geworden! 
 
Lieve familie van ’t Veen, dank jullie wel voor het warme ontvangst in de familie. Iedere keer weer 
sta ik weer versteld van hoeveel er toch te bepraten is met jullie en hoe gezellig dat altijd is. Ik hoop 
dat jullie, ondanks alle moeilijke termen, iets mee krijgen van de promotie, en ach, anders is er altijd 
een lekker wijntje na afloop… Ik ben blij om tegenwoordig ook een Van ’t Veen te mogen zijn! 
 
Lieve zus, ondanks dat we elkaar weinig spreken, vind ik het heel fijn te weten dat er toch altijd 
iemand is die me al mijn hele leven kent en met wie ik samen mijn jeugd heb beleefd. Het komt wel 
goed met ons, dat weet ik zeker! Guusje en Teuntje, wat een heerlijke meiden zijn jullie geworden. 
En wat is het leuk dat jullie ook zoveel plezier aan het hockeyen beleven, dat heb ik maar mooi voor 
elkaar gekregen! Ik ben blij jullie tante te mogen zijn! 
Lieve mama, wat is het toch altijd weer ouderwets thuiskomen als we elkaar zien. We groeien steeds 
meer naar elkaar toe en hebben steeds meer te bepraten, ook op het diepere, emotionelere vlak, 
maar ik vind het ook altijd heerlijk om gewoon samen op de bank televisie met je te kunnen kijken. 
Dank je wel dat het nog steeds hetzelfde is als altijd! 
Lieve papa, wat vond jij het onderzoek toch interessant en wat had jij hier graag bij willen zijn. En 
dat ben je ook ergens, dat weet ik zeker. Ik ben zo blij dat je Margje nog goed mee hebt kunnen 
maken, hoe kort dan ook, en ik ga er vanuit dat je ons daarboven goed in de gaten blijft houden. 
 
Liefste Margje, hoeveel vrolijkheid kan een meisje van één toch brengen. Met je ondeugende 
glimlach en je sprankelende oogjes kun je altijd weer een lach op mama’s gezicht toveren. Alleen al 
daarvoor kon ik het werk het werk laten, wat soms hard nodig was. Je wordt een top grote zus! 
 
Allerliefste Gerrit, jij bent de rots en de houvast die ik in de afgelopen jaren nodig had. De stabiele 
thuisbasis met een gesprek over van alles en nog wat dat jou op dat moment bezig hield, ook als ik 
daar soms iets minder zin in had, heeft mij de mogelijkheid geboden om alles te kunnen relativeren 
en de nodige rust te vinden. Samen met ons gezin gaan we nog heel veel mooie, fijne jaren 
tegemoet en daar zie ik erg naar uit. Ik hou van je! 
  
 
De kindernefrologen van het Radboud wil ik bedanken voor al die buisjes bloed die afgenomen 
moesten worden bij de HUS patiëntjes. Moest het nou een rode of een paarse buis zijn, wel of niet 
op ijs, waar ligt die trialbon: sorry voor de onduidelijkheid soms! Michiel, dank je wel dat jij uit jezelf 
een soort van mentorrol op je nam en in de auto op de terugweg van de Nefrologiedagen tegen me 
zei dat ik moest gaan nadenken over waar ik wilde staan over 5 jaar. Dankzij die tip zit ik waar ik nu 
zit, ondanks dat dat betekende dat ik de HUS groep vaarwel moest zeggen. Ook wil ik Jacqueline, 
Karen en Mariëtte bedanken voor al die controlesamples die zij hebben verzameld. Zonder jullie 
waren we nooit tot over die 100 gekomen! 
 
De kindernefrologen in de rest van het land, dank voor het insturen van al die samples die wij aan 
jullie vroegen. Ook vond ik het altijd erg gezellig op alle congressen waar we elkaar tegen kwamen.  
Alle patiënten die hebben mee willen werken aan de verschillende onderzoeken: zonder jullie was 
dit proefschrift nergens geweest! Duizendmaal dank! 
 
All collaborators are being thanked for all the work we could perform together. Prof. dr. Pickering, 
thank you for the Cfh-/- mouse and for the opportunity to have a week in your lab in London for the 
CFHR5 article. Dr. Gershagen and mrs. Anderson from Eurodiagnostica in Sweden, Sten and Felicia, 
thank you for all the trouble shooting in Sweden and in Nijmegen with the Wielisa assay. Dr. van der 
Molen, Renate, dank je wel dat ik bij LMI al die C3d en AP/CP ELISA’s mocht komen runnen. Ik hoop 
dat het complementsysteem een speerpuntje van je blijft, we hebben een medisch immunoloog 
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